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Summary
Chronic skin wounds (CW) represent a significant world health problem including 
reservoirs of multi-drug resistant bacterial biofilms. The precise role of bacteria in the 
aetiology of chronic inflammation and non-healing remains unclear. This study 
characterised MRSA from human CW and investigated how they inhibit wound healing, 
modulate immunological responses and resist treatment in comparison to control MRSA 
from asymptomatic nasal carriers (NC).
Routine cultural analysis of 150 chronic wounds revealed 50% were colonised with S'. 
aureus, of which 22.6% were MRSA. Multi-locus sequence typing identified two new 
sequence types and demonstrated that wound MRSA represented two clonal complexes 
(22 and 30) with almost 90% identified as hospital-acquired EMRSA-15. MRSA 
isolated from CW and NC were characterised for virulence factor (VF) expression and 
modulation of the innate immune system. Presence and expression of MRSA VFs 
indicated an association with sequence type. Greater expression of colonisation- (cna) 
and degradation- associated (hysA) VFs was evident in the wound MRSA, suggesting 
that modulation of virulence is important for non-healing. The ability of conventional 
biocides (iodine, silver, and potassium permanganate) to treat chronic wound bacteria, 
using the carrier-test method, revealed iodine as the only effective biocide.
In vitro stimulation of the ability of the MRSA to induce innate immunity showed that 
CW-MRSA exhibited decreased TLR, cytokine and complement responses compared 
with NC-MRSA (IL-8, TNFa, complement activation; P<0.05). Moreover, biofilm- 
induced reductions in immunogenicity were observed compared with planktonic growth 
in monocyte and complement assays (P<0.05). Scratch wound assays indicated that 
MRSA failed to inhibit keratinocyte migration (P>0.05), although bacterial growth 
conditions (biofilm vs. planktonic) significantly affected the observed cellular migration 
(P<0.05).
Virulence factor production and ability to modulate/evade the host innate immune 
response are important potential mechanisms by which MRSA are able to colonise 
chronic wounds. These studies provide important new insights into the role of MRSA in 
delayed dermal healing.
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Chapter 1: 
General introduction
1.1 Introduction
In health the skin is colonised by the resident microflora, a diverse collection 
of microorganisms, including bacteria, archaea, fungi, viruses and mites, all of which 
form part of the human microbiome (Kong, 2011). The human microbiome project 
has been initiated to investigate all human habitats including skin, oral cavity and 
gastro-intestinal tract, in part to determine the role of bacteria in health and disease 
(Grice, 2008, Hsiao and Fraser-Liggett, 2009, Wade, 2010). These studies have 
shown that factors such as age, moisture and body site affect the microbial 
composition (Carlisle and Morowitz, 2011, Grice and Segre, 2011). It has been 
estimated that the normal flora consists of 1014 microbes (Tlaskalova-Hogenova et al., 
2004) with approximately 106 bacteria/cm2 on the skin, based on punch biopsy 
sampling (Grice, 2008).
One of the principal functions of the skin is as a barrier to prevent the ingress 
of colonising bacteria and potential pathogens to the internal milieu, thus forming an 
integral part of the innate immune system (Paige, 2005). Following injury, disruption 
of the normal barrier of human skin (Figure 1.1) induces a complex series of inter­
related but overlapping events, which constitute normal wound healing i.e. 
haemostasis, inflammation, re-epithelialisation, angiogenesis, granulation tissue 
formation, wound contraction, scar formation and tissue remodelling (Blakytny and 
Jude, 2006). The events involve both resident (keratinocytes, fibroblasts) and 
migratory cells e.g. neutrophils (PMNL) and monocyte/macrophages (Mo/M0). 
These processes are coordinated by the expression of cytokines, autocrine and 
paracrine growth factors, released at the site of injury, and cues from the extracellular 
matrix (ECM; Xu and Clark, 1996, Gill and Parks, 2008, Vorotnikova et al., 2010). 
Interruption in this process can lead to wound breakdown and failed or delayed 
healing.
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Figure 1.1 Diagrammatic representation of skin structure. Courtesy o f Miss R. Bowen, Illustration Department, Cardiff University.
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1.2 The skin microbiome
Not only does the skin provide an innate immunological barrier to the ingress 
of pathogens it harbours complex microbiological communities, which is affected by 
environmental factors such as temperature, light, humidity, e.g. host factors such as 
gender, immune status, genotype and cosmetic use (Gao et al., 2007). The ecology of 
the skin forms a significant part of the human microbiome.
As part of the human microbiome project to determine whether a core 
microbiota in healthy humans exist and further recent molecular studies, the skin 
microbiome has been obsereved to be diverse and topographically distinct (Grice, 
2009). Whereby local factors e.g. anatomy, lipid content, pH, sweat and sebum play 
a significant role in microbial colonisation. A major challenge for the human 
microbiome project is to ascertain an accurate study sample (Grice, 2008), studies by 
Gao et al., (2007) indicate that cultivation methods of the human skin significantly 
underestimate bacterial diversity.
Proteobacteria, Actinobacteria, Firmicutes, and Bacteroidetes have been 
observed to be the typical colonising phyla of human skin (Grice, 2008, Grice, 2009). 
Characterisation of the skin microbiota may provide insight into the development of 
dermatological disease, indicated by the predilection of microorganisms for specific 
skin sites (Grice, 2009). Gao et al., (2007) presented evidence that the skin 
microbiota is a frequently fluctuating dynamic system; this diversity was also 
reflected by a study by Grice et al., (2009) observing 205 genera on 10 healthy 
humans over 20 sites. Propionibacteria spp. and Staphylococci spp. were 
predominant in sebaceous sites, whilst Corynebacteria spp. was dominant in moist 
sites, although Staphylococci spp. were also present. Furthermore the skin 
microbiome not only is vastly different to the gut microbiota, which primarily are of 
the Firmicutes and Bacteroidetes division, but also indicates a low level of 
interpersonal variation unlike the gut (Grice, 2008).
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1.3 Normal wound healing
1.3.1 Inflammation
Following injury, inflammatory cells are attracted to the site of injury by 
chemotactic factors such as platelet-derived growth factor (PDGF), and transforming 
growth factor-P (TGF-p), damaged ECM and complement fractions. In the acute 
phase of inflammation PMNL predominate and act to remove damaged host tissue 
and kill invading pathogens via phagocytosis, free-radical generation and enzymatic 
degradation. Following this (>24 h) Mo are recruited to the site of injury and release 
an array of cytokines e.g. tumour necrosis factor-a (TNF-a), chemokines e.g. 
interleukin-8 (IL-8) and growth factors e.g. TGF-p and fibroblast growth factor 
(FGF). These cytokines stimulate cellular proliferation and migration in the resident 
wound cells and, in the case of fibroblasts, ECM synthesis in the adjacent dermis 
(Cotton, 1998, Sorrell et al., 2008).
1.3.2 Proliferation
During this phase, cellular proliferation and contraction occurs to close the 
defect. Fibroblasts are involved in the secretion of ECM and matrix remodelling via 
matrix metalloproteinases (MMPs), whilst endothelial cells and pericytes are 
involved in angiogenesis. In the epidermis, PDGF synergistically induces cellular 
proliferation in the basal layer, with epidermal growth factor (EGF) produced from 
keratinocytes and somatomedins (insulin-like growth factor; IGF-1 and IGF-2). In 
the dermis, myofibroblasts migrate in response to PDGF and TGF-p, the secreted 
collagen and fibronectin aids migration of epithelial cells (Parsons, 1998, Jones et al.,
2004). Wound closure is induced immediately upon wounding; keratinocytes in the 
adjacent epithelia or hair follicles within the wound proliferate and migrate across the 
provisional wound matrix. Following wound closure, remodelling occurs over many 
months (up to 1 year following initial injury) mediated principally by fibroblasts and 
myofibroblasts.
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The rapidity of wound closure and re-epithelialisation is evolutionary 
important to minimise the risk of infection supervening (Ferguson, 1993, Moulin et 
al., 2000). In wounds which heal with primary intention (with the wound edges 
approximated) this process is complete within 24 hours. In more extensive wounds 
however, where the edges are not approximated, the wound bed may be exposed to 
the external environment and potential colonisation/invasion of bacteria for many 
days (Bowler, 2003).
1.4 Chronic wounds
Chronic, non-healing skin wounds are a major cause of disability and distress 
occurring principally in the extremities of elderly individuals. They present in 3 
typical forms: pressure ulcers (PU), diabetic foot ulcers (DFU) and venous ulcers, 
and are defined as chronic if they fail to show a 40% reduction in area in a 2 -  4 
week period following optimal therapy (Siddiqui and Bernstein, 2010). Such wounds 
annually account for the loss of >2 million workdays in the US (McGuckin et al.,
2002); with an associated estimated cost of $13 to $15 billion (Siddiqui and 
Bernstein, 2010).
Interestingly, the majority of non-healing wounds will occur in 
individuals/tissue exhibiting impaired immunological responsiveness (diabetic 
ulcers), inadequate perfusion (venous leg ulcers) and chronic trauma (pressure 
ulcers). The wounds, therefore, occur in populations with increased risk of bacterial 
carriage. Indeed, whilst the precise aetiology of these wounds is uncertain, all 
chronic wounds harbour bacteria (Davies et al., 2004, Davies et al., 2007). 
Moreover, a number of the changes which characterise the wounds at the gene, 
protein and cellular level may be directly or indirectly related to bacteria present 
within the wound bed (Wall et al., 2002, Stephens et al., 2003). Workers have 
demonstrated that the histological features of chronic, ineffectual inflammation may 
be mediated by alterations in fibroblast chemokine profiles and immunosuppressive 
effects of local anaerobic bacteria, and that the elevated levels of proteases in the
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wounds may be induced by bacterial activation of local immune responses (Wall et 
al., 2002, Wall et al., 2008). The observed degradation of the ECM may also be 
mediated by bacterial proteolytic activity, as might the defective re-epithelialisation 
and angiogenesis which is observed within the wound bed (Stephens et al., 2003). 
Workers have suggested that the changes in cellular senescence observed in the 
wound may directly influence healing. Fibroblasts cultured from chronic wounds 
exhibit reduced population doublings and early senescence compared with matched 
normal dermal fibroblasts (Mendez et al., 1998, Wall et al., 2008). Along with this, 
decreased cytokine production facilitates dysfunction in immune, ECM and 
keratinocyte regulation all of which are significant for healing (Rodero and 
Khosrotehrani, 2010).
1.5 The microflora of skin wounds
Skin wounds provide an ideal environment for microbial colonisation and 
proliferation, and these wounds harbour both aerobic and anaerobic bacterial 
populations (Bowler et al., 2001, Davies et al., 2007, Dowd, 2008). The bacterial 
species isolated from individual wounds are dependent upon wound site and typically 
derived from the local resident population (Thomson and Smith, 1994). A systematic 
review (Bowler, 1998) demonstrated that S. aureus is the most frequently isolated 
organism from skin wounds, being commonly associated with P. aeruginosa in both 
chronic skin and particularly bum wounds. Similar findings have been observed in 
prospective studies of infected surgical wounds, demonstrating that S. aureus was the 
most frequently encountered wound isolate followed by; P. aeruginosa, E. coli, S. 
epidermidis and Enterococcus faecalis (Giacometti et al., 2000). Perera et al., (2005) 
attempted to categorise the distribution of normal and pathogenic skin flora (Table 
1.1).
Past characterisation of chronic wound bacteria has however, relied upon 
culture techniques alone, which have many limitations. Culture-based methodologies
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Table 1.1 Distribution of normal and pathogenic cutaneous flora (aerobic and facultative anaerobes)
Normal flora Common pathogens Uncommon pathogens
Phylum Species
Proteobacteria Acinetobacter spp. 
Comamonas spp. 
Delftia spp. 
Enterobacter spp. 
Haemophilus spp. 
Halomonas spp. 
Janthinobacterium spp.
Candida spp. 
Corynebacterium spp. 
Enterococcus spp. 
Escherichia coli 
Group A Streptococcus 
Morganella morganii 
Proteus mirabilis
Acinetobacter spp. 
Enterobacter spp.
Group B, C, G streptococci 
Klebsiella spp. 
Pseudomonas mallei 
Serratia marcescens 
Streptococcus faecalis
Firmicutes
Klebsiella spp. 
Methylobacterium spp. 
Neisseria spp. 
Pasteurella spp. 
Pseudomonas spp. 
Serratia spp. 
Sphingobacterium spp. 
Stenotrobacteria spp.
Clostridium spp. 
Enterococcus spp. 
Lactobacillus spp. 
Staphylococcus spp. 
Streptococcus spp.
Diabtetic wounds
Proteus vulgaris 
Pseudomonas aeruginosa 
Staphylococcus aureus 
Staphylococcus epidermidis 
Shigella spp.
Serratia spp. 
Stenotrophomonas spp.
Rhodopseudomonas spp.
(Adapted from Perera and Hay, 2005, Sra et al., 2005, Gao et al., 2007, Dowd et al., 2008, Grice, 2008, Grice, 2009, Price et al., 2009, 
Gontcharova et al., 2010, Grice, 2010, Grice and Segre, 2011)
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Table 1.1 continued Distribution of normal and pathogenic cutaneous flora (aerobic and facultative anaerobes)
Normal flora Common pathogens Uncommon pathogens
Phylum Species
Bacteroidetes
Actinobacteria
Fungal
Acidobacteri spp. 
Chryseobacterium spp. 
Cyanobacteria spp. 
Sphingobacterium spp.
Actinomyces spp. 
Brevibacterium spp. 
Corynebacterium spp. 
Goronia spp.
Kocuria spp. 
Microbactium spp. 
Micrococcus spp. 
Mycobacterium spp. 
Rhodococcus spp. 
Rothia spp.
Cryptococcus spp. 
Debaryomyces spp. 
Malassezia spp.
(Adapted from Perera and Hay, 2005, Sra et al., 2005, Gao et al., 2007, Dowd et al., 2008, Grice, 2008, Grice, 2009, Price et al., 2009, 
Gontcharova et al., 2010, Grice, 2010, Grice and Segre, 2011)
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Table 1.1 continued Distribution of normal and pathogenic cutaneous flora (anaerobes)
Normal flora Common pathogens Uncommon pathogens
Phylum Species
Proteobacteria Anaerococcus spp. 
Finegoldia spp. 
Helcococcus spp. 
Parvimonas spp. 
Peptoniphilus spp.
Bacteroides fragilis 
Clostridium perfringens
Firmicutes Anaerococcus spp. 
Clostridium spp. 
Gemella spp. 
Veillonella spp.
Diabetic wound Bacteroides spp. 
Clostridium spp. 
Peptostreptococcus spp. 
Prevotella spp. 
Veillonella spp.
Bacteroidetes Porphyromonas spp. 
Prevotella spp.
Actinobacteria Propionibacterium acnes 
Propionibacterium avidum
(Adapted from Perera and Hay, 2005, Sra et al., 2005, Gao et al., 2007, Dowd et al., 2008, Grice, 2008, Grice, 2009, Price et al., 2009, 
Gontcharova et al., 2010, Grice, 2010, Grice and Segre, 2011)
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rely upon the growth of bacteria in an artificial environment, which preferentially 
nurtures rapidly growing organisms. Hence, it has been estimated that only 1% of 
bacteria have been cultured (Wade et al., 1997, Dowd, 2008), with many human 
pathogens, particularly anaerobes being uncultivatible e.g. 50% oral microflora 
(Wade et al., 2005). The last two decades has seen the advent of molecular methods 
to identify pathogens associated with disease (Dymock et al., 1996, Davies et al., 
2001, Dowd, 2008), e.g. 16S rRNA random fragment length polymorphism (RFLP), 
denaturing gradient gel electrophoresis (DGGE) and more recently high-throughput 
sequencing methods such as pyrosequencing and whole-genome shotgun 
sequencing. A limitation of such DNA sequencing methods is the inability to 
discriminate between live and dead bacteria (Grice, 2008). Functional genomic 
studies e.g. metagenomics, including metabolomic investigations, have led to a 
greater understanding of bacterial ecology and function in health and disease as 
observed in gut microbiota (Preidis and Versalovic, 2009, Yang et al., 2009). These 
methods have been used in comparative analysis of sampling methods and reveal 
that although bacterial numbers present were significantly different using swab and 
biopsy techniques, similar bacterial communities were identified (Grice, 2008).
Longitudinal studies of the skin microbiota have shown stable bacterial skin 
colonisation over time, although this was dependant on sample site, and indicated 
that healthy individuals demonstrate little inter-person variation (Grice, 2008, Grice,
2009). Conversely in leg ulcers, biofilm bacterial colonisation was highly diverse 
between patients. Pressure (62%) and diabetic (30%) leg ulcers were likely to 
harbour anaerobes, whilst venous leg ulcers had much fewer numbers (1.6%; Dowd,
2008). Murine models have shown longitudinal shifts in bacterial presence with 
non-healing wounds (Grice et al., 2010).
Within wounds bacterial presence has been artificially and arbitrarily 
categorised into: “contamination”, “colonisation”, “critical-colonisation” and 
“infection” (Edwards and Harding, 2004); where “critical colonisation” describes the 
level of colonisation that begins to adversely affect wound healing. Infection has
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been defined as “the product of the entrance, growth, metabolic activities, and 
resultant pathophysiologic effects o f microorganisms in the tissues o f the patient” 
(Robson, 1997). The cardinal signs of infection are: ‘dolor’ (pain), ‘tumor’ 
(swelling), ‘calor’ (heat), ‘rubor’ (erythema) and Toss of function’. Other signs 
indicative of infection are suppuration and in terms of chronic skin wounds i.e. 
ulceration, an increase in size and depth of the wound. However, clinical assessment 
of chronic wounds has proven to be variable and of low reliability (Lorentzen and 
Gottrup, 2006). The transition from critical colonisation to infection is not simply 
related to bacterial density but reflects changes in host susceptibility, increased 
microbial numbers, and alteration in bacterial virulence. It is evident that the deep 
tissues of all non-healing wounds harbour bacteria, whether infected or not (Cooper 
et al., 2009). Attempts to correlate the outcome of wound healing with individual 
bacteria and bacterial density have been made for over 40 years, with varying 
outcomes.
1.5.1 Microbiology and the healing of chronic wounds
Although there is a dense microflora associated with chronic wounds, they 
have relatively low rates of infection <5% (Bowler et al., 2001). Some authors 
hypothesise that the density of the microorganisms is critical to healing, whilst others 
argue that the presence of specific pathogens is of primary importance. A third 
argument is that organisms themselves play a minimal role (Eriksson et al., 1984, 
Bowler et al., 2001). The mean number of species isolated from a chronic wound 
has been noted to be between 1.6 and 5.8 (Hansson et al., 1995a, Howell-Jones et al., 
2005, Cooper et al., 2009). In terms of bacterial load, workers have suggested that 
the risk of infection is associated with bacterial numbers in the tissue >106 CFU/g 
(Ferguson, 1993) however; this is based on traumatic wound studies.
Many studies have investigated the relationship between bacterial 
quantification and non-healing. The debate over the significance of microbial load 
originated in 1964, where Bendy et al., (1964) reported that healing in decubitus
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ulcers only progressed when the bacterial load was <106 CFU/ml, whilst Robson et 
al., (1999) postulated that bacterial presence >105 CFU/g tissue, based on biopsies, 
was indicative of infection risk and non-healing. Further to this, healing in acute 
wounds has been associated with bacterial loads <105 CFU/g tissue (Bowler, 1998). 
Whist Breidenbach and Trager et al., (1995) demonstrated that a critical load of >104 
CFU/g tissue was needed to cause an infection in extremity wounds. Thus, much 
debate regarding quantitative bacteriology and non-healing has occurred. However, 
due to the variety of techniques utilised in these studies it is difficult to ascertain 
whether bacterial load, was more important than species present, e.g. p-haemolytic 
streptococci counts associated with non-healing are estimated to be <104 CFU/g 
(Heggers, 1994, Thomson and Smith, 1994, Edwards and Harding, 2004). More 
significantly, many researchers have found a limited use of the 105 CFU/g rule in 
chronic wounds due to their complex aetiology and pathogenesis compared with 
acute wounds (Bowler, 2003) whereby >106 CFU/ml bacteria have been associated 
with non-infected chronic wounds (Hill et al., 2003, Davies et al., 2007, Cooper et 
al., 2009).
The presence of multiple species within a wound appears to be of more 
importance. Trengove et al., (1996) found that healing was inversely associated with 
>4 bacterial species isolated from venous ulcers. These findings have been further 
corroborated by other researchers (Davies et al., 2007, Cooper et al., 2009), and it 
would appear that bacterial diversity is more likely to be of significance in healing 
than the number of bacteria isolated, particularly in chronic wounds.
1.5.2 Disease association with individual bacteria
A number of studies have identified potential pathogens associated with the 
chronic wound environment. Cultural analysis of wounds via swab and biopsy 
techniques have indicated S. aureus, P. aeruginosa and p-haemolytic streptococci to 
be the most frequent isolates from delayed healing and infected wounds (Bowler et 
al., 2001, Davies et al., 2007, Cooper et al., 2009). Specific studies of particular
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wound types e.g. DFU, observed that S. aureus was the most prevalent isolate along 
with S. epidermidis, Streptococcus spp. P. aeruginosa, Enterococcus spp. and 
coliforms (Armstrong et al., 1995a). Interestingly, although often overlooked, 
detailed microbiological analysis of DFU infections revealed that >90% of wounds 
contained anaerobes e.g. Peptostreptococcus, Bacteroides and Prevotella sp. 
(Gerding, 1995).
Studies employing molecular techniques have characterised the microflora of 
chronic wounds. Molecular based techniques have been applied to characterise both 
the number (DGGE) and via sequencing, the identity of uncultivable organisms 
within chronic wounds (Hill et al., 2002, Davies et al., 2004, Dowd, 2008, Melendez 
et al., 2010). DGGE studies having demonstrated a greater number of species (band 
profiles) in non-healing wounds than those identified by culture techniques alone e.g. 
Pseudomonas sp. were present in all samples, even though it was not always cultured 
(Davies et al., 2004). Sequencing studies by Hill et al., (2003), demonstrated for the 
first time the increased diversity of the wound microflora compared to purely 
cultural analysis, and recent molecular studies employing high-throughput 
sequencing screening (Dowd, 2008, Price, 2009, Wolcott et al., 2009) have 
demonstrated similar substantially greater diversity in the bacterial communities of 
the wound. Wolcott et al., (2009) identified a total of 62 genera in 40 wounds using 
pyrosequencing. Also, these methods have identified the relative stability of the 
microflora of the uninjured skin microbiome (Grice, 2009). The use of imaging 
techniques have provided insight into the topographical arrangements of bacteria 
within wounds (Bjamsholt et al., 2008, Kirketerp-Moller et al., 2008, Malic et al.,
2009). In almost all studies, be they cultural or molecular, the importance of and 
prevalence of S. aureus in the wound environment has been stressed (Martin et al., 
2009, Siddiqui and Bernstein, 2010, Grice and Segre, 2011, Kong, 2011).
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1.6 Staphylococcus aureus
Staphylococci are Gram and catalase-positive cocci that are frequently 
isolated from skin infections. They are approximately 0.5 to 1.5 pm in diameter and 
form grape-like clusters under light microscopy. They are non-motile and non-spore 
forming facultative bacteria. The genus consists of >30 species with 17 sub-species 
(Bannerman, 2003, Massey et al., 2006), and the genome ranges from 2000 to 3000 
kilobases (kb) in size, and contain a variable number of mobile genetic elements 
(Bannerman, 2003, Witte et al., 2006, Tristan et al., 2007).
S. aureus is the most prevalent member of the staphylococcal family and is 
responsible for a diverse range of human diseases; from minor soft-tissue to life- 
threatening systemic infections (Perera and Hay, 2005, Petkovsek et al., 2009). S. 
aureus is part of the resident flora in the anterior nares of approximately 30% of the 
population, whilst up to 60% of the population show a transient colonization of the 
nares, axilla, perineum or vagina (Breuer et al., 2002, Aires de Sousa and Lencastre, 
2004, Miller and Diep, 2008). Colonisation with S. aureus is increased in 
immunosuppressed individuals (e.g. diabetic and renal patients), disorders of the skin 
and hospitalisation (Breuer et al., 2002, Reich-Schupke et al., 2010, Schechter- 
Perkins et al., 2011). The mode of spread has been demonstrated to follow a regular 
pattern; colonisation, in-particular of the nares, by S. aureus leads to hand carriage 
and from the hands, the organisms frequently spread to other body areas (Tenover 
and Gorwitz, 2006).
Following the introduction of penicillin in the 1940s, the ability of S. aureus 
to resist treatment by the production of penicillinase was evident (Boyle-Vavra and 
Daum, 2007), and in 1959 the first semi-synthetic penicillin, methicillin was 
introduced (now named meticillin) to combat this problem (Livermore, 2000a, 
Zhang et al., 2005). Whilst meticillin and flucloxacillin have been the mainstay of 
treatment for S. aureus infections for the last 50 years, within 2 years of its 
development meticillin resistant S. aureus (MRSA) clinical isolates were observed 
(Shanson, 1981, Ayliffe et al., 1998) and are now a major nosocomial pathogen
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(Oztoprak et al., 2006, Niederman, 2009). The cost of hospital-acquired infection is 
estimated to be £1 billion per year (Plowman et al., 2001) with MRSA accounting 
for 10% of hospital-acquired infections (Higgins et al., 2010)
1.7 Antimicrobial resistance in chronic wound patients
The emergence of antibiotic resistance and multi-drug resistant (MDR) 
organisms as a major world health problem, with its associated morbidity and 
mortality, has been inexorable (Colsky et al., 1998, Gould, 2008, French, 2010, Jean 
and Hsueh, 2011, Lo et al., 2011). Whilst consideration is most commonly given to 
antibiotic prescription, it is important to also recognise that antibiotic resistance may 
be acquired due to community environmental acquisition (Hosein et al., 2002, 
Moellering, 2006). Due to the difficulties in characterising infection (Section 1.5) 
patients with chronic wounds are at increased risk of (often inappropriately) 
receiving antibiotics (Howell-Jones et al., 2005). Price et al., (2009) showed that 
the use of antibiotics in wound patients significantly affected bacterial presence with 
an increase in pseudomonadaceae, corynebacteriaceae and oxalobacteraceae. 
Numerous studies have demonstrated the increased prevalence of antibiotic-resistant 
and MDR organisms within the microflora of chronic wounds (Perera and Hay, 
2005, Stanaway et al., 2007, Jappe et al., 2008). Interestingly, the first two cases of 
vancomycin resistant S. aureus in the US were isolated from chronic wound patients 
(Prevention, 2002a, Prevention, 2002b)
1.7.1 Mechanisms of resistance
Resistance falls into one of three mechanistic classes; firstly, prevention of 
the accumulation of an antimicrobial within the bacterial cells usually by either 
dedicated or general efflux pumps frequently seen with biocide resistance e.g. 
quaternary ammonium compounds (QAC). Secondly, an alteration of the molecular 
target; thirdly, inactivation of the substance (Perera and Hay, 2005). From a genetic 
point of view, resistance is achieved by mutation or acquisition. The most adaptable
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mechanism of antibiotic resistance is by the exchange of genetic material, as 
observed by the acquisition of the staphylococcal cassette chromosome mec in S. 
aureus species. Horizontal transfer of genes by bacteriophage and plasmids is a 
common route for acquisition of antibiotic resistance (Perera and Hay, 2005, Kong, 
2011). The chronic wound environment is conducive to the transfer of genetic 
resistance, due to the diversity of the microflora present and the persistent use of 
antibiotics to which these bacteria are exposed (Colsky et al., 1998)
1.7.2 MRSA resistance
The term MRSA is misleading because these microbes are resistant to a 
number of antibiotics. It is thought that 36% of S. aureus isolates in the UK are 
resistant to meticillin (Woodford and Livermore, 2009). Meticillin resistance is 
associated with the mec A  gene which encodes a 76 kilo Dalton (kDa) low-affinity 
penicillin binding protein (PBP2) named PBP2a, which has a low affinity for all p- 
lactam antibiotics e.g. penicillin. PBP2a is a transpeptidase that is assisted by the 
transglycosidase domain of the native PBP2 of S. aureus and this takes over the 
function of cell wall biosynthesis in the presence of P-lactam antibiotics (Aires de 
Sousa and Lencastre, 2004). The mec A  gene is a 2.1 kb exogenous DNA fragment 
that is carried on the mobile genetic element, the staphylococcal cassette 
chromosome mec (SCCmec), which inserts at site-specific locations on the 
staphylococcal chromosome, and is acquired via horizontal gene transfer (Enright 
and Spratt, 1999, Enright et al., 2000a, Enright et al., 2002, Enright, 2003, Hanssen 
et al., 2004, Enright, 2006, Piette and Verschraegen, 2009). Due to the acquisition of 
plasmids and transposons, MRSA has successfully acquired resistance to multiple 
antibiotics including quinolones, and more recently reports of glycopeptide 
(vancomycin) resistance in Japan, US and Europe (Wootton et al., 2001, 
Strommenger et al., 2006a). Figure 1.2 shows the distribution of MRSA within 
Europe during 2009.
17
Percentage resistance
■■ < 1%
■ I  1 to < 5%
IB  5 to < 10%
B  10 to <25%
B  25 to < 50%
B  > 50%
B  No data reported or less than 10 isolates 
□  Not included v
Liechtenstein
Luxembourg
Malta
'C ) eCOC/Oundn/TeSSy
Figure 1.2 Proportion o f MRSA bacteraemias within Europe in 2009 (reproduced 
with permission from http://ecdc.europa.eu/en/activities/surveillance/EARS- 
Net/database)
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1.7.2.1 Staphylococcal cassette chromosome (SCCmec)
The staphylococcal cassette chromosome (SCC/wec) is a mobile genetic 
element approximately 20-70 kb in size, containing the mec region which encodes 
for meticillin resistance (Zhang et al., 2005). There are 8 types (I to VIII) of 
SCC mec to date (IWG-SCC, 2009, Basset et al., 2010, Ghaznavi-Rad et al., 2010) 
which are further sub-classified, with novel variants found on a frequent basis. 
SCC mec elements typically share four characteristics: firstly, they carry the mec gene 
complex {mec) consisting of the meticillin resistance determinant mecA and its 
regulatory genes and insertion sequences mec\ and mecRI. It is this region where 
antimicrobial resistance determinants associated with transposable elements are 
found; secondly, they carry the cassette chromosome recombinase (ccr) gene 
complex responsible for the mobility of the element; thirdly, present at both ends, is 
a characteristic directly-repeated nucleotide sequence; and finally, all cassettes 
integrate at the same chromosomal site (attBscc) into the 3' end of an open reading 
frame (ORF), orfX(Shore et al., 2005, Kondo et al., 2007).
The mec gene complex, for which 5 have been described, (A to D; C has 2 
sub-divisions) is composed of IS431 mec, mec A and an intact or truncated set of 
regulatory genes mecRl and mecl. The ccr gene complex, five of which have been 
described, consists of the ccr genes ccr A and ccrB in combination {ccr AW) or ccrC 
alone (Shore et al., 2005, IWG-SCC, 2009). The rest of the SCC mec element 
previously described as the junkyard rejoin due to its content of non-essential genes, 
currently referred to as the joining region (J) for which 3 regions have been 
described. The SCCmec type is defined by the mec gene complex, the ccr gene 
complex and the J region. Figure 1.3 shows a schematic diagram of SCC mec (IWG- 
SCC, 2009).
Risk factors for the acquisition of MRSA include: previous hospitalisation, 
intravascular lines, pressure ulcers, underlying disease and recent antibiotics 
(Maslow et al., 1995, Ayliffe et al., 1998). Some recent studies have also shown that 
household pets may be additional reservoirs for community-acquired (CA) MRSA
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Figure 1.3 Schematic diagram of all SCCmec, types I to VIII. (Reproduced with 
permission from International Working Group on the Classification of 
Staphylococcal Cassette Chromosome Elements, 2009).
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(Moellering, 2006). Due to the rise in both CA-MRSA and patient colonisation, 
occasionally requiring hospitalisation, there has been a blurring of the distinction 
between hospital-acquired (HA) MRSA and CA-MRSA, and this represents a major 
problem in infection control. The main circulating epidemic strains in UK hospitals 
are EMRSA-3, EMRSA-15 and EMRSA-16.
1.8 Chronic wounds and MRSA
Patients with skin lesions are particularly susceptible to long-term carriage of 
MRSA as this provides a niche which bacteria can colonise (Reich-Schupke et al.,
2010). As these chronic skin wounds may lead to hospitalisation, they therefore 
expose others who are vulnerable to this pathogen, perpetuating the cross infection 
cycle (Halcon and Milkus, 2004). In a prospective population study of skin and soft 
tissue infections caused by MRSA, 75% of infections were associated with CA- 
MRSA in comparison to only 37% HA-MRSA (Naimi et al., 2003). S. aureus and 
MRSA have been implicated as major colonisers of chronic wounds (Jappe et al.,
2008), with studies implicating nasal carriage as a major route of transmission to the 
wound (Stanaway et al., 2007).
Genetic studies have identified 5 major lineages of MRSA (clonal 
complexes) associated with HA-MRSA. These clonal complexes (CCs) are: CC5, 
CC8, CC22, CC30 and CC45 (Tristan et al., 2007). They have arisen from the 
successful acquisition of the SCC mec element by S. aureus. Clones of these lineages 
are responsible for most of the HA-MRSA globally (Robinson and Enright, 2003, 
Deurenberg and Stobberingh, 2008). Due to the significant increase in CA-MRSA, 
the need to track this pathogen is important in our understanding of its ancestry, 
development and clonal expansion.
1.9 Typing of MRSA
A number of epidemiological typing methods have been used to describe 
MRSA including: antimicrobial susceptibility testing, genomic restriction fragment
2 1
length polymorphism analysis using pulsed-field gel electrophoresis (PFGE), DNA 
hybridisation, phage typing, multilocus enzyme electrophoresis, genotypic and 
sequence-based typing methods. These are used to understand the spread of the 
organism and cross-infection control.
1.9.1 Genetic based typing methods
1.9.1.1 Pulsed field gel electrophoresis (PFGE)
Pulsed Field Gel Electrophoresis was considered the “gold standard” typing 
method for the investigation of outbreaks, until recently. This method is based on 
the distribution of restriction endonuclease cleavage sites on the bacterial genome 
and is reflected by fragment length. Large lengths of uncharacterised DNA are 
resolved by PFGE and agarose gels. Strain differences relate to genetic events e.g. 
point mutations, which change the endonuclease restriction site, i.e. insertions, 
deletions, inversions or transpositions. It is a highly discriminatory method and has 
added to the knowledge of epidemiology of many pathogenic bacteria in nosocomial 
outbreak settings e.g. MRSA, vancomycin resistant enterococci (VRE) and E. coli. 
Such fragment pattern changes appear to accumulate rapidly, which is important in 
the epidemiology of bacterial studies during outbreaks (Enright and Spratt, 1999, 
Enright et al., 2000b). This rapid variation in fragment patterns within the same 
clone however, makes it difficult to determine (with 100% accuracy) ancestral 
lineage using this method (Enright et al., 2000a, Enright et al., 2000b). PFGE has 
excellent discriminatory power; however it is a difficult method to standardise 
between laboratories (Shopsin et al., 1999).
1.9.1.2 Random amplified polymorphic DNA (RAPD)
Random amplified polymorphic DNA is a PCR based method for the typing 
of MRSA and other bacteria. RAPD utilises single, short primers of arbitrarily 
chosen (8-10) nucleotide sequences which are employed in comparatively low 
annealing temperature PCRs, and allow random amplification of the genomic DNA.
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These primers recognise sequences only partly complementary or homologous to 
them. The products are separated on agarose gels producing a fingerprint for the 
strain in question, which can be compared with others to identify polymorphisms. 
This method has been used to study the diversity of plant, animal and bacterial 
species, and requires no previous information of the genomic structure. This method 
shows similar disadvantages to PFGE in terms of inter-laboratory and strain 
variability (Witte et al., 2006).
1.9.1.3 Multilocus sequence typing (MLST)
MLST, is based on nucleotide sequencing and is believed to represent the 
“gold standard” for MRSA typing (Urwin and Maiden, 2003) allowing unambiguous 
characterisation of bacterial strains via the existing databases (Enright and Spratt, 
1999). Enright was the first to describe the use of MLST in the typing of MRSA 
(Enright and Spratt, 1999). This method compares internal fragment size (402 -  516 
bp) of 7 housekeeping genes (Enright et al., 2002) avoiding parts of the genome that 
are rapidly evolving due to strong selective pressures, e.g. antibiotic and 
immunological factors (Urwin and Maiden, 2003) and thus are stable over time. The 
genes used are: carbamate kinase (arcC), shikimate dehydrogenase (aroE), glycerol 
kinase (glp), guanylate kinase (gmk), phosphatase acetyltransferase (pta), 
triphosphate isomerase (tpi), and acetyl coenzyme A acetyltransferase iyqil), which 
are highly conserved (Urwin and Maiden, 2003). Each fragment of the 7 
housekeeping gene sequences are assigned a distinct allele number and each isolate 
is defined by the alleles at each of the seven housekeeping loci i.e. the allelic profile. 
This corresponds to a sequence type (ST), enabling the researcher to distinguish 
between billions of different allelic profiles (Enright et al., 2000a). Accumulation of 
nucleotide changes is relatively slow and the allelic profile is sufficiently stable over 
time for the method to be ideal for global epidemiological purpose (Enright et al., 
2000a). MLST therefore allows international comparison of isolates, whilst 
recording the emergence of antibiotic-resistant bacteria.
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1.9.1.4 Staphylococcal cassette chromosome mec (SCCmec) typing
The acquisition of meticillin resistance by S. aureus is via the transfer of the 
mobile genetic element the staphylococcal cassette chromosome (SCC) which 
carries the resistance gene mecA (Katayama et al., 2000). The SCC mec is typed via 
multiplex PCR technology by defining the mec gene complex, the cassette 
chromosome recombinase {ccr) gene complex, and in the case of a class IV 
SCCmec, the joining region (Chapter 1, Section 1.7.2.1; Kondo et al., 2007, IWG- 
SCC, 2009). Long-term epidemiological studies of MRSA and its evolution have 
shown that complete characterisation of MRSA lineage requires identification of the 
core mecA gene.
The proposed nomenclature is that MLST is reported with the SCCmec type 
(Urwin and Maiden, 2003). Epidemiological studies have shown that CA-MRSA 
contain SCC mec IV and V, whilst HA-MRSA strains tend to harbour the larger 
SCCmec elements I, II, III (Zhang et al., 2005). The typing of the SCCmec has 
increased the precision of strain typing and epidemiological evolution (Ito and 
Hiramatsu, 1998).
Combination of MLST and SCC mec in the study of MRSA has provided 
three important insights. Firstly, meticillin resistance has emerged in multiple 
phylogenetically distinct lineages. Secondly, meticillin resistance has emerged on 
multiple occasions within a given phylogenetic lineage; and finally, MRSA disease 
is caused by a relatively small number of pandemic clones (Robinson and Enright, 
2003).
1.9.1.5 Staphylococcal protein A (spa) typing
Further sequence-based methods have now been developed. Staphylococcal 
protein A (spa) typing is based on the polymorphic region of the protein A gene 
which consists of direct repeats (Malachowa et al., 2005, Strommenger et al., 
2006b). This is of particular interest in the hospital setting because it is a rapid
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method and offers high isolate resolution (Shopsin et al., 2000, Harmsen et al.,
2003).
1.10 Microbial virulence
A virulence factor can be defined as a substance, which when purified and 
introduced into a host, produces a pathogenic reaction (Projan and Novick, 1997). 
Bacterial-host interactions depend on several factors, including the efficiency of the 
host defense mechanism, bacterial growth rate, and production of virulence factors. 
Analysis of virulence genes, either by allelic replacement, insertion or inactivation of 
particular genes, has given some evidence to the role of virulence factors in disease.
It has been postulated that successful MRSA clones have acquired virulence 
factors to compensate for the loss of fitness associated with antibiotic resistance 
(Tristan et al., 2007). Such virulence factors produced by the bacteria can be cell- 
associated or extracellular and contribute to the evasion of the host defence system. 
These virulence factors enable the organism to attack the local cellular and structural 
elements of diverse tissues and organs, while the surface components enable the 
bacteria to adhere to the tissue components to resist phagocytosis and other host 
defences. Bacteria regulate their virulence factors so that they are used only at a 
time and stage appropriate to their disease progression e.g. once the infection has 
become systemic, there is a down-regulation of factors required to adhere and 
colonise the host tissues (Camara et al., 2002).
1.11 Quorum sensing and the accessory gene regulator (agr)
The expression of virulence factors and indeed biofilm phenotypic changes 
are globally regulated via quorum sensing. This complex regulatory network is 
arranged around a two component regulatory system, one of which is the accessory 
gene regulator locus (agr). Via the production of an auto-inducing peptide 
pheromone, quorum sensing interacts with the agr to sense cell density and allows 
for cell-to-cell interactions to aid bacterial infiltration of the host and development of
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communities (Novick and Muir, 1999, Camara et al., 2002, Siddiqui and Bernstein,
2010) The agr system coordinates the production of virulence factors during the 
different phases of the cell cycle, e.g. it down-regulates the production of cell-wall 
associated proteins and up-regulates secreted proteins at late to stationary growth 
phase in vitro (Ji et al., 1995, Mullarky et al., 2001, Camara et al., 2002, Bjamsholt 
et al., 2008). This density-dependant regulation of virulence factors becomes 
particularly important in biofilm formation (Iwatsuki et al., 2006).
1.11.1 Accessory gene regulator (agr) specificity
The accessory gene regulator has been shown to regulate the synthesis of 
many virulence factors during bacterial growth (Mullarky et al., 2001). The agr is 
conserved throughout the staphylococcal family. There are 4 (I-IV) specific agr 
groups in S. aureus. Mutual inhibition exists between separate agr groups where the 
agrD-derived peptide pheromone from strains of one group can cross-activate an agr 
of the same group to produce a response e.g. an up-regulation of virulence factors in 
other strains of the same group. It can also inhibit the agr of members of other 
groups (Camara et al., 2002). Many studies have identified this as a potential for 
new anti-infective therapy (Finch et al., 1998, Hentzer and Givskov, 2003, 
Rasmussen and Givskov, 2006, Clatworthy et al., 2007, Raina et al., 2009).
The agr type has been linked with disease processes e.g. toxic shock 
syndrome (TSS) and CA-MRSA have been linked with agr III, and staphylococcal 
scalded skin syndrome (SSSS) has been linked with agr IV, whilst enterotoxin 
mediated disease with agr I and II (Ji et al., 1995, Jarraud et al., 2000, Jarraud et al., 
2002, Vandenesch et al., 2003, Robinson et al., 2005). agr type has also been linked 
to the severity of disease; agr I has been associated with invasive infections such as 
bacteraemia and agr III associated with non-invasive infections (Ben Ayed et al., 
2006).
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1.12 Virulence factors
Sotto et al., (2008) looked at the virulence potential of S. aureus in DFU. 
They found that the presence of 5 virulence genes (cap%, sea, sei, lukE and hlgv) 
could distinguish between non-infected and infected wounds and also predict healing 
outcome. The Health Protection Agency (HPA) frequently examines the toxin genes 
present in referred staphylococci associated with disease.
1.12.1 Pyrogenic toxin superantigens
Pyrogenic toxin superantigens classically include the staphylococcal 
enterotoxin type A to E and toxic shock syndrome toxin-1 (TSST-1). Most are 
regulated by the agr and staphylococcal accessory regulator (sar) loci. Depending 
on the toxin, the gene may be harboured on a mobile genetic element such as a 
plasmid, or bacteriophage, or on pathogenicity islands. Toxic shock syndrome 
(TSS) is an acute illness, and the patient classically presents with hypotension, fever, 
rash and desquamation of hands and feet during convalescence, with the involvement 
of at least three organ systems and may be categorised as menstrual or non-menstrual 
(Bohach, 2006). S. aureus is known to elicit a host immune response via pathogen 
associated molecular patterns (PAMPs) e.g. lipoteichoic acid (LTA) and capsular 
polysaccharide both induce the production of IL-8 by Mo, and endothelial cells 
(DeLeo et al., 2009). The production of this chemokine allows the transmigration of 
neutrophils to the site of infection. Virulence factors e.g. TSST-1, enterotoxin A 
(SEA) and enterotoxin B (SEB) can also elicit an IL-8 response. Superantigens 
interact with the immune system to cause polyclonal proliferation of T-cells and bind 
specifically to the major histocompatibility complex (MHC) class II, which results in 
the deletion of p-expressing T-cells. It has been proposed that S. aureus benefits 
from the immunosuppression induced by pyrogenic toxin superantigens (Bohach, 
2006).
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1.12.2 Exfoliative (epidermolytic) toxins
Exfoliative toxins have been conclusively implicated in SSSS, which is 
characterised by the formation of bullae or skin blisters. The lesions are 
characterised by the separation of the stratum granulosum cells, causing intradermal 
skin peeling leading to desmosome degeneration. The structural gene eta, 
responsible for the expression of this virulence factor, is generally located on the 
chromosome and is sometimes harboured on a phage, while etb and etd are located 
on plasmids and pathogenicity islands (Bohach, 2006); all of which are associated 
with severe skin reactions.
1.12.3 Leucotoxins
Leucotoxins are a family of toxins encoded by several genetic loci, and are 
able to cause cellular lysis of host leucocytes and erythrocytes. Staphylococci have 
many leucotoxins e.g. y-haemolysin and Panton-Valentine leucocidin (PVL). They 
contain two synergistically active proteins: one S component and one F component, 
designated according to their mobility in ion exchange chromatography as “slow” or 
“fast”. Synergistic functions involve sequential binding of the F and S components.
1.12.3.1 Panton-Valentine leucocidin (PVL)
PVL is a pore-forming cytotoxin that targets human and rabbit mononuclear 
and polymorphonuclear cells (Holmes et al., 2005). When injected intradermally 
into rabbits, PVL induces severe inflammatory lesions, leading to capillary dilation, 
chemotaxis, polymorphonuclear karyorrhexis and skin necrosis (Holmes et al.,
2005). Exposure of neutrophils to PVL in vitro leads to swelling and rounding of the 
cells and their nuclei, followed by degranulation and nuclear rupture, leading to cell 
lysis. It is thought to be linked to specific human S. aureus infections such as 
primary skin and soft tissue disease and severe necrotising pneumonia, where the 
mortality rate is about 75% (Holmes et al., 2005, Health Protection Agency et al., 
2006a Tristan et al., 2007, Ellington et al., 2009). Dufour et al., (2002) and Van der
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Mee-Marquet et al., (2004) found that PVL producing S. aureus strains could also 
cause chronic cutaneous infections.
PVL is coded by lukS-PV and lukF-PV genes, previously used as a marker of 
CA-MRSA (Vandenesch et al., 2003, Holmes et al., 2005) and was associated with 
disease in healthy individuals. PVL has been reported to be produced by 2-15% of 
all S. aureus (Lina et al., 1999, Holmes et al., 2005, Wannet et al., 2005, Ellington et 
al., 2007), although this low number may be a function of under-reporting. The 
significance of PVL has been investigated in the clinical setting following outbreaks 
of skin and soft tissue infection and clusters of death from necrotising pneumonia in 
atypical patients. Often the presence of the PVL gene (lukF-PV & lukS-PV) has 
been investigated by routine testing in combination with superantigen toxins by 
PCR. Many researchers have used PCR to investigate disease processes associated 
with PVL-negative and PVL-positive strains, whilst others have purified this protein 
and introduced it to animal models to investigate its potency with conflicting results 
(Voyich et al., 2006, Dumitrescu et al., 2007, Ellington et al., 2007, Labandeira-Rey 
et al., 2007).
1.12.3.2 Gamma haemolysin (hlg)
y-haemolysin is thought to be produced by >99% of staphylococci. The 
composition and activity of Hlg is associated with 3 proteins. HlgA and HlgC 
belong to the S class and HlgB belongs to the F class, thus forming two pairs of units 
(Prevost et al., 1995a, Prevost et al., 1995b, Lina et al., 1999). Animal studies 
(rabbits), have shown that Hlg is inflammatory but not necrotic (Konig et al., 1995, 
Konig et al., 1997) and that a- and p-haemolysins are able to induce caspase-1 
(Munoz-Planillo et al., 2009).
1.12.4 Extracellular enzymes
S. aureus produces a large number of extracellular enzymes which may be 
important virulence factors. They can degrade organic macromolecular tissue
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constituents to promote the spread of the bacterium in host tissues e.g. hyaluronate 
lyase and lipases, which break down hyaluronic acid and fatty tissue respectively 
(Arvidson, 2006).
1.12.4.1 Glycerol ester hydrolase (geh)
Many lipases suppress immune function (Lee and Iandolo, 1986, Rollof et 
al., 1988, Izdebska-Szymona et al., 1992, Rollof et al., 1992, Staffan, 2006). 
Staphylococcal lipase with fatty acid modifying enzyme (FAME) is able to interact 
with bactericidal lipids to enhance survival within an abscess (Kapral et al., 1992, 
Lowe et al., 1998). Previously, lipase activity has been tested in mouse models with 
abscess formation and chromogenic plate assays (Burlak et al., 2007, Gould et al.,
2009). Currently, lipase producing S. aureus strains are strongly linked to invasive 
disease and phagocytosis interference (Rollof et al., 1992, Rosenstein and Gotz, 
2000).
1.12.4.2 Hyaluronate lyase (hysA)
Linker et al., (1956) postulated that hyaluronate lyase from S. aureus worked 
by (3-elimination of the uronic acid unit within hyaluronic acid, and is thought to be 
present in >90% of S. aureus (Choudhuri and Chakrabarty, 1969). Murine models 
have shown that wild-type S. aureus with hysA were able to affect wound healing 
and associated subcutaneous infections when compared with -negative strains 
(Makris et al., 2004).
1.12.5 Attachment and collagen binding protein (cna)
In a study by Holderbaum et al., (1987) only 43% of clinical S. aureus 
isolates were able to bind collagen, and it was concluded that cna was not a 
constitutive element for all S. aureus strains. They postulated that strains able to 
bind collagen were more likely to be adherent in tissue beds and associated with 
invasive disease, than those with uncomplicated bacteraemia (without other
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infections). A study by Xu et al., (2004) observed that S. aureus with a higher 
affinity for collagen possessed a greater virulence potential. However, expression of 
cna was not enough to produce pathogenic staphylococci sp. in a septic arthritis 
model.
1.13 The immune system
The immune system is crucial to the survival of man, and is essential in 
protection against invading organisms and tumour cells. The innate immune system 
represents the “first line” of defence, with the adaptive immune system providing 
specific cytotoxicity and immunological memory to the immune system (Lien and 
Ingalls, 2002, Fournier and Philpott, 2005).
1.13.1 The innate immune system
The innate immune response forms the early host response to infection which 
is present in all individuals (Lien et al., 1999, Fournier and Philpott, 2005, 
Thorgersen et al., 2009). The cells involved instigate the removal of bacteria and 
modulate the adaptive immune responses (Lien et al., 1999, Miyake, 2003). The 
major cellular components of the innate immune system are the PMNL, Mo and 
dendritic cells (DC). These cells are able to identify microbes via pathogen 
associated molecular patterns (PAMP) and host damage via damage associated 
molecular patterns (DAMP) by pattern recognition receptors (PRR), the most 
extensively studied of these being the Toll-like receptors (TLR).
1.13.1.1 Toll-like receptors
TLR were originally identified in Drosophila associated with the 
dorsoventral pattern in developing embryos of fruit flies (Takeda and Akira, 2004, 
Mollen et al., 2006). Since their discovery it has been found that these receptors 
form an essential part of the mammalian immune system. Flies with mutated Toll- 
receptors have been found to be more susceptible to infections from fungi and
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bacteria (Lemaitre et al., 1996, Lien and Ingalls, 2002, Fournier and Philpott, 2005). 
TLR are expressed on immunocompetent cells such as PMNL, Mo, M0, microglia, 
DC, B-cells, T-cells, natural killer (NK)-cells, mast cells, astrocytes, epithelial cells 
and a number of endothelial cells (Homef et al., 2002, Zhang and Schluesener, 2006, 
Morris et al., 2009, Pukstad et al., 2010). TLRs are able to identify bacteria, virus, 
fungi and protozoa and to date, 13 mammalian TLRs have been identified, of which 
10 have been reported active in humans (Table 1.2; Konat et al., 2006, Etokebe et al., 
2010, Pukstad et al., 2010, Yamamoto and Takeda, 2010). Dendritic cells and Mo 
express the greatest number of TLR (Baiyee et al., 2006). Ligand recognition via 
TLR at sites of skin wounding stimulates the release of cytokines and pro- 
inflammatory cytokines, as a result of nuclear factor kB (NF-kB) translocation to the 
nucleus. This signalling pathway is a complex concert of adapter molecules which 
activate NF-kB. Figure 1.4 is a schematic diagram of TLR signalling pathways.
1.13.2 The role of the immune system in wound healing
Following wounding there is an up-regulation of pro-inflammatory cytokines 
and chemokines to activate the resident population of inflammatory cells and 
stimulate recruitment of inflammatory cells from the circulatory system via the up- 
regulation of adhesion molecules such as integrins and selectins (Jones et al., 2004). 
The importance of the immune system in mediating response to injury is evident in 
experimentally (chemical) immunosuppressed animals and knock-out studies 
(Grabig et al., 2006, Mirza et al., 2009, Ueda et al., 2010). Significantly, it is also 
evident in the context of chronic wounds in diabetic animals and patients (Jiwa, 
1997, Currie et al., 1998, Harding et al., 2002, Oncul et al., 2007).
PMNL and Mo migrate into the wound; effecting the removal of invading 
pathogens and damaged ECM via phagocytosis following TLR recognition (Chapter 
4). The subsequent release of cytokines stimulates cellular migration of resident 
fibroblasts and keratinocytes to repair the wound and close any breach in the surface 
barrier, which intact normal skin represents (Rodero and Khosrotehrani, 2010).
32
Table 1.2 Human Toll- like receptors (TLR)
TLR Cellularcompartment Identify Ligand
Heterodimer
formation
TLR1 Extracellular Borreliaburgdorferi
Pani3CysSK4 
Protein A TLR2
TLR2 Extracellular Gram positive 
bacteria
Fungi
Neisseria
Spirochetes
LTA
PGN
Lipoprotein
Zymosan
Lipoarabinomannan
Porins
Glycolipids
TLR6 Extracellular Mycobacterium LTA
Lipopeptide
TLR2
TLR3 Intracellular Virus dsRNA
TLR4 Extracellular Gram negative 
bacteria
Host cell
Gram positive 
bacteria
LPS
HA 
Fibrinogen 
Fibronectin 
Heparan sulfate
Lipoteichoic acids
TLR5 Extracellular Bacteria Flagellin
TLR7 Intracellular Virus ssRNA
TLR8 Intracellular Virus G-rich
oligonucleotides
TLR9 Intracellular Unmethylated 
bacterial DNA
CpG
TLR10 Extracellular Unknown Unknown TLR1 & 
TLR2
CpG, deoxycytidyl-deoxyguanosine; dsRNA, double stranded ribonucleic acid; HA, 
hyaluronic acid; LPS, lipopolysaccharide; LTA, lipoteichoic acid; Pani3CysSK4; N- 
palmitoyl-S-dipalmitoylglyceryl-Cys-Ser-Lys; PGN, peptidoglycan; ssRNA, single 
stranded ribonucleic acid; TLR, toll-like receptor.
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Figure 1.4 TLR signalling pathway and downstream mediators.
dsDNA, double stranded deoxyribonucleic acid; dsRNA, double stranded ribonucleic 
acid; IkB, inhibitor o f nuclear factor kappa B; IKK, IicBa kinase complex; IRAK, 
interleukin-1 receptor associated kinase; IRF, interferon (INF) regulatory factor; LPS, 
lipopolysaccharide; MAP, mitogen activating protein; MyD88, myeloid differentiation 
factor 88; NEMO, NF-kB essential modulator (or IKKy); NF-kB, nuclear factor -  kappa 
B; RIP, receptor interacting protein; ssRNA, single stranded ribonucleic acid; TAK, 
TGF p- activated kinase; TANK, TRAF family member associated NF-kB activator; 
TBK, TANK binding kinase; TIR, toll-IL-1 receptor; TIRAP, TIR domain-containing 
adaptor molecule; TLR, toll-like receptor; TRAF, tumour necrosis factor receptor 
(TNFR) associated factor; TRAM, TRIF-related adapter molecule; TRIF, TIR-domain- 
containing adapter-inducing interferon-p. (Reproduced with permission Zhu and Mohan, 
2010).
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The removal of antigenic stimuli by these processes result in resolution of the acute 
immune response and the wound is healed. These processes are disordered in 
chronic wounds (Falanga, 2005, Kirketerp-Moller et al., 2008, Mirza et al., 2009).
Chronic wounds are characterised by the protracted elevation of chronic 
inflammatory cells from Mo and lymphocyte lineages, the wounds being “arrested” 
in the inflammatory phase of the healing cycle (Schultz et al., 2003, Kirketerp- 
Moller et al., 2008, Pukstad et al., 2010). The continuing influx of inflammatory 
cells and their potent inflammatory mediators e.g. matrix metalloproteinases 
(MMPs), cytokines/chemokines and free-oxygen radicals play a significant role in 
mediating further tissue damage and immune responses in a negative-feedback loop. 
A further example is the generation of low molecular weight (mw) ECM degradation 
products perpetuate immune response (Termeer et al., 2000, Taylor et al., 2004). 
The important role of the immune system in impaired healing has been highlighted 
in a recent study by Pukstad et al., (2010) using wound fluid from chronic and acute 
wounds. The authors observed that alterations in wound cytokine profiles (e.g. IL-8, 
IL-la, IL-lp, TNFa) were related to healing and wound chronicity. Moreover, these 
authors demonstrated that healing correlated with a decreased TLR-stimulating 
ability of the wound fluid, suggesting a microbial role.
1.14 Biofilms and chronic wounds
Whilst studies of wound bacteria and their activity and response to treatment 
have been carried out in planktonic systems, increasingly attention has been directed 
to the bacterial biofilm of the chronic wound (Mertz, 2003, Davis et al., 2008, 
Charles et al., 2009). Biofilms have been described as ‘a microbially-derived sessile 
community characterised by cells that are irreversibly attached to a substratum or 
interface or to each other, are embedded in a matrix o f extracellular polymeric 
substances that they have produced, and exhibit an altered phenotype with respect to 
growth rate and gene transcription’ (Donlan and Costerton, 2002).
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Biofilms have been estimated to be associated with 65% of nosocomial 
infections (Percival and Bowler, 2004), and are associated with many chronic 
disease processes e.g. dental caries, cystic fibrosis, periodontal disease and urinary 
tract infections (Davis et al., 2008, Burmolle et al., 2010). Many of the chronic 
wound bacteria produce biofilms, including S. aureus (Evans et al., 1998, Elasri et 
al., 2002, Gilbert et al., 2002, Kropec et al., 2005, Toledo-Arana et al., 2005, Davis 
et al., 2008, Percival et al., 2008, Hill et al., 2010, Percival et al., 2011a). Clear 
evidence for the presence of biofilms in chronic wounds has been established. 
Confocal laser scanning microscopy (CLSM) of wound biopsies {in vivo) and 
reconstituted human epidermis (RHE) models have observed the presence of bacteria 
and biofilms (Bjamsholt et al., 2008, Malic et al., 2009). James et al., (2008) 
suggested that polymicrobial biofilm formation was more evident in chronic rather 
than acute wounds. The exact role that the biofilm itself plays in wound healing has 
yet to be elucidated.
A number of methods have been employed to study the ability of S. aureus to 
form a biofilm. These have included PCR-based methods for the identification of 
the ica operon, as well as more qualitative methods such as tube-based assays, tissue 
culture plate assays, and the use of Congo red agar (Knobloch et al., 2002). Many of 
these tests have resulted in conflicting results in vitro and thus it has been suggested 
that the expression of ica is environmentally regulated (Knobloch et al., 2002, 
Beenken et al., 2004, Cafiso et al., 2007, O'Neill et al., 2007), with laboratory 
manipulation of media having a significant impact (Fitzpatrick et al., 2005, O'Neill et 
al., 2007). Within S. aureus, the conserved ica operon is responsible for the 
production of polysaccharide intercellular adhesion (PIA), which is important in the 
formation of a biofilm (Cramton et al., 1999, Cafiso et al., 2004, Fluckiger et al., 
2005). Moreover, studies have shown that S. aureus isolates associated with clinical 
infection, such as prosthetic joint infections, bacteraemia and catheter-related disease 
showed the presence of the ica locus (Cramton et al., 1999, Arciola et al., 2001,
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Fowler et al., 2001, Knobloch et al., 2002, Martin-Lopez et al., 2002, Fluckiger et 
al., 2005).
1.15 Bacterial evasion of the immune system
In parallel with the possession of antibiotic resistance, the acquisition of 
specific immune evasion tactics allow these wound bacteria to subvert the host 
immune response (Rooijakkers et al., 2005). The immune system not only 
comprises physical barriers to the entrance of bacteria, and cells to remove invading 
pathogens, but is complemented by host production of many molecules e.g. soluble 
opsonising factors, antibodies and antimicrobial peptides. Bacteria have overcome 
many of these soluble molecules by the production of degradative peptides (Chapter 
3 & 4). Bacteria are also able to avoid phagocytosis by the production of capsules 
and toxins which can cause host cell lysis (Homef et al., 2002).
An interesting method by which bacteria evade recognition is by steric 
alterations in PAMPs, e.g. Salmonella lipopolysaccharide (LPS) and Yersinia pest is, 
which has a tetra-acetylated LPS that does not activate TLR4 (Homef et al., 2002, 
Comer et al., 2010). Y. pestis has an ability to delay/suppress the immune system, as 
indicated by the moderate collection of PMNL following infection, whilst TNFa and 
y-interferon (IFNy) are found only in the advanced stages of infection (Comer et al., 
2010). The ability of S. aureus to become internalised via fibronectin bridges and to 
replicate intracellularly, can lead to cellular apoptosis or chronic infection, which 
again is a mechanism for protection from the immune system and antimicrobial 
therapy (Jevon et al., 1999, Kahl et al., 2000, Foster, 2005, Keiji et al., 2006). The 
ability of S. aureus to colonise skin and the anterior nares reflects its relative 
resistance to lysozyme, which is secreted to control colonisation (Bera et al., 2005, 
Foster, 2005, Fournier and Philpott, 2005, Herbert et al., 2007). Fibrinogen-binding 
protein, found on the surface of many S. aureus and the production of staphylococcal 
complement inhibitor (SCIN) can lead to the prevention of complement factor C3 
deposition by blocking C3 convertase complexes (C4bC2a; classic/lectin pathway,
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C3bBb; alternate pathway). This can result in decreased phagocytosis and inhibition 
of the complement cascade (Lee et al., 2004, Foster, 2005, van Belkum, 2006, Nizet,
2007). S. aureus is also able to cleave immunoglobulins IgG, IgM and IgA by the 
action of serine proteases, thus escaping opsonization and clearance via 
phagocytosis.
Biofilms are associated with persistent infections and delayed wound healing 
(Mah and O'Toole, 2001, Percival et al., 2008, Martin et al., 2009). There are a 
number of human diseases associated with chronic bacterial colonisation in which 
the biofilm state is believed to resist the action of the immune system and contribute 
to the chronicity of the disease e.g. chronic leg ulcers, periodontal disease, cystic 
fibrosis (Mori et al., 2003, Davis et al., 2008, Burmolle et al., 2010). The physical 
biofilm phenotype allows colonising bacteria to protect themselves from 
antimicrobial agents and host responses by providing protection against 
phagocytosis, complement and free-oxygen radicals (Johnson et al., 1986, Davis et 
al., 2008, Percival et al., 2008, Martin et al., 2009). Moreover, the secretion of 
various virulence factors by pathogens within biofilms e.g. leucocidins and proteases 
may induce apoptosis of host immunological effector cells (Kahl et al., 2000, Homef 
et al., 2002, Kirketerp-Moller et al., 2008, DeLeo et al., 2009, Comer et al., 2010).
1.16 Biocides and chronic wounds
Biocides can be broadly described as “chemical agents that inactivate 
microorganisms” (McDonnell and Russell, 1999). Due to the increasing incidence 
of antimicrobial resistance, the use of biocides to control bacterial colonisation 
within the chronic wound bed is gradually being more advocated (O'Meara et al., 
2010). In particular, the potential for biocides to treat the biofilms present within 
wounds has attracted special attention. Biocides used in chronic wounds have been 
employed in many forms e.g. iodine compounds, silver compounds, chlorhexidine, 
potassium permanganate, hydrogen peroxide, honey and benzalkonium chloride 
(Fonder et al., 2008, Atiyeh et al., 2009, BNF, 2010). Hill et al., (2010)
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demonstrated the efficacious ability of iodine over that of silver with mature 
biofilms. In contrast to antibiotics, biocides have many modes of activation and 
target a number of bacterial structures (Figure 1.5).
1.16.1 Biocide resistance
Concerns have been raised regarding biocide resistance or tolerance in recent 
years. Bacteria are able to use intrinsic resistance mechanisms such as alterations in 
cell wall thickness, efflux-pump systems, alterations in surface porins, biofilm 
production and hydrophobicity to decrease their sensitivity to biocides (McDonnell 
and Russell, 1999, Russell, 2001, Russell, 2003, Maillard, 2007). Moreover, the 
effectiveness of biocides may be reduced in the proteinaceous wound environment 
(Russell, 1995, McDonnell and Russell, 1999, Khan and Naqvi, 2006, Narui et al.,
2007). Specific acquired resistances have also been identified, and the acquisition of 
these via genetic mutations or transfer of plasmids and transposons has been 
previously studied e.g. quaternary ammonium compound (QAC) resistance genes 
(qacABCD), silver-resistance genes {silE, silS, and silP) and the biocide resistance 
gene sepA found in S. aureus (McDonnell and Russell, 1999, Russell, 2001, Drosou 
et al., 2003, Russell, 2003, Maillard, 2007, Narui et al., 2007, Loh et al., 2009). 
Biofilms play a significant role in resistance to biocide treatments (Hill et al., 2010); 
the biofilm itself poses a diffusion barrier to the actions of biocides and 
antimicrobials and also the ionic charge of the biofilm may be significant to the 
entrance of biocides (Percival et al., 2011a). Coupling the effects of decreased 
uptake of the antimicrobial into the biofilm is the likely reduced bacterial growth rate 
and metabolic activity, leading to suboptimal biocide activities (Cloete, 2003, 
Buckingham-Meyer et al., 2007, Hoiby et al., 2010).
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1.16.2 Biocides used in chronic wound treatments
Povidone-iodine (PVP-I) is now routinely used in surgical scrubs, ointments 
and dressings (Drosou et al., 2003, Cooper, 2004). Recent formulations include 
cadexomer iodine; a controlled-release system. Many studies have shown the 
efficacy of PVP-I to decrease bacterial load and its rapidity of action (Berkelman et 
al., 1982, McLure and Gordon, 1992, Brown et al., 1995, Khan and Naqvi, 2006, 
Durani and Leaper, 2008). A systematic review by Vermeulen et al., (2010) showed 
that iodine did not have deleterious effects on wound healing and was as effective as 
other biocide agents, although inferior to topical antibiotics. The exact mode of 
action of iodine is unknown, but it is thought to affect protein structure, amino acids 
and to react with nucleotides (Cooper, 2004). The bactericidal effect of iodine is 
dependent on the concentration of PVP-I, as this affects the free iodine available in 
the wound. The concentration of free iodine follows a bell shaped curve starting 
from a 10% solution and increases reaching a maximum value at 0.1% strength 
solution and then decreases with further dilution (Berkelman et al., 1982, Durani and 
Leaper, 2008). The development of resistance to iodine is rare, as this requires the 
alteration of cellular proteins (Khan and Naqvi, 2006, Durani and Leaper, 2008). 
Whilst PVP-I is sensitive to organic matter, it is still able to reduce bacterial numbers 
in a wound (Lawrence, 1998).
The use of silver in wounds has been well documented; specifically in bums 
(Drosou et al., 2003, Cooper, 2004). Silver sulfadiazine and silver nitrate were 
amongst the more common applications although, because of skin discolouration and 
the advent of dressings containing nanocrystalline silver, there has been a decline in 
their use (Leaper, 2006, Walker et al., 2006). Ionic silver binds to negatively 
charged proteins and nucleic acids, thus affecting the viability of the cell. The effects 
are dependent upon the physical structure of the silver nano-particles used, reflecting 
differences in cellular uptake (Ruparelia et al., 2008). Silver ions are thought to 
interact with thiol-groups, carboxylates, phosphates, hydroxyls and amines (Feng et 
al., 2000, Cooper, 2004, Woo et al., 2008). Although silver exerts a broad-spectrum
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antimicrobial effect, resistance is sporadic and rare. Silver resistance is linked to 
mobile genetic elements such as plasmids, which also confer resistance to other 
heavy metals. Resistance to silver was first reported in Salmonella sp. in the mid 70s 
(Gupta et al., 1999). Interestingly, silE was the only gene of three possible silver 
resistance genes found in an MRSA study, although this did not confer in vitro 
resistance to silver (Loh et al., 2009).
1.17 Aims
It is well documented that MRSA and S. aureus are present in chronic 
wounds, however, their role and relationship within the non-healing of these wounds 
or most effective treatment has yet to be determined. MRSA is classically a MDR 
bacterium, thus, it is difficult to treat without the use of potent systemic antibiotics, 
which poses inherent risks to the patient. Chronic wound treatment practices are not 
consistent with many being ineffective. Biocides are frequently employed as a 
treatment modality, yet there is little evidence of their benefit in the treatment of 
chronic wound MRSA. The aims of this study are to further our understanding of 
the interaction between MRSA and the resident host cell populations in the 
pathogenesis of non-healing chronic skin wounds by the study of produced virulence 
factors. These studies also aim to further our understanding of the role of MRSA 
and S. aureus in the chronicity of non-healing skin wounds and to examine their 
interaction with host-mediated immunological responses and their resistance to 
treatment by the study of frequently prescribed antibiotics and biocides. To this end, 
this study is expected to answer; if MRSA is present in a wound, what is its role; is it 
associated with the non-healing phenotype and what is the best treatment choice?
The specific aims of this study are to:
1. Investigate bacterial resistance and genetic diversity of chronic wound
MRSA isolates using cultural and molecular techniques.
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2. Investigate the effectiveness (at a cellular and structural level) of 
conventional biocide treatments against chronic wound bacteria.
3. Characterise, at a molecular level, the expression of virulence factors by 
chronic wound MRSA isolates in comparison to MRSA isolates colonising 
healthy individuals.
4. Investigate the interaction between wound MRSA isolates and other 
frequently identified colonisers from chronic non-healing wounds and the 
host resident immunological cells by characterising the effect of bacteria and 
their metabolites on Toll-Like Receptors (TLRs) and keratinocyte function in 
a series of cellular and immunological assays.
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Chapter 2: 
Characterisation of the antibiotic 
resistance profiles of chronic 
wound staphylococci and biocide 
efficacy on chronic wound MRSA
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2.1 Introduction
2.1.1 Chronic wounds
Chronic wounds are wounds which fail to heal within the normal time frame. 
They involve a complex relationship between bacteria, host immune response and 
underlying co-morbidities (Pukstad et al., 2010, Percival et al., 2011a). They 
encompass a spectrum of diseases which are typically classified as pressure, venous 
and diabetic ulcers (Fonder et al., 2008), and arise as a result of a breakdown in the 
normal healing processes (Bjamsholt et al., 2008).
Chronic wounds are classically known to be polymicrobial in nature, with 
colonisation arising from external environments, or local reservoirs such as 
surrounding skin, the gastro-intestinal tract and oral mucosa (Bowler, 2003). The 
role of micro-organisms in non-healing wounds has been extensively studied. 
However, due to variation in study approach e.g. microbial collection, culture and 
identification technique and patient demographics, it is difficult to elicit the exact 
relationship that bacteria have within the wound healing process, and to identify a 
single causative organism (Davies et al., 2001, Howell-Jones et al., 2005, Melendez 
et al., 2010). This is most likely to be a multi-factorial process involving many 
organisms.
2.1.2 Chronic wound microbiology
The role of microorganisms have been extensively investigated in many 
disease states, most notably in the case of oral disease e.g. periodontitis and peri- 
implantitis, and chronic lung disease e.g. cystic fibrosis (Listgarten and Lai, 1999, 
Davies and Bilton, 2009). There exists considerable evidence, which both directly 
and indirectly link microorganisms to the chronicity of disease processes. The 
presence of any organism in a wound may be due to contamination, colonisation or 
infection (Ueda et al., 2010). Bacterial colonisation alone is unlikely to mediate non­
healing, and it is difficult to differentiate which bacteria have a detrimental effect on 
healing, particularly if synergistic effects are taken into account in the clinically non­
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infected wound (Trengove et al., 1996, Davies et al., 2007). Pseudomonas 
aeruginosa has been used as a predictor of non-healing, because wounds harbouring 
this organism are frequently larger than wounds without (Kirketerp-Moller et al.,
2008). The transition to infection, with bacterial invasion and invoked host response 
in patients with chronic skin wounds poses the risk of sepsis and subsequent 
bacteraemia (Ueda et al., 2010).
Molecular based techniques have changed our understanding of the ecology 
of microbes in wounds e.g. presence of anaerobes, biofilm formation and diversity 
(Davies et al., 2004, Dowd et al., 2008, Wolcott et al., 2009). Many investigators 
have tried to decipher the critical mass of bacteria in these wounds because studies 
have indicated that either the number of bacteria (Robson et al., 1999) or species 
present are important in non-healing (Davies et al., 2001, Davies et al., 2007; 
Chapter 1, Section 1.5). Not only has increased bacterial diversity and population 
complexity been characterised using molecular techniques, but studies also suggest 
that a single bacterial species is unlikely to be solely responsible for the non-healing 
phenotype. These facts suggest that, consortia of genotypically distinct bacteria 
symbiotically produce a pathogenic community in these wounds (Trengove et al., 
1996, Davies et al., 2007, Dowd et al., 2008).
Within sites of persistent diseases bacterial populations are often highly 
organised and may exist as communities in biofilms (Martin et al., 2009) which may 
significantly contribute to the non-healing phenotype of chronic wounds. Recent 
work by Hill et al., (2010) identified P. aeruginosa and S. aureus, as common wound 
isolates. They have a tendency to co-aggregate, indicating their potential 
involvement in the initiation of biofilm formation in vivo. This biofilm state also 
makes it difficult to recover and culture bacteria (Kirketerp-Moller et al., 2008).
Wound cultures can be obtained in many ways e.g. superficial wound swabs, 
deep swabs, tissue biopsy, curetting and aspiration. Superficial swabs are most 
frequently employed as they pose no significant discomfort to patients, and are less 
technically demanding, but the results obtained are highly reliant upon the efficiency
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of the individual carrying out the task (Verran et al., 2010a). In clinical practice, 
routine microbiological culture swabs typically identify easy to culture key 
organisms such as S. aureus and P. aeruginosa, with corresponding antimicrobial 
therapy often directed only at these organisms (Howell-Jones et al., 2006). 
However, cultural analysis of anaerobes from the wound environment, which are 
known to play a role in non-healing, is poor (Wall et al., 2002, Price, 2009). Studies 
by Stephens et al., (2003) have also shown that bacterial supernatants from anaerobic 
chronic wound organisms e.g. peptostreptococci sp. have an ability to impair 
keratinocyte cellular responses.
2.1.2.1 Bacteria associated with chronic wounds
Chronic wounds are colonized by a diverse array of organisms, however, 
appear clinically non-infected. Many studies have demonstrated that the organisms 
frequently isolated are; S. aureus, coagulase negative staphylococci (CNS; e.g. S. 
epidermidis), P. aeruginosa, Proteus sp., Enterococcus sp., Streptococcus sp., 
Clostridium, Peptoniphilus, Bacteroides sp. (Sapico et al., 1986, Gerding, 1995, 
Johnson et al., 1995, Hill et al., 2003, Wolcott et al., 2009).
2.1.3 Antibiotic resistance
Antibiotic resistance is a vital public health issue. Due to the distress that 
non-healing wounds pose to the patient, and probable lack of understanding of their 
aetiology, antibiotic prescriptions are a common feature of their treatment. Despite 
GP guidelines, > 65% of patients suffering with chronic wounds receive at least one 
course of systemic antibiotics over the period of a year (Howell-Jones et al., 2005). 
Moreover, it is evident that flucloxacillin, co-amoxiclav and ciprofloxacin were 
significantly prescribed more frequently for chronic wound patients than age- 
matched non-wound patients (Howell-Jones et al., 2006). Furthermore, transfer of 
antibiotic resistance can result from cross-contamination of wounds by patients, 
inanimate objects, health care personnel, and also other risk factors including;
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antibiotic use, prior hospitalisation or long term institutionalisation (Livermore, 
2000a, Livermore, 2000b, Howell-Jones et al., 2005).
Many studies have identified antibiotic resistant organisms in chronic 
wounds e.g. meticillin resistant Staphylococcus aureus (MRSA) has been shown to 
be present in 30 to 50% of all leg ulcers (Colsky et al., 1998, Tentolouris et al., 
1999). Unsurprisingly, ciprofloxacin resistant P. aeruginosa was found to be present 
in a third of leg ulcers, which is concerning because this is a common antibiotic used 
for treatment of these wounds (Colsky et al., 1998, Howell-Jones et al., 2005). Price 
at al., (2009) observed in a group of patients suffering with chronic wounds that 
antibiotic use altered the bacterial community structure by reducing streptococci 
present and increasing the presence of pseudomonads. Due to their polymicrobial 
nature, the chronic wound environment makes a perfect niche for the transfer of 
antibiotic resistance (Howell-Jones et al., 2005).
Recently using an in vivo wound biofilm model, Hill et al (2010) showed that 
mixed Pseudomonas and Staphylococcus biofilms were unaffected by two common 
chronic wound antibacterial agents, ciprofloxacin and flucloxacillin, even when used 
at concentrations equivalent to twice that of the therapeutic dose, and at 5 or 15 times 
the minimum inhibitory concentration (MIC) of planktonically grown S. aureus or P. 
aeruginosa respectively. Therefore, within chronic wounds, empirical antibiotic 
prescription, long-term antibiotic use and patient non-compliance, indicates that 
further antibiotic resistance is likely to arise in this vulnerable patient group 
(Armstrong et al., 1995b).
Increase in antibiotic resistance incidence has led to surveillance by the 
European Antimicrobial Resistance Surveillance Network (EARS-Net) and the need 
for more stringent antibiotic susceptibility testing and cross-infection procedures. 
Antibiotic susceptibility is tested using a variety of methods, such as the disc 
diffusion assay, broth dilution and agar dilution methods, or using automated 
systems e.g. BD Phoenix™ (Moran et al., 1988, Andrews, 2009).
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2.1.3.1 Meticillin Resistant Staphylococcus aureus (MRSA)
Meticillin resistant Staphylococcus aureus was first discovered in the 1960s 
(O'Neill et al., 2001), and has become a popular political topic, with many hospitals 
graded on the number of hospital aquired MRSA infection. The presence of a 
chronic wound is an associated risk factor for MRSA carriage (Stanaway et al., 2007, 
Reich-Schupke et al., 2010). Meticillin resistance is tested with the use of cefoxitin, 
oxacillin or meticillin and is associated with a chromosomal genetic determinant, 
mecA (Chapter 1, Section 1.7.2).
2.1.4 Biocides and wounds
Whilst many topical agents are employed in chronic wounds to promote 
healing and decrease infection, the advent of antibiotic resistance e.g. MRSA and 
lack of new formulations has seen a resurgence of interest in the use of biocides 
(Cooper, 2004, Lipsky and Hoey, 2009). Whilst chronic wounds are clinically non­
infected almost all harbour multi-resistant bacteria (Hill et al., 2010). These bacteria 
may impair wound healing either directly or indirectly (White et al., 2001, Drosou et 
al., 2003, White et al., 2006b).
In terms of their use in medical practice, biocides have been categorised as 
antiseptics and disinfectants. In the treatment of wound bacteria, biocides have a 
number of advantages; they target all bacteria including MRSA and are associated 
with a lower level of resistance development and hypersensitivity (McDonnell and 
Russell, 1999, Drosou et al., 2003, Niedner, 1997). Some authors suggest that 
biocides encourage cutaneous healing (White et al., 2001, Harding, 2008).
2.1.4.1 Povidone-Iodine
Iodine has been used in the prevention of infection and treatment of wounds 
for more than a century (Cooper, 2004). The use of iodine fell out of vogue 
following problems with molecular iodine, such as tissue staining and sensitisation 
(Berkelman et al., 1982, Durani and Leaper, 2008). Since 1949 iodine use has
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increased following the development of iodophores (Cooper, 2004), such as 
polyvinylpyrrolidone (PVP) which is used as a carrier, forming povidone-iodine 
(PVP-I). PVP has an affinity for cell membranes (Durani and Leaper, 2008) and 
interestingly PVP-I has been shown to be highly effective against chronic wound 
biofilms (Hill et al., 2010). Whilst conflicting evidence regarding the efficacy of 
PVP-I exists, much of this is due to variation in concentration, exposure time, 
organic substance presence and diversity of test procedures e.g. animal models, 
minimum inhibitory concentration (MIC) and suspension tests. Furthermore, iodine 
preparation and test strains may significantly affect the outcome of iodine activity 
(Drosou et al., 2003, Cooper, 2004, Khan and Naqvi, 2006, Durani and Leaper,
2008). PVP-I has been demonstrated to be almost 100% effective at removing 
MRSA colony forming units (CFU) on artificially contaminated healthcare workers 
hands (Guilhermetti et al., 2001).
2.1.4.2 Silver compounds
Silver is extensively utilised in wound treatments in 3 forms; silver salts 
(silver nitrate), compounds (silver sulfadiazine) and nanocrystalline silver (silver 
dressings e.g. Acticoat™; Fong and Wood, 2006, White and Cutting, 2006a). Silver 
exerts its antimicrobial activity by disrupting the function of bacterial cell 
membranes, decreasing bacterial metabolism and binding to DNA and RNA 
preventing division (Leaper, 2006). Silver is effective against a broad range of 
microbes (Feng et al., 2000, Woo et al., 2008) and some animal studies have 
suggested that silver compounds may promote wound healing (Geronemus et al., 
1979, Lansdown et al., 1997). The antimicrobial effect of silver is dependant on the 
achieved bacterial intracellular concentrations (Cooper, 2004).
2.1.4.3 Potassium permanganate
Potassium permanganate use has declined with the advent of silver and 
iodine wound dressings, and due to its associated skin staining, but it is still
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employed in the management of chronic wounds, dermatitis, psoriasis and eczema to 
reduce bacterial load (Breuer et al., 2002, Harding, 2008). Gauze dressings soaked 
in potassium permanganate have been shown to reduce the bacterial count of venous 
leg ulcers (VLU; Hansson and Faergemann, 1995b).
Potassium permanganate is a strong oxidative agent which is the basis of its 
antimicrobial activity (McDonnell and Russell, 1999). It is extensively employed in 
aquaculture (Darwish et al., 2008) and water purification; despite its effectiveness in 
other models it has received little attention in chronic wounds.
2.1.5 Biocides and their cellular effects
The mechanisms by which biocides exert their cidal effects is undetermined 
but imaging techniques such as transmission electron microscopy (TEM; Hobot et 
al., 2008) and scanning electron microscopy (SEM; Wale et al., 1989) have been 
employed extensively to visualise disruption of bacterial cell walls and cellular 
contents as an indication of cell damage. TEM has previously been utilised to study 
the effects of various wound dressings on bacteria. Such studies have indicated 
cellular disruption by silver ions on common wound isolates (Feng et al., 2000, 
Hobot et al., 2008).
2.1.6 Biocide testing
Numerous methods have been described to test the antimicrobial efficacy of 
biocides, including: disc diffusion, MIC, minimum bactericidal concentration 
(MBC), suspension and carrier tests. A lack of consistency in the reported literature 
reflects variation in test conditions e.g. temperature, organic matter, concentration, 
contact times and preparation (McDonnell and Russell, 1999, Koburger et al., 2010). 
European and British standards have established standardised methods for biocide 
testing. Simple conventional tests such as the MIC, MBC and disc diffusion assays 
assess the sensitivity of the microorganism. They do not however, test the cidal vs. 
static properties of a biocide. In this respect, the “carrier test” method distinguishes
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the “cidal” vs. “static” properties of the biocide by incorporating a biocide 
neutralisation step (Lambert, 2001, Johnston et al., 2002). Quenching agents 
employed to neutralise the biocide prevent over-estimation of the activity of a 
biocide for any given exposure time (Johnston et al., 2002). In vitro and in vivo 
many biocides are inactivated by the presence of organic substances which are 
omnipresent in the wound environment. The British/European standards therefore 
also describe the use of “dirty” conditions, by the addition of bovine serum albumin 
(BSA) to the experiments.
Quantifying a bacterial response to biocide exposure may be performed using 
manual or automated methods. The “drop count” method first described by Miles 
and Misra (Miles et al., 1938) is less labour-intensive than “pour plate” methods 
(Herigstad et al., 2001). Automated systems, such as the Bioscreen Microbial 
Growth Analyser, measure the optical density (OD) of bacterial suspensions over a 
given time and CFU can be deduced (Lambert et al., 1998, Johnston et al., 2002).
2.1.7 Hydrophobicity and biocides
Cell surface hydrophobicity is important in bacterial adherence, colonisation 
of surfaces and their consequent pathogenicity (Rosenberg et al., 1983, Das et al., 
2001, Kustos et al., 2003, Kouidhi et al., 2010). Surface hydrophobicity reflects the 
presence of protein or protein-associated molecules on the cell surface (Reifsteck et 
al., 1987). In the case of staphylococci, protein A is believed to be of particular 
importance to the hydrophobic nature of the cell (Miomer et al., 1982). A variety of 
cellular and electrophysiological methods exist to test the hydrophobicity of bacterial 
cells, e.g. salt aggregation test (SAT), microbial adhesion to hydrocarbons (MATH), 
zeta potential and polystyrene affinity measurement (Rosenberg, 1981, van 
Loosdrecht et al., 1987, Denyer et al., 1993, Geertsema-Doombusch et al., 1993). 
Growth and environmental conditions may affect the analysis of hydrophobicity. 
Bacteria grown on blood-containing culture media may express greater 
hydrophobicity, whilst some tryptone soy broth (TSB) cultures may lower
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hydrophobicity (Pembrey et al., 1999, Das et al., 2001, Das and Kapoor, 2004). 
Hydrophobicity can affect the action of biocide diffusion, which is dependent both 
on the hydrophobic nature of the bacteria tested and the antimicrobial used (Russell, 
1995, McDonnell and Russell, 1999).
2.2 Aims
The aims of this study were to determine the antibiotic susceptibility profiles 
for aerobic bacteria isolated from a group of chronic wound patients, specifically;
1. To phenotypically characterise isolated aerobic Gram-positive chronic wound 
bacteria by gram-stain, and identification of catalase and coagulase factor.
2. To determine the antibiotic susceptibility profiles of the staphylococcal 
isolates using disc diffusion assays and molecular techniques.
3. To determine meticillin resistance carriage amongst bacteria isolated from 
chronic wound patients.
Due to the identification of multiple multi-drug resistant bacteria present in 
the wounds of these patients, further investigation into the treatment modalities to 
eradicate these bacteria was thought to be of significant importance. In these studies, 
three common biocides were investigated to determine the most efficacious for the 
treatment of chronic wound MRS A (characterised in Chapter 3) using a combination 
of cellular and structural analyses. The specific aims were to:
4. Characterise the biocide effectiveness of povidone-iodine, potassium 
permanganate and silver nitrate against MRSA isolated from chronic wound 
patients using the carrier test method, enumerated by employing the drop 
count and Bioscreen analysis.
5. Determine if MRSA strain type or previous biocide treatment is associated 
with biocide resistance.
6. Investigate the structural effects of iodine exposure using SEM and TEM.
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2.3 Materials and Methods
2.3.1 Collection of wound bacterial isolates
The isolates utilised in this study were collected as part of a routine audit by 
Dr R. S. Ho well-Jones (2007) at the specialist Wound Healing Research Unit, 
Cardiff University with permission from the local clinical governance committee 
(Appendix I). The out-patients that participated in the audit had been referred for 
assessment, diagnosis and treatment of non-healing skin wounds. The audit was 
undertaken over a 10-week period in May - July 2005 and included all patients 
attending the clinics with a variety of non-healing wounds (leg ulcers, diabetic foot 
ulcers and surgical wounds). Data on antibiotic prescription from general practice 
and hospital notes, and patient’s medical history and wound data were recorded 
contemporaneously.
Microbiological samples (n = 151 patients) were taken by nurses present at 
the specialist clinic by irrigating the test wound with saline prior to swabbing the 
entire wound with an Aimes and Charcoal cotton-tipped swab (Sterilin, UK). If 
more than one wound was present, the largest was sampled. Swabs were then 
transported to the Cardiff School of Dentistry Microbiological Laboratory and 
processed within 2 hours. Bacteria were identified following plating onto four 
different agars. Growth media used included; blood agar (BA; LabM 15, Bury, UK) 
supplemented with 5% defibrinated sheep blood (Oxoid) and selective media; 
mannitol-salt agar (MSA; Oxoid, Basingstoke, UK), Pseudomonas agar (PA; LabM) 
supplemented with 200 mg/1 cetrimide and 15 mg/1 of nalidixic acid; and bile 
aesculin agar (BAA, Oxoid) supplemented with 6 pg/1 vancomycin to facilitate 
selection of Staphylococcus, Pseudomonas, and Enterococcus respectively. 
Following incubation (37°C, 48 h) Pseudomonas aeruginosa, Staphylococcus sp. 
and vancomycin resistant enterococci (VRE) were identified using Gram stain, 
catalase, oxidase, coagulase tests and Streptococcus antigen grouping (Howell-Jones, 
2007). Isolates and swabs were stored at -80°C in microbank vials containing
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cryopreservative fluid and porous beads (Pro-Lab diagnostics, UK) and were used in 
the following experiments.
2.3.2 Culture of bacterial isolates
Samples previously identified as S. aureus and CNS (Section 2.3.1) were 
recovered from the microbank vials aseptically and incubated overnight on BA 
(LabM 15, Bury, UK) supplemented with 5% sheep defibrinated blood at 37°C. 
Frozen swabs recorded as “no growth” or “no growth of staphylococci” were also 
recovered from the microbank vials, plated on MSA and BA and incubated overnight 
(O/N) at 37°C. Plates which failed to produce any growth were re-incubated for a 
further 24 h at 37°C. Individual colonies from MSA were transferred to BA and 
incubated (37°C, O/N) for identification. Single colonies from each plate were then 
transferred to new individual microbank vials and stored at -80°C for future use.
2.3.3 Identification of isolates
2.3.3.1 Classification of cell wall using Gram stain
The Gram stain is a commonly used technique to identify eubacteria 
according to cell wall type; Gram-positive bacteria stain purple due to crystal violet 
in the peptidoglycan layer, whilst Gram-negative bacteria are pink due to carbol- 
fuchsin counterstain.
A single colony of bacteria from the BA was smeared onto a glass slide in 
distilled sterile water, allowed to air-dry and then heat-fixed briefly. Slides were 
flooded with 1% (v/v) crystal violet for 2 min. Following brief washing with water, 
the slide was flooded with 3% (v/v) Lugol’s iodine for 2 min. Slides were 
decolourised with 100% acetone for 2 s, rinsed with distilled water, flooded with 1% 
(v/v) carbol-fuchsin (counterstain) for 2 min, washed with distilled water, blotted 
and air-dried (all reagents were supplied by Pro lab diagnostics, Cheshire, United 
Kingdom). Samples were viewed using light microscopy (Carl Zeiss Ltd., UK)
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using immersion oil at x40 and xlOO magnification (Figure 2.1), cell colour, shape 
and morphology were recorded.
2.3.3.2 Coagulase test to identify Staphylococcus aureus
An accepted identification characteristic of S. aureus is its ability to produce 
coagulase (clumping factor), differentiating S. aureus from CNS. The coagulase test 
was performed using a Staphylase test kit (Oxoid, Basingstoke, UK) according to the 
manufacturer’s instructions. Briefly, test and control reagents were shaken 
vigorously before use; two-three identical colonies of each test bacteria were 
smeared into a drop of distilled water on each of the two test circles. The test 
suspensions were then mixed and both circles were observed for agglutination. A 
positive test result (positive S. aureus identification) was indicated by clumping of 
the test cells in the test reagent solution and no clumping in the control reagent 
(Figure 2.2).
2.3.3.3 Catalase test
The catalase test employs hydrogen peroxide to identify the presence of 
catalase enzyme and enables differentiation of staphylococci from streptococci with 
the aid of the Gram stain. A single test colony was transferred to a glass slide and 1 
drop of 3% (v/v) hydrogen peroxide (Oxoid) was added to the smear. The 
development of foaming was indicative of a positive catalase reaction.
2.3.4 Antibiotic susceptibility testing
2.3.4.1 Testing of meticillin resistance
Initial identification of meticillin resistance was performed using a meticillin 
strip (Mast Diagnostics, Bootle, UK). A single colony from bacterial cultures grown 
O/N on BA was streaked onto iso-sensitest™ agar (ISA; Oxoid) in a horizontal line. 
A meticillin strip was aseptically placed perpendicular to the culture streak and the 
plate incubated (30°C, 24 h). Positive (MRSA; NCTC 12493) and negative
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Figure 2.1 Gram stain of Staphylococcus aureus isolate.
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Figure 2.2 Staphylase test to identify Staphylococcus aureus. Circles 1 and 4, S. 
aureus positive control (NCTC 6571); Circles 2 and 5, negative control (NCTC 
11047); Circles 3 and 6, false positive using a wound isolate.
(meticillin sensitive S. aureus, MSS A; NCTC 6571) control strains were employed 
for each test plate (Figure 2.3).
2.3.4.2 Susceptibility testing -  disc diffusion assay
The disc diffusion assay was performed as per British Society for 
Antimicrobial Chemotherapy guidelines (BSAC, 2007).
2.3.4.2.1 Preparation of inoculum
The inoculum was prepared by direct colony suspension method. Colonies 
from pure O/N (37°C) growth on BA were re-suspended in 5 ml of sterile distilled 
water to an optical density (OD) equivalent to that of 0.5 McFarland standard 
(BSAC, 2007). The suspensions were used to inoculate the test agar plate within 15 
mins of preparation. Mueller-Hinton (MH) and Columbia agar (CA) supplemented 
with 2% (w/v) NaCl were used as test agar for oxacillin and meticillin, while iso- 
sensitest™ agar was used to test other antibiotics.
2.3.4.2.2 Inoculation of agar plate
Sterile cotton wool swabs were dipped into bacterial suspensions (Section
2.3.4.2.1) and excess liquid removed on the side of the container. The inoculum was 
then spread over the surface of the plate in three directions. Plates were allowed to 
dry at room temperature (RT). Antibiotic discs (Table 2.1; Mast Diagnostics, 
Bootle, UK) were aseptically placed onto the inoculated agar plate within 15 min of 
inoculation. A maximum of 6 discs were applied to each plate. The agar plates were 
stacked (<3 plates high) within 15 min of the application of discs, and incubated for 
18 - 20 h at 35°C, (30°C; 24 h when testing oxacillin and meticillin). Reference 
strains used as controls are listed in Table 2.2.
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MRSA (positive control)
Wound isolates
MSSA (negative control)
Figure 2.3 Meticillin resistance testing using a meticillin strip.
Meticillin strip
Antibiotic
disc
Figure 2.4 Antibiotic susceptibility testing using a disc diffusion assay. Zones of 
inhibition for meticillin susceptible S. aureus (NCTC 6571); a) oxacillin disc (1 pg); 
b) meticillin disc (5 pg).
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Table 2.1 Antibiotic discs and concentrations used for susceptibility testing
Antibiotic Disccontent Antibiotic
Disc
content
Cefoxitin 10 ng Oxacillin lug
Chloramphenicol 10|j.g Penicillin 1 unit
Ciprofloxacin lug Quinupristin/Dalfopristin 15|ig
Clindamycin 2ng Rifampicin 2ng
Co-trimoxazole 25ng Tetracycline 10ng
Erythromycin 5fig Trimethoprim 5ng
Fusidic acid 10ng Vancomycin 5ng
Gentamicin 10ng Sulfamethoxazole 25 ng
Meticillin 5ng Fosphomycin glucose 6 phosphate 30 Mg
Mupirocin 5ng
Table 2.2 National Collection of Type Cultures (NCTC) reference strains used as 
controls
Control strain Isolate information
NCTC 6571 MSSA
NCTC 12493 MRSA
NCTC 11047 Staphylococcus epidermidis TcR
MSSA, meticillin sensitive Staphylococcus aureus; MRSA, meticillin resistant 
Staphylococcus aureus; TcR, tetracycline resistant.
Table 2.3 Primer sequence for mecA gene PCR amplification and identification
Primer
name Sequence S’ to 3’
Amplicon 
size (bp) Reference
MR1 (F) 
MR2 (R)
GT GGAATT GGCC AAT AC AGG 
TGAGTTCTGCAGTACCGGAT
1.339 kb Tokue et al., (1992)
bp, base pair.
60
2.3.4.2.3 Zone of inhibition measurement
Plates were examined under direct light to determine colony growth in the 
zone of inhibition and the zone measured (Figure 2.4). The measurement was then 
compared to zone breakpoints found in the BSAC guidelines for staphylococci 
(BSAC, 2007).
2.3.4.3 Identification of meticillin resistance gene (mecA)
2.3.4.3.1 DNA preparation for mecA identification
An O/N culture of test organisms was prepared in 5ml Tryptone soya broth 
(TSB; Oxoid) and incubated at 37°C. One ml of culture was centrifuged (9500 xg , 5 
min) and the supernatant removed. The bacterial pellet was washed twice with 1 ml 
lysis buffer (50 mM Tris-HCl, pH 8.0; 5 mM EDTA, pH 8.0; 50 mM NaCl), and re­
centrifuged (9500 x g, 5 min), then re-suspended in 1 ml lysis buffer with 20 pi 
lysostaphin (1 mg/ml; Sigma Aldrich, UK), and 5 pi RNase A (5 mg/ml; Sigma 
Aldrich, UK) added. The lysis mix was incubated (37°C, 30 min) with agitation. 
The lysate was centrifuged (9500 x g, 10 min) and the supernatant used as the DNA 
template for PCR amplification (Araj et al., 1999).
2.3.4.3.2 mecA identification by PCR
Bacterial DNA template was prepared as previously described (Section
2.3.4.3.1). Twenty-five pi PCR reactions were performed in thin-walled PCR tubes 
(all reagents were supplied by Promega, UK unless otherwise stated). A mixture of 1 
pi of DNA template, 200 pM (each) deoxynucleoside triphosphates (dNTPs), 1 pM 
(each) of forward and reverse primers (Table 2.3; MWG-biotech, Ebersberg, 
Germany), 2.5 U Taq DNA polymerase, 2.5 pi of 10X buffer, 1.5mM MgCb and 
16.8 pi of nuclease-free water was amplified in a thermal cycler. PCR reactions 
were performed with an initial denaturation step (94°C, 10 s), followed by 25 cycles; 
denaturation (94°C, 30 s), annealing (55°C, 30 s), elongation (72°C, 2 min); then a
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final extension step (72°C, 5 min). Ten pi of PCR product was combined with 2 pi 
of loading dye and loaded onto a 1% agarose gel (Fisher Scientific Ltd) with 
ethidium bromide incorporated (0.5 pg/ml). The product was separated by 
electrophoresis alongside a 100 bp molecular weight standard in IX Tris-borate- 
EDTA (TBE; 0.1 M Tris Base; 0.09 M Boric Acid; 1 mM EDTA, pH 8.0) running 
buffer at 70 V for 1 h. The resultant gel was visualised under UV light (Gel Doc™, 
Bio-Rad®) and a 1.3 kb product was indicative of the mecA gene and therefore 
positive for meticillin resistance (Tokue et al., 1992).
2.3.5 Biocide testing
2.3.5.1 Growth of bacterial isolates
Seven MRSA isolates from chronic wound patients were used, to represent 
appropriate examples of sequence types (ST), wound origin (chronic leg wound, 
chronic surgical wound) and previous biocide exposure. In addition, a control 
MRSA (ITU2) isolated from an intensive therapy unit patient (ITU) with 
bacteraemia kindly provided by Dr R. Howe (Specialist Antimicrobial 
Chemotherapy Unit; SACU, University Hospital Wales, Cardiff). A meticillin 
sensitive Staphylococcus aureus (MSSA) NCIMB 9518/ATCC 6538 described by 
British and European (BS EN) Standard 13697: 2001 was used as a control strain. 
Table 2.4 shows the isolates employed to test the biocides. In these experiments, 
strains were grown overnight (O/N) on tryptone soy agar (TSA) plates at 37°C. 
Biocide testing was performed using prepared 10 ml TSA slopes. A representative 
colony of each strain was used to inoculate a bacterial slope which was incubated 
O/N at 37°C.
62
Table 2.4 Isolates employed in biocide testing
Isolate Isolate information aST bPulse type
ATCC 6538 Control strain (MSSA) ND ND
1004 Chronic Leg Wound 22 A
1011 Chronic Surgical wound 30 Ci
1021 Chronic Leg Wound 36 Cii
1106 Chronic Surgical wound 22 B
1108 Chronic Surgical wound 970 A
2018 Chronic Surgical wound 22 A
2124 Chronic Surgical wound 22 A
ITU2 ITU isolate 1 ND
“Sequence type, defined by MLST; bpulse type, as defined by PFGE (Chapter 3); 
ND, not determined; MSSA, meticillin Staphylococcus aureus.
Table 2.5 Tested biocide concentrations and neutralising agent
Biocide
Working biocide 
concentration
(w/v)
Neutralising agent
Povidone-iodine 1%
Lecithin (3 g/1) 
Polysorbate 80 (30 g/1)
Potassium permanganate 0.05% Sodium thiosulphate (5 g/1)
Silver nitrate 0.45% Sodium thiosulphate (5 g/1)
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2 3 .5.2 Experimental materials
The “carrier test” was performed using 1.5 mm thick, 20 mm diameter grade 
2B finish stainless steel (SS) discs (Goodfellows Cambridge Ltd, Huntington, UK). 
Each disc was marked with a permanent marker to allow identification of the test 
side. Following use, the discs were autoclaved and rinsed with water then placed in 
5% (v/v) Decon®90 (Decon Laboratories Ltd, Hove, UK) in de-ionized water for 60 
mins, then rinsed with de-ionized water and allowed to dry. Discs were then 
sterilised (121°C, 15 min) in a sealed Duran® bottle until use. Sterile tryptone 
sodium chloride (TSC) solution (tryptone 1 g/1; NaCl 8.5 g/1) was used as a diluent 
for each test procedure and was freshly prepared every 3 d.
PVP-I, silver nitrate and potassium permanganate (Sigma-Aldrich Ltd, 
Dorset, UK) were tested for their efficacy against wound MRSA. Each test biocide 
and neutraliser (Table 2.5) was freshly prepared every 3 d and sterilised (121°C, 15 
min), then stored at 4°C and kept in darkness until use. Bovine Serum Albumin 
(BSA) solution was freshly prepared every 3 d with 60 g/1 BSA (Acros Organics, 
Geel, Belgium) in de-ionized water and kept at 4°C. The required volume was filter- 
sterilised using a 0.2 pm filter prior to use. A final BSA concentration of 3g/1 was 
used in each test procedure as described in BS EN 13697; 2001.
Sterilised 100 ml Duran® bottles containing 5 g of 3 mm borosilicate glass 
beads (Sigma-Aldrich) were used to retrieve bacteria from the SS discs in each 
biocide test.
Terminology used in this Chapter to describe biocide test conditions are as 
follows: working bacterial suspension, obtained suspension following washing an 
inoculated TSA slope with TSC, and used to inoculate SS disc subsequent to the 
addition of BSA; test biocide, biocide under investigation i.e. PVP-I, silver nitrate, 
potassium permanganate; control biocide, sterile distilled water; test solution, 
neutralised test biocide; control solution, neutralised control biocide; test suspension, 
bacteria isolated from SS discs treated with test biocide and neutralised; control
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suspension, bacteria isolated from SS discs treated with control biocide and 
neutralised.
2.3.5.3 Validation of drop count
The drop count method was performed using an adaptation of the method 
described by Miles and Misra (1938). A working bacterial suspension of S. aureus 
ATCC 6538 was prepared by harvesting the bacterial growth on an O/N TSA slope 
with 5 ml of sterile TSC. The suspension was centrifuged (2000 x g, 10 min) and the 
supernatant discarded. The bacterial pellet was washed with 5 ml of TSC (x2) and 
re-suspended in 5 ml TSC. One ml of the working bacterial suspension was diluted 
in 4 ml of TSC and cell suspension corrected to approximately 109 CFU/ml cells 
using an ODsoonm- BSA (final concentration 3 g/1) was added to the test solution and 
10-fold serial dilutions of the working bacterial suspension were performed (xlO). 
Ten pi of each dilution were pipetted in triplicate onto triplicate agar plates (Figure 
2.5), allowed to air-dry and then incubated (37°C, 24 h).
The dilution series yielding counts 3<n<45 CFU was used to determine the 
average number of colonies per plate dilution. Counts were expressed as CFU/ml 
(Herigstad et al., 2001). Intra-experimental variations were determined using a one­
way analysis of variance (ANOVA) with a 95% confidence interval for logio 
transformed data in Minitab® (Release 14 software, Minitab® Inc, USA; Appendix 
Ill.i).
2.3.5.4 Validation of neutraliser efficacy
Validation of the neutralising agents was performed to confirm its ability to 
quench the biocides (Table 2.5) without detrimental effect on the test bacteria. Tests 
were performed using “dirty conditions” and the validation methods in BS EN 
13697: 2001. Working bacterial suspensions of S. aureus ATCC 6538 were 
prepared (Section 2.3.5.3) the resultant bacterial pellet was re-suspended in 2 ml 
TSC and then 1.5 ml of the working bacterial suspension was combined with 0.5 ml
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Figure 2.5 Representation of the drop count method.
-Bacterial suspension drop (10 p.1)
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of BSA (final concentration 3 g/1). Six SS discs were transferred aseptically to a 
sterile Petri dish and inoculated with 20 pi of the bacterial/BSA suspension 
(unmarked side), these were incubated (37°C, 25 min) to dry. Ten ml of the 
neutralising agent was pipetted into each of 6 sterile Duran® (100 ml) bottles 
containing 5g of 3 mm glass beads. Once the inoculated disc had dried, 100 pi of the 
test biocide was added into 3 Duran® bottles containing neutraliser solution (test 
solution) and 100 pi of control biocide (sterile distilled water) was added to the other 
3 Duran® bottles containing neutraliser solution (control solution). The biocide or 
control and neutraliser were left in contact for 5 min. Single inoculated SS discs 
were then aseptically transferred to a Duran® bottle containing the test solution or 
control solution, leaving the marked side facing up. These were then placed on a 
rotating platform (Grant Bio POS 300, Patterson Scientific, Luton UK) for 1 min at 
150 rpm to re-suspend the bacterial cells. Viable counts were performed on 10-fold 
serial dilutions (in triplicate) from the initial working bacterial suspension, test 
suspension and control suspension as described in Section 2.3.5.3 and the drop count 
method performed (in triplicate). The CFU/ml for the working bacterial suspension, 
test suspension and control suspension were calculated. Validation of the neutraliser 
was based on the equations and rules of BS EN 13697: 2001, shown in Table 2.6.
2.3.S.5 Bioscreen optical density values and viable count relationship
To correlate viable bacterial counts for each serial dilution with observed 
optical density (OD), the Bioscreen Microbial Growth Analyser (Oy Growth Curves 
Ab Ltd, Finland) was employed. A working bacterial suspension of S. aureus ATCC
o
6538 was prepared and serially diluted (10 ') in triplicate, CFU/ml was recorded for 
each dilution (Section 2.3.5.3). Using a 100-well Thermo Labsystems Honeycomb 2 
plate (Thermo Electron Corporation, UK), 350 pi of TSB and 50 pi of each bacterial 
serial dilution (neat to 10'8) was added to 5 replicate wells. Control wells contained 
350 pi TSB and 50 pi of TSC. Plates were incubated (37°C, 14 h) in the Bioscreen 
and growth recorded at OD420-580 using a wideband filter, at 15 min intervals with
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Table 2.6 Equations used to validate neutralises and biocides tested and the rules applied to each test (BS EN 13697: 2001)
Test Equation Rules
Recovery test
MVC control suspension (CFU/disc)
Recovery (%) x 100 
MVC working suspension (CFU/20 pi)
Neutraliser
toxicity
Logio of CFU working suspension 
(CFU/disc)
Logio of CFU neutraliser solution 
(CFU/disc)
If <2, the neutraliser is not 
toxic
Neutraliser
efficacy
Logio CFU of neutralised control
solution (CFU/disc) "
Logio CFU of neutralised biocide 
solution (CFU/disc)
If <0.3, the neutraliser is 
effective
Biocide efficacy Logio CFU of control suspension (CFU/disc)
Logio CFU of test suspension 
(CFU/disc)
If > logio 3 reduction, the 
biocide is effective
MVC, mean viable count; CFU, colony forming units.
68
shaking (10 s) prior to each reading (ten replicates). The logio CFU/ml for each 
dilution from the plate count was plotted against the time taken to reach an OD420-580 
of 0.2 as this showed the greatest distinction between the dilutions. A “fitted line” 
plot was produced using Minitab® and the resulting linear equation used to 
determine logio CFU/ml for subsequent analyses based on the time to reach an 
OD420-580 of 0.2 (Appendix Ill.ii).
2.3.5.6 Biocide efficacy using the carrier test method
Biocides (Table 2.5) were tested using the carrier test method described in 
BS EN 13697: 2001 modified with logio reductions for efficacy based on BS EN 
1499: 1997. Briefly bacteria were cultured and working bacterial suspensions 
supplemented with BSA (Sections 2.3.5.1 and 2.3.5.4). SS discs were inoculated as 
previously described (Section 2.3.5.4) and CFU/ml calculated for serial dilutions of 
the prepared working bacterial suspensions (Sections 2.3.5.3 and 2.3.5.4). Ten ml of 
the appropriate neutralising agent (Table 2.5) was transferred into Duran® bottles 
containing glass beads. Then 100 pi of test biocide (Table 2.5) was added to the 
dried inoculated test SS disc, and 100 pi of sterile water (control) was added to the 
control SS discs (Figure 2.6). The SS discs were left at room temperature for the test 
contact times (1,15 and 30 min). Each SS disc were then aseptically transferred to 
an individual Duran® bottle containing the neutralising agent with test side 
downwards. The bottles were placed onto a rotator platform (150 rpm, 1 min) then 
the discs and solution left in contact for a further 4 min. The Duran® bottles were 
then vortexed for 30 s and samples taken for drop count serial dilution (100 pi), and 
Bioscreen analysis (50 pi). Each biocide and contact time was performed in 
triplicate using freshly prepared bacterial culture on 3 separate days.
2.3.5.7 Drop count method
Ten-fold serial dilutions (neat to 108) of the working bacterial suspension, 
test suspension and control suspension were performed in triplicate using 100 pi of
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Figure 2.6 Stainless steel discs during carrier test experiment. A) biocide potassium 
permanganate and bacteria; B) sterile water and bacteria.
Figure 2.7 TSA plate following drop count method and 24 h incubation.
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the suspension and drop counts performed (Section 2.3.5.3; Figure 2.7). The 
CFU/ml was calculated for the working bacterial suspension, test suspension and 
control suspension. Recovery and biocidal efficacy was determined using the 
defined equations (Table 2.6). Plate readings of 0 CFU were set as 1 CFU/ml due to 
the limits of the assay (BS EN 1499: 1997).
2.3.5.8 Bioscreen method
A volume of 350 pi tryptone soya broth (TSB; Oxoid) was aseptically added 
to each well of the honeycomb plate. To this, 50 pi of serially diluted working 
bacterial suspension or test suspension or control suspension or neutraliser or a 
further 50 pi of TSB was added in 5 replicate wells (Appendix Ill.iii). Plates were 
incubated in the Bioscreen (37°C, 14 h; Section 2.3.5.5) and mean CFU/ml 
calculated for the test suspension, control suspension and working bacterial 
suspension (serial dilution). Using the fitted line plot (Section 2.3.5.5) the logio 
CFU/ml values were calculated and logio reduction calculated (Table 2.6).
Statistical analysis was performed to determine differences in drop count and 
Bioscreen methods using the logio values for all investigated biocides and contact 
times using GraphPad InStat3® (GraphPad Software Inc, California, USA). A one­
way ANOVA with a 95% level of significance between the means of the data sets 
was performed, with a Tukey post-test, to compare biocides. A paired T-test was 
used with confidence intervals of 95% to test if the difference in the mean of 
Bioscreen and drop count methods were significant.
2.3.5.9 Hydrophobicity determination using salt aggregation testing (SAT)
Salt aggregation testing for hydrophobicity (Lindahl et al., 1981) is based on 
the precipitation (“salting out”) of cells from a suspension. Bacteria were grown 
O/N on TSA slopes (Section 2.3.5.1) the slopes were washed with 0.002 M PBS (pH 
6.8) and bacterial suspension centrifuged (2000 x g, 5 min). The supernatant was 
discarded and bacterial pellet washed (x3) in 5 ml PBS before the final bacterial
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pellet was re-suspended in 2 ml PBS and the OD660nm adjusted to 1 to yield 3 x 109 
CFU/ml. Varying molarities of ammonium sulphate (0.2 to 4 M) were prepared in 
0.002 M PBS (pH 6.8) and 25 pi of solution was pipetted into 24-well microtitre 
plate (Greiner Bio-One, UK). To each well, 10 pi of bacterial suspension was added 
and the plate was placed on a rotating platform (80 rpm, 2 min, RT). Visualisation 
of aggregation was facilitated by reading against a black background.
2.3.5.10 Hydrophobicity determination using microbial adherence to 
hydrocarbons (MATH) testing
Microbial adhesion to hydrocarbons (MATH) was employed to study the 
hydrophobicity of S. aureus (Rosenberg et al., 1980, Greene et al., 1992, Galliani et 
al., 1994, Das et al., 2001), to determine whether surface charge influences 
susceptibility to iodine, and to determine if PVP-I can change bacterial surface 
hydrophobicity. Bacterial slopes were prepared (Section 2.3.5.1) and incubated 
(37°C, 24 h). The bacterial slopes were washed with 5 ml of sterile PBS (Oxoid) 
and centrifuged (2000 x g, 10 min), washed (x2) with 5 ml of PBS and centrifuged 
(2000 x g, 10 min) then re-suspended in 5 ml of PBS. The ODs^nm was corrected 
with PBS to an OD of 0.5 for testing with n-hexadecane (hexadecane adherence 
assay; HAA) and cyclohexane (cyclohexane adherence assay; CAA; Greene et al., 
1992) and to an ODs^nm of 1 for testing with p-xylene (xylene adherence assay; 
XAA; Galliani et al., 1994, Das et al., 2001). These tests employed disposable glass 
culture tubes 16 x 150 mm (Fisher Scientific UK Ltd, Loughborough, UK). Three 
ml of bacterial suspension was transferred to each tube, (2 sets of tubes were used for 
each hydrocarbon to compare iodine treated and control solutions for increasing 
quantities of hydrocarbon). To one set of tubes, 0.5 ml of PBS was added and to the 
second set of tubes 0.5 ml of a “non-lethal” concentration of stock 0.1% PVP-I was 
added. After 1 min, the OD54onm for the control (PBS/iodine) was recorded. To the 
remaining test tubes, the test hydrocarbon was added in increasing volumes; n- 
hexadecane or cyclohexane 0.4 to 1.6 ml (0.2 ml increments), p-xylene 250 pi to
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1750 pi (250 j l i I  increments). Tubes were sealed with parafilm® (Fisher Scientific) 
and vortexed (30 s) and left to phase separate for 30 min and 1 h. After separation, 1 
ml of the aqueous phase was transferred to disposable cuvettes (Fisher Scientific). 
The OD540nm of each solution was recorded, corrected against PBS or PBS with 
0.01% PVP-I controls. Tests were performed in triplicate. Readings were plotted on 
a line graph and relative hydrophobicity calculated using the following equation and 
rules (Greene et al., 1992). A paired T-test was performed using GraphPad InStat3® 
to determine if there was a significant change in hydrophobicity following PVP-I 
treatment.
A540 (initial OD) -  A540 (final OD)
% adherence = A54# (initial OD) x 1 0 0
Initial OD = A540 of bacterial suspension without adding hexadecane
Final OD = A540 of bacterial suspension on adding hexadecane
Rules for grading hydrophobicity: strong positive if >75%; intermediate if 25 to
75%; negative if <25%.
2.3.5.11 Effect of PVP-I on the cellular structure of MRSA using scanning 
electron microscopy (SEM)
2.3.5.11.1 Preparation of SEM sample
Shaking overnight cultures of test MRSA were grown in TSB at 37°C for 24 
h. Purity plates were performed on blood agar to confirm purity of sample. Cultures 
were diluted 1:500 and 2 ml was pipetted directly onto a Nucleopore 0.2 pm track- 
etched polycarbonate/ester membrane disc (Whatman® Ltd, GE Healthcare, UK) in 
24-well tissue culture plate (Coming Life Sciences, Amsterdam). The tissue culture 
lid was sealed with parafilm® and the plates incubated (37°C, 24 h). Three wells 
were inoculated per test isolate.
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These experiments were performed at RT. TSB was aspirated from each well 
and 200 pi PVP-I (0.1%; 1%), or sterile water (control) added to individual wells. 
One minute later, 1 ml of sodium thiosulphate was added to “quench” the biocide 
(determined as described in Section 2.3.5.4), and allowed to stand for 5 min. The 
quenched biocide was aspirated and 1 ml of 2.5% (v/v) glutaraldehyde added for 1 h. 
The glutaraldehyde was removed and each well washed (x3) with 1 ml of distilled 
sterile water. Membranes were covered with 1 ml of distilled sterile water and 
stored O/N at -80°C, and then placed O/N in a high vacuum freeze drier (Modulyo- 
Edwards, Edwards High Vacuum International, UK).
2.3.5.11.2 Specimen Preparation for SEM
Sample processing and imaging was performed with the help of Mrs W. 
Rowe, Cardiff University. Briefly, nucleopore membranes were mounted onto 
specimen stubs and placed into an Argon vacuum specimen chamber. Specimens 
were sputter-coated with a 7-10 nm layer of gold, using a K675 sputter coater 
(Quorum Emitech Ltd. UK). Samples were viewed using an EBT1 scanning electron 
microscope (SEM Tech Ltd, Derbyshire, UK). Representative images were recorded 
at 7 different sites in each sample.
2.3.5.12 Effect of PVP-I on the internal structure of MRSA using transmission 
electron microscopy (TEM)
2.3.5.12.1 Broth culture preparation for 1% PVP-I testing
Overnight cultures (MRSA isolate 1106) were prepared in 10 ml TSB, and 
used to prepare a 1:500 bacterial dilution in three 50 ml conical plastic flasks 
(Coming B.V. Life Sciences, Amsterdam) which were incubated in a shaking 
incubator (Innova 4330, New Brunswick Scientific, Cambridge, UK) at 37°C until 
mid-log phase. Purity plates were used to ensure no sample contamination. A final 
concentration of 1% PVP-I was added to two flasks and left at RT (1 and 30 min) 
before fixing. The third flask was used as a control. Then, 25% glutaraldehyde in
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0.1 M Sorensen’s phosphate buffer (0.1M Na2HP04.2H20 ; 0.3M NaH2P04.H20 , 
pH7.2; stock sol. 25% glutaraldehyde; TAAB, UK, No. G004) was added to each 
flask to give a final concentration of 2.5% v/v. The flasks were fixed O/N at RT.
2.3.5.12.2 TSC bacterial culture preparation for 1% PVP-I testing
To investigate the effect of PVP-I on MRS A under “contact test” conditions, 
bacterial cultures (MRSA isolate 1106) were prepared (Section 2.3.5.12.1). All 
bacterial cultures were centrifuged (13000 x g, 10 min), supernatants discarded, the 
bacterial pellet washed in TSC (50 ml) and re-centrifuged (13000 x g, 10 min). The 
resultant bacterial pellet was re-suspended in either TSC (50 ml) containing 3 g/1 
BSA (n = 3 flask) or TSC (50 ml; control). PVP-I (1%) was added to 2 flasks 
containing the bacterial suspension in TSC and BSA and left at RT for 1 and 30 min 
before fixing (Section 2.3.5.12.1). The third flask containing the bacterial 
suspension in TSC with 3 g/1 BSA was used as a second control.
2.3.5.12.3 Bacterial harvesting and preparation of bacterial samples for TEM
Samples were processed and imaged by Dr J. Hobot, Cardiff University. 
Bacteria were isolated from the fixation solution by filtration (0.45 pm Whatman 
cellulose nitrate filters) and carefully removed from the surface of the filter using a 
spatula and re-suspended in molten (37°C) low melting point agarose 2% (w/v; 
Sigma-Aldrich) prepared in TSB containing 3 drops of blue beads (Immobilised 
Cibacron Blue F3Ga; Pierce, USA). The agarose was allowed to solidify, and then
- j
sectioned (approx. <lmm ) and placed in ethanol (50%) for processing. Samples 
were fully dehydrated (Table 2.7). Agar blocks were then placed into a ‘size O’/vol 
0.68 ml gelatine capsule to which 0°C LR White resin (Hard Grade; London Resin 
Co, London, UK), containing accelerator was added. This was allowed to 
polymerise at 0°C for 24 h, followed by 2 h at 50°C.
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Table 2.7 Dehydration steps for the preparation of agarose slices for TEM imaging
Dehydration step Time required
50% ethanol 10 min
70% ethanol 10 min
90% ethanol 10 min
100% ethanol 60 min
1:1 LR White: 100% ethanol 30 min
1:0 LR White 20 min
1:0 LR White 20 min
1:0 LR White 20 min
1:0 LR White 20 min
LR, London resin white acrylic resin
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2.3.5.12.4 TEM imaging
The samples were cut into ultra thin sections using a LKB III Ultra­
microtome. Sections were stained with aqueous uranyl acetate (4% w/v; 5 min), 
washed with water, and counterstained with Millonig’s lead acetate for 30 s. 
Sections were viewed using a Philips/FEI CM 12, (80 kV) and images recorded (SIS 
MegaView III digital camera).
2.4 Results
2.4.1 Demographic data
The initial audit cohort of patients collected by Dr R. S. Howell-Jones 
(Howell-Jones, 2007) included 81 (54%) female and 69 (46%) male patients, and 
observed a wide age range (from 24 to 93 years). The number of wounds per patient 
ranged from 1 to 8 wounds, with a wound duration period between 3 months and 42 
years. The aetiology of wounds represented a full spectrum, with the majority of 
patients (51%) having chronic venous leg ulcers. Chronic surgical wounds 
represented 28% of patients and foot ulcers represented 13.3% of patients, whilst 
7.3% of patients were categorised as having miscellaneous chronic wounds e.g. 
perineal sinus, pressure ulcers.
2.4.2 Identification of isolates
Cultural analysis of swab samples in this thesis found that 75 (50%) patients 
were colonised with S. aureus. Of these 58 (77.3%) isolates were meticillin and 
oxacillin sensitive and 17 (22.6%) isolates were found to be MRSA. Three of the 
patients found to be colonised by MRSA were positive on two sampling occasions; 
two patients were colonised with MRSA on the second visit but not the first. Four 
patients identified as having a wound colonised with MRSA at the first visit were not 
found to be MRSA positive at the second sampling. MRSA was isolated in; 4 (20%)
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patients with foot ulcers, 5 (6.5%) patients with leg ulcers, 1 (9%) miscellaneous 
wound and 7 (16.6%) surgical wounds.
CNS were harboured by 57 (38%) patients, of which 36 (63.2%) were 
sensitive to meticillin, and 17 (29.8%) were meticillin resistant. Interestingly, 4 
(7%) patients were colonised with CNS that were meticillin sensitive but oxacillin 
resistant.
2.4.3 Antibiotic susceptibility testing
2.4.3.1 Disc diffusion assay
The antibiotic susceptibilities of all S. aureus and CNS isolated from chronic 
wounds using the disc diffusion assay are shown in Table 2.8. All isolated MRSA 
were resistant to meticillin, oxacillin, cefoxitin, ciprofloxacin and penicillin. 
However, there was low resistance to tetracycline, chloramphenicol, and 
fosphomycin glucose-6-phosphate and no vancomycin resistant strains in this group 
of MRSA isolates. A number of the isolates however exhibited multi-resistance. 
Seven (41.2%) of the isolated MRSA indicated resistance to beta-lactams and a 
further 5 groups of antibiotics (Table 2.9). No resistance to meticillin, oxacillin, 
cefoxitin or vancomycin was identified amongst the MSSA isolates (Table 2.8). The 
majority of MSSA were resistant to penicillin, trimethoprim, co-trimoxazole, 
rifampicin and ciprofloxacin.
All isolated meticillin resistant CNS were resistant to meticillin, oxacillin, 
cefoxitin, ciprofloxacin and penicillin. There were no vancomycin resistant strains. 
In spite of this, a number of the isolates were multi-resistant, with 6 (35.3%) 
meticillin resistant CNS indicating resistance to beta-lactams and a further 5 groups 
of antibiotics (Table 2.10). Oxacillin resistant, meticillin sensitive, coagulase 
negative staphylococci were also resistant to penicillin. None showed resistance to 
meticillin, cefoxitin, tetracycline, chloramphenicol or vancomycin, although there 
was mixed antibiotic resistance to the other antibiotics tested. Of the isolated 
meticillin and oxacillin sensitive CNS, none were resistant to meticillin, oxacillin,
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Table 2.8 Antibiotic resistance of chronic wound staphylococci
Antibiotic MRSA (n=17)
Number of bacterial isolates with resistance 
MSSA (n=58) CNS met11 (n=17) CNS oxaR (n=4) CNS (n=36)
Meticillin 17 (100%) 0  (0 %) 17 (100%) 0  (0 %) 0  (0 %)
Oxacillin 17 (100%) 0  (0 %) 17 (100%) 4 (100%) 0  (0 %)
Vancomycin 0  (0 %) 0  (0 %) 0  ( 0 %) 0  (0 %) 0  (0 %)
Penicillin 17 (100%) 50 (86.2%) 17 (100%) 4 (100%) 31 (86.1%)
Clindamycin 14 (82.4%) 19 (32.8%) 10 (58.8%) 4 (100%) 16 (44.4%)
Gentamicin 7 (41.2%) 10 (17.2%) 9 (52.9%) 1 (25%) 4 (11.1%)
Fusidic acid 14 (82.4%) 36 (62%) 14 (82.4%) 4 (100%) 29 (80.6%)
Erythromycin 9 (53%) 4 (6.9%) 14 (82.4%) 4 (100%) 17 (47.2%)
Trimethoprim 15 (88.3%) 48 (82.8%) 16 (94.1%) 3 (75%) 30 (83.3%)
Co-trimoxazole 6  (35.3%) 45 (77.6%) 16 (94.1%) 3 (75%) 3 4  (94.4%)
Tetracycline 1 (5.9%) 4 (6 .8 %) 3 (17.6%) 0  (0 %) 1 (2 .8 %)
Chloramphenicol 1 (5.9%) 0  (0 %) 0  (0 %) 0  (0 %) 0  (0 %)
Fosphomycin glucose-6 -phosphate 2  (1 1 .8 %) 1 (1.7%) 2  (1 1 .8 %) 2 (50%) 11 (30.6%)
Cefoxitin 17 (100%) 0  (0 %) 17 (100%) 0  (0 %) 0  (0 %)
Rifampicin 13 (76.5%) 46 (79.3%) 8 (47%) 2 (50%) 10 (27.8%)
Ciprofloxacin 17 (100%) 41 (70.7%) 17(100%) 4 (100%) 19 (52.8%)
Mupirocin 6  (35.3%) 4 (6.9%) 6  (35.3%) 2 (50%) 6  (16.7%)
Quinupristin/Dalfopristin 4 (23.5%) 1 (1.7%) 5 (29.4%) 0  (0 %) 0  (0 %)
MRSA, meticillin resistant Staphylococcus aureus; MSSA, meticillin sensitive Staphylococcus aureus; CNS metR, meticillin resistant 
coagulase negative staphylococci; CNS oxaR, oxacillin resistant coagulase negative staphylococci; CNS, coagulase negative staphylococci.
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Table 2.9 Antibiotic resistance profiles of wound MRSA isolates
Isolate MET OXA PEN CEF TMP SMX GEN ERY
Antibiotic 
VAN TET CIP SYN CLIN FUS CHL MUP RIF FOS
1001 R R R R R R R R R R R R
1004 R R R R R R R R R R R
1009 R R R R R R R R R R R
1011 R R R R R R R R R R
1021 R R R R R R R R R R R R
1044 R R R R R R R R R
1047 R R R R R R R R R R R R
1051 R R R R R R R R R R R R R
1057 R R R R S R R R R R R
1067 R R R R R R R R R S
1103 R R R R R R R R R
1106 R R R R R R R
1108 R R R R R R R R
1141 R R R R R R R R R R R R
1150 R R R R R R R R R R R R
2018 R R R R R R R R R R R
2124 R R R R R R R R R
MET, meticillin; OXA, oxacillin; PEN, penicillin; CEF, cefoxitin; TMP, trimethoprim; SMX, sulfamethoxazole; GEN, gentamicin; ERY, 
erythromycin; VAN, vancomycin; TET, tetracycline; CIP, ciprofloxacin; SYN, quinupristin/dalfopristin; CLI, clindamycin; FUS, fusidic acid; 
CHL, chloramphenicol; MUP, mupirocin; RIF, rifampicin: FOS, fosphomycin glucose-6-phosphate.
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Table 2.10 Antibiotic resistance profiles of wound meticillin resistant CNS isolates
Isolate MET OXA PEN CEF TMP SMX GEN ERY
Antibiotic 
VAN TET CIP SYN CLIN FUS CHL MUP RIF FOS
1015 R R R R R R R R R R
1038 R R R R R R R R R R R R
1040 R R R R R R R R R R R R
1056 R R R R R R R R R R R R
1057 R R R R R R R R R R
1064 R R R R R R R R R R R
1067 R R R R R R R R R R R
1084 R R R R R R R R R R
1088 R R R R R R R R R R R
1090 R R R R R R R R R
1096 R R R R R R R R R
1112 R R R R R R R R R
1142 R R R R R R R R R R R
1143 R R R R R R R R R R R R
1147 R R R R R R R R R R R
2023 R R R R R R R R R R R R
2072 R R R R R R R R R R
MET, meticillin; OXA, oxacillin; PEN, penicillin; CEF, cefoxitin; TMP, trimethoprim; SMX, sulfamethoxazole; GEN, gentamicin; ERY, 
erythromycin; VAN, vancomycin; TET, tetracycline; CIP, ciprofloxacin; SYN, quinupristin/dalfopristin; CLI, clindamycin; FUS, fusidic acid; 
CHL, chloramphenicol; MUP, mupirocin; RIF, rifampicin: FOS, fosphomycin glucose-6-phosphate.
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cefoxitin, chloramphenicol, or vancomycin. However, almost all were resistant to 
penicillin, and approximately 53% were resistant to ciprofloxacin.
2.4.3.2 mecA gene identification by PCR
PCR of the mecA gene was used to identify the presence of meticillin 
resistance in isolates that exhibited oxacillin, meticillin and cefoxitin resistance. All 
CNS and S. aureus sensitive to meticillin and oxacillin were also tested.
The mecA PCR demonstrated that all isolates deemed MRSA or meticillin 
resistant CNS from susceptibility testing were positive for the mecA gene. Of those 
isolates classified as meticillin sensitive (including oxacillin resistant CNS) none 
were positive for the mecA gene (Table 2.11). Figures 2.8 and 2.9 demonstrate 
agarose gel separation of the mecA PCR products for S. aureus and CNS wound 
isolates.
2.4.4 Effectiveness of biocides using carrier test methodology
2.4.4.1 Validation of drop count method
Validation of the drop count method (Appendix Ill.i) demonstrated there was 
no significant intra-researcher or method variance between the replicates (P>0.05).
2.4.4.2 Validation of neutraliser efficacy
Table 2.12 shows the mean CFU/ml for the working bacterial suspension, test 
solution (test biocide), control solution (control biocide), plus efficacy of each 
neutralising agent and its toxicity values. All neutralising agents were found to have 
<2 logio difference, indicating that none were toxic to S. aureus. All neutralisers 
were effective at quenching the known biocide, indicated by values <0.3 difference 
between control and test solution viable bacterial counts.
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Table 2.11 Number of isolates with meek, as identified by PCR
Isolate Number of tested isolates
Number of isolates with meek 
present
MRSA 17 17 (100%)
MSSA 58 0 (0%)
CNS metR 17 17(100%)
CNS oxaR 4 0 (0%)
CNS 36 0 (0%)
MRSA, meticillin resistant Staphylococcus aureus; MSSA, meticillin sensitive 
Staphylococcus aureus\ CNS metR, meticillin resistant coagulase negative 
staphylococcus; CNS oxaR, oxacillin resistant coagulase negative staphylococcus, 
meticillin sensitive; CNS, coagulase negative staphylococcus.
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Figure 2.8 Amplified mecK PCR product (1339 bp) for Staphylococcus aureus 
isolates. Lanes 1 and 16, 100 bp molecular weight standard (Promega); lane 2 and 3, 
negative controls, H2 O and NCTC 6571; lane 4, positive MRSA control NCTC 
12493; lanes 5 to 12, wound MRSA isolates; lanes 13 to 15, wound MSSA isolates.
1500 bp 
500 bp
Figure 2.9 Amplified mecK PCR product (1339 bp) for coagulase negative 
staphylococci isolates. Lanes 1 and 16, 100 bp molecular weight standard 
(Promega); lane 2 and 3, negative controls, H2 O and NCTC 11047; lane 4, positive 
MRSA control NCTC 12493; lane 5, wound meticillin sensitive CNS; lanes 6 to 15, 
wound meticillin resistant CNS.
Table 2.12 Validation of the neutraliser for each test biocide in terms of toxicity and efficacy
Mean CFU/ml Mean CFU/ml 
biocide
Mean CFU/ml 
control
Mean Mean
Biocide Neutraliser working neutraliser neutraliser
suspension toxicity (logio) efficacy (logio)
Silver nitrate Sodium thiosulphate 9.09 8.37 8.64 0.45 ±0.09 0.25 ±0.02
Povidone-
iodine
Lecithin and 
polysorbate 9.05 8.68 8.82 0.23 ±0.15 0.14 ±0.11
Potassium
permanganate Sodium thiosulphate 8.3 7.37 7.38 0.95 ± 0.03 0.03 ± 0.02
Povidone-
iodine Sodium thiosulphate 9.70 8.65 8.67 1.03 ±0.04 0.09 ± 0.02
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2.4.4.3 Biocide efficacy using the carrier test and drop count enumerating 
method
The exposure times required to achieve a 3 logio bacterial reduction for each 
biocide and test bacteria are outlined in Table 2.13. No isolates achieved the 
required bacterial log reduction with any biocide using a 1 min exposure time.
Of the isolates exposed to PVP-I, 88.9% achieved the target bacterial growth 
reduction with a 30 min exposure, with 55.6% of isolates reaching the target logio 
reduction within 15 min of exposure. Like PVP-I, 88.9% of isolates achieved a 3 
logio reduction with a 30 min contact time with potassium permanganate. In 
comparison, of the isolates exposed to silver nitrate only 55.6% of isolates reached 
the target bacterial reduction with a 30 min contact time.
2.4.4.4 Biocide efficacy using the carrier test and Bioscreen enumerating 
method
The required contact time to achieve a 3 logio reduction in bacterial growth 
following exposure to each biocide is shown in Table 2.13. Marked variation 
between biocide and strain was evident. The onset of a biocidal effect was evident 
with PVP-I
with one third demonstrating the 3 logio reduction in one minute. Furthermore, the 
majority of isolates (78%) achieved the target bacterial reductions in <15 min contact 
with PVP-I. Of the two isolates that did not achieved this, isolate 1108 fell just short 
(2.9 at 15 min). One strain (ATCC 6538) remained resistant to the action of PVP-I 
at 30 min.
Isolates exposed to silver nitrate and potassium permanganate failed to 
achieved the required 3 logio reduction with 1 min contact times using the Bioscreen 
method. For silver nitrate and potassium permanganate longer contact times (>30 
min) were necessary to achieve an effective biocidal effect in all strains save 1021 
with silver nitrate. Wound MRSA isolate (1106) was tolerant to the biocidal action 
of silver nitrate over the duration of the experiment.
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Table 2.13 Biocide contact times (min) necessary to achieve a 3 logio (CFU/ml) reduction in bacterial growth using the drop count and 
Bioscreen method
Drop count Bioscreen
Isolate Povidone-iodine Silver nitrate Potassiumpermanganate Povidone-iodine Silver nitrate
Potassium
permanganate
ATCC
6538 15 30 30 "2.5 at 30 30 "2.9 at 30
1004 15 N/A N/A 1 30 30
1011 30 N/A 30 "2.5 at 1 "2.8 at 30 30
1021 15 30 30 15 15 30
1106 *2.7 at 30 N/A 30 1 N/A 30
1108 30 N/A 30 "2.9 at 15 30 30
2018 30 30 30 15 30 30
2124 15 30 30 "2.8 at 1 30 30
ITU 2 15 30 30 1 30 30
N/A, not applicable, did not reach a 3 logio reduction; an at x, n logio reduction with x min contact time.
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2.4.4.5 Comparison of contact times to achieve 3 logio bacterial growth 
reductions using the Bioscreen and Drop count methods
Inter-experimental variation was clearly evident between the Bioscreen and 
drop count methods, although similar trends were observed. Contact times necessary 
to reach the required logio reduction, were generally higher for the drop count 
method than for the Bioscreen (Table 2.13). This is illustrated in the data for PVP-I 
where the contact times necessary for the required biocidal effect were less with the 
Bioscreen in 77.7% of isolates tested. The biocidal effect (logio reductions) 
generally increased with contact time for all biocides. However, the rapidity of this 
was greater with PVP-I. It was observed that the drop count method had increased 
logio reductions at contact times >15 min with PVP-I when compared with the 
Bioscreen method. Similar patterns were observed for isolates treated with 
potassium permanganate at contact time’s >30 min, and were observed in 40% of 
isolates treated with silver nitrate at contact times >30 min.
Statistical analysis of the logio results comparing the drop count and 
Bioscreen methods are shown in Table 2.14. The table demonstrates significant 
differences (P<0.05) in the results using the two enumerating methods obtained for 
PVP-I, silver nitrate, and potassium permanganate, for the 3 contact times. A large 
number of isolates treated with PVP-I showed a significant statistical difference 
(P<0.05) when comparing logio reductions using the Bioscreen and drop count 
method, with the drop count accounting for greater logio reductions (>15 min). In 
contrast, all of the obtained statistical differences (P<0.05) in logio reductions 
associated with enumerating methods for potassium permanganate and silver nitrate 
were associated with increased Bioscreen reductions.
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Table 2.14 Statistical differences (P<0.05) in logio reduction for Bioscreen and Drop count method
Isolate Silver nitrate Povidone-iodine Potassium permanganate
1 min 15 min 30 min 1 min 15 min 30 min 1 min 15 min 30 min
ATCC 6538 g** £)** £)**
1004 g** D* g**
1011 B*
1021 g * * * D*
1106
1108 B* g**
2018 D*
2124 g* g** B** D* B*
ITU 2 B* B**
Significant difference between Bioscreen and drop count for each isolate at the contact times; B, greatest logio reduction observed with 
Bioscreen method; D, greatest logio reduction observed with Drop count method; *, significant P<0.05; **, very significant P<0.01; ***, 
highly significant P<0.001
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2.4.5 Hydrophobicity testing
Hydrophobicity testing was performed on isolates exposed to PVP-I, 
beacause this was the most efficacious biocide. The aim was to determine if the 
biocide altered the hydrophobicity of the cells, indicating causality for the decreased 
magnitude of alterations in logio reductions with increased contact times.
2.4.5.1 Hydrophobicity testing using Salt aggregation test
This method did not show aggregation of any MRSA isolates in this study 
(Results not shown) at any of the concentrations previously described by Lindahl 
(1981).
2.4.5.2 Hydrophobicity testing using the n-hexadecane adherence assay (HAA)
The changes in percentage (%) adherence of isolates following exposure to 
PVP-I using 0.8 ml n-hexadecane is shown in Figure 2.10a. In these studies there 
was a wide variation in strain hydrophobicity. Following PVP-I exposure, there was 
an increase in % adherence of the cells tested. Prior to treatment, 33.3% of the 
isolates were classified as hydrophilic and 66.6% as intermediately hydrophobic. 
However, following 1 min treatment with PVP-I, 88.8% were classified as 
intermediately hydrophobic and 11.1% as hydrophobic. A statistical significant 
difference (P<0.05) in hydrophobicity between pre- and post-treatment of S. aureus 
isolate ATCC 6538 was achieved.
2.4.5.3 Hydrophobicity testing using the cyclohexane adherence assay (CAA) 
The changes in % adherence of isolates following exposure to PVP-I using
0.8 ml cyclohexane is shown in Figure 2.10b. Like the HAA assay, inter-strain 
hydrophobic variability was observed and following PVP-I treatment cell adherence 
increased. Prior to treatment with PVP-I, all of the isolates were classified 
intermediately hydrophobic. Following treatment, 88.9% were classified as 
intermediate and only 11.1% as hydrophobic. Statistical differences (P<0.05) in
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Figure 2.10 Changes in mean adherence/hydrophobicity of MRSA isolates 
following exposure to povidone-iodine. a) n-Hexadecane; b) Cyclohexane; c) p- 
Xylene.
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pre- and post-treatment hydrophobicities for isolates 1011, 1108 and ITU2 were 
observed. An increase in hydrophobicity for isolates 1021, 1004, 1106 post­
treatment was also observed but this was not statistically significant (P>0.05).
2.4.5.4 Hydrophobicity testing using the p-xylene adherence assay (XAA)
Changes in % adherence of isolates following exposure to PVP-I using 0.25
ml p-xylene is shown in Figure 2.10c. Again from these data it was observed that 
following the exposure of PVP-I there was an increase in % adherence of cells. Prior 
to treatment 66.6% of the isolates were classified as hydrophilic and 33.3% as 
intermediately hydrophobic. Following treatment 77.8% were classified as 
intermediate hydrophobic and 22.2% as hydrophilic. A statistical difference was 
achieved for pre- and post-treatment hydrophobicity (P<0.05) of isolates 1011,1004, 
1106 and ITU 2. Hydrophobic changes post PVP-I exposure were also observed for 
isolates 1021,2018,1108. However, this was not statistically significant (P>0.05).
2.4.5.5 Comparison of adherence assays and hydrophobicity of MRSA following 
iodine exposure
Table 2.15 shows comparison of changes in hydrophobicity post-exposure to 
PVP-I for all isolates in all three adherence assays. Each isolate exhibited increased 
hydrophobicity following exposure to PVP-I, except for isolate 2018 using the CAA 
assay. Both HAA and XAA placed 44.4% of isolates into a different hydrophobic 
category post PVP-I exposure. Only 11.1% of isolates were placed into a different 
hydrophobic category following PVP-I exposure using the cyclohexane assay.
Contrasting results for HAA and XAA pre- and post-exposure to PVP-I were 
observed with 33.3% of isolates placed in a different hydrophobic category (Table 
2.15). Similar hydrophobicity results were observed pre-treatment using HAA and 
CAA, 33.3% were categorised as different hydrophobic natures, yet post-exposure 
all isolates were similarly typed. Greater disparity of isolate hydrophobicity 
categorisation was observed using XAA and CAA pre-and post-exposure to PVP-I.
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Table 2.15 Comparison of hydrophobicity changes associated with the adherence
assays post-exposure to povidone-iodine
Adherence assay
Isolate n-Hexadecane p-Xylene Cyclohexane
ATCC 6538 * t t
1004 t ** t
1011 t * *
1021 t t t
1106 t * t
1108 t t ^ *
2018 t t 4
2124 t t t
ITU 2 t ^ ** *
t ,  increase in % adherence; i ,  decrease in % adherence; * statistical significant 
difference (P<0.05) pre- and post-exposure to PVP-I % adherence; **statistical 
significant difference (P<0.01) pre- and post-exposure to PVP-I % adherence.
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2.4.6 Effect of PVP-I on the cellular structure of MRSA
SEM images of the S. aureus isolates following 1 min treatment with 0.1 % 
and 1 % PVP-I, the most efficacious of the 3 biocides tested in this study, are shown 
in Figure 2.11. The control samples show multiple cell layers and varying levels of 
bacterial cell coverage with a strain dependant extracellular polysaccharide 
substance (EPS; glycocalyx). Dose-dependent effects were observed following 
application of PVP-I. In all samples, there was a decrease in matrix covering the 
bacteria using 0.1% PVP-I compared with the control, with the decrease more 
apparent with 1% PVP-I. No cellular conformational changes were observed 
following treatment with PVP-I.
2.4.7 Effect of 1% PVP-I on internal cellular structures of MRSA using 
transmission electron microscopy (TEM)
The effects of PVP-I exposure on the internal structure of MRSA isolate 
1106 is shown in Figures 2.12 and 2.13. This isolate was chosen as it was the wound 
isolate most tolerant to PVP-I and showed the greatest hydrophobic change. 
Bacterial cells in broth culture exhibited normal organisation of the nuclear material 
and cell wall (Figures 2.12a and b). Bacterial cells treated with PVP-I in broth 
showed an electron dense cell membrane, with movement of the cellular contents 
from the membrane and partitioning of the cytoplasm. Loss of cellular material was 
also observed in broth bacteria treated with PVP-I (Figures 2.12c and d), alongside 
time-dependent reconfiguration and rearrangement of the nucleoid material (Figures 
2.12e and f).
As biocides may be affected and neutralised by proteins and organic matter, 
TEM was repeated in TSC and BSA to confirm if images from TSB broth with PVP- 
I could be replicated. Artifactual differences including “collapse” and DNA 
aggregation consistent with centrifugal forces, prior to re-suspension of bacteria 
were evident (Figures 2.13a and b).
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Isolate Control 0.1% Povidone-iodine 1% Povidone-iodine
ATCC
6538
1004
1021
1106
1108
Figure 2.11 Scanning electron micrographs of Staphylococcus aureus cells treated 
with povidone-iodine. A), multiple cell biofilm; B), loss of extracellular 
polysaccharide substance (glycocalyx); C), extracellular polysaccharide substance 
(glycocalyx); D), single Staphylococcus aureus cell.
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Figure 2.12 Transmission electron micrographs of MRSA isolate 1106 under TSB 
broth conditions, a, b) Control; c, d) 1 min PVP-I; e, f) 30 min PVP-I; a, c, e, x
100,000 magnification; b, d, f, x 40,000 magnification; A), cell wall; B), ribosome; 
C), nucleoid and nuclear contents; D), ghost cells; E), dividing bacterial cell; F), 
cellular leakage; G), nucleoid collapse; H), DNA aggregation; I), nucleoid recovery; 
J), cytoplasm.
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Figure 2.13 Transmission electron micrographs o f MRSA isolate 1106 under 
tryptone sodium chloride (TSC) conditions, a) Control TSC; b) Control TSC & 
BSA; c) 1 min PVP-I, TSC & BSA; d) 1 min PVP-I, TSC & BSA; e) 30 min PVP-I, 
TSC & BSA; f) 30 min PVP-I, TSC & BSA. a, b, c, e), x 40,000 magnification; d, 
f), x 20,000 magnification; A), cell wall; B), dividing cell; C), nucleoid collapse 
associated with centrifugal forces; D), DNA aggregation; E), nucleoid; F), severe 
collapse of nucleoid; G), loss of cellular material; H), cytoplasm; I), nucleoid 
recovery.
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In 1% PVP-I, bacterial cells showed collapse of the nucleoid structure, 
aggregation of DNA with a finger like projection arrangement, and significant loss 
of cellular material in bacteria suspended in TSC and BSA (Figures 2.13c-f). 
Recovery of the bacterial cells in TSC with BSA was not evident unlike that 
observed with TSB broth cultures and is likely to be associated with the initial 
severity of damage seen at one minute exposure, and may also be associated with 
initial centrifugal force alterations.
2.5 Discussion
2.5.1 Antibiotic resistance
A total of 150 patients were included in this study, (one was rejected on the 
basis of insufficient data). Of the 150 patients, 39 had repeat sampling over the 10 
week period. Detailed microbiological investigation of these wounds demonstrated 
that Staphylococcus aureus was isolated from 50% of patients in this study, of which 
the majority 77.3% were meticillin sensitive, with 22.6% of isolates being meticillin 
resistant. This relates to 11.3% of the total cohort. Many studies have investigated 
the isolation of S', aureus in chronic wounds; for example Bowler and Davies (1999) 
employed samples from infected and non-infected wounds and found that 33% of 
wounds carried S. aureus. A prospective study by Davies et al. (2007) found a 
34.8% surface carriage and 25.8% deep tissue carriage (via biopsy) of S. aureus in 
non-infected wounds. In contrast, this study shows greater carriage of S. aureus than 
both previous studies. This may indeed be the case in relation to Davies et al. (2004) 
because some of the patients identified in this study showed signs of infection.
Surveillance of pathogens has identified that 30-50% of the population show 
transient colonisation of S. aureus (Tenover and Gorwitz, 2006) and that certain 
groups show greater tendencies to colonisation. The nature of these wounds may 
explain the greater carriage of S. aureus by this particular patient group, as patients 
with skin lesions are known to be more susceptible to long-term carriage of MRSA
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(Halcon and Milkus, 2004, Bimie et al., 2008, Haslund et al., 2009, Kim et al., 2009) 
and also improved isolation and culture techniques may have been employed.
The carriage rate of MRSA was relatively low (11.3%), and accounted for 
22.6% of the total number of staphylococci isolated. This is half of the national 
average percentage of MRSA associated with bacteraemia and invasive disease, 
purported to be 40% prior to 2008 (Ayliffe et al., 1998, Tiemersma et al., 2004, Coia 
et al., 2006, Health Protection Agency., 2006b). There are obvious differences in the 
pathology and bacterial roles in chronic skin wounds compared to MRSA 
bacteraemia, which may partly explain the differences in isolation rates. However, 
one would expect carriage rates to be significantly greater than in the general 
population, especially when looking at risk factors for colonisation of MRSA; 
antibiotic usage, hospitalisation and diabetes which are prevalent in these patients. 
The results observed reflected recent (2009) MRSA resistance rates of 28%, (ECDC, 
2005 - 2011). Possible reasons for lower observed rates of MRSA isolation in this 
study may be associated with; microbial sampling methods (and culture techniques), 
or a low number of MRSA colony forming units (CFU) present in the wound or 
possibly better infection-control measures used by the wound clinic.
CNS is found as a normal skin commensal, and the exact role of the organism 
in wounds has yet to be established; it may only be present as a coloniser. 
Importantly, however, CNS has been demonstrated to play a role in the transmission 
of resistance; MSSA acquisition of the SCCmec by horizontal transfer from 
meticillin resistant CNS has been demonstrated (Hanssen and Ericson Sollid, 2006). 
Significantly, CNS is also increasingly implicated in biofilm-related persistent 
infection and associated diseases e.g. catheter related disease (Marques de Mattos et 
al., 2003, Piette and Verschraegen, 2009, Hellmark et al., 2010). The pathogenicity 
of this particular microorganism may therefore have been previously underestimated, 
in the chronic wound biofilm.
A higher percentage of MRSA was isolated from patients with foot ulcers 
and surgical wounds (20% and 16.6% respectively) when compared to leg ulcers.
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The increased prevalence of carriage in these wounds in comparison to leg ulcers 
(6.5%) and miscellaneous wounds (9%) may be associated with wound aetiology. 
Surgical wounds are associated with increased hospitalisation, whilst patients with 
foot ulcers have underlying wound aetiologies and a greater tendency to be diabetic, 
a further risk factor for colonisation by this pathogen (Tenover and Gorwitz, 2006, 
Stanaway et al., 2007, Schechter-Perkins et al., 2011).
Antibiotic susceptibility testing using the disc diffusion assay demonstrated 
multiple resistances among the MRSA isolates. All of the MRSA isolates were 
resistant to meticillin, oxacillin, penicillin and cefoxitin as would be expected due to 
the presence of PBP2a used in cell wall formation. In addition, unsurprisingly, all of 
the isolates were resistant to ciprofloxacin, a common antibiotic prescribed for the 
treatment of chronic wound Pseudomonas sp. infections and is frequently prescribed 
in these patients (Howell-Jones et al., 2006). Reassuringly, no vancomycin resistant 
isolates were identified. Only one isolate was resistant to tetracycline and 
chloramphenicol and may reflect the infrequent use of these antibiotics to treat 
staphylococcal and soft tissue chronic wound infections, and as a consequence a lack 
of selective pressure. This finding is further supported by Strommenger et al. (2003) 
who postulated that ‘old’ antibiotics should now be included in susceptibility testing 
due to decreased resistance frequencies. The observed number of MRSA (35%) 
isolates identified as resistant to mupirocin, (the current preferred mode of treatment 
for MRSA colonisation) was concerning and highlights the importance of 
susceptibility testing in chronic wound patients.
Antibiotic susceptibility testing amongst the MSS A isolates proved that none 
were resistant to meticillin, oxacillin or cefoxitin which is as would be expected as 
these organisms did not harbour the mecA gene. No isolates were resistant to 
chloramphenicol or vancomycin and only 4 of the isolates were resistant to 
tetracycline, erythromycin and mupirocin. The resistance to penicillin by S. aureus 
isolates in this study is similar to those previously reported (Ayliffe et al., 1998, 
Deurenberg et al., 2007), where approximately 80% of the MSSA were resistant to
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penicillin, (associated with penicillinase production by the organism). Four CNS 
isolates showed resistance to oxacillin but not to meticillin or cefoxitin, even with 
prolonged incubation. Due to the ability of CNS to frequently indicate a decreased 
susceptibility to meticillin via disc and broth susceptibility testing methods, the 
identification of the mecA gene is imperative in this circumstance. Therefore, for 
correct classification, the determinant of genetic resistance mechanisms must be 
proved. In these four isolates, no genetic resistance (mecA) was observed and, 
therefore, the isolates were classified as hyper-producers of penicillinase (Brown, 
2001, Buchan and Ledeboer, 2010).
Identification of the mecA gene by PCR is a simple and specific method to 
identify meticillin resistance, and proved to be 100% effective in this study, with no 
false positives produced. Hence overall, mecA PCR identification of meticillin 
resistance is likely to be more accurate than the disc diffusion assay. Particularly as 
there is risk of significant inter-researcher variance, predominantly in the preparation 
of the inoculum (0.5 McFarland standard turbidity) and in reading the zones of 
inhibition with the disc diffusion assay.
This study has demonstrated that non-healing skin wounds harbour multiple 
staphylococci spp. many of which show multi-drug resistance (MDR) which may 
play a crucial role in their wound aetiology. These MDR organisms moreover, are 
able to transfer pathogenicity and resistance via horizontal gene transfer, and are of 
utmost importance in terms of cross infection policies and hazards to health. These 
patients represent important reservoirs of cross-infection due to hospitalisation, 
communal residences and interactions with healthcare professionals. It is therefore 
important to continue to screen patients with chronic wounds for the inevitable 
increase in antibiotic resistance that is expected based on current prescribing 
practices.
Further cultural analysis of wound patients should include the culture of 
normal skin and other areas of colonisation e.g. nose, to determine if chronic wound 
microbes are simply wound colonisers or more worryingly, the patient is a persistent
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reservoir for infection. Determining a comprehensive bacterial molecular and 
resistance profile for chronic wound patients over time may provide insights into 
possible risk factors for the development of these debilitating wounds, and act as an 
aid to treatment and future prevention.
2.5.2 Biocide efficacy
These antibiotic resistance studies observed a significant number of MDR 
bacteria, which are present in these chronic wounds. The use of systemic antibiotics 
should be limited to the systemically unwell patient, yet there is a need to control the 
bacterial burden in these wounds.
These studies investigated the antimicrobial efficacy of three clinically 
utilised biocides, based upon iodine, silver and potassium permanganate, used in the 
treatment of chronic wounds to decrease bacterial colonisation. To date, this is the 
first time the efficacies of these biocides have been investigeated using the carrier 
test method against MRSA. The methods utilised, and the test conditions employed 
were based upon published standards, but varied in their ease of use and reliability. 
The carrier test was labour-intensive, requiring the use of large volumes of analysis 
compared with MIC and broth dilution methods. However, the test at least 
resembled the wound environment with direct surface contact and incorporation of 
the effect of organic matter in the test system, unlike disc diffusion and MIC assays.
This experiment negated the effects that broths may have (e.g. neutralisation 
by proteins) on the tested biocides. In nature, bacteria exist as biofilms and the 
carrier test method is more representative of this than traditional MIC tests 
(particularly broth dilution testing). It is important to note that the growth conditions 
of the bacteria during biocide testing may affect the results (Johnston et al., 2002, 
Hill et al., 2010). The carrier test method investigated the effect of a biocide on 
bacteria in multiple layers and examined the effectiveness of a biocide to kill 
bacteria at specific exposure times due to the use of neutraliser which can rapidly
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and specifically quench biocidal activity (Lambert et al., 1998, Johnston et al., 2002, 
Johnston et al., 2003).
The drop count method was able to quantify the biocidal effects of each 
antimicrobial agent, obviating the need for multiple plate testing (as in the pour plate 
method) and hence was a more convenient means of enumerating bacterial growth. 
In contrast, Bioscreen analysis allowed higher sample throughput when compared 
with the drop count method. In these experiments, PVP-I was clearly the most 
effective biocide studied, adequately reducing bacterial growth within comparatively 
short contact times (<15 min). Potassium permanganate required increased exposure 
times to induce the required biocidal effect (>30 min). Silver nitrate was less 
effective than either PVP-I or potassium permanganate, only achieving the required 
3 logio reduction in <50% of the isolates within a 30 min contact time. Despite these 
observations, and previous studies questioning usefulness of silver, there is 
increasing interest and widespread use of silver-containing medicaments. Previous 
studies have shown that extended contact times (>2 h) are necessary to demonstrate 
silver biocidal activity (Woo et al., 2008). The data in this study shows that silver 
products have a limited effect against MRSA in wounds, a finding suggested 
recently by other authors (Hill et al., 2010).
The techniques utilised demonstrated considerable variation in the time 
dependant logio reduction induced by the biocides. The variation observed here 
between the Bioscreen and drop count methods is well described (Lambert and van 
der Ouderaa, 1999, Cheeseman et al., 2009). The Bioscreen method is known to 
overestimate logio reduction with respect to the drop counts. In these experiments 
PVP-I achieved a 3 logio reduction with the Bioscreen within 1 min, whilst with the 
drop count method was more commonly 15 min. Inter-assay variation is likely to be 
related to the Bioscreen method only accounting for intact healthy cells and not 
damaged (but viable) cells. The repair time needed for such cells to start proliferating 
is know as the lag phase (Lambert et al., 1998, Lambert and van der Ouderaa, 1999) 
and describes the ability of bacteria to recover following sub-lethal injury
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(Cheeseman et al., 2009). To overcome the discrepancies in quantification, selective 
counting of large colonies on the plate could have been used (Lambert and van der 
Ouderaa, 1999) assuming that all small colonies have arisen from injured bacterial 
cells taking longer to grow. The demonstration here that Bioscreen logio reductions 
were increased in comparison to the drop count reflects this sub-lethal damage to 
cells (Lambert et al., 1998). The exposure time for iodine to achieve the target logio 
reduction with the Bioscreen was far quicker than for the other biocides (89% in 15 
min), with the Bioscreen and drop count methods demonstrating similar exposure 
times (>30 min) to achieve a 3 logio reduction using potassium permanganate and 
silver nitrate.
Increased PVP-I contact times (>15 min) resulted in greater logio reductions 
for the drop count method over the Bioscreen that were statistically significant 
(P<0.05), indicating that irreversible damage had been achieved. In contrast, for 
silver nitrate 5 isolates showed increased logio reductions with the Bioscreen 
compared to the drop count analysis, indicating non-lethal damage was occurring 
using this biocide at the 30 min contact time, from which the cells were able to 
recover.
From these analyses PVP-I appeared the most efficacious biocide. Clinically, 
iodine is usually employed at maximum concentrations of 10% (w/v; Durani and 
Leaper, 2008). This data demonstrates a rapid (>1 min) and pronounced biocidal 
activity of PVP-I using a 1% (w/v) solution. Interestingly, the dissociation of “free 
iodine” from PVP-I is known to increase with dilution, which shows a corresponding 
increase in bactericidal effect. It is conceivable from these data that a 1% solution 
may be as effective as the surgical scrub application (Berkelman et al., 1982, Brown 
et al., 1995, Durani and Leaper, 2008).
This study raises further concerns over the effectiveness of silver compounds 
for the treatment of MRSA. In these studies, bacteria inoculated onto a flat dry 
surface exhibited minimal bacterial reduction despite prolonged contact times with 
silver. It is therefore conceivable that this poor efficiency is repeated in the in vivo
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situation when utilising silver-impregnated dressings. For effective activity against 
bacteria in the wound environment, the biocide must penetrate the tissues, and any 
associated bacterial biofilms, to exert its bacteriocidal effect; a far more complex 
interaction than that replicated in these studies which showed silver to have poor 
biocide efficacy. In vivo it has been suggested that >20 ppm of silver needs to be 
released into the wound bed for effective bacterial killing (Wright et al., 1998, 
Edwards-Jones, 2006). Evidence exists that nanocrystalline silver formulations, e.g. 
Acticoat®, are more effective due to an ability to increase the bioavailability of silver 
ions in solution (approximately >3 times the concentration of bound silver; Dunn and 
Edwards-Jones, 2004, Fong et al., 2005, Edwards-Jones, 2006, Newman et al., 2006, 
Woo et al., 2008). Silver containing dressings have also been developed to adsorb 
bacteria, facilitating increased contact times and the removal of wound exudates, 
which may neutralise the silver. In this respect, the use of nanocrystalline silver with 
increased contact times may be informative. Necessary contact times for silver (>7 
h) have been attributed to the Gram-positive cell wall (Newman et al., 2006), whilst 
Hill et al., (2010) observed that silver dressings were not effective against 7 day old 
biofilms. It is conceivable that the slow activation of silver nitrate in this study is 
associated with the release of silver ions into solution or the formation of chemical 
complexes (reducing silver ion availability). This chemical complexing is clinically 
avoided by repeated application of the agent (<12 times a day; Dunn and Edwards- 
Jones, 2004).
Interestingly, whilst PVP-I showed large initial logio reductions (with short 
contact times) using the Bioscreen and drop count methods, longer contact times did 
not result in logio reductions of such magnitude, as previously described (McLure 
and Gordon, 1992, Koburger et al., 2010). It is likely that these represent binding of 
iodine with the organic load (Khan and Naqvi, 2006) which may be both 
concentration and temperature dependant (Traore et al., 1996). Increases in logio 
reductions using the drop count method with increased contact time (i.e. no marked 
increase with the Bioscreen method observed) may indicate that the severity of the
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cellular damage induced by PVP-I was irreversible. The reduction in effect of 
prolonged activity was a marked feature of the chronic wound isolate 1106, and was 
thought to be associated with the isolates ability to recover following chemical 
insult; perhaps due to specific cell surface characteristics e.g. hydrophobicity. These 
findings indicate a need for regular dressing changes to ensure complete 
effectiveness of iodine as a wound antimicrobial. Recently, attempts have been 
made to produce “smart dressings” to aid clinicians in the identification of pathogens 
within wounds, to complement their clinical presentation (Jenkins and Young, 2010).
In this relatively small number of isolates, it was possible to examine 
previous patient biocide exposure and compare with the carrier test results (see 
Appendix Ill.iv). These experiments demonstrated that prior treatment with iodine 
and potassium permanganate did not increase the contact time necessary to achieve 
the required logio reduction. An interesting finding was that 2/3 of the patients in this 
study received >2 applications of silver treatment. Two MRSA strains previously 
exposed to silver did not achieve the required logio reduction; but neither did MRSA 
strains not previously treated with silver. The small number of patient isolates, and 
the limited data on previous treatment for the patients in this study make it difficult 
to definitively state whether biocide tolerance/resilience were associated with 
previous exposure. The small sample size of this study precludes deductions 
regarding the relationship between ST and biocide sensitivity, although previous 
studies have failed to reveal a relationship between phage variants and antibiograms 
with antiseptic susceptibility (McLure and Gordon, 1992).
There are inherent problems in the carrier test method, such as potential inter- 
researcher/inter-experiment differences characterised by the wide range of standard 
deviations obtained. This test does not adequately represent the dynamic wound 
environment, and in particular the representation of quenching effects of the skin and 
plasma proteins which are far more pronounced in vivo (Verran, 2002, Cheeseman et 
al., 2009). Like many disinfectant tests, the relevance of the laboratory to the 
clinical setting is also not clear (Fong et al., 2005, Verran, 2010b), making
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interpretation of the results more difficult and indicating that further clinical studies 
are required to fully understand the fundamentals of biocides currently in medical 
use.
Microbial adhesion to hydrocarbon (MATH) studies showed that exposure to 
PVP-I induced changes in percentage adherence or hydrophobicity of MRSA. It is 
interesting that isolate 1106 (showing greatest tolerance to PVP-I) became 
hydrophobic whilst all other isolates remained intermediately hydrophobic. These 
changes in hydrophobicity could be a way for bacteria to mitigate biocide attacks. 
Hydrophobicity of the isolate potentially prevented penetration of iodine (a 
hydrophile) into the cell. It is known that hydrophobicity of bacteria may modulate 
biocide tolerance (Maillard, 2007) as has been described in Pseudomonas 
aeruginosa (Russell, 1995).
MATH hydrophobicity testing was performed using 3 hydrocarbons at 
different volumes, decrease in absorbance of the aqueous phase of the bacterial 
suspension being used to measure hydrophobicity (Rosenberg, 2006). Hence, 
adhesion to the liquid hydrocarbon is associated with the hydrophobic nature of the 
cellular surface (Rosenberg et al., 1980, Rosenberg et al., 1983). Adherence 
increased with increasing test volumes (Rosenberg, 2006) which is likely associated 
with the greater number of hydrocarbon droplets to adhere to (van Loosdrecht et al., 
1987). Greene et al., (1992) observed that the volume of hydrocarbon may be 
important in hydrophobicity testing. In this study, the ideal hydrocarbon test volume 
was 0.8 ml (n-hexadecane, cyclohexane) and 0.25 ml (p-xylene), both previously 
identified (Greene et al., 1992, Galliani et al., 1994). Hence, the inter-strain and 
hydrocarbon variation may reflect the ability of the organism to bind to the phase- 
separating medium (Das et al., 2001) which can be affected by both the growth 
medium and centrifugation (Pembrey et al., 1999, Das and Kapoor, 2004). The 
bacteria in this study were grown on TSA to maintain consistency between 
experiments, and strains were generally classified as intermediately hydrophobic,
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unlike a study by Kouidhi et al, (2010), which classified most S. aureus strains 
(grown on blood agar containing 4% NaCl) as hydrophilic using n-hexadecane.
n-hexadecane (aliphatic) and cyclohexane (cyclo-aliphatic) treatment 
produced similar hydrophobic profiles, whereas p-xylene treatment resulted in 
decreased adherence of cells, which may be a feature of the ability of aromatic 
hydrocarbons like p-xylene to cause bacterial lysis (Pembrey et al., 1999). n- 
hexadecane testing was biased towards greater hydrophobicity; this may be 
associated with its chemical structure and lower water solubility.
Structural studies were employed to investigate the effect of PVP-I (the most 
active biocide) on the cell surface of the MRSA isolates. SEM analysis 
demonstrated the effective action of PVP-I on the presence of EPS. In these studies, 
PVP-I (<1% w/v) exhibited a concentration dependant loss of EPS. The loss of EPS 
and disruption of bacterial adhesion reflected the increased killing observed in the 
carrier test (drop count) assay with increased contact times; bacterial exposure to 
biocide surface area increasing with time. Studies have demonstrated that effective 
concentrations of biocides vary in 3-dimentional structures, allowing cell survival in 
the centre of a biofilm (Brown et al., 1995, Oie et al., 1996, Buckingham-Meyer et 
al., 2007, Maillard, 2007). These structural effects in the SEM studies were 
observed within a 1 min contact time, and it is anticipated that increased contact 
would result in more antimicrobial effects.
The intracellular effects of exposure to the effective biocide (1%) PVP-I was 
studied using two contact times employing TEM. Wound isolate 1106 was used as 
this was the most recalcitrant of the isolates. Bacteria treated with PVP-I appeared 
to exhibit a difference to the control (broth and TSC cultures). PVP-I treated cells 
exhibited coagulation of nuclear material and partitioning of the cytoplasm, a feature 
seen by Schreier et al., (1997) reflecting the likely denaturation of cellular proteins 
(Cooper, 2007). Evidence of cytoplasmic recovery (reorganisation) was observed 
for experiments conducted in the nutrient rich broth >30 min PVP-I exposure. This 
finding has been attributed to the organic load (proteins and extracts) of the broth
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effectively neutralising the iodine (Koburger et al., 2010) and to the cells innate 
capacity to recover following sub-lethal stresses. This corresponds to the limited 
decrease in CFU/ml with greater contact times that were observed during the carrier 
tests. These findings may potentially reflect either efflux-pump activity or 
hydrophobic changes, decreasing the amount of intracellular iodine. This notion is 
supported by studies demonstrating no biocidal activity with increased contact times 
(McLure and Gordon, 1992, Koburger et al., 2010).
Interestingly, bacteria grown in broth and then re-suspended in TSC/BSA 
displayed specific artifact (centrifugal-related) changes in the nucleoid region, prior 
to biocide treatment. It is important to note that the damage observed is not simply a 
result of exposure to PVP-I in this experiment. Following biocide treatment 
however, significant changes were evident; gross cell lysis; loss of cellular content as 
a result of pore formation, leading to empty cells and accumulation of extracellular 
debris were evident from even 1 min PVP-I exposure. Few cells were able to 
recover from this in the 30 min period of the experiment.
Topical antiseptics still have a significant role in the control of wound 
bacteria. In these experiments using chronic wound MRSA, iodine proved to be an 
effective antimicrobial, whilst silver and potassium permanganate were not. As only 
a single concentration of each biocide was tested in these studies, it would be 
prudent to perform dose response curves for each biocide examined using these test 
conditions as future work.
Further investigation is required to determine how bacteria recover following 
biocide insult to ascertain if this is as a result of intrinsic or acquired resistance 
patterns. For example, biocide resistant mobile genetic elements may exist in the 
wound environment, much like antibiotic resistance. Investigation of other silver 
biocides would also be interesting e.g. nanocrystalline dressings, which may prove to 
be more effective than the silver compound used here. Further research is also 
necessary to determine if tolerance is associated with ST of the MRSA or previous 
biocide exposure.
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Chapter 3: 
Investigation of MRSA virulence
factors
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Chapter 3 Part I: MRSA typing and virulence factor profiles of chronic wound 
and asymptomatic nasal carrier MRSA 
3.1 Introduction
Meticillin resistant Staphylococcus aureus (MRSA) poses a worldwide 
nosocomial problem, which resulted in greater than 2000 deaths in 2005 in the UK 
alone (www.statistics.gov.uk/pdfdir/deaths0207.pdf; accessed 04/05/10). The globed 
nature of MRSA has led to attempts to track the pathogen, identify genotypic 
diversity and descriptive epidemiological studies. In this time, a number of 
laboratory methods for the identification of MRSA have been developed, revealing 
that epidemic MRSA (EMRSA) 15 and 16 are most commonly identified strains in 
UK hospitals (Holden et al., 2004, Ellington et al., 2010).
MRSA is frequently identified as an acute wound isolate, and can be 
associated with colonisation of the healthy host. The role of MRSA in chronic 
wound healing is however unclear. Moreover, it is known that MRSA produce a 
range of virulence factors which facilitate survival and enhance pathogenicity. A 
number of these factors are attributed to specific disease processes e.g. toxic shock 
and staphylococcal scalded skin infections (SSSI; Jarraud et al., 1999, Peacock et al., 
2002). Such virulence factors may clearly play specific roles in modulating the non­
healing of chronic wounds.
3.1.1 Typing MRSA isolates
In outbreak settings of MRSA, typing may facilitate bacterial identification, 
and identify “clusters” of patients or those at risk; leading to implementation of 
prevention strategies. Due to the emergence of MRSA, further acquisition of 
resistance genes and associated healthcare risks, active monitoring is performed to 
aid cross infection programmes e.g. the European Antimicrobial Resistance 
Surveillance Network (EARS-Net) provides European reference data on 
antimicrobial resistance and search and destroy strategies (Higgins et al., 2010).
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Numerous typing methods are employed, with the most contemporary being 
sequence based (Chapter 1, Section 1.9)
3.1.2 Chronic wound carriage of MRSA
Chronic wounds are known to be polymicrobial. Both S. aureus and 
coagulase-negative staphylococci (CNS) were found to be the predominant 
organisms isolated from both prospective (Davies et al., 2007) and retrospective 
(Tentolouris et al., 1999) studies. A recent study by Yates et al., (2009) in diabetic 
foot ulcers, found that patients were twice as likely to harbour MRSA in their 
wounds if they had received in-patient care, and that MRSA carriage was 
significantly higher in chronic vs. acute wounds. Whilst MRSA have been described 
in numerous microbiological studies of chronic wounds, little is know about their 
role in non-infected wounds.
3.1.3 Colonisation and nasal carriage of MRSA
Little is understood about the risk factors for nasal carriage of S. aureus. 
However, there are three lines of evidence to show a link between S. aureus carriage 
and staphylococcal infection (Peacock et al., 2001). Many studies link S. aureus 
colonisation of the nares with disease. There is less data however, on the carriage of 
MRSA, and there is significant discrepancy in the literature on this. The prevalence 
of MRSA has increased, and that this has been associated with the development of 
community-acquired (CA) MRSA (Miller and Diep, 2008). Surprisingly, many of 
the outbreaks associated with CA-MRSA have been in the young and healthy e.g. 
school children, sport teams, and institutionalised individuals (Fergie and Purcell, 
2001, Begier et al., 2004, Zinderman et al., 2004, Lee et al., 2005).
Colonisation by MRSA frequently results in skin and soft tissue infections 
(Elston and Barlow, 2009). Transmission and dissemination of this pathogen is 
chiefly associated with colonisation of the normal skin flora, and intimate contact, 
more so than associated with nasal colonisation alone (Miller and Diep, 2008). The
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normal colonising area for MRSA and S. aureus is the anterior nares. However, a 
study by French et al., (2009) demonstrated <80% of MRSA-positive individuals 
were identified by nasal swabbing alone, suggesting that in screening this should be 
supplemented with additional swabs from the throat and perineum.
Difficulties in providing actual carriage rates for MRSA have arisen due to 
the number of studies performed in countries which have high MRSA rates (e.g. 
Portugal, Malta, and Cyprus). In addition, many studies make no distinction 
between MRSA and meticillin sensitive S. aureus (MSSA). This is compounded by 
isolation and technical problems, e.g. the previous use of media supplemented with 
ciprofloxacin which selects against CA-MRSA carriage. Such techniques have led 
to under-reporting, as CA-MRSA is ciprofloxacin sensitive; hospital-acquired (HA) 
MRSA is resistant. In the US, there has been a >15 fold rise in CA-MRSA related 
disease between 1996 and 2004 (Miller and Diep, 2008). The most endemic US 
strain is USA300 (CA-MRSA), which is Panton-Valentine leucocidin (PVL) 
positive. Whilst MRSA, and in particular HA-MRSA have been reported since 
1959, CA-MRSA has only been recognised since 1980 (Elston and Barlow, 2009). 
However, authors cannot agree on this due to terminology confusion in the literature.
The carriage rate of MRSA in the UK is approximately 6.5% based on 
hospital studies (Gopal Rao et al., 2007, Jeyaratnam et al., 2008). Of this, <1% is 
associated with CA-MRSA (Elston and Barlow, 2009), although this is likely to be 
an underestimate and is dependant on the population studied. Prevalence rates of 
CA-MRSA are primarily based on rates of infection. Kearns et al., (2004) reported 
an unusual single clone of MRSA associated with an intravenous drug abuser. This 
was believed to be the first CA-MRSA strain in the UK; and has been prevalent in 
the UK since 2001 (Holmes et al., 2005, Health Protection Agency, 2005). CA- 
MRSA is frequently associated with a type IV SCCmec and clonal complexes ST30, 
ST80 and ST8 (de Lencastre et al., 2007). The HPA has confirmed that the 
proportion of CA-MRSA is increasing including those identified within hospitals;
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specifically clone USA300 described in the US (Klevens et al., 2006, Maree et al., 
2007).
3.1.4 Virulence factors
S. aureus may present in a variety of disease states, varying both in 
symptoms and severity. It is believed there are over 40 virulence factors associated 
with S. aureus, involved in colonisation, nutrition and dissemination (Argudin et al., 
2009, Tubby et al., 2009). The expression of many surface and secreted proteins 
(including enzymes) facilitate survival. Wassenaar and Gaastra (2001) categorised 
virulence genes into three distinct roles; true virulence genes, virulence-associated 
genes and virulence life-style genes.
3.1.4.1 Previous virulence testing
Research of S. aureus virulence factors has focused primarily on MSSA, with 
attempts to correlate virulence factor production and specific disease processes e.g. 
endocarditis, acute soft tissue infections and osteomyelitis, using principally 
characterisation of enterotoxins, and superantigen presence. Recently, reports of 
PVL in healthy individuals have led to increased research interest in this area. 
Previous laboratory investigations have relied upon the identification of virulence 
genes. However, few studies have attempted to investigate their expression. More 
recently quantitative RT-PCR and microarray technology have attempted to address 
this issue. To date, most studies have limited testing to the expression of 
enterotoxins, exfoliative toxins and PVL.
Analysis of virulence genes either by allelic replacement, insertion or 
inactivation provides some evidence to the role of virulence factor activity. Results 
however, are difficult to interpret due to the presence of multiple virulence factors 
(Wassenaar and Gaastra, 2001). Additionally, the loss of one virulence factor does 
not necessarily make the organism less pathogenic.
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Early studies on virulence factors employed enzyme-linked immunosorbent 
assay (ELISA), radioimmunoassay or commercial kits such as the semi-quantitative 
reversed passive latex agglutination toxin detection kits (Johnson et al., 1991b). 
These methods are limited by their variable sensitivity and are highly dependent on 
adequate gene expression and protein formation. Low toxin-producing strains or 
cross-reactive antigens can frequently provide false results (Johnson et al., 1991b, 
Klotz et al., 2003, Varshney et al., 2009).
3.1.4.2 Accessory gene regulator and disease
The regulation of virulence expression is tightly coordinated by the accessory 
gene regulator (agr). This quorum sensing mechanism is able to globally regulate 
transcription associated with cell-density, growth phase and stage of infection 
(Cheung et al., 2004, Korem et al., 2010). A study of the virulence potential of S. 
aureus in diabetic foot ulcers showed that MRSA and agr I were more likely to be 
associated with infection and poor outcome for healing (Sotto et al., 2008).
3.1.4.3 Staphylococcal Toxins
Staphylococcal enterotoxins (SE) genes, of which many have been identified
i.e. sea to seu (Argudin et al., 2009) are frequently responsible for toxin-mediated 
disease. Staphylococcal toxic shock syndrome toxin (TSST-1) and SE are potent T- 
cell activators which lead to the release of pro-inflammatory cytokines (Argudin et 
al., 2009). Studies have attempted to correlate the presence of various SEs with the 
outcome of S. aureus infections, although this is still unclear (Varshney et al., 2009).
3.1.4.4 Collagen binding protein (end)
Collagen binding protein has been described as a virulence factor in septic 
arthritis, osteomyelitis, endocarditis and keratitis. CNA has also been associated with 
invasive pathological disorders (Switalski et al., 1993, Gillaspy et al., 1997, Rhem et
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al., 2000, Elasri et al., 2002, Peacock et al., 2002, Nashev et al., 2004, Zong et al., 
2005) suggesting collagen binding is an advantage for pathogenesis.
3.1.4.5 Glycerol ester hydrolase (geh)
Fatty acids and lipids can act to disrupt bacterial membranes; as such many 
staphylococci are thought to be lypolytic (Gould et al., 2009). geh encodes a lipase 
enzyme, which hydrolyses long-chain triacylglycerols, water-soluble triacylglycerols 
and Tweens® (Arvidson and Tegmark, 2001, Arvidson, 2006), which may 
additionally facilitate the acquisition of bacterial nutrients.
3.1.4.6 Leucotoxins
Leucotoxins e.g. PVL and haemolysins (e.g. a , P, y), are believed to be 
involved in host defence evasion. They are able to lyse polymorphonuclear 
leucocytes (PMNL) and erythrocytes in the case of haemolysin, via the formation of 
pores in the cell membranes, leading to cell death.
3.1.4.6.1 Panton-Valentine leucocidin (PVL)
Panton-Valentine leucocidin (PVL) is a two component toxin composed of 
proteins LukS-PVL and LukF-PVL. Researchers have investigated the PVL protein 
by purifying and injecting it intradermally in animal models. This demonstrated its 
ability to induce a severe inflammatory lesion (Ward and Turner, 1980). The genes 
for these proteins are carried by a temperate bacteriophage, which integrates its DNA 
into the Staphylococcus aureus chromosome. Eight lysogenic bacteriophages are 
known to carry the lukS and lukF genes (Kaneko et al., 1998, Wirtz et al., 2010). 
Induction of these bacteriophage has been purported to be initiated by p-lactams, 
ciprofloxacin, trimethoprim and mitomycin C (Lindsay, 2009, Wirtz et al., 2009).
Since 2006 there has been an explosion in the number of UK studies 
involving the PVL virulence factor amongst S. aureus species, particularly meticillin 
resistant S. aureus (MRSA) following the deaths of a nurse and patient in a West
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Midlands hospital. PVL has commanded global notoriety due to its ability to affect 
otherwise young and healthy individuals. Infections caused by strains with the gene 
for the toxin are prevalent in close communities or clusters, such as children’s 
playgrounds, and sports teams. Presenting with a range of symptoms from minor 
skin infections to necrotising pneumonia which has a mortality rate of 75% 
(Dumitrescu et al., 2007). As a result, diagnostic laboratories have been inundated 
with requests from clinicians for testing of this virulence factor.
3.1.4.6.2 Community-acquired MRSA and Panton-Valentine leucocidin
Originally it was thought that PVL was solely associated with MRSA in the 
community setting and as such it was used as a marker for community-acquired 
(CA) MRSA (Vandenesch et al., 2003, Boyle-Vavra and Daum, 2007). Typically 
PVL has been associated with MRSA sequence types (ST) 1, 30 and 80 which are 
found within the community setting (Holmes et al., 2005, Takizawa et al., 2005) and 
contain the SCCmec IV element. The presence of PVL genes within the CA-MRSA 
genome has been suggested as the cause of the enhanced virulence of these strains 
(Lindsay, 2009). However, more recent studies have found that PVL cannot be used 
as a sole marker for CA-MRSA, because the gene has also alarmingly appeared in 
ST22 i.e. EMRSA-15 (Rossney et al., 2007).
3.1.4.7 Hyaluronate lyase (hysA)
Hyaluronic acid forms a major component of the extracellular matrix (ECM) 
(Farrell et al., 1995), and bacterial extracellular hyaluronidase (encoded by hysA) , 
cleaves hyaluronan, and has been implicated in the spread of Streptococcus pyogenes 
(Hynes et al., 2000).
3.1.4.8 Biofllm (ica)
Biofilm formation has been implicated in the failure of prosthetic implants 
and infections associated with indwelling devices; S. aureus being frequently
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associated with these infections (Zimmerli and Ochsner, 2003, Fluckiger et al., 
2005). Clinical isolates associated with biofilm-associated disease show the 
presence of the intercellular adhesion (ica) locus (Fluckiger et al., 2005).
3.1.5 Chronic wound healing and potential virulence factors
A number of the staphylococcal virulence factors described above may play 
obvious roles in the failure of cell migration, defective ECM and persistence of 
MRSA in chronic wounds. In this study the presence and expression of these 
virulence factors was systematically investigated in MRSA isolated from chronic 
wounds and contrasted with asymptomatic nasal carriers. It is possible that the 
MRSA clonal type and virulence gene expression may contribute to the chronicity of 
the chronic wound lesion.
3.2 Aims
The aims of this study were to:
1. Investigate the clonal types of MRSA isolated from chronic wounds 
compared to nasal carriage using RAPD, PFGE, MLST and SCCmec.
2. Determine the difference in the presence of virulence genes in MRSA 
isolated from chronic wounds compared to nasal carriage.
3. Compare expression of virulence factors of MRSA isolated from chronic 
wounds compared with nasal carriage to determine if they play a role in 
chronic wounds.
3.3 Materials and Methods
3.3.1 Culture of bacterial isolates
Isolation of chronic wound MRSA (n = 17) is described in Chapter 2 Section
2.3.1 and 2.3.2. Nasal MRSA isolates were obtained from 7 asymptomatic nasal
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carriers following routine nasal screening by the National Public Health Services 
(NPHS), Cardiff. Isolates were cultured on blood agar (BA; LabM) supplemented 
with 5% (v/v) defibrinated sheep blood (Oxoid) overnight (O/N) at 37°C.
3.3.2 MRSA Typing
3.3.2.1 DNA preparation for Random Amplified Polymorphic DNA (RAPD) 
analysis
Overnight cultures of the test organism were grown at 37°C in 5 ml tryptone 
soya broth (TSB; Oxoid). One ml of culture was centrifuged (9500 x g, 5 min), and 
the supernatant removed. Following washing (x2) with 1 ml lysis buffer (50 mM 
Tris- HC1, pH 8.0; 5 mM EDTA, pH 8.0; 50 mM NaCl), the pellet was re-suspended 
in 1 ml of lysis buffer containing 0.02 mg/ml lysostaphin (Sigma), and 0.025 mg/ml 
RNaseA (Sigma). Following incubation (37°C, 30 min) with agitation, the lysate 
was centrifuged (9500 x g, 10 min). The supernatant was used as a RAPD DNA 
template following quantification (Nano-drop; Nano-Vue, GE Healthcare) and 
dilution (5 ng/pl) with nuclease free water.
3.3.2.1.1 Random amplified polymorphic DNA (RAPD)
Bacterial DNA templates were prepared (Section 3.3.2.1). All PCR reagents 
were supplied by Promega, Southampton, UK unless otherwise stated. A 50 pi PCR 
reaction was performed in thin-walled PCR tubes; consisting of 2 pi of DNA 
template; 0.2 mM (dGTP, dCTP, dATP, dTTP; each) deoxynucleoside triphosphates 
(dNTPs); 50 pM of primers 1, 7 and E2 (Table 3.1; MWG-Biotech) in 3 individual 
PCR reactions; 5 U Taq DNA polymerase; 10 pi of 1 OX buffer; 2.5 mM MgCL and
6.6 pi of nuclease-free water was amplified in a thermal cycler using conditions 
described in Table 3.2. Thirty-five pi of the PCR product was combined with 8 pi of 
loading dye and separated by electrophoresis using a 1.5% (w/v) of a 1:1 ratio 
agarose (Fisher Scientific UK Ltd, Leicestershire, UK) and NuSieve GTG Agarose
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Table 3.1 Primer sequences employed in typing analysis
Typing
method Target gene Primer name Sequence 5’ to 3’
Amplicon 
size (bp) Reference
RAPD
1
7
ERIC2 (E2)
GGTT GGGT GAGAATT GC ACG 
GTGGATGCGA
AAGTAAGTGACTGGGGTGAGCG
(van Belkum et al., 1995)
Carbamate kinase arcC (F) arcC (R)
TTGATTCACCAGCGCGTATTGTC
AGGTATCTGCTTCAATCAGCG 456
Shikimate
dehydrogenase
aroE (F) 
aroE (R)
ATCGGAAATCCTATTTCACATTC
GGTGTTGTATTAATAACGATATC 456
Glycerol kinase glpF (F) glp? (R)
CTAGGAACTGCAATCTTAATCC
TGGTAAAATCGCATGTCCAATTC 465
MLST Guanylate kinase gmk( F) gmk{R)
ATCGTTTTATCGGGACCATC
TCATTAACTACAACGTAATCGTA 429 (Enright et al., 2000a)
Phosphate transferase P‘a (F) pta (R)
GTTAAAAT CGT ATT ACCT G AAGG 
GACCCTTTTGTTGAAAAGCTTAA 474
Triphosphate
isomerase
‘Pi (F) 
tpi (R)
TCGTTCATTCTGAACGTCGTGAA
TTTGCACCTTCTAACAATTGTAC 402
Acetyl coenzyme A 
acetyltransferase
yqiL (F) 
yqiL (R)
CTGCATACAGGACACCTATTGGC
CGTTGAGGAATCGATACTGGAAC 516
mec Class A mec mI6 CATAACTTCCCATTCTGCAGATG 1963
Class B mec 
Class C mec
IS7 
IS2(iS-2) 
mA7 (R)
ATGCTTAATGATAGCATCCGAATG
TGAGGTTATTCAGATATTTCGATGT
ATATACCAAACCCGACAACTACA
2827
804
(Kondo et al., 2007)
RAPD, random amplified polymorphic DNA; MLST, multilocus sequence typing; mec, meticillin resistance gene; (F), forward primer; (R), 
reverse primer; bp, base pair.
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Table 3.1 continued Primer sequences employed in typing analysis
Typing
method Target gene Primer name Sequence 5’ to 3’
Amplicon 
size (bp) Reference
mec mAl (F) mA2 (R)
TGCTATCCACCCTCAAACAGG
AACGTTGTAACCACCCCAAGA 286
ccr
ccrl
ccr2
ccrS
a l
a2
a3
Be (R)
AACCTATATCATCAATCAGTACGT 
TAAAGGCATCAATGCACAAACACT 
AGCT C AAAAGC AAGC AATAGAAT
ATTGCCTTGATAATAGCCITCT
695
937
1791
(Kondo et al., 2007)
ccr4 a4.2 (F) 
B4.2 (R)
GTATCAATGCACCAGAACTT
TTGCGACTCTCTTGGCGTTT 1287
ccrC y (R)
y (F)
CCTTTATAGACTGGATTATTCAAAATAT 
CGTCT ATT AC AAG AT GTTAAGG AT AA 518
ccr, cassette chromosome recombinase gene; (F), forward primer; (R), reverse primer; bp, base pair; mec, meticillin resistance gene.
Table 3.1 continued Primer sequences employed in typing analysis
Typing
method Gene Primer name Sequence 5’ to 3’
Amplicon size 
(bp) Reference
ccrBl (internal positive 
control)
ccrBl (F) 
ccrBl (R)
CGAACGTAATAACATTGTCG
TTGGCWATTTTACGATAGCC 203
Type IVa JIVa (F) J IVa(R)
ATAAGAGATCGAACAGAAGC
TGAAGAAATCATGCCTATCG 278
Type IVb and IVF J IVb (F) J IVb (R)
TTGCTCATTTCAGTCTTACC 
TTACTT C AGCT GC ATTAAGC 336
J type Type IVc and IVE J IVc (F) J IVc (R)
CCATTGCAAATTTCTCTTCC
ATAGATTCTACTGCAAGTCC 483 (Milheirico et al., 2007)
Type IVd J IVd (F) J IVd (R)
TCTCGACTGTTTGCAATAGG
CAATCATCTAGTTGGATACG 575
Type IVg JIVg(F)JIVg(R)
TGATAGTCAAAGTATGGTGG 
G AAT AAT GC AAAGT GG AACG 792
Type IVh JIVh(F)JIVh(R)
TTCCTCGTTTTTTCTGAACG
CAAACACTGATCTTGTGTCG 663
J, joining; (F), forward primer; (R), reverse primer; bp, base pair; ccr, cassette chromosome recombinase gene.
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Table 3.2 PCR and electrophoresis conditions
Thermocycler conditions Electrophoresis
PCR
reaction
Activation
step
Initial
Denature Cycles Denature Annealing Elongation
Final
Extension
Agar
%
Ethidium
bromide Voltage Time
(°C - min) (°C - min) (°C - min) (°C - min) (°C - min) (°C - min) (w/v) (pg/ml) (v) (h)
RAPD 9 4-4 35 94-1 25-1 7 4 -2 74-10 1.5 0.5 40 12
MLST 95-3 30 95-1 55-1 72-1 72-10 1 0.5 70 1
ccr type 9 4 -2 30 94 -2 57-1 72-2 7 2 -2 2 0.5 70 2
mec type 94-2 30 9 4 -2 60-1 72-2 72 -2 2 0.5 70 2
J type 9 4 -4 35 94 -2 48 - 0.5 72-2 7 2 -4 2 0.5 70 2
agrtype 94-3 30 94-1 55-1 72-1 72-3 2 0.5 105 4
enterotoxin 95-2 28 95-1 55-1 72-2 72-5 2.5 0.5 120 2
4 in-house’
virulence
factor
94-1 30 94 - 0.5 55 - 0.5 72-1 7 2 -4 1 0.5 70 1
RT-PCR
reaction
enterotoxin 50-30 95-15 35 94 - 0.5 55 - 0.5 72-1 72-10 2.5 0.5 120 2
4 in-house’
virulence
factor
50-30 95-15 35 94 - 0.5 55 - 0.5 72-1 72-10 1 0.5 100 1
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(Cambrex IEP, Wiesbaden, Germany) gel using parameters described in Table 3.2, 
with 100 and 500 bp molecular weight standard (Fermentas, York, UK) in a IX Tris- 
Borate-EDTA (TBE; 0.1 M Tris Base; 0.09 M Boric Acid; 0.1 mM EDTA) running 
buffer. Gels were visualised using a UV transilluminator GelDoc® (Bio-Rad®, 
Hertfordshire, UK) and analysis of the resulting RAPD fingerprint was performed 
using the software package Quantity One® (Bio-Rad®) to produce an Unweighted 
Pair Group Method with Arithmetic Mean (UPGMA) to study phylogeny.
3.3.2.2 Pulsed field gel electrophoresis (PFGE)
Bacterial suspensions were prepared by inoculating 3 ml of brain heart 
infusion broth (BHI; Oxoid) with an individual colony from test isolates. Following 
incubation (37°C, 16-18 h), 150 pi of suspension was transferred into sterile 
microfuge tubes (Fisher Scientific) and centrifuged (18000 x g, 2 min) and the pellet 
re-suspended in 150 pi cell suspension buffer (10 mM Tris -  HC1, pH 7.2; 20 mM 
NaCl; 50 mM EDTA).
PFGE plugs were prepared by adding 0.06 mg/ml of lysostaphin to each 
bacterial suspension, and incubating at room temperature (RT, 30 min). Following 
this, 150 pi of 20% (w/v) low melting point agarose (Bio-Rad®) made with IX TBE 
buffer was added, gently mixed and used to overfill the plug mould (Bio-Rad®). The 
plugs were allowed to set (RT, 20 min) and then extruded into a 24-well tissue 
culture plate (Greiner Bio-One Ltd, Stroudwater, UK) containing 500 pi lysis buffer 
(10 mM Tris- HC1, pH 7.2; 50 mM NaCl; 50 mM EDTA; 2% w/v, Deoxycholate; 
0.5% w/v, Sarkosyl, Sigma) and incubated (37°C, 1 h). The lysis buffer was then 
removed and 500 pi of proteinase K (PK) buffer (250 mM EDTA, pH 9.0; 1% 
Sarkosyl), and 2.73 mg/ml of proteinase K (Sigma) added and incubated (50°C, 30 
min). The PK buffer was removed and the samples washed (x3) in 1.4 ml wash 
buffer (10 mM Tris-HCl, pH 7.6; 0.1 mM EDTA) for 30 min each time at RT. The 
plugs were then stored at 4°C in wash buffer until required.
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Each PFGE plug was cut into 3 segments, with the middle section placed into 
a 96-well microtiter plate for digestion with Smal (Invitrogen Ltd, Paisley, UK). 
Restriction digests were prepared by diluting (1:10) the buffer React®4 (supplied 
with the Smal enzyme; Invitrogen) with sterile distilled water, adding 300 pi to each 
plug. These were incubated (25°C, 10 min), the buffer removed and 150 pi of 
diluted React®4 restriction buffer and 25 U (2.5 pi) of Smal added to each sample 
well and incubated (25°C, 2 h).
A pulsed field gel was created by using a 1% (w/v) agarose gel (Fisher 
Scientific) prepared with 120 ml IX TBE buffer and 0.5 pg/ml ethidium bromide. 
The digested plugs were assembled onto the comb of the pulsed field mould, along 
with a 2 mm slice of the molecular weight standard PFG Lambda ladder (New 
England Biolabs Ltd, Hertfordshire, UK) and were affixed using melted agarose. 
The comb with the attached plugs was inserted into the setting mould.
The pulsed field gel was placed in the PFGE tank (CHEF-DR®-III; Bio- 
Rad®). Electrophoresis was performed in 0.5X TBE buffer at 6 V/cm with the 
following settings; 120 included angle, initial switch time of 5.3 min and a final 
switch time of 34.9 min, run time 18 h, buffer temperature 14°C (Mulvey et al., 
2001). The gel was stained for 20 -  60 min in 200 ml water containing 1 pg/ml of 
ethidium bromide, visualised and recorded using GelDoc™ (Bio-Rad®). Analysis of 
the PFGE fragment fingerprint was assessed using the set of standard criteria in 
Table 3.3.
3.3.2.3 Multilocus sequence typing (MLST)
3.3.2.3.1 DNA preparation using the Qiagen® DNeasy® kit
Test MRS A were grown on tryptone soy agar (TSA; Oxoid) O/N at 37°C. 
An individual colony from each purity plate was streaked in a 2.5 x 2.5 cm patch on 
half of a TSA plate and incubated (37°C, O/N). Cells harvested from the TSA plates 
were added to 250 pi of lysis buffer (10 mM Tris-HCl, pH 8.0; 1 mM EDTA, pH
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Table 3.3 Criteria for interpreting PFGE patterns
Category
No. of genetic 
differences 
compared with 
outbreak strain
Typical no. of fragment 
differences compared with 
outbreak pattern
Epidemiologic
interpretation
Indistinguishable 0 0 Isolate is part of the outbreak
Closely related 1 2-3 Isolate is probably part of the outbreak
Possibly related 2 4-6 Isolate is possibly part of the outbreak
Different >3 >7 Isolate is not part of the outbreak
(Tenover et al., 1995)
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8.0) containing 0.05 mg/ml lysostaphin, and 20 mg/ml lysozyme. Samples were 
vortexed for 30 s and incubated (37°C, 3 h), vortexing at 30 min intervals. Then 25 
pi of the supplied proK and 200 pi of buffer AL were added; samples were vortexed 
and incubated (70°C, 30 min). Following incubation, 200 pi ice cold 95% (v/v) 
ethanol (EtOH) was added and each sample inverted (x4). The total content of each 
tube was pipetted into individual DNeasy® minicolumns nested in 2 ml collection 
tubes and then centrifuged (9500 x g, 1 min). The collection tube was discarded and 
the centrifuge minicolumn was placed in a new 2 ml collection tube, and 500 pi 
AW1 buffer (Qiagen® kit) added. Following centrifugation (11500 x g, 1 min), the 
centrifuge minicolumn was placed in a new 2 ml collection tube and 500 pi of AW2 
buffer (Qiagen® kit) added. Samples were centrifuged (18600 x g, 3 min). The 
collection tube was discarded and the centrifuge minicolumn placed in a sterile 1.5 
ml microfuge tube. Then 100 pi AE buffer (Qiagen® kit) was added directly onto 
the membrane of each sample column and left for 5 min at RT. Samples were 
centrifuged (11500 x g, 1 min). The eluent was used as template DNA for MLST. 
Quality assurance of DNA samples was performed using 5 pi of each sample run on 
a 0.8% (w/v) agarose gels containing ethidium bromide (0.5 pg/ml) and visualised 
(Section 3.3.2.1.1).
3.3.2.3.2 PCR for multilocus sequence typing (MLST)
MLST typing was performed as described previously (Enright et al., 2000a). 
For each isolate, internal DNA fragments of seven housekeeping genes were 
amplified in individual PCR reactions using the MLST primer pairs (Table 3.1). The 
PCR reaction was carried out in 96-well plates with a total reaction volume of 50 pi 
containing 1 pi of chromosomal DNA, 200 pM of forward and reverse primers, 1U 
of Taq DNA polymerase, 5 pi of 10X buffer, 2.5 mM MgCL and 0.2 mM dNTPs. 
PCR reactions were performed using the conditions described in Table 3.2 The PCR
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products were separated by electrophoresis and compared with a 100 bp molecular 
weight standard (Promega) in lx TBE running buffer (Table 3.2; Section 3.3.2.1.1).
3.3.2.3.3 Purification of PCR products using the QIAquick® 96 PCR 
purification kit: Method 1
PCR products were purified using the QIAquick® 96 PCR Purification Kit 
(Qiagen®) as per the manufacturer’s instructions. PCR products (45 pi) of each 
isolate were transferred to a provided 96-well plate containing 3X volume of buffer 
PM (Qiagen® QIAquick® kit). The liquid phase was removed using a QIAvac 
vacuum pump (Qiagen®). The wells were washed with 900 pi of the supplied buffer 
PE and the buffer was removed using the pump. This step was repeated, and a 
vacuum was then applied at maximum for 10 min to dry the membrane of each 
column. The nozzle of the QIAquick® plate was “blotted” onto paper towels. The 
QIAquick® waste tray was then replaced with the supplied blue collection microtube 
rack upon which the 96-well microplate was placed. The final elution step was 
performed by adding 60 pi of the supplied buffer EB directly to the centre of each 
well and applying a vacuum for a further 5 min. Purified PCR products (2 pi) were 
separated on a 0.8% (w/v) agarose gel as previously described (Section 3.3.2.3.1) for 
quality assurance.
3.3.2.3.4 Purification of PCR products using ExoSAP-IT®: Method 2
PCR products were purified using ExoSAP-IT® solution (GE Healthcare, 
Buckinghamshire, UK). ExoSAP-IT® solution contains exonuclease I and shrimp 
alkaline phosphatase. The perceived advantages are; no loss of sample, less chance 
of contamination and fewer steps. The Exo-SAP-IT® solution was maintained on ice 
during the procedure; 15 pi of PCR product with 6 pi of Exo-SAP-IT® solution were 
mixed and incubated (37°C, 15 min) to degrade any unincorporated nucleotides and 
primers. The samples were then incubated (80°C, 15 min) to inactivate Exo-SAP- 
IT® enzymes. The samples were used directly for sequencing. Purified PCR
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products (2 pi) were separated on a 0.8% (w/v) agarose gel as previously described 
(Section 3.3.2.3.1) for quality assurance.
3.3.2.3.5 Sequencing of PCR products and MLST analysis
PCR products were sequenced using forward and reverse MLST PCR 
primers (Table 3.1). Sequencing was performed by either Lark, Co Genetics, Essex 
using an ABI 3730*/ sequencer (Applied Biosystems, USA) or at the DNA 
Sequencing Core facility, Molecular Biology Unit, School of Biosciences, Cardiff 
University using an ABI 3130jc/ sequencer (Applied Biosystems, USA). For each 
isolate, the alleles at each of the seven housekeeping loci were identified by 
comparing the sequences obtained from the test isolates with sequences held in the 
MLST database (http://saureus.mlst.net). Allelic profiles and sequence types (ST) 
for each isolate was determined using this database.
3.3.2.4 SCC/iiec typing
3.3.2.4.1 ccr gene complex typing
Bacterial DNA template was prepared with the Qiagen DNeasy® kit as 
previously described (Section 3.3.2.3.1). A 50 pi reaction was performed for each 
isolate in a 96-well plate. The ccr gene complex and internal mec control gene were 
identified using a multiplex PCR reaction using 10 primer sequences (6 primer pairs; 
Table 3.1). A PCR reaction mixture of 1 pi DNA template, 26.35 pi nuclease-free 
water, 0.1 pM each primer, 2.5 U of Taq DNA polymerase, 10 pi of 1 OX buffer, 3.2 
mM MgCh and 200 pM (each) dNTPs, was amplified in a thermal cycler (Table
3.2). The amplified product was separated by electrophoresis and compared with a 
100 bp molecular weight standard (Promega) in a IX TBE running buffer using the 
parameters described in Table 3.2. The resulting gel was visualised (Section
3.3.2.1.1) using the mec gene as an internal control. The ccr gene complex was 
assigned by size of PCR product (Table 3.1).
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3.3.2.4.2 mec class typing
A bacterial DNA template was prepared using the Qiagen DNeasy® kit 
(Section 3.3.2.3.1). For each isolate a 50 pi reaction was performed in a 96-well 
plate where the mec gene complex was identified using a multiplex PCR of 4 primer 
sequences (3 primer pairs, Table 3.1). A PCR reaction mixture of 1 pi DNA 
template, 31.75 pi nuclease-free water, 0.1 pM each primer, 2.5 U of Taq DNA 
polymerase, 10 pi of 10X buffer, 2 mM MgCh and 200 pM (each) dNTPs, was 
amplified in a thermal cycler (Table 3.2). The amplified products were compared 
with a 100 bp and 1 kb molecular weight standard (Promega; Table 3.2). The mec 
gene complex was assigned by the size of PCR product (Table 3.1)
3.3.2.4.3 Joining (J) region typing for sub-classification of SCCmec IV variants
A bacterial DNA template was prepared using the Qiagen DNeasy® kit. A 25 
pi reaction was performed in a 96-well plate to determine the SCCmec IV subtype 
by determining the J type using a multiplex PCR of 7 primer pairs (Table 3.1). A 
PCR reaction mixture of 1 pi DNA template, 10.25 pi nuclease-free water, 1.25 U of 
Taq DNA polymerase, 10 pi of 1 OX buffer, 1.5 mM MgC^ and 40 pM dNTPs, 0.2 
pM of primers J IVa, J IVb; 0.4 pM of primers ccrB2 (F), J IVc; 0.8 pM of primers 
ccrB2 (R), J IVd; 0.9 pM of primers J IVg and 1.8 pM of primers J IVh was 
amplified in a thermal cycler (Table 3.2). The amplified products were compared 
with a 100 bp molecular weight standard (Thermo Scientific, Northumberland, UK) 
and 50 bp molecular weight standard (Fisher Scientific) with a IX TBE running 
buffer (Table 3.2). The resulting gel was visualised (Section 3.3.2.1.1), J type was 
assigned by size of PCR product (Table 3.1).
3.3.2.4.4 Assignment of SCC mec type
The assignment of each SCC mec type is based on the combination of the ccr allotype 
and mec class, followed by the J type, if SCC mec IV is present. Table 3.4
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Table 3.4 Assignment of SCC mec type based on ccr and mec complex
SCCmec type ccr allotype mec class aJ  type
I 1 B n/a
II 2 A n/a
III 3 A n/a
IV 2 B a to j
V 5 C2 n/a
VI 4 B n/a
VII 5 Cl n/a
VIII 4 A n/a
n/a -  not applicable; aJoining region SCCmec subtype.
Table 3.5 Primer sequences used for agr typing
Primer name Sequence 5’ to 3’ Amplicon size 
(bp)
pan-agr (F) 
agr I(R)
ATGCACATGGTGCACATGC
GT C AC AAGT ACT AT A AGCT GCG AT 440 bp 
572 bp 
406 bp 
588 bp
agr II (R) GTATTACTAATTGAAAAGTGCCATAGC
agr III (R) CTGTTGAAAAAGTCAACTAAAAGCTC
agr IV (R) CGATAATGCCGTAATACCCG
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assigns SCC mec I to VIII (Zhang et al., 2005, Kondo et al., 2007, Milheirico et al., 
2007, Chen et al., 2009, IWG-SCC, 2009).
3.3.3 Virulence profiles
3.3.3.1 Accessory gene regulator typing (agr)
Bacterial DNA templates were prepared using the Qiagen DNeasy® kit 
(Section 3.3.2.3.1). A 50 pi reaction was performed in a 96-well plate. The agr type 
was determined by using one forward primer and 4 reverse primers in a multiplex 
PCR reaction (Table 3.5). A PCR reaction mixture of 1 pi DNA template, 13.8 pi 
nuclease-free water, 20 pM each primer, 2.5 U of Taq DNA polymerase, 5 pi of 10X 
buffer, 2 mM MgCh and 350 pM dNTPs was amplified in a thermal cycler (Table
3.2). The amplified product was diluted 1:4 with nuclease-free water and separated 
by electrophoresis with a 50 bp molecular weight standard (Fisher Scientific) in a IX 
TBE running buffer (Table 3.2). The resulting gel was visualised (Section 3.3.2.1.1) 
and agr type assigned by PCR product (Table 3.5; Shopsin et al., 2003, Ben Ayed et 
al., 2006).
3.3.3.2 Multiplex PCR detection of Staphylococcal toxin genes
Bacterial DNA templates were prepared using the Qiagen DNeasy® kit 
(Section 3.3.2.3.1) and diluted 1:10 in nuclease free water. Holmes et al., (2005) 
described a method for detecting multiple toxin genes in staphylococci. Using 
Holmes’ method, adapted by the Health Protection Agency (HPA), London, the 
presence of genes encoding 14 toxins was determined by the use of four multiplex 
PCR reactions (Table 3.6). All multiplex reactions consisted of primers for 16S 
rRNA gene as an internal control, and reaction 4 also utilised internal control mec A  
primers.
A primer mastermix was prepared for each reaction. The final concentration 
for multiplex reaction 1 (enterotoxin A to E) was 1 pM for 16S rRNA primers and
4.8 pM for sea, seb, sec, sed, see primers; for multiplex reaction 2 (enterotoxin G to J)
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Table 3.6 PCR primer sequences for multiplex toxin screening of MRS A
Multiplex
reaction Primer name Sequence 5’to 3’ Toxin name
Amplicon size 
0>p)
Reference
sea-3 (F) 
sea-4 (R)
CCTTTGGAAACGGTTAAAACG
TCTGAACCTTCCCATCAAAAAC Enterotoxin A 127
seb-1 (F) 
seb-4 (R)
TCGCATCAAACTGACAAACG
GCAGGTACTCTATAAGTGCCTGC Enterotoxin B 477
1 sec-3 (F) sec-4 (R)
CTCAAGAACTAGACATAAAAGCTAGG
TCAAAATCGGATTAACATTATCC Enterotoxin C 271
(Becker et al., 
1998)
sed-3 (F) 
sed-4 (R)
CTAGTTTGGTAATATCTCCTTTAAACG
TTAATGCTATATCTTATAGGGTAAACATC Enterotoxin D 319
see-3 (F) 
see-2 (R)
CAGTACCTATAGATAAAGTTAAAACAAGC
TAACTTACCGTGGACCCTTC Enterotoxin E 178
seg (F) 
seg (R)
CGTCTCCACCTGTTGAAGG
CCAAGTGATTGTCTATTGTCG Enterotoxin G 327
seh (F) 
seh (R)
CAACTGCTGATTTAGCTCAG
GTCGAATGAGTAATCTCTAGG Enterotoxin H 360 (Monday andz
sei (F) 
sei (R)
CAACTCGAATTTTCAACAGGTAC
CAGGCAGTCCATCTCCTG Enterotoxin I 465
Bohach, 1999)
sej{F) 
sej(R)
CATCAGAACTGTTGTTCCGCTAG
CTGAATTTTACCATCAAAGGTAC Enterotoxin J 142
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Table 3.6 continued PCR primer sequences for multiplex toxin screening of MRS A
Multiplex
reaction Primer name Sequence 5’to 3’ Toxin name
Amplicon 
size (bp)
Reference
tst-3 (F) 
tst-6 (R)
AAGCCCTTTGTTGCTTGCG
ATCGAACTTTGGCCCATACTTT
Toxic shock syndrome 
toxin 445
3 eta-3 (F) eta-4 (R)
CTAGTGCATTTGTTATTCAAGACG
TGCATTGACACCATAGTACTTATTC Exfoliative toxin A 119
(Becker et al., 
1998)
etb-3 (F) 
etb-4 (R)
ACGGCTATATACATTCAATTCAATG
AAAGTTATTCATTTAATGCACTGTCTC Exfoliative toxin B 262
etd-l (F) 
etd-2 (R)
AACTATCATGTATCAAGG
CAGAATTTCCCGACTCAG Exfoliative toxin D 376
(Yamaguchi et 
al., 2002)
4
PVL-1 (F) 
PVL-2 (R)
ATCATTAGGTAAAATGTCTGGACATGATCCA
GCATCAASTGTATTGGATAGCAAAAGC
Panton Valentine 
Leucocidin 433
(Lina et al., 
1999)
mecA- P4 (F) 
mecA-P7 (R)
TCCAGATTACAACTTCACCAGG
CCACTTCATATCTTGTAACG mec A  gene 162
(Oliveira and 
de Lencastre, 
2002)
1 - 4 16SrRNA(F) 16S rRNA (R)
GTAGGT GGC AAGCGTTAT CC 
CGCACATCAGCGTCAG 16S rRNA gene 228
(Monday and 
Bohach, 1999)
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1 pM of 16S rRNA primers and 2.7 pM for seg, seh, sei, and sej primers; for multiplex 
reaction 3 (exfoliatin toxin A and B and TSST-1) 1 pM for 16S rRNA primers and 2.7 
pM for eta, etb, and tst, primers; for multiplex reaction 4 (exfoliative toxin D and PVL) 
0.9 pM for 16S rRNA primers, 4.5 pM for mec A  primers and 14.5 pM for etd and 
PVL primers.
For each isolate, a 50 pi reaction was performed in a 96-well plate. A PCR 
reaction mixture of 2 pi DNA template, 31.75 pi nuclease-free water, 2.5 mM 
dNTPs, 5 pi of 10X buffer, 3 mM MgCh, 1.25 U Taq DNA polymerase and 1 pi of 
the corresponding reaction primer mix was amplified in a thermal cycler (Table 3.2). 
The amplified products (10 pi) were separated by electrophoresis with a 100 bp 
(Thermo Scientific) and 50 bp (Fisher) molecular weight standard with 0.5X TBE 
running buffer (Table 3.2). The resulting gel was visualised (Section 3.3.2.1.1), and 
genes for toxin presence were identified by PCR product size (Table 3.6).
3.3.3.3 PCR detection of staphylococcal virulence factors
Many of the virulence factors produced by staphylococci may have an impact 
on the healing of wounds. A number of these were identified and investigated. 
Using the nucleotide search on the National Centre for Biotechnology Information 
(NCBI) website (http://www.ncbi.nlm.nih.gov; accessed 10/4/08), sequences for the 
identified virulence factors were obtained and primers designed using Primed® 
(http://primer3.sourceforge.net/; accessed 11/4/08; Table 3.7). DNA was isolated 
using a Qiagen DNeasy® kit (Section 3.3.2.3.1). A 25 pi reaction for each virulence 
factor was performed in a 96-well plate. A PCR reaction mixture of 1 pi DNA 
template, 12.5 pi ABgene® master mix (Thermo Scientific) 9.5 pi of nuclease-free 
water, and 0.4 pM of each primer was amplified in a thermal cycler (Table 3.2). The 
amplified products were separated by electrophoresis using a 100 bp molecular 
weight standard (Thermo Scientific) with a 0.5X TBE running buffer (Table 3.2; 
Section 3.3.2.1.1), and virulence genes identified (Table 3.7).
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Table 3.7 Primer sequences for the detection of virulence factors
Gene Virulence factor Primers (5’-3’) Amplicon size (bp)
housekeeping
gene
b Accession 
No/Reference
cna Collagen-bindingprotein
CAGCAGTTAGATTTAAGCAC
CCTTGTGGAATTGTTACATC 161 yqil AB266877
hlgA Gamma-haemolysin
GC AAGGCTTC ATTAGCT CT AG A 
ATATTATAGCCTAATTTCTGAC 189 yqil L0055
hlgB Gamma-haemolysin
GGTACTGCTAAT GCT G AAGG 
GTACTAAAGTATCTTTATCAT 172 yqil L0055
hlgC Gamma-haemolysin
ATCTGTGAGCTTACTTGCC
GCTAATGAATCCTTGCATC 226 yqil L0055
geh Lipase (glycerol ester hydrolase)
CGACAAGGTTCTAAACAGT
TGTAGTTGAAGTTGGTGCTG 207 yqil NC009641
hysA Hyaluronate lyase TCAAATCGCTGTGGCTGATACCGCTCCTGACCACAAGTAT 209 yqil NC00964
luk-PV-1
luk-PV-2
Panton-Valentine
Leukocidin
ATCATTAGGTAAAATGTCTGGACATGATCCA
GCATCAASTGTATTGGATAGCAAAAGC 433 yqil
(Lina et al., 
1999)
icaA
Intercellular 
adhesion protein 
(biofilm)
TGGCTGTATTAAGCGAAGTC
CCTCTGTCTGGGCTTGACC
669 pta (Knobloch et al., 2002)
a Table 3.1 shows the amplicon size of each housekeeping gene (MLST)’b Accession number of the sequences used for primer design; bp, 
base pair
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3.3.3.4 Expression of virulence factors and toxins
3.3.3.4.1 Preparation of RNA using an RNeasy® Qiagen Kit
One bacterial colony from TSA was used to inoculate 10 ml of TSB, and 
incubated at 37°C using agitation until log phase, optical density (OD) of 0.7 at A600 
(6 to 8 h approximately). Bacterial cultures were maintained on ice until use. For 
RNA preparation, 4.5 ml of bacterial culture was centrifuged (16000 x g, 4°C, 6 
min). The pellet re-suspended and washed in 3 ml of diethyl pyrocarbonate water 
(DEPC, Nuclease-free water: DEPC 1:2000) then centrifuged (16000 x g, 4°C, 6 
min). The pellet was re-suspended in 100 pi of TE buffer (10 mM Tris-HCl, pH 7.5; 
1 mM EDTA), to which 6.06 mg/ml lysozyme (Sigma) and 0.12 mg/ml lysostaphin 
(Sigma) was added and incubated (RT, 90 min).
The RNA extraction was performed using an RNeasy® Kit (Qiagen), as per 
the manufacturer’s instructions. To the bacterial/enzymatic suspension 350 pi of the 
supplied Buffer RLT (containing 10 pl/ml of P-mercaptoethanol) was added and 
vortexed (30 s), then 350 pi of 70% (v/v) EtOH added and mixed gently by 
pipetting. The resulting liquid and precipitate was transferred to an RNeasy® 
column. The column was centrifuged (9500 x g, 15 s) and collection tube discarded. 
The column was placed in a new collection tube and 350 pi of the supplied RW1 
buffer added. Following centrifugation (9500 x g, 15 s) the column was placed in a 
new collection tube and DNase digestion performed by adding 80 pi of the supplied 
DNase 1 incubation mix (10 pi of DNase 1 stock solution: 70 pi of buffer RDD) 
directly onto the membrane and incubating (RT, 15 min). Then 350 pi of the 
supplied buffer RW1 was added to the column and centrifuged (9500 x g, 15 s) the 
column placed in a new collection tube and 500 pi of buffer RPE (containing 4 
volumes of 100% ethanol) was added. Following centrifugation (9500 x g, 15 s) the 
column was placed in a new collection tube and centrifuged to dry the membrane 
(16000 x g; 1 min) then placed into a clean 1.5 ml microfuge tube. RNase free water 
(50 pi) was added directly onto the membrane and allowed to stand (1 min) followed
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by centrifugation (9500 xg , 1 min) the final elution step was repeated using the RNA 
elute.
3.3.3.4.2 RNA quantification and standardisation
Prepared RNA was quantified using a Nano-drop system (Nano-Vue, GE 
Healthcare). RNA was standardised by diluting (330 ng/pl) with DEPC water prior 
to toxin and virulence factor expression investigation.
3.3.3.4.3 Expression of virulence factors using reverse transcription (RT) PCR
The isolates confirmed by PCR to harbour genes for the tested virulence 
factors (Section 3.3.3.2 & 3.3.3.3) were investigated further using RT-PCR. 
Expression of the individual virulence factors was investigated, followed by 
expression in a multiplex reaction with an internal control (MLST housekeeping 
gene) to attempt to semi-quantitatively assess levels of expression.
For each positive isolate, a 25 pi reaction was performed using OneStep RT- 
PCR kit (Qiagen®). A PCR mixture of 5 pi of 5X Qiagen® OneStep RT-PCR buffer, 
400 pM dNTPs, 1 pi of Qiagen® OneStep Reverse Transcriptase (RT) enzyme mix, 
0.6 pM final concentration of primer, 1 pi of standardised RNA template (330 ng/pl) 
and 15 pi of RNase free water was amplified in a thermal cycler (Table 3.2). Ten pi 
of product was separated with a 100 bp (Thermo Scientific) molecular weight 
standard in 0.5X TBE running buffer (Table 3.2). Products were visualised using UV 
light and expression confirmed by correct band size (Table 3.7). To compare 
expression levels for each virulence factor, a multiplex PCR reaction was used with a 
suitable control (MLST housekeeping gene; Table 3.7). A 25 pi reaction mixture as 
described for the singleplex ‘in-house’ virulence factor using the OneStep RT-PCR 
kit (Qiagen®) was performed in a thermal cycler (Table 3.2). The amplified products 
were separated using the parameters in Table 3.2. The products were visualised 
under UV light using GelDoc™ software (Bio-Rad®). Band intensity was assessed
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and visually assigned a numerical value I to III in order of increasing intensity 
(Figure 3.10).
3.3.3.4.4 Expression of toxins using reverse transcription (RT)-PCR
Expression of toxins was completed using the four multiplex reactions (Table
3.6). A 25 pi reaction was performed using OneStep RT-PCR kit (Qiagen®) as per 
the manufacturer’s guidelines. A PCR mixture of 5 pi of 5X Qiagen® OneStep RT- 
PCR buffer, 400 mM of dNTPs (each), 1 pi of OneStep RT enzyme mix, 2 pi of 
toxin primer mix (Section 3.3.3.2), 1 pi of diluted RNA template and 16 pi of RNase 
free water was amplified in a thermal cycler (Table 3.2). Electrophoresis was used 
to separate 10 pi of the amplified product with a 100 bp (Thermo Scientific) and 50 
bp (Fisher Scientific) molecular weight standards in 0.5X TBE running buffer (Table
3.2). The products were visualised and assigned intensities (Section 3.3.3.4.3).
3.4 Results
3.4.1 Genetic typing of MRSA
3.4.1.1 Random Amplified Polymorphic DNA (RAPD) of MRSA wound isolates
RAPD fingerprints and analysis using Quantity One® Bio-RAD for each 
MRSA isolate using RAPD primers 7, E2 and 1 is demonstrated in Figures 3.1 and 
Appendix IV.i. Unweighted Pair Group Arithmetic Method Analysis (UPGMA) was 
used to identify relatedness between MRSA isolates and to produce phylogenetic 
trees for each primer.
In these experiments it was evident that each primer used to determine the 
phylogeny of the isolates produced different results. For example, primer 7 
separated the collected MRSA isolates into 2 major clusters termed A and B (Figure
3.1). In each cluster there were 9 and 8 isolates respectively. Both these groups 
were similar at 0.60. Primer E2 grouped the wound MRSA isolates into 2 clusters
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Figure 3.1 (a) Agarose gel showing RAPD fingerprint using Primer 7; (b) 
Phylogenetic tree using UPGMA analysis o f Primer 7 fingerprints produced by 
Quantity One® software. Lane numbers match those denoted on the phylogenetic 
tree. Lanes 1, 10, 19, 28 and 40, 100 bp and 500 bp molecular weight standard 
(Fermentas; Figure 3.1a); lane 2, MRSA wound isolate; lane 3, EMRSA 15; lane 4, 
EMRSA 16; lane 5, NCTC 13143; lane 6, NCTC 6571; lane 7, NCTC 12493; lanes 
8, 9, 11 to 18, 20 to 27, 29, 31 & 32, MRSA wound isolates; lanes 30 and 33 to 37, 
CNS, MSSA wound isolates; lane 39, negative H20  control.
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termed A and B whilst cluster C contained only the control isolates. Cluster A and B 
contained 5 and 12 isolates respectively; both were similar at 0.60 indicating that the 
isolates were similar in all groups. Primer E2 grouped duplicate test isolates and 
indicated high similarity indices (-0.85). Primer 1 separated the majority of isolates 
into a single group termed C; with only 6 isolates in group B and 1 in group A. 
Primer 1 showed similarities between these groups at 0.70, indicating similarity 
between isolates. It was clear from this analysis that none of the primers had 100% 
matching of group types.
3.4.1.2 Pulsed Field Gel Electrophoresis (PFGE) of MRSA wound isolates
The analysis of the PFGE macrorestriction profile (Table 3.8) separated the 
MRSA wound isolates into three major pulse-types; A, B and C, with pulse type C 
being further subdivided into two subgroups (i and ii). Pulse-type A (Figure 3.2) 
contained seven (41.2%) isolates and was an exact match to the EMRSA-15 control, 
whilst pulse-type B (Appendix IV.ii) contained eight (47.1%) isolates closely related 
to EMRSA 15 (with a maximum of three fragment differences). Pulse-type C 
(Appendix IV.ii) differed from EMRSA-15 and other isolates by 7 bands, which 
indicated that they were unrelated. The latter group had a similar fragment pattern to 
control NCTC 13143 (EMRSA-16). Pulse-type C was further subdivided into Ci 
and Cii as isolate 1011 did not have an exact match of band patterns but was deemed 
possibly related as there were only 5 fragment differences.
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Figure 3.2 Pulse-type A fragment restriction digests from PFGE of MRSA wound 
isolates. Lanes 1 and 14, PFG lambda ladder (standard; New England Biolabs; 
NEB); lane 2, EMRSA-15 control isolate; lanes 3 to 5, Intensive Therapy Unit (ITU) 
MRSA control isolate (provided by Dr Robin Howe); lanes 6 to 13, MRSA wound 
isolates.
Table 3.8 Distribution o f pulse-types associated with fingerprint analysis of MRSA 
wound isolates using PFGE
Pulse Types
A B Ci Cii
Number of
isolates 7(41.2%) 8(47.1%) 1(5.9%) 1 (5.9%)
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3.4.1.3 Multilocus Sequence Typing (MLST) of MRSA isolates
MLST differentiated the wound MRSA isolates into four sequence types (ST; 
Table 3.9). ST22 was the most common, representing 82.4% of the MRSA isolates, 
frequently associated with the hospital (HA-MRSA) setting in the UK. ST30, ST36 
and ST970 represented a single isolate in each group. ST970 was associated with 
patient 1108 and represents a novel sequence type due to a single locus variant (slv) 
of ST22 at the aroE allele (i.e. shikimate dehydrogenase). Amongst the 17 MRSA 
wound isolates, two clonal complexes or ancestral lines were identified (CC22 and 
CC30).
In contrast to the MRSA wound isolates, the nasal isolates exhibited a greater 
variation of ST. This diversity is typical in CA-MRSA (Table 3.10). Isolate S07 
150 was associated with a novel ST, 1509 and is related to ST 1 via a slv of the pta 
allele (i.e. phosphate transferase).
3.4.1.4 ccr gene complex typing by PCR
Results of the analysis of the ccr gene complex for the isolated MRSA are 
shown in Tables 3.9 & 3.10. All (100%) of the chronic wound MRSA isolates in 
this study were shown to harbour a type 2 ccr, which is a combination of ccrB2 and 
ccrAl elements (Zhang et al., 2005). Of the nasal isolates studied, 71.4% 
represented a type 2 ccr, with 14.3% representing type 1 (ccrBl-ccrAl) and type 5 
ccr (ccrC). Figure 3.3 shows separation of the multiplex PCR products for the ccr 
gene complex typing.
3.4.1.5 mec gene complex typing by PCR
Analysis of wound MRSA mec gene complex demonstrated that 16 (94.1%) 
MRSA isolates in the study harboured Class B mec gene complex, composed of 
!S431-mecA-mecRl-lS1272 (Zhang et al., 2005). One (5.9%) isolate harboured the 
Class A mec element composed of \S431-mecA-mecRl-mecI (Zhang et al., 2005).
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Table 3.9 Chronic wound MRSA isolate typing
No. of 
isolates
Pulse
type
*PFGE
synonym
b__
group
Sequence
Type
Clonal
Complex Allelic Profile ccr type
mec
class
SC Cmec 
type CJ type
6 (35.3%) A EMRSA-15 I 22 22 7.6.1.5.8.8.6 2 B IV h
8 (47.1%) B EMRSA-15 I 22 22 7.6.I.5.8.8.6 2 B IV h
1 (5.9%) A EMRSA-15 I d970 22 7.159.1.5.8.8.6 2 B IV h
1 (5.9%) Cii III 30 30 2.2.2.2.6.3.2 2 B IV c & E
1 (5.9%) Ci EMRSA-16 III 36 30 2.2.2.2.3.3.2 2 A II n/a
EMRSA, epidemic MRSA; n/a, not applicable; aPFGE synonym based on similarities in finger print patterns to EMRSA-15 and EMRSA-16; 
Accessory gene regulator; joining region; dnovel ST assigned by MLST database curator.
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Table 3.10 Typing of asymptomatic nasal carrier MRSA isolates
No. of a Sequence Clonal ... ., n . . SCCmec bT ^■ x W  group 2, ^ . Allelic Profile ccr type mec class . J typeisolates Type Complex type
2 (28.6%) III 1 1 1.1.1.1.1.1.1 2 B IV a
1 (14.3%) II 5 5 1.4.1.4.12.1.10 2 B IV a
1 (14.3%) III 34 30/39 8.2.2.2.6.3.2 1 B I n/a
1 (14.3%) III 45 45 10.14.8.6.10.3.2 2 B IV a
1 (14.3%) IV 121 51 6.5.6.2.7.14.5 5 C V
1 (14.3%) III c1509 1 1.1.1.1.169.1.1 2 B IV a
n/a, not applicable; Accessory gene regulator; joining region; °Novel ST assigned by the MLST database curator.
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1OOObp 
7 0 0  bp 
5 0 0  bp
3 0 0  bp
Figure 3.3 PCR products for ccr gene complex typing. The smallest PCR amplicon 
(286 bp) is the internal mec control. Lanes 1 and 20, 100 bp molecular weight 
standard (Promega); lanes 2 to 13, MRSA wound isolates; lane 14, control isolate 
PHII.43.2 for type ccr 1 (695 bp); lane 15, control isolate CA05 type ccr 2 (937 bp); 
lane 16, control isolate E0898 type ccr3 (1791 bp) and type ccrC (518 bp); lane 17, 
control isolate M001.005.2 type ccr 4 (1287 bp); lane 18, Irish clinical isolate; lane 
19, negative H20  control.
M H I] 3000 bp
2000 bp
800 bp
Figure 3.4 PCR products for mec class type. Lanes 1 and 19, molecular weight 
standard 100 bp and 1 kb respectively (Promega); lanes 2 to 12, MRSA wound 
isolates; lane 13, control isolate CA05 for Class B mec type (2827 bp); lane 14, 
control isolate E0898 for Class A mec (1963 bp); lane 15, control isolate WIS for 
Class C mec (804 bp); lane 16, negative H20  control; lane 17, negative control 
NCTC 6571; lane 18, positive control NCTC 12493.
ccr type
mec internal
10 11 12 13 14 15 16 17 18 192
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Of the nasal isolates, 85.7% harboured a Class B mec, one (14.3%) isolate associated 
with a Class C mec complex composed of IS4 31-mecA-A-mecRl-lS4 31 (Zhang et 
al., 2005) which was first described by Ito et al., (2004). Figure 3.4 shows the 
separation of the PCR products and determination of the mec class.
3.4.1.6 Combined SCC mec typing
All (100%) chronic wound MRSA isolates harboured type 2 ccr, of which 16 
isolates (94.1%) carried the Class B mec gene complex, and one isolate (5.9%) 
contained the Class A mec element The combination of these elements designates 
the SCC mec type, for which the majority, 16 (94.1%) of MRSA wound isolates, 
were type IV, with one patient harbouring the SCC mec II element. Of the nasal 
isolates 85.7% harboured Class B mec and one isolate (14.3%) was associated with a 
Class C mec complex and 71.4% of isolates had a type 2 ccr and 14.3% were type 1 
and 5 ccr. Hence, the majority of nasal isolates (71.4%) were classified as SCCmec 
IV, whilst the remainder (14.3%) were SCC mec I and V.
3.4.1.7 Joining (J) region typing for classification of SCC mec IV variants
All wound (100%) isolates associated with a ST22-MRSA-IV had an ‘h’ J 
region. The one wound isolate identified as ST30-MRSA-IV was sub-typed as IVc 
& IVE J region. In contrast, all (100%) of the nasal isolates with a class IV SCCmec 
were subtyped as J type ‘a’. Figure 3.5 shows the separation of the multiplex 
reaction for typing of the J region. Tables 3.9 & 3.10 show the distribution of the J 
typing amongst the MRSA isolates tested.
3.4.1.8 Epidemiology of isolates
Based on their sequence types, the epidemiology of the MRSA isolates 
identified amongst the patient group with wounds showed two clonal complexes 
(CC) or ancestry lines CC22 and CC30. The majority of patients (94.1%) harboured 
the SCC mec element IV, with one patient harbouring the SCC mec II element. The
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600 bp 
200 bp
Figure 3.5 PCR products to determine the joining rejoin for MRSA isolates. Lanes 
1 and 28, molecular weight standard 100 bp and 500 bp ladder (Fermentas); lanes 2 
to 20, MRSA wound isolates; lane 9, positive control ccr, negative for a J region, 
corresponding to a ST and SCC mec o f ST36-MRSA-II; lanes 21 to 27, 
asymptomatic nasal MRSA isolates.
Chronic wound
650 bp 
500 bp 
400 bp
Figure 3.6 Agarose gel showing the separation of PCR amplified products used to 
determine the agr locus. Lanes 1 and 36, 50 bp molecular weight standard 
(exACTGene®, Fisher); lane 2, negative H20  control; lanes 3 and 4, 0.5 and lp l 
DNA respectively o f control isolate RN4850; lane 4, control agr IV locus (588 bp); 
lane 5, control isolates TY114 showing agr locus III (406 bp); lane 6, control isolate 
MRSA 252 showing agr locus I (440 bp); lane 7, control isolate NCTC 8178 
showing agr locus III (406 bp); lanes 8 and 9, control isolates Mu50 and NCTC 
13130 showing agr locus II (572 bp); lane 10; control isolate HT2000132 showing 
agr locus III (406 bp); lanes 11 to 27, MRSA wound isolate; lanes 28 to 35, nasal 
MRSA isolate.
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epidemiological classification for this group of wound MRSA isolates was therefore; 
14 (82.4%) ST22-MRSA-IVh, 1 (5.9%) ST30-MRSA-IVc & IVE, 1 (5.9%) ST36- 
MRSA-II and 1 (5.9%) ST970-MRSA-IVh. In contrast, a greater number of 
ancestral lines were identified for nasal isolates with 42.9% of isolates associated 
with a CC1, and the remaining isolates representing CC5, 30/39, 45 and 51. The 
majority of the nasal isolates harboured SCCmec IV (71.4%).
3.4.2 Accessory gene regulator (agr) typing of MRSA isolates
PCR amplification was used to identify the agr locus. Two agr types were 
identified amongst the wound isolates; 15 (88.2%) were associated with agr I, and 2 
(11.8%) were associated with agr III (Table 3.9). Further analysis of the ST and agr 
locus type identified all ST22 & ST970 (CC22) as agr I, and ST30 and ST36 (CC30) 
as agr III. agr typing of the nasal carrier isolates showed that five (71.4%) were 
classified as agr III and one isolate each (14.3%) as agr II or agr IV (Table 3.10). 
Figure 3.6 shows separation of the amplified product used to classify the agr types.
3.4.3 Virulence factor analysis
Virulence factor profiles for nasal isolates and chronic wound MRSA isolates are 
shown in Table 3.11. The table shows the percentage of isolates with the presence 
and expression of the genes studied; whilst also indicating the level of expression 
intensity.
3.4.3.1 Enterotoxin gene analysis
Holmes’ multiplex toxin screen (Holmes et al., 2005) was an efficient 
method to determine the presence and expression of toxins (Table 3.11 & Figure
3.7). This demonstrated diversity in toxin profile gene presence, and variable levels 
of gene expression in the MRSA isolates.
Several toxin genes (sea, sed, sej, etA and etB) were only found to be present 
in the nasal MRSA isolates, with their presence ranging from 14.3% to 71.4% of
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Table 3.11 Virulence factor profiles of MRSA isolates
Virulence
factor
Gene present in 
wound isolate 
(n=17)
Expression level (%)
Gene present in 
nasal isolate 
(n=7)
Expression level (%)
0 I II III 0 I II III
seb 0 0
see 0 0
etD 0 0
etA 0 1 1 (100)
etB 0 1 1(100)
sed 0 2 i (50) HMI
sej 0 2 1(50) 1(50)
sea 0 5 1 (20) 2 (40) 2(40)
PVL ■ 1 (100) 0
tst 1 1(100) 3 1(33) 2(67)
seh 1 1 (100) 5 1 (20) 1 (20) 3(60)
sec 13 2(15) 11(85) 3 1 (33) 1 (33) 1(33)
cna 14 1(7) 13 (93) 7 4 (57) 2 (29) 1(14)
sei 17 1(6) 4(23) 12(71) 4 1 (25) 2 (50) 1 (25)
seg 17 1(6) 16(94) 4 1(25) 1(75)
geh 17 17(100) 7 7(100)
htgA 17 1 (6) 3 (18) 13 (76) 7 7(100)
hlgB 17 2 (12) 5 (29) 10(59) 7 1 (14) 2 (29) 4(57)
hlgC 17 17 (100) 7 7(100)
hysA 17 1(6) 16 (94) 7 2 (29) 4 (57) 1 (14)
icaA 17 17(100) 7 7(100)
I  Greatest presence of virulence gene comparing wound and nasal groups; BGreatest gene expression comparing wound and nasal groups
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Figure 3.7 Typical agarose gel showing PCR products from the four Holmes’ 
multiplex reactions; Lanes 1 and 14, molecular weight standard (Hyperladder II; 
Bioline); lane 12, positive control; lane 13, negative control; lanes 2 to 11, MRSA 
wound isolates; lanes 2 to 6 and 9 to 11, ST22-MRSA-IVh; lane 7, ST30-MRSA-IVc 
& IVE; lane 8, ST36-MRSA-II.
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isolates. For toxin sea, 40% of isolates expressed the gene as grade III or I, whilst 
20% did not express this gene despite its presence being detected. Moreover, those 
isolates showing grade III expression were associated with type III agr. Only 50% 
of isolates expressed sed and sej, as grade II and III respectively. Toxins etA and etB 
were present and both highly expressed (grade III) by the same single isolate; which 
was also associated with a type IV agr. Three genes (seb, see and etD) were not 
present in any of the isolates.
Presence and expression levels of genes varied between MRSA sources. 
Genes sec, seg and sei were found to be present in a high proportion (76.5% to 100% 
respectively) of the wound MRSA isolates. Conversely, approximately 50% of the 
nasal MRSA isolates harboured these genes. A high proportion (84.6%) of wound 
isolates showed a high (grade III) level of expression for toxin sec, for which all 
isolates were associated with an agr I type. Only 33.3% of the nasal isolates 
expressed the sec toxin as grade III.
Toxin seg showed comparable high levels of expression; (94.1% and 75% 
with a grade III expression for wound and nasal isolates respectively). Similarly sei, 
like sec and seg, showed a predominant gene presence in the wound isolates, with 
70.6% of the wound isolates having grade III expression of the sei toxin. MRSA 
isolates associated with the sei toxin were classed as type I agr. In contrast, none of 
the nasal isolates showed high expression of the sei gene.
Whilst seh and tst were found to be present in both the nasal and wound 
MRSA isolate groups, they were more prevalent in the nasal isolates (71.4% and 
42.9% respectively); both genes were only found in one (5.9%) wound isolate. The 
toxin gene seh was expressed highly (grade III) in 60% of the nasal isolates and all 
of these were associated with an agr III type. The remaining isolates showed low 
(grade I) or no expression at all. Only one wound isolate carried the seh gene, 
although this was not expressed. PVL was present in only one isolate, associated 
with a chronic wound and was highly expressed (grade III).
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3.4.3.2 ‘In-house’ virulence factor analysis
Additional virulence factors, which could possibly play a role in the non­
healing phenotype of a chronic wound, were tested. Again, MRSA isolates from 
wound and nasal carriers showed the presence of the majority of these virulence 
factors, however, there was variation in the expression in the two MRSA groups 
(Table 3.11). The use of control strains demonstrated that the ‘in-house’ PCR 
primers were appropriate to identify the presence and expression of the genes under 
investigation.
The genes for the virulence factors geh, hlgA, hlgB, hlgC, hysA and icaA 
were present in all isolates, with geh, hlgC and icaA classed as grade III expression 
for all wound and nasal isolates. Figure 3.8 shows the separation of multiplex RT- 
PCR products for icaA and internal control pta.
Conversely, collagen binding protein {cna) was present in all of the nasal 
isolates but only 82.4% of wound isolates harboured the gene. Nonetheless, the 
expression profile was the opposite. A high proportion (92.9%) of all the wound 
isolates were classed as having grade III expression, with the remaining having grade 
II expression for the cna gene. The majority (57.1%) of the nasal isolates were 
found to have low expression of the cna gene, and only a small number (14.3%) 
found to have grade III expression for cna. Figure 3.9 shows the separation of 
multiplex RT-PCR products for cna and internal control yqil.
The hysA gene was present in 100% of wound and nasal isolates. In spite of 
this, the expression of the hysA showed considerable variability. Similar to that of 
cna, the majority of the wound isolates (94.1%) were classed as having a high (grade 
III) expression. The nasal isolates in contrast were found to have a low expression of 
hysA, with 57.1% being classed as grade I and approximately 30% not expressing 
this virulence factor at all.
Figures 3.10 and 3.11 show separation of singleplex and multiplex RT-PCR 
electrophoretic gels for the hysA and housekeeping gene respectively. When the RT-
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Figure 3.8 Separation of RT-PCR products for yqil (516 bp) and icaA (669 bp). 
Lanes 1 and 27, 100 bp molecular weight standard (Thermo); lanes 2 and 3, positive 
control isolates PJ141 and PJ156 respectively for the icaA operon; lanes 4 to 17, 
wound MRSA isolates; lanes 18 to 24, nasal carrier MRSA isolates; lane 25, 
negative H2O control; lane 26, blank.
Figure 3.9 Separation of RT-PCR products for yqil (516 bp) and cna (161 bp). 
Lanes 1 and 27, 100 bp molecular weight standard (Thermo); lane 2, nasal carrier 
MRSA isolate; lane 3, cna negative control isolate Mu50; lane 4, positive control 
isolate MRSA 252; lane 5 to 9, nasal carrier MRSA isolate; lane 10 to 24, wound 
MRSA isolates, lane 25, cna negative control isolate NCTC 8178; lane 26, negative 
H2O control.
500 bp 
100 bp
Figure 3.10 Separation of RT-PCR products for hysA (438 bp). Lanes 1 and 28, 100 
bp molecular weight standard (Thermo); lane 2 negative H2 O control; lane 3 positive 
control isolate MRSA 252; lane 4, positive control NCTC 8178; lanes 5 to 15, 22 to 
24 and 26 to 27, wound MRSA isolates; lanes 16 to 21 and 24, nasal carrier MRSA 
isolates. Lane 5, represents grade III expression; lane 18, represents grade II 
expression and lane 20, represents grade I expression.
Figure 3.11 Separation of RT-PCR products fox yqil (516 bp) and hysA (438 bp). 
Lanes 1 and 20, 100 bp molecular weight standard (Thermo); lane 2, and 4, negative 
controls H2 O, NCTC 8325 respectively; lane 3 and 5, positive control isolates NCTC 
8178, MRSA 252 respectively; lanes 6 to 11, nasal MRSA isolates; lanes 12 to 19, 
wound MRSA isolates; lanes 5, 6, 7 and 8 correspond to lanes 3, 25, 20 and 21 in 
Figure 3.10 respectively, classed as grade I expression; Lanes 9, 10 and 11 
correspond to lanes 16, 19 and 17 in Figure 3.10 respectively, classed as a grade 0 
expression; lanes 12 to 19 correspond to lanes 5 to 12 in Figure 3.10 respectively, 
classed as grade III expression.
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PCR was performed in a multiplex fashion, faint bands (equivalent to grade I 
expression in the singleplex PCR) were not produced suggesting a possible risk for 
under-reporting of this gene (Figure 3.11). Those isolates classed as grade III 
expression however were still distinct. This phenomenon may have resulted from 
exhaustion of dNTPs or Taq polymerase enzyme in the reaction mixture leading to 
preferential competition with the housekeeping gene. PVL or lukS/lukF was only 
found in one (5.9%) of all the wound patient isolates. Nevertheless, this was 
expressed as a grade III level and found to be associated with ST30-MRSA-IVa & 
IVE. None of the nasal isolates harbored or expressed this virulence factor.
3.4.3.3 Comparison of virulence factor profiles for chronic leg and chronic 
surgical wound MRSA isolates
Isolates in this study were obtained from wounds representing chronic leg 
wounds (CLW) and chronic surgical wounds (CSW) as their primary aetiology. 
Table 3.12 shows the comparison of virulence gene presence and expression between 
the two wound types.
Whilst the patterns for presence of the virulence genes sec, seg, sei, geh, 
hlgA, hlgB, hlgC, hysA and icaA were similar irrespective of wound source, variation 
in gene expression was observed. All the isolates in both the CLW and CSW groups 
were classed as having a grade III expression for the genes hlgC, icaA and geh. Of 
those isolates found to have the genes sec or seg present, all of the CLW’s were 
classed as having grade III expression, whilst between 66.7% and 87.5% of CSW’s 
were classed as a grade III expression respectively.
The expression of HysA, hlgA, cna, and hlgB in all (100%) CSW isolates was 
high (grade III). This expression intensity was not observed in the CLW group for 
the same genes. The tst gene was only harboured by a CLW isolate and was 
associated with an ST36 MRSA. PVL was present in one CSW isolate and 
associated with ST30.
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Table 3.12 Expression levels of virulence factors present in chronic leg wound, chronic surgical wound and nasal MRSA isolates
Virulence
factor
Gene
present
aCLW
MRSA
(n=9)
Expression level aCLW 
MRSA (%)
II TIL
Gene
present
bCSW
MRSA
(n=8)
seb 0 0
see 0 0
etD 0 0
etA 0 0
etB 0 0
sed 0 0
sej 0 0
sea 0 0
PVL 0 1
tst 1 1 (100) 0
seh 1 1 (100) 0
sec 7 7(100) 6
cna 7 1(14) 6(86) 7
seg 9 9(100) 8
sei 9 3(33) 6(67) 8
hlgB 9 2 (22) 3 (33) 4(44) 8
hlgA 9 1(11) 3(33) 5(56) 8
hysA 9 1(H) 8(89) 8
hlgC 9 9(100) 8
geh 9 9(100) 8
icaA 9 9(100) 8
Expression level bCSW 
MRSA (%)
0 I I I
1(13)
1(13)
TIL
( 100)
2 (33) 4 (67)
7(100)
7(88)
8 ( 100)
8 ( 100)
8 ( 100)
Gene
present
nasal
MRSA
(n=7)
Expression level nasal 
MRSA (%)
0 I II III
0
0
0
1 1 (100)
1 1 (100)
2 1(50) 1(50)
2 1(50) 1 (50)
1 (20) 2 (40) 2(40)
0
3 1(33) 2(67)
1 (20) 1 (20) 3(60)
3 1(33) 1(33) 1(33)
7 4(57) 2(29) 1(14)
4 1(25) 1(75)
4 1 (25) 2 (50) 1(25)
7 1(14) 2(29) 4(57)
7 7(100)
7 2 (29) 4 (57) 1(14)
7 7(100)
7 7(100)
7 7(100)
®  Greatest presence of virulence gene comparing wound and nasal groups; H  Greatest gene expression comparing wound and nasal groups;
aChronic leg wound; bChronic surgical wound. 157
The following parameters were further correlated with virulence factor 
presence and associated wound type: relative pain, inflammatory and clinical score 
based on clinical wound presentation. In this respect, no correlation between wound 
types, virulence factor profile or any clinical parameters were found.
3.5 Discussion
These studies demonstrated the comparative benefits of the currently 
available methods for genetic typing of MRSA. RAPD was technically, relatively 
simple in comparison to the other typing methods described here. The three primers 
used in this study separated the isolates into two or three clusters with varying 
results; none of the primers placed the isolates into the same cluster of relatedness. 
Inter-primer and inter-cluster variance made interpretation of the results ambiguous. 
Interestingly, Primer 1 placed the majority o f isolates in one group which correlated 
with the more complex techniques. However, the three primers highly related each 
cluster.
RAPD is a recognised method for rapid initial identification of relatedness in 
outbreaks of nosocomial isolates (Witte et al., 2006), yet, this study demonstrated 
that multiple variables affected the distinction of groups e.g. thermo cycler used 
(results not shown) and primer design. This is supported by similar studies, which 
demonstrated similarly contrasting results obtained in individual laboratories 
(personal communication with Dr A. Shore; Witte et al., 2006). In these studies, the 
analysis of band patterns was difficult to perform and essentially arbitrary, a finding 
which may explain the significant grouping differences. These discrepancies have 
been predominantly attributed to the detection of small/faint bands, accuracy of the 
software package, and UV exposure of the original gel.
In contrast to RAPD, PFGE was highly discriminatory, although associated 
with significant cost and time implications. These studies demonstrated that the use 
of the criteria described by Tenover et al., (1995) to interpret patterns was both
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simple and reproducible. The PFGE method identified the isolates into three main 
groups or pulse-types and was able to relate the isolates to their clonal ancestry. 
Whilst PFGE has its place in an outbreak setting, variances in switch times and inter­
laboratory equipment may produce varying patterns of fragments between 
laboratories.
Multilocus sequence typing is described as the “gold standard” of MRSA 
typing (Urwin and Maiden, 2003). This method was simple and the least ambiguous 
of the typing methods employed. Methodological complexity and cost were, 
however, inherent. Comparing PFGE and MLST data; it is important to note that 
those isolates classified as ST22 via MLST were represented by PFGE pulse types A 
and B. For this discriminatory reason and cost implications, many hospital 
microbiological laboratories continue to use PFGE in an outbreak situation; as point 
mutations may not be identified using MLST if the genetic mutation has occurred 
outside the house-keeping gene, causing less accurate resolution of the isolates 
(Shopsin et al., 1999, Grundmann et al., 2002, Montesinos et al., 2002, Harmsen et 
al., 2003).
MLST divided wound isolates into four sequence types. The two clonal 
types associated with the wound patient cohort were, ST22 representing MRSA 
clone EMRSA-15 and ST36 representing EMRSA-16. These are the two most 
common hospital-acquired pandemic clones circulating in the UK. In this study 
population, it is impossible to determine whether these isolates were acquired due to 
hospitalisation, outpatient attendance, or long-term community residences, which are 
risk factors for colonisation in this elderly population. Whilst healthcare providers 
are blamed for the spread of MRSA (due to lack of hygiene), no consideration of the 
possible role that patients who harbour these isolates attending out-patient clinics 
and hospitals, interacting with other vulnerable patients may play (Halcon and 
Milkus, 2004). A study of skin and soft tissue infections associated with MRSA 
identified that 75% were associated with CA-MRSA compared to 37% of HA- 
MRSA (Tenover and Gorwitz, 2006). These proportions were not seen in this group
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of isolates, presumably because these are chronic wounds and hence more likely to 
be associated with hospital contact.
The study of the SCCmec element by Oliviera et al., (2002) showed evidence 
that MRSA clones have arisen more than once by the acquisition of different 
SCC mec elements (Urwin and Maiden, 2003); MLST alone has now been described 
as not being discriminatory enough for detailed epidemiological typing (Witte et al., 
2006). All of the wound MRSA isolates were identified as harbouring type 2 ccr 
and having either a Class B mec or Class A mec gene complex. These SCC mec types 
are typical for EMRSA-15 and EMRSA-16 respectively. When ST36 (i.e. EMRSA- 
16) evolved from ST30 it exchanged its SCCmec element from a IV to II, examples 
of which are observed here in patients 1011 (ST30 SCCmec IV) and 1021 (ST36 
SCC mec II; Robinson and Enright, 2003).
The wound MRSA isolates in this study were associated with two ancestor 
clonal complexes CC22 and CC30, whilst the nasal MRSA isolates were associated 
with a more diverse range of clonal complexes. This was expected due to the 
likelihood of harbouring CA-MRSA in the asymptomatic nasal carriers. This pattern 
is typical of CA-MRSA and HA-MRSA, with CA-MRSA being more diverse due to 
the frequent acquisition and loss of the SCCmec element (Holden et al., 2004, 
Collery et al., 2008, Diep and Otto, 2008, Argudin et al., 2009).
The SCC mec type of nasal isolates was typically associated with a type IV 
mec element (71.4%); asymptomatic carrier status is more likely to be associated 
with CA-MRSA, for which this SC Cmec element is common. Isolates S07 229 and 
S07 191 were classified as ST5-MRSA-IV and ST45-MRSA-IV respectively which 
represent the ‘paediatric’ and ‘Berlin’ clone of MRSA (Enright et al., 2002). The 
type IV mec element is smaller and believed to be more mobile, facilitating transfer 
between staphylococcal sp. and of less ‘fitness cost’ (Lee et al., 2007, Diep and Otto, 
2008, Zakour et al., 2008, Elston and Barlow, 2009).
EMRSA-15 or ST22 predominated in the wound group of patients (82.4%) 
and was classed as HA-MRSA (as is ST36 or EMRSA-16). The greater proportion
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of ST22 seen in this cohort of patients may be associated with a transition of ST in 
the hospital setting. Indeed this has been noted previously; ST36 or EMRSA-16 is 
now becoming less prevalent in the hospital setting (O'Neill et al., 2001, Murchan et 
al., 2004, Ellington et al., 2010). This may be related to the acquisition of the 
smaller SCC mec IV, or in this patient cohort associated with the wound 
environment.
Use of the SCC mec element as a typing tool is evolving, with additional 
genetic components being used in the typing of MRSA. It is now common to 
distinguish the J region of isolates with SC Cmec IV. This has arisen as there are a 
number of ST’s, with specific reference to community isolates, that contain the 
SCCmec type IV. The J region sits outside of the ccr/mec gene complex on the 
SCC mec element. A large proportion (88.2%) of the wound group isolates were 
associated with an ‘h’ type J region. This is a similar finding to other studies 
(Milheirico et al., 2007, IWG-SCC, 2009). All nasal isolates with a SCC mec IV had 
an ‘a’ type J region.
MRSA is continuously in the press and continues to cause problems in the 
medical world. With the advent of increased CA-MRSA carriage rates, MRSA 
associated infections are likely to increase. There has also become a blurring of the 
boundaries regarding CA-MRSA and HA-MRSA. This is, in part, associated with 
insufficient clarity of definitions in previous publications, plus some ST associated 
CA-MRSA isolates are now becoming resident in the hospital setting e.g. USA300. 
In the long-term, it is likely, therefore, that typing methods in hospital settings will 
become increasingly sequence-based. In future studies, the use of more recent 
typing methods e.g. single-nucleotide polymorphisms may provide greater 
discrimination between isolates and improve disease and virulence factor correlation 
(Harris et al., 2010).
Due to the low numbers of wound isolates with MRSA in this study and an 
uneven distribution of the STs, it was impossible to describe correlation with wound 
severity/chronicity and ST. The accessory gene regulator (agr) type has been linked
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to disease (Robinson et al., 2005) with agr types I and II linked with enterotoxin 
mediated disease and agr types III and IV associated with non-invasive and 
exfoliating disease (Jarraud et al., 2002). Further analysis of the ST and agr type 
identified all ST 22 & 970 (CC 22) as agr I and finally ST30 and ST36 (CC30) as 
agr III, in keeping with previous studies (Rossney et al., 2007). It is interesting that 
the majority of wounds (88%) were associated with ST22 and agr I in keeping with 
the invasive nature of the disease process. Furthermore, it is remarkable that the 
majority of the isolates obtained from asymptomatic nasal carriers were associated 
with an agr III, which is typically associated with non-invasive disease (Jarraud et 
al., 2002, Holtffeter et al., 2007).
This observational study aimed for the first time to identify potential 
virulence factors associated with disease in wound patients and asymptomatic nasal 
carriers. The virulence factors tested were chosen based on their potential advantage 
within the host tissues i.e. colonisation of the host {cna, icaA; Holderbaum et al., 
1987, Arciola et al., 2001), survival and evasion of the host immune system (geh, 
hlgA, hlgB, hlgC, icaA, PVL; Dalla Serra et al., 2005, Holmes et al., 2005, Kropec et 
al., 2005), and importance in tissue destruction (geh, and hysA; Makris et al., 2004, 
Burlak et al., 2007).
Virulence factor screening of enterotoxins and PVL has become more 
common in reference laboratories (Monday and Bohach, 1999, Holmes et al., 2005), 
yet little is known of the expression of other virulence factors produced by 
staphylococci in human diseases states, where they may play a role in disease 
progression/chronicity e.g. chronic wounds.
In this study, the expression of a number of enterotoxins (i.e. sec, seg, and 
sei) were significantly greater in the wound isolates associated with agr I type (data 
not shown). This resembled previous studies (Jarraud et al., 2002), where the genes 
seg and sei were found grouped in the enterotoxin gene cluster (egc) on a genomic 
island vSAp (Lindsay and Holden, 2006, Tristan et al., 2007, Sauer et al., 2008, 
Argudin et al., 2009, Varshney et al., 2009). Enterotoxin-mediated disease is usually
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associated with gastro-intestinal (GI) bacteria, causing lysis and affecting epithelial 
permeability of the intestinal wall (Johnson et al., 1991b). It is possible that these 
enterotoxins may play a role in the damage of skin epithelial cells and therefore a 
link to epithelial disruption and non-healing of these wounds.
As previously described, only isolates associated with agr III expressed etA, 
etB and tst, (Jarraud et al., 2002, Argudin et al., 2009), with etA and etB present only 
and expressed by the same isolates. Co-expression of tst with sea has previously 
been described (Johnson and Yu, 1991a, Nashev et al., 2004, Tristan et al., 2007, 
Argudin et al., 2009) and is often related to EMRSA-16 or ST36 (Murchan et al., 
2004) as in this study.
Biofilm production is an aid to bacterial colonisation, but also provides a 
barrier to host defences, antibiotics, and may help with genetic transfer between the 
various species that form the biofilm (Gilbert et al., 2002, Peacock et al., 2002, Diep 
and Otto, 2008, Varshney et al., 2009). Biofilms cause major problems in the health 
care setting in terms of colonisation of medical devices such as catheters and 
titanium implants (Fiirst et al., 2007, Salvi et al., 2008). Unsurprisingly, both wound 
and nasal isolates harboured and expressed icaA. Clinical strains of S. aureus 
commonly harbour the icaA operon (Cramton et al., 1999, Fluckiger et al., 2005, 
Otto, 2008). A recent study by Kouidhi et al., (2010) found that only 60% of S. 
aureus from the oral cavity harboured the icaA operon were able to produce a slime 
layer. Whilst genetic testing is valid, gene expression alone however, does not 
necessarily reflect biofilm synthesis. This may be interesting to investigate further, 
comparing the two distinct groups (wound vs. nasal). It is important to remember 
however, that a large number of environmental factors (e.g. shear forces, oxygen 
concentration and bacterial species) regulate biofilm establishment in the in vivo 
environment, all of which are difficult to reproduce in vitro.
The ability of an organism to bind to extracellular matrix (ECM) may play a 
role in adhesion, colonisation and persistence. In this study, whilst the presence of 
cna was predominent in the nasal isolates, the expression of cna in wound isolates
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was significantly greater; a finding which may relate to exposure of the wound 
bacterium to collagen in the wound bed. The level of cna gene presence reported 
here is greater than reported in other studies, which have shown that 50% of isolates 
carried the gene and that cna is not constitutively present (Holderbaum et al., 1987, 
Deurenberg et al., 2007). A possible reason for the greater predominance of cna in 
this study may be due to the large numbers of ST22 isolates. Several studies show 
that S. aureus harbouring the cna gene are associated with increased pathogenicity 
(Holderbaum et al., 1987, Patti et al., 1994, Wassenaar and Gaastra, 2001). In 
support of this, cna has been reported to be less important in the adherence of 
bacteria in “collagen-free” environments, but more important for persistence when 
there is exposed collagen as would be the case in the wound environment (Patti et 
al., 1994). Confirming these results, other studies show a greater association of cna 
with disease than colonisation (Peacock et al., 2002, Nashev et al., 2004). In 
comparing the chronic surgical and leg wound isolates, a difference was observed in 
the level of cna expression. All the surgical wound isolates expressed this gene at a 
high level; a finding which may reflect the lack of environmental advantage. Rather, 
cna may confer further resilience in an environment rich in ECM e.g. collagen in the 
exposed wound bed.
y-haemolysin is a complex protein made of a number of subunits. It is able to 
lyse erythrocytes and leucocytes, leading to evasion of the host and aid bacterial 
colonisation. Whilst the expression of these genes was similar in wound and nasal 
isolates, a significant difference in expression was observed when comparing chronic 
leg and surgical wounds. In this case, all surgical wound isolates harboured all 3 
genes (hlgA, hlgB and hlgC), all with high levels of expression (grade II and III). In 
comparison, chronic leg isolates expressed hlgA and hlgB proportionally less. 
Although PVL may play a role in destruction of the host immune response, it was 
only found in a single surgical wound. Interestingly, PVL subunits may unite with 
components of the hlg family to produce a functional protein for leucocytosis 
(Cooney et al., 1993, Lina et al., 1999, Dalla Serra et al., 2005).
164
Hyaluronate lyase (hysA) is able to degrade hyaluronic acid (HA) which is a 
major component of the ECM in the skin and consequently in wounds. It has been 
suggested that degradation of HA in tissue facilitates bacterial invasion of the tissues 
(McClean, 1943). HA degradation and the generation of low mw HA fragments 
stimulate the immune response via Toll-like receptor (TLR) mediated mechanisms 
(Chapter 4). The degradation of this important ECM component may contribute to 
prolonged inflammation and a non-healing phenotype. In keeping with this, a 
significant difference in expression of hysA was observed between wound (94.1%) 
and nasal (0%) isolates at grade III expression. Moreover wound isolates from 
surgical and leg wounds exhibited high (grade III) expression of hysA, (100% and 
88.9% respectively), suggesting a potential role in wound colonisation and 
persistence of MRSA.
Overall this study has demonstrated clear differences in the expression of 
virulence factors by MRSA isolates, which are dependant on their colonising 
environment. This may indicate that the bacteria present and their secretory factors 
have an important role in the non-healing phenotype of chronic wounds, as observed 
for the expression of cna, and hysA genes when comparing the wound vs. 
asymptomatic carrier.
The results of this study should, however, not be overestimated. It is a 
relatively small study group (24 patients) and the relationships merely observational. 
Areas where the data are less easy to interpret include the finding that 6 STs were 
present in the nasal carrier group; whereas within the chronic wound group ST22 
was predominant, thus it is not possible to say if these isolates express these factors 
based on environment or due to its strain genetic background.
Retrospectively, a more satisfactory study design would be to include patient 
matched samples including both wound and non-wound sites e.g. nose, skin 
(undamaged), for comparison with asymptomatic carriers. In these studies RT-PCR 
was employed to study the expression of virulence factors of interest. Whilst it is a 
useful screening tool, the categorisation of expression by this technique, although
I
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employed in previous studies, is by no means definitive. Further analysis with 
Northern blotting or quantitative RT-PCR (qRT-PCR) to identify real-time 
expression of the virulence factors would be needed to confirm these data 
quantitatively. Further investigation into other virulence factors such as proteases 
may also prove valuable. The use of gene array technology would be a valuable 
screening tool followed by proteomic and metabolomic studies to study bacterial 
physiology as a whole.
A consideration in the interpretation of these results and other studies is that 
the expression of virulence factors in this study was performed using bacteria grown 
in a planktonic environment. It is known that bacterial gene/protein expression is 
influenced by a variety of factors (e.g. matrix, O2 stress, biofilm formation and 
growth states) and it is impossible to exactly model these environmental features. 
As biofilms characterise human wounds, studies of these bacteria in a biofilm 
environment may be useful.
The study shows a potential role for virulence factor expression in wound- 
associated MRSA on non-healing. Virulence factor expression was generally 
widespread amongst the MRSA isaoltes. Notionally, the moist, nutrient-rich bed of 
the wound is an ideal environment for the exchange of genetic resistance, 
pathogenicity islands and mobile virulence factors. Therefore, further study of 
virulence factors, to decipher their effect on wound healing is warranted. This may 
lead to the development of new therapeutics to control virulence factor production, 
to potentially aid the healing of wounds and with that, associated increases in patient 
care.
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Chapter 3 part II: Problems associated with PVL detection
Whilst investigating the virulence profiles of MRSA isolated from chronic 
wounds and asymptomatic nasal carriers (Chapter 3, part I) it was observed that a 
number of the wound isolates associated with ST22-MRSA-IVh (EMRSA-15) 
appeared to be borderline positive for PVL. Using PCR primers designed by Lina et 
al., (1999) faint bands were sporadically observed on agarose gels, whilst negative 
controls were clearly negative and positive controls clearly positive. It was thought 
unlikely that so many ST22 (EMRSA-15) from such a small study group were likely 
to harbour the PVL gene based on previous reports (Vandenesch et al., 2003, 
Rossney et al., 2007). However, due to this banding inconsistency, it was difficult to 
assign a virulence profile for these particular isolates. Interestingly, following 
personal communication, this phenomenon had previously been experienced by Dr 
M. Wootton of the Specialist Antimicrobial Chemotherapy Unit (SACU), Cardiff, 
Wales and Dr A. Shore, Trinity College, Dublin; however the reason for this had not 
been investigated.
3.6 Aims
The aim of this chapter was:
1. To further investigate the cause of inconsistent ambiguous band profiles 
experienced with the clinical wound isolates when investigating the presence 
of the PVL gene.
2. To determine the presence of PVL in chronic wound MRSA isolates using 
PCR-based techniques (using three different DNA preparations), sequence- 
based identification, Southern hybridisation and DNA microarray techniques 
to describe their true virulence profile.
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3.7 Materials and Methods
3.7.1 Bacteria and growth media
All chronic wound MRSA isolates (n = 17) were cultured as previously 
described (Chapter 2, Section 2.3.2). In addition sixteen MRSA bacterial isolates 
positive and negative for PVL carriage were acquired from Dr M. Wootton, SACU, 
Cardiff, for blind testing alongside the chronic wound isolates. Each isolate was 
cultured on blood agar (BA; LabM) supplemented with 5% defibrinated sheep blood.
3.7.2 DNA preparation using Qiagen DNeasy® kit and 3 h lysis (Qiagen® 3 h)
The isolation of DNA from the chronic wound MRSA, PVL control MRSA 
strains and nasal MRSA carrier isolates has been previously described (Section 
3.3.2.3.1).
3.7.3 DNA preparation using microLYSIS® kit
This method is employed by the Health Protection Agency (HPA), London. 
Freshly subcultured bacteria were grown O/N on nutrient agar (Oxoid) at 37°C. One 
colony of the test isolate was re-suspended in 20 pi of microLYSIS® solution 
(Microzone Ltd, West Sussex, UK) and placed in a thermocycler to isolate DNA 
using the following parameters; 65°C for 5 min, 96°C for 2 min, 65°C for 4 min, 
96°C for 1 min, 65°C for 1 min and 96°C for 30 s; hold at 20°C until use.
3.7.4 DNA preparation using Qiagen DNeasy® kit and 30 min lysis (Qiagen® 30 
min)
This method is employed by SACU. Bacteria were grown overnight on TSA 
plates at 37°C. Half a loop of bacterial growth was added to 200 pi of distilled water 
in microfiige tubes and mixed by pipetting. The bacterial suspensions were 
centrifuged (7500 x g, 10 min). The supernatant was removed and re-suspended in 
180 pi of lysis buffer (20 mM Tris-HCl, pH 8.0; 2 mM sodium EDTA pH 8.0; 1.2% 
Triton® X I00; 20 mg/ml lysozyme), then 10 pi of 1 mg/ml of lysostaphin was added
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to each bacterial suspension and mixed gently by pipetting. The suspension was 
incubated (37°C, 30 min), then 25 pi of proteinase K and 200 pi buffer AL (Qiagen® 
kit) was added and the suspension vortexed for 5 s, followed by incubation (56°C, 30 
min). Following incubation, 200 pi ethanol (96%; v/v) was added and mixed by 
pipetting and again vortexed for 5 s. The suspension was then transferred to a 
DNeasy® mini spin column, and centrifuged (8000 x g, 1 min). The flow-through 
was discarded, 500 pi of buffer AW1 (Qiagen® kit) added and the column was 
centrifuged (8000 x g, 1 min). The flow-through and collection tube was once again 
discarded, 500 pi buffer AW2 (Qiagen® kit) added and the column was centrifuged 
(18600 x g, 3 min) to dry the DNeasy membrane. The column was placed in a sterile 
microfuge tube and 100 pi of buffer AE (Qiagen® kit) was pipetted directly onto the 
DNeasy® membrane and incubated for 1 min at RT. The column was subsequently 
centrifuged (8000 x g, 1 min) to elute the DNA.
3.7.5 Identification of PVL using Lina PVL PCR primers
Identification of PVL in both chronic wound and SACU control PVL MRSA 
isolates was performed using primers designed by Lina et al (1999), Table 3.13. 
DNA was isolated from wound MRSA using two DNA preparation methods; 
Qiagen® 3 h and Qiagen® 30 min DNA preparations (Section 3.7.2 & 3.7.4), and 
DNA for the SACU control PVL MRSA isolates using Qiagen® 3 h method only 
(Section 3.7.1 & 3.7.2). PCR was performed as previously described (Section
3.3.3.3).
3.7.6 Identification of PVL using Fey PVL PCR primers
DNA was extracted using the Qiagen® 3 h method (Section 3.7.2). A 25 pi 
PCR reaction was performed using the Fey PVL PCR primers (Table 3.1.3; Fey et 
al., 2003). The PCR reaction mixture consisted of 1 pi of DNA template, 5 pi of 
10X buffer, 3 mM MgCL, 0.4 pM of each primer, 1.25 U of Taq DNA polymerase,
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Table 3.13 PCR primers used to amplify Panton-Valentine leucocidin (PVL) gene
Primer name Virulence factor Primers (5’ to 3’) Amplicon size 
(bp)
Reference
luk-PV-1
luk-PV-2
PVL ATCATTAGGTAAAATGTCTGGACATGATCCA
GCATCAASTGTATTGGATAGCAAAAGC
433 Lina et al., (1999)
lukS-PV
lukF-PV
PVL GGCCTTTCCAATACAATATTGGCCCAATCAACTTCATAAATTG 1554 Fey et al., (2003)
PVL, Panton-Valentine Leucocidin; bp, base pair.
Table 3.14 PCR primers used in reaction 4 of multiplex toxin screen (Holmes et al., 2005)
Primer name Virulence factor/ Gene Primers (5’ to 3’)
Amplimer size 
(bp)
Reference
etd A  
etd- 2 
luk-PV-1 
luk-PV-2 
mecA- P4 
mecA- P7
etd
PVL
mecA
AACTATCATGTATCAAGG
CAGAATTTCCCGACTCAG
ATCATTAGGTAAAATGTCTGGACATGATCCA
GCATCAASTGTATTGGATAGCAAAAGC
TCCAGATTACAACTTCACCAGG
CCACTTCATATCTTGTAACG
376
433
162
Yamaguchi et al., 
(2002)
Lina et al., (1999)
Oliveira and de 
Lencastre (2002)
sal6S 16S rRNA GTAGGTGGCAAGCGTTATCCCGCACATCAGCGTCAG
228 Monday and Bohach (1999)
etd, exfoliative toxin D; PVL, Panton-Valentine Leucocidin; mec A, meticillin resistance determinant; rRNA, ribosomal ribonucleic acid; bp, 
base pair.
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200 pM (each) deoxynucleoside triphosphates (dNTPs) and 11.25 pi of nuclease free 
water, all reagents were obtained from Promega, UK. The PCR reactions were 
performed with an initial denaturation step (94°C, 5 min), followed by 35 cycles 
(denaturation, 94°C, 45 s; annealing, 55°C, 45 s; extension, 72°C, 105 s), followed 
by a final extension step (72°C, 10 min). The products were separated using 
electrophoresis alongside Hyperladder III molecular weight standard (Bioline Ltd, 
London, UK) in a 2% agarose gel containing ethidium bromide (0.5 pg/ml) for 1 h at 
120 V.
3.7.7 Identification of PVL using a multiplex toxin screen
PVL presence in the chronic wound MRSA was identified using Holmes et 
al., (2005) multiplex PCR toxin screen reaction 4 (Section 3.3.3.2; Table 3.14) using 
1:10 diluted Qiagen® 3 h (Section 3.7.2) and microLYSIS® prepared DNA (Section
3.7.3).
3.7.8 Identification of PVL using Southern blotting and DNA hybridisation
Following multiple PCR amplification attempts to correctly identify the PVL 
positive chronic wound isolates using the Qiagen® 3 h DNA preparation and Lina 
PVL PCR primers (Section 3.7.2 & 3.7.5). Southern hybridisation was performed on 
an agarose gel of separated PVL PCR products. The gel was photographed 
(GelDoc™, Bio-Rad®) and then placed in denaturing solution (0.5 M NaOH; 1.5 M 
NaCl) for 30 min at RT with continuous agitation. The gel was then soaked at RT 
for 30 min in a neutralising solution (0.5 M Tris-HCl, pH 7.5; 1.5 M NaCl). A nylon 
membrane (Hybond™, GE Healthcare, Amersham) was cut to the size of the gel and 
soaked in 2X saline-sodium citrate buffer (SSC; 3 M NaCl; 0.3 M Na3C6Hs0 7 , pH 
7.0) for 5 min. The neutralised gel was blotted using a wick of Whatman 3MM 
paper (Whatman® Ltd, GE Healthcare, UK) with each end submerged in 20X SSC. 
The pre-soaked nylon membrane was placed over the gel. A sheet of 3MM 
Whatman filter paper previously soaked in 20X SSC was placed over the nylon
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membrane followed by 3 sheets of dry 3 MM Whatman filter paper and 5 sheets of 
absorbent blotting paper (Quickdraw, Amersham). Several layers of paper towels 
were placed on the blotting stack. A Perspex plate and weight were finally placed on 
the filters O/N.
The nylon membrane was then removed and DNA fixed using UV light for 4 
min. The nylon membrane was placed into a glass hybridisation tube (Hybaid) and 
20 ml of pre-hybridisation solution was added (6X SSC, 0.1%, w/v, 
polyvinylpyrrolidone; 0.1%, w/v, ficoll; 0.1%, w/v, bovine serum albumin, BSA; 
0.5%, w/v, sodium-dodecyl sulphate, SDS; lOmg/ml herring DNA) and incubated 
(65°C, 5 h).
A probe for the identification of PVL was prepared by extracting the positive 
control (NCTC 6571) PVL band from an agarose gel followed by purification using 
QIAquick® Gel Extraction Kit. Briefly, the agarose gel band was placed in a 
microfuge tube, and 300 pi of buffer QG (supplied) was added and incubated (RT, 
15 min), to which 100 pi isopropanol was added. The sample was applied to a 
QIAquick® spin column and centrifuged (17900 x g, 1 min) the flow through was 
discarded and 500 pi of buffer QG added to the membrane and re-centrifuged (17900 
x g, 1 min) the membrane was washed with 750 pi buffer PE (supplied) for 2 min, 
then centrifuged (17900 x  g, 1 min) the flow through was discarded and column re­
centrifuged (17900 x g , 1 min). The column was placed in a clean microfuge tube 
50 pi of nuclease-free water was added directly to the membrane and incubated (RT, 
1 min) followed by centrifugation (17900 x g, 1 min) to elute the DNA. The 
resulting flow through (extracted band) was labelled with 32P dCTP random primer 
extension (Prime-It II Random Primer Labelling Kit, Stratagene, USA).
Twenty-one pi of the DNA was combined with 10 pi of random primers 
(Stratagene kit). The sample was placed in a boiling waterbath for 5 min, then 10 pi 
of buffer dCTP (Stratagene kit), 2.5 pi of 32P and 1 pi Klenow was added to the 
sample and placed in a lead jar (37°C, 15 min). Removal of unused nucleotides was
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performed using a G50 Sephadex column (Nick column, Pharmacia). After putting 
the sample onto the column it was washed with 320 pi of buffer (0.1 M Tris-HCl, pH 
7.5). The column was then placed over a new collecting tube to collect the probe by 
washing the column with 430 pi of buffer (0.1 M Tris-HCl, pH 7.5). The collected 
solution was placed in a boiling waterbath for 6 min to denature the DNA. This 
probe was immediately added to the hybridisation tube containing the nylon 
membrane and allowed to incubate (65°C, O/N).
Following hybridisation, the probe was removed and stringency washes 
performed; the nylon membrane was washed in 300 ml of 2X SSC containing 0.1% 
(w/v) SDS (65°C, 15 min), followed by 0.1X SSC containing 0.1% (w/v) SDS 
(65°C, 15 min). The membrane was blotted with 3MM Whatman paper and 
wrapped in clingfilm. Using an intensifying screen and Amersham Hyperfilm™-MP 
(GE Healthcare, UK) an autoradiographic image was recorded (4 h exposure).
3.7.9 Sequencing of PVL products
A number of PCR reactions for the chronic wound MRSA resulted in faint 
bands of the correct size for PVL (433 bp) using the Lina PVL PCR primers. In 
contrast, the positive controls using these primers had brightly defined bands and the 
negative controls (H2O and Mu50) showed no bands at all. The Fey PVL PCR 
primers also produced some faint bands for the chronic wound MRSA isolates. 
Again the negative controls produced no bands and the positive controls produced 
bright, defined bands of the correct size (1554 bp). The PCR products for chronic 
wound isolates exhibiting faint indiscriminate bands, and PCR products for positive 
and negative controls and a selection of positive SACU PVL controls were 
sequenced. The PCR products were purified using ExoSAP-IT® (Section 3.3.2.3.4), 
and sequenced as described (Section 3.3.2.3.5) using the appropriate primer set 
(Table 3.13). The sequences were analysed using Basic Local Alignment Search 
Tool (BLAST; http://blast.ncbi.nlm.nih.gov).
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3.7.10 PVL identification by DNA microarray
DNA microarray analysis was performed by Dr A. Shore, School of Dental 
Science, Trinity College, Dublin on three isolates from the chronic wound patients 
exhibiting faint PCR bands (1009, 1057, 2018), chronic wound isolate 1011 and 
positive control NCTC 6571 (showing an unequivocal positive signal) using the 
StaphType kit (Alere, Jena, Germany).
3.8 Results
3.8.1 Identification of PVL with Lina PVL PCR primers (Qiagen® 3 h)
Using this method, no nasal isolate was found to harbour PVL genes. Figure 
3.12 demonstrates a representative agarose gel of PCR products produced by DNA 
from chronic wound isolates using Lina PVL PCR and the Qiagen® 3 h DNA 
preparation method. The gel shows that whilst the PCR products were of the correct 
size (433 bp) a range of band intensities was produced. The positive control isolates 
(NCTC 6571) was significantly positive, and the negative control isolates (H2O and 
Mu50) showed no band at all. However, there were faint bands for a number of 
samples (e.g. lanes 4, 5, 6, 7, 15, 22). Lane 4 contained isolate (NCTC 8178, 
Newman stain) previously used in Lina et al., (1999) as a negative control. Indeed, 
47% of the chronic wound isolates showed ambiguous faint bands which were not 
consistent for each PCR reaction.
3.8.2 Identification of PVL using Fey PVL PCR primers and Qiagen® 3 h DNA 
preparation
Again the positive controls and chronic wound isolate 1011 exhibited intense 
bands for the PVL product (1554 bp), whilst 65% of the chronic wound isolates and 
NCTC 8178 exhibited faint bands. The negative controls Mu50 and H2O exhibited 
no bands. Figure 3.13 shows an agarose gel with the separated PCR products using 
the Fey PVL PCR primers.
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Figure 3.12 Agarose gel showing separation o f Lina PVL PCR products. Lanes 1 
and 28, 100 bp molecular weight standard (Thermo Scientific); lane 2, negative H20  
control; lane 3, positive control, NCTC 6571 (MSSA); lane 4, negative control, 
NCTC 8178; lanes 5 to 7, chronic wound MRSA isolates; lane 8, clinical isolate, 
ITU 3; lane 9, negative control NCTC 13143 (EMRSA-16); lane 10, chronic wound 
isolate; lane 11, chronic wound MRSA isolate; lane 12, control isolate NCTC 13130 
(EMRSA-03); lane 13, positive control isolate NCTC 6571 (MSSA; SACU); lanes 
14 to 19, chronic wound MRSA isolates; lane 20, control isolate NCTC 12493 
(MRSA); lane 21, chronic wound MRSA isolate; lane 22, clinical isolate ITU 4; 
lanes 23 to 24, chronic wound MRSA isolate; lane 25, clinical isolate ITU1; lane 26, 
chronic wound MRSA isolate; lane 27, negative control Mu50.
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Figure 3.13 Agarose gel showing the separation o f Fey PVL PCR products. Lanes 1 
and 26, molecular weight standard Hyperladder III (Bioline Ltd); lane 2, negative 
H20  control; lane 3, negative control isolate NCTC 8178; lane 4, positive control 
isolates NCTC 6571; lane 5, positive control isolates HT2000.132; lanes 6 to 9, 
chronic wound MRSA isolates; lane 10, chronic wound isolate 1011 (ST30-MRSA- 
IVc & E); lanes 11 to 22, chronic wound MRSA isolates; lane 23, negative control 
isolate Mu50; lanes 24 and 25, blank.
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3.8.3 Identification of PVL with Holmes’ multiplex toxin reaction 4
PCR products using both the microLYSIS® DNA and 1:10 diluted Qiagen® 3 
h DNA preparation in conjunction with the Holmes’ multiplex toxin reaction 4 
resulted in only one chronic wound MRSA isolate (1011; ST30-SCCmec IVc & E) 
demonstrating positivity for PVL. None of the isolates with previous ambiguous 
bands were positive for PVL using this PCR method with either of the DNA 
preparations (Figure 3.14).
3.8.4 Comparison of PVL identification with Lina PVL PCR primers using 
Qiagen® 30 min and Qiagen® 3 h DNA preparations
Figures 3.15 and 3.16 show a comparison of PVL identification with Lina 
PVL PCR primers using DNA prepared using Qiagen® 30 min (Section 3.7.4) or 
Qiagen® 3 h (Section 3.7.2). All the nasal isolates were negative for PVL using 
both DNA extraction methods. Positive controls and chronic wound isolate 1011 
(ST30-MRSA-IVc & E) were positive for PVL with distinct unequivocally bright 
bands. Negative controls showed no bands with either method. The Qiagen® 30 min 
DNA preparation showed that a single chronic wound isolate (6.25%) had a faint 
ambiguous band, whilst the Qiagen® 3 h DNA preparation produced four (25%) 
chronic wound isolates with faint ambiguous bands. The isolates exhibiting these 
ambiguous bands differed for both DNA preparation methods used.
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Figure 3.14 Agarose gel showing the separation o f PCR products for a) 
microLYSIS^ DNA and b) 1:10 diluted Qiagen 3 h DNA preparation performed 
with Holmes’ reaction 4 (i.e. PVL, etd, 16S rRNA and mecA). Lanes 1 and 14, 
molecular weight standard Hyperladder II (Bioline Ltd, London); lanes 2 to 5, 
wound isolates, ST22-MRSA-IVh; lane 6, wound isolate, ST30-MRSA-IVc & IVE; 
lane 7, wound isolate, ST36-MRSA-II; lanes 8 to 11, wound isolates, ST22-MRSA- 
IVh; lane 12, PVL positive control NCTC 13300, etd positive control clinical isolate; 
lane 13, negative H2O control, all controls were kindly provided by the HPA.
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Figure 3.15 Separation o f PVL products using Lina PVL primers and the Qiagen® 
30 min DNA preparation. Lanes 1 and 20, 100 bp molecular weight standard 
(Thermo Scientific); lane 2, positive control NCTC 6571; lane 3, negative control 
Mu50; lanes 4 to 6, chronic wound MRSA isolates; lane 7, faint positive band 
chronic wound isolate 1108 (ST 970-MRSA-IVh; CC22); lanes 8 to 10, nasal 
MRSA isolates; lane 11, chronic wound MRSA isolate; lanes 12 to 14, nasal MRSA 
isolates; lanes 15 to 16, chronic wound MRSA isolate; lane 17, chronic wound 
MRSA isolate 1011 (ST30-MRSA-IVc & E); lane 18 to 19, chronic wound MRSA 
isolates.
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Figure 3.16 Separation o f PVL products using Lina PVL primers and Qiagen® 3 h 
DNA preparation. Lanes 1 and 20, 100 bp molecular weight standard (Thermo 
Scientific); lane 2, positive control NCTC 6571; lane 3, negative control Mu50; 
lanes 4 to 6, chronic wound MRSA isolates; lane 7, faint ambiguous band, chronic 
wound MRSA isolate 1141 (ST22-MRSA-IVh; CC22); lane 8, faint ambiguous 
band, chronic wound MRSA isolate 1051 (ST22-MRSA-IVh; CC22); lane 9, intense 
PVL band, chronic wound MRSA isolate 1011 (ST30-MRSA-IVc & E); lanes 10 to 
19, chronic wound MRSA isolates.
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3.8.5 Identification of PVL using Southern hybridisation
PCR products which resulted in ambiguous faint PCR bands like those in 
Figure 3.12 were separated on an agarose gel alongside appropriate positive and 
negative controls (Figure 3.17a). Southern transfer confirmed that faint bands 
present on an agarose gel were positive for PVL (Figure 3.17b). However, positive 
control isolate (NCTC 6571, lane 2) showed a more intense band on the 
autoradiograph than those isolates with the ambiguous faint PCR bands (chronic 
wound MRSA isolates). Lanes 4 to 7, 9,10 and 12 of chronic wound MRSA isolates 
all contained indistinct faint bands on the agarose gel, but showed positive banding 
on the autoradiograph. Negative controls (lanes 15 and 16) had no bands on the 
agarose gel or the autoradiograph as did a nasal MRSA isolate (lane 14) previously 
shown to be PVL negative.
3.8.6 Sequencing of PVL PCR products
Sequences obtained from the PCR products of both the Lina and Fey PVL 
PCR primers were analysed using an alignment program 
(www.ebi.ac.uk/Tools/emboss/align) and a Basic Local Alignment Search Tool 
(http://blast.ncbi.nlm.nih.gov; Tables 3.15-3.18; Appendix V).
Forty-two products using the Lina PVL PCR primers were sequenced. 
Included were positive (5%) and negative controls (5%) for PVL; PVL positive 
SACU isolates (26%); chronic wound isolates identified by hybridisation (12%); a 
positive chronic wound isolate (2%); chronic wound isolates with ambiguous PCR 
results (48%) and one PVL negative nasal MRSA isolate (2%). Of this selection 20 
(48%) produced a readable sequence (Table 3.15), of which 15 isolates were able to 
provide a consensus sequence (sequenced in both directions), two of which were 
associated with chronic wound isolates (Table 3.16). Five isolates produced only a 
good reverse sequence and were related to the chronic wound MRSA isolates.
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Figure 3.17 Southern transfer o f Lina PVL PCR products a) Agarose gel following 
the separation o f the PVL PCR products (433 bp) prior to Southern hybridisation; b) 
Autoradiographic image o f the agarose gel Figure 3.17a. Lanes 1 and 17, 100 bp 
molecular weight standard (Thermo Scientific); lane 2, positive control NCTC 6571; 
lanes 3 to 13, chronic wound MRSA; lane 14, nasal MRSA isolate; lane 15, negative 
control Mu50; lane 16, negative H2 O control.
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Table 3.15 Sequence analysis using Lina PVL PCR primers showing closest sequence match
Forward sequence Reverse sequence
Isolate Isolatetype
Sequence
length
(bp)
Homology Homology 
with (%)
Accession 
No. of closest 
match
Sequence
length
(bp)
Homology
with
Homology
(%)
Accession 
No. of closest 
match
H20 Negative NP
MU50 Negative NP
NCTC 6571 Positive 362 lukS-PVlukF-PV
HT2000.132 Positive 367 lukS-PVlukF-PV
554 SACU 351 lukS-PVlukF-PV
597 SACU 365 lukS-PVlukF-PV
5121 SACU 349 lukS-PVlukF-PV
5122 SACU 297 lukS-PVlukF-PV
5126 SACU 358 lukS-PVlukF-PV
NP
NP
100 AB532026 367 lukS-PVlukF-PV 100 AB532026
100 GU360978 368 lukS-PVlukF-PV 100 AB532026
100 AB532026 364 lukS-PVlukF-PV 99 AB532026
100 AB532027 336 lukS-PVlukF-PV 100 AB532027
100 AB532026 365 lukS-PVlukF-PV 99 AB532026
100 GU360978 35 lukS-PVlukF-PV 100 AB532027
100 GU360978 354 lukS-PV 100 AB532026
NP, did not prime; SACU, Specialist Antimicrobial Chemotherapy Unit isolates; bp, base pair; Positive, positive control; Negative, negative 
control; lukS-PV, lukF-PV, Staphylococcus aureus Panton-Valentine leucocidin genes.
Table 3.15 continued Sequence analysis using Lina PVL PCR primers showing closest sequence match
Isolate Isolatetype Forward sequence Reverse sequence
Sequence 
length (bp)
Homology
with
Homology
(%)
Accession No. 
of closest match
Sequence 
length (bp)
Homology
with
Homology
(%)
Accession No. 
of closest match
5127 SACU 334 lukS-PVlukF-PV 100 AB532026 363
lukS-PV
lukF-PV 100 AB532026
5131 SACU 334 lukS-PVlukF-PV 100 AB532026 372
lukS-PV
lukF-PV 99 AB532026
5145 SACU 356 lukS-PVlukF-PV 100 AB532026 366
lukS-PV
lukF-PV 99 AB532026
5151 SACU 355 lukS-PVlukF-PV 100 GU360978 356
lukS-PV
lukF-PV 96 AB532027
5155 SACU 348 lukS-PVlukF-PV 100 AB532026 345
lukS-PV
lukF-PV 100 AB532027
5160 SACU 360 lukS-PVlukF-PV 100 GU360978 344
lukS-PV
lukF-PV 100 AB532026
S07146 Nasal NP NP
1011 Chronic 365 lukS-PVlukF-PV 100 GU360978 365
lukS-PV
lukF-PV 100 AB532026
1057 Chronic 320 lukS-PVlukF-PV 100 AY508231 361 02958 PVL 99 AP009363
NP, did not prime; SACU, Specialist Antimicrobial Chemotherapy Unit isolates; bp, base pair; lukS-PV, lukF-PV, Staphylococcus aureus 
Panton-Valentine leucocidin genes; 02958 PVL, Staphylococcus aureus bacteriophage 02958 PVL, proviral DNA; chronic, chronic wound 
MRSA isolate; nasal, nasal MRSA isolate.
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Table 3.15 continued Sequence analysis using Lina PVL PCR primers showing closest sequence match
Isolate Isolatetype Forward sequence Reverse sequence
Sequence
length
(bp)
Homology
with
Homology
(%)
Accession No. 
of closest match
Sequence
length
(bp)
Homology
with
Homology
(%)
Accession No. 
of closest match
1047 Chronic NP 298 02958 PVL 100 AP009363
1047 Chronic NP 375 02958 PVL 98 AP009363
1106 Chronic NP 220 02958 PVL 97 AP009363
1108 Chronic NP 375 02958 PVL 99 AP009363
2018 Chronic Noise 296 02958 PVL 96 AP009363
NP, did not prime; SACU, Specialist Antimicrobial Chemotherapy Unit isolates; bp, base pair; 02958 PVL, Staphylococcus aureus 
bacteriophage 02958 PVL, proviral DNA; chronic, chronic wound MRSA isolate.
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Table 3.16 Consensus sequence identification using Lina PVL PCR primers showing closest sequence match
Isolate Isolate Type Consensus sequence
Sequence length (bp) Homology with Homology % Accession No. of closest match
NCTC 6571 Positive control 357 II 100 AB532026
HT2000.132 Positive control 322 lukS-PV
lukF-PV
100 AB532026
554 SACU 310 lukS-PVlukF-PV 99 AB532026
597 SACU 324 lukS-PVlukF-PV 100 AB532027
5121 SACU 310 lukS-PV
lukF-PV 99 AB532026
5122 SACU 66 lukS-PV
lukF-PV 100
AB532027
5126 SACU 283 lukS-PV
lukF-PV 100
AB532026
5127 SACU 295 lukS-PV
lukF-PV 100
AB532026
5131 SACU 303 lukS-PVlukF-PV
100 AB532026
SACU, Specialist Antimicrobial Chemotherapy Unit isolates; bp, base pair; Positive, positive control; lukS-PV, lukF-PV, Staphylococcus 
aureus Panton-Valentine leucocidin genes.
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Table 3.16 continued Consensus sequence identification using Lina PVL PCR primers showing closest sequence match
Isolate Isolate Type
Sequence length (bp)
Consensus sequence 
Homology with Homology % Accession No. of closest match
5145 SACU 314
lukS-PV
lukF-PV 100
AB532026
5151 SACU 280
lukS-PV
lukF-PV 100
AB532026
5155 SACU 283
lukS-PV
lukF-PV 100
AB532026
5160 SACU 286 lukS-PV
lukF-PV 100 AB532026
1011 Chronic wound 312 lukS-PV
lukF-PV 100 AB532026
1057 Chronic wound 252 02958PVL 100 AP009363
SACU, Specialist Antimicrobial Chemotherapy Unit isolates; bp, base pair; lukS-PV, lukF-PV, Staphylococcus aureus Panton-Valentine 
leucocidin genes; 02958 PVL, Staphylococcus aureus bacteriophage 02958 PVL, proviral DNA; chronic, chronic wound MRSA isolate.
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The two positive control isolates NCTC 6571 and HT2000.132 returned a 
consensus sequence showing 100% homology to the PVL genes. Both negative 
controls as expected did not prime (Table 3.15). All SACU isolates, which had 
shown intense bands, returned consensus sequences with >99% homology to PVL 
genes. One chronic wound isolate (1011) showed a 100% homology to the PVL 
gene. One further chronic wound isolate associated with an ambiguous PCR band, 
returned a consensus sequence that showed 100% homology to 02958 PVL a 
bacteriophage known to encode the PVL locus.
Five (21%) of the remaining chronic wound isolates associated with 
ambiguous bands resulted in a readable reverse sequences (but the forward sequence 
did not prime). These sequences were associated with >96% homology with 02958 
PVL a bacteriophage know to harbour the PVL locus.
Thirteen PCR products were sequenced using Fey PVL PCR primers, of 
which two were positive controls (showing intense PCR bands) and one negative 
control (NCTC 8178), which had shown faint ambiguous bands. The remaining 10 
were chronic wound MRSA isolates, one of which had shown an intense PCR band 
(1011), whilst the others showed ambiguous bands (Table 3.17). Only 46% of the 
isolates returned both forward and reverse sequences for consensus sequence 
analysis (Table 3.18). Two of these were associated with the positive control 
isolates. Isolate NCTC 6571 showed a 100% homology to PVL genes, whilst the 
consensus sequence of HT2000.132 only showed a 85% homology to PVL genes 
despite 99% homology with individual sequences. Four chronic wound isolates 
returned a consensus sequence, one of which (1011) was 100% homologous to the 
PVL genes. Of the three remaining, one was 100% homologous to OPVL-CN125 a 
bacteriophage known to harbour the PVL locus, and the two other were >87% 
homologous to S. aureus leuF-P83, a gene associated with the F component of 
leucocidin R. Five other chronic wound isolates also showed >95% homology to the 
S. aureus leuF-P83, but only by the reverse sequence as the forward did not prime. 
The isolates associated with bacteriophage PVL and leucocidin R sequence
homology all indicated faint ambiguous bands when testing for PVL by PCR. No 
isolate associated with faint PCR bands resulted in a 100% homologous sequence for 
PVL with either the Lina or Fey PVL PCR primers.
3.8.7 Identification of PVL using microarray analysis
This method proved that there was only one truly PVL positive isolate from 
amongst the chronic wound isolates, isolate 1011 (ST30-MRSA-IVc & E). This 
isolate was continuously represented by an intense PCR and autoradiograph band 
when tested using the Lina and Fey PVL PCR primers. All isolates with faint bands 
were negative for PVL using microarray analysis.
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Table 3.17 Sequence analysis using Fey PVL PCR primers showing the closest match
Isolate Isolatetype Forward sequence Reverse sequence
Sequence 
length (bp)
Homology
with
Homology
(%)
Accession 
No. of closest 
match
Sequence 
length (bp)
Homology
with
Homology
(%)
Accession 
No. of closest 
match
NCTC 8178 Negative NP NP
NCTC 6571 Positive 888
lukS-PV
lukF-PV
99 AB532026 908
lukS-PV
lukF-PV 99 AB532026
HT2000.132 Positive 732
lukS-PV
lukF-PV
99 EU518769 890
lukS-PV
lukF-PV
99 EU518764
1011 Chronic 852
lukS-PV
lukF-PV
100 AB532026 885
lukS-PV
lukF-PV
100 AB532024
1021 Chronic 532 lukS-PV
lukF-PV
100 AB532027 794 OPVL-CN125 100 FJ713816
1067 Chronic 572 Leucocidin subunit S 98 EF672356 758 leuF-P83 98
X64389
1106 Chronic 795 leuF-P83 96 X64389 841 leuF-P83 97 X64389
1004 Chronic NP 775 leuF-P83 98 X64389
NP, did not prime; bp, base pair; Positive, positive control; Negative, negative control; lukS-PV, lukF-PV, Staphylococcus aureus Panton- 
Valentine Leucocidin genes; OPVL-CN125, Staphylococcus phage OPVL-CN125; Chronic, chronic wound MRSA isolate; LeuF-P83, 
Staphylococcus aureus leuF-P83 gene for F component of leucocidin R; leucocidin subunit S gene, Staphylococcus aureus leucocidin subunit 
S gene.
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Table 3.17 continued Sequence analysis using Fey PVL PCR primers showing the closest match
Isolate Isolatetype Forward sequence Reverse sequence
Sequence
(bp)
Homology Homology 
with (%)
Accession 
No. of closest 
match
Sequence
(*>P)
Homology (%) Homologywith
Accession 
No. of closest 
match
1044 Chronic NP 665 leuF-P83 97 X64389
1047 Chronic NP 301 leuF-P83 95 X64389
1103 Chronic NP 225 leuF-P83 93 X64389
2124 Chronic NP 567 leuF-P83 97 X64389
NP, did not prime; bp, base pair; chronic, chronic wound MRSA isolate; leuF-P83, Staphylococcus aureus leuF-P83 gene for F component of 
leucocidin R.
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Table 3.18 Consensus sequence analysis using Fey PVL PCR primers showing the closest match
Isolate Isolate type Consensus sequence
Sequence (bp) Homology with Homology % Accession No. of closest match
NCTC 6571 Positive 335
lukS-PV
lukF-PV 100
AB532027
HT2000.132 Positive 997
lukS-PV
lukF-PV 85
EU518768
1011 Chronic 227
lukS-PV
lukF-PV 100
AB532027
1021 Chronic 193 OPVL-CN125 100 FJ713816
1106 Chronic 201 leuF-P83 98 X64389
1067 Chronic 780 leuF-P83 87 X64389
Positive, positive control; lukS-PV, lukF-PV, Staphylococcus aureus Panton-Valentine leucocidin genes; OPVL-CN125, Staphylococcus 
phage OPVL-CN125; chronic, chronic wound MRSA isolate; LeuF-P83, Staphylococcus aureus leuF-P83 gene for F component of 
leucocidin R.
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3.9 Discussion
The accurate identification of PVL is of paramount importance in 
understanding the epidemiological evolution and treatment of disease by S. aureus. 
The identification of faint bands associated with the Lina PVL PCR primers and 
ambiguous products associated with the Fey PVL PCR primers in this study 
highlights the potential for false reporting, or worse, under reporting of the presence 
of such a potentially harmful virulence factor.
The results obtained with the Lina PVL PCR primers were very sensitive to 
the DNA preparation method used. DNA isolated with long lysis steps (>3 h) 
produced a number of faint ambiguous bands of the expected product size (433 bp), 
although true positive isolates produced distinct bright bands and were 
unequivocally PVL positive. A reduction in the number of ambiguous bands was 
seen with DNA prepared using the Qiagen® kit but with a shorter lysis step (30 min). 
However, again only the true positive isolates had distinct bright bands. Using a 
microLYSIS® kit or a 1:10 dilution of Qiagen® 3 h DNA preparation, it was 
observed that true PVL positive isolates had intense bright bands and there were no 
ambiguous faint bands.
Sequencing of the PCR products with intense PVL bands showed that they 
had 100% homology with the PVL gene, regardless of whether Fey or Lina PVL 
PCR primers were used. The faint bands occasionally associated with the Lina PVL 
PCR primers using the highly concentrated DNA (Qiagen® 3 h) highlighted also 
with Southern hybridisation did not show PVL homology with sequencing. The 
sequencing of the chronic wound PCR products using the Lina PVL PCR primers 
resulted in priming only of the reverse sequence, and was homologous to 
bacteriophage OPVL. These bacteriophages are involved in the original genetic 
transfer of this virulence factor to S. aureus.
Sequencing of the Fey PVL PCR products indicated that truly positive 
isolates with strong positive PCR bands were homologous with PVL. The 
moderately strong bands were associated with wound isolates using these primers
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and could easily be inadvertently treated as PVL positive. Sequencing of these 
products indicated again homology with bacteriophage OPVL but more commonly 
leuF-P83 gene for the F component of leucocidin R. Leucocidin R has only a 43% 
homology with PVL. However, as the Fey PVL PCR primers had a 100% homology 
with a priming site in the leucocidin R gene, it is therefore unsurprising that 
leucocidin R was amplified. Due to the high homology of the other leucocidins and 
leucotoxins associated with S. aureus to PVL, is it difficult to prevent this type of 
non-specific primer attachment. An attempt to design new PVL primers, in this 
study was unsuccessful due to the high number of homologous binding sites within 
the S. aureus leucocidin family. Interestingly, NCTC 8178 (Newman strain), used 
by Lina as a negative control, demonstrated faint ambiguous bands when using 
concentrated DNA (Qiagen® 3 h), this product, however, did not result in a 
sequence. The sequence analysis of NCTC 8178 
(www.ncbi.nlm.nih.gov/nuccore/NC_009641; accessed 24/4/11) demonstrated that 
bacteriophage PVL ONM3 was present, and possibly priming during PVL PCR.
From the investigations performed using this selection of isolates presenting 
with faint bands with PVL PCR, it is hypothesized that during DNA preparations 
using long lysis extraction methods (and thereby producing highly concentrated 
DNA) that DNA from the extra-chromosomal bacteriophage genetic elements 
associated with the Staphylococcus host is isolated, and that these temperate phage 
(OPVL) harbour PVL genes. Temperate bacteriophages play an important role in S. 
aureus pathogenicity through their horizontal gene transfer of virulence factors such 
as PVL. It is clear that this bacteriophage DNA was only isolated due to protocols 
containing long lysis steps. Hence, to ensure the prevention of these ambiguous 
PCR results and misinterpretation, either dilution of target DNA or less rigorous 
DNA isolation methods should be employed such as the DNA release methods, e.g. 
the microLYSIS®.
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Chapter 4: 
Characterisation of the innate 
immunological responses to 
chronic wound bacteria i n  v i t r o
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4.1 Introduction
The immune system is a collection of cellular and humoral components 
enabling the discrimination of self and non-self and is essential for protection against 
invading pathogens. The immune system can be sub-divided into the innate and 
adaptive systems (Lien and Ingalls, 2002, Fournier and Philpott, 2005).
4.1.1 The innate immune system
The innate immune system is our first line non-specific response to microbial 
invasion, and constitutes the preventive and immediate response of the host (Lien et 
al., 1999, Fournier and Philpott, 2005, Thorgersen et al., 2009). Innate immunity is 
composed of anatomic barriers (e.g. skin, ciliated epithelia), secretory molecules 
(e.g. antimicrobial peptides) and cellular response elements (e.g. neutrophils, PMNL; 
monocytes, Mo; macrophages, M 0; dendritic cells, DC) recruited to the site of 
injury (Froy, 2005, Mollen et al., 2006, Nizet, 2007).
4.1.1.1 Toll-like receptors
Toll-like receptors (TLR) play a pivotal role in the recognition of invading 
pathogens and the regulation of the innate immune response. TLRs are type I 
transmembrane signalling pathogen recognition receptors (PRR), with an 
extracellular domain made up of leucine-rich repeats (LRR) and a Toll/IL-1 receptor 
(TIR) cytoplasmic domain (Lien et al., 1999, Mori et al., 2003, Jin and Lee, 2008). 
Thirteen mammalian TLRs have been identified to date (Etokebe et al., 2010, 
Gon9alves et al., 2011, Michailidis et al., 2011). Each TLR forms an essential part 
of the innate immune system by identifying specific conserved patterns on pathogens 
known as pathogen associated molecular patterns (PAMP). TLRs are expressed on 
both “classical” immunocompetent cells (PMNL, Mo, B and T-cells) and resident 
cell populations in the dermis e.g. keratinocytes and endothelial cells (Morris et al., 
2009, Pukstad et al., 2010).
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TLRs are activated by the binding of ligands to the LRR domain which then 
induces a complicated series of intracellular signalling events via the TIR domain 
and its adapter molecules. For example myeloid differentiation factor 88 (MyD88) 
activates translocation of nuclear factor kB (NF-kB), which induces transcription of 
cytokines and chemokines such as tumour necrosis factor-a (TNFa), interleukin 
(IL)-lp, IL-8 and IL-6 (Takeuchi et al., 2000, Hume et al., 2001, Zhang and 
Schluesener, 2006, Morris et al., 2009) which in turn initiate immune responses at 
the site of injury (Mori et al., 2003, Moller et al., 2005, Baiyee et al., 2006).
4.1.1.2 TLR and pathogen associated molecular patterns
Individual TLRs recognise specific PAMPs, which are usually structures 
essential to the invading organism or ligands. For example, TLR4, in complex with 
myeloid differentiation protein 2 (MD-2) and cluster of differentiation (CD) 14, 
recognises lipopolysaccharide (LPS) from Gram-negative bacteria (Miyake, 2003, 
Adib-Conquy et al., 2006, Mollen et al., 2006, Jin and Lee, 2008). In contrast, 
TLR2 recognises Gram-positive bacteria via signalling induced by ligands such as 
peptidoglycan (PGN), lipopeptides, lipoproteins and lipoteichoic acid (LTA; 
(Shaykhiev et al., 2008). TLR2 is also able to form heterodimers with other TLRs 
e.g. TLR1 and TLR6 enabling the identification of further ligands/pathogens e.g. 
zymosan (yeast particles). TLR5 is responsible for the identification of flagellin (a 
principal component of bacterial flagella), and TLR9, an intracellular receptor 
signalling unmethylated cytosine-guanosine (CpG) dinucleotide-rich DNA released 
from bacteria or endogenous cells. Mammalian DNA has a less stimulatory effect 
via TLR9 due to decreased CpG expression and extensive (80%) methylation of 
cytosine (Weiner et al., 1997, Wooldridge et al., 1997, Lien and Ingalls, 2002, Konat 
et al., 2006, Baiyee et al., 2006, Morris et al., 2009). Studies of TLR knock-outs 
have broadened our knowledge of their role in infection. Many studies on TLR- 
deficient mice have shown that clearance of an invading pathogen is reduced, and 
that intranasal carriage is increased in these mutants (Takeuchi et al., 2000,
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Gonzalez-Zom et al., 2005, Hoebe et al., 2005). It has also been observed that 
genetic polymorphism in ligand-binding regions of TLR5, (found in mice and 
humans) may lead to hypersusceptibility to pneumonic legionellosis (Morris et al., 
2009). TLRs identify not only invading pathogens, but are able to distinguish host 
tissues damaged and/or degraded by the process of injury (Mollen et al., 2006, Zhang 
and Schluesener, 2006). For example, low molecular weight (mw) hyaluronan 
products (4-16 oligosaccharides in length) may signal through TLR4 following 
tissue injury, to activate DC and endothelial cells via the NF-kB pathway (Termeer 
et al., 2000, Taylor et al., 2004).
4.1.2 Wound bacteria and inflammation
Whilst the precise molecular pathogenesis of chronic wounds is unclear, the 
sustained inflammatory response and persistence of bacteria are likely to play an 
important role in non-healing. To date, whilst no individual bacterial species has 
been identified as the cause of chronic wound persistence (Chapter 1, Section 1.5.1), 
the presence of >4 bacterial sp. may have a detrimental effect on healing (Davies et 
al., 2007). Following a break in epithelial integrity, TLRs are employed by 
immunocompetent cells to prevent bacterial ingress. TLR activation by exogenous 
ligands have been reported to promote wound healing via TLR2 and TLR4 (Pukstad 
et al., 2010). The absence of TLR4 may play a significant role in normal healing, as 
shown in wound repair models. TLR4-deficient mice show early reduction in TNFa, 
with increased collagen production, leading to increased wound strength (Bettinger 
et al., 1994, Mollen et al., 2006). The problematic nature of bacterial wound 
colonisation, like other chronic diseases, is the continuous influx of inflammatory 
cells and their release of active molecules (e.g. cytokines, free oxygen radicals and 
proteolytic enzymes) into the wound bed mediating increased inflammation and 
further tissue damage (Kirketerp-Moller et al., 2008).
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4.1.3 Complement
Complement forms an important fluid-phase of the innate immune response 
and has three major activating pathways; the classical, alternate and lectin pathways. 
Complement is a “cascade” of proteins and proteolytic fragments, derived by 
enzymatic cleavage, to form the potent terminal complement complex (TCC; C5b-9) 
which leads to cellular lysis (the membrane-attack complex). Complement also 
regulates further immune responses via cytokine production and opsonization via 
C3b and C5a (Kirschfink and Mollnes, 2003, Sprong et al., 2004, Foster, 2005, Keiji 
et al., 2006, Thorgersen et al., 2009). Figure 4.1 is a schematic overview of the main 
components and effecter actions of complement. Deficiencies in the complement 
system frequently lead to increased risk of infection (Kirschfink and Mollnes, 2003, 
Hellerud et al., 2008). Peptidoglycan from S. aureus is able to directly induce the 
alternate pathway, whilst the mannose-binding lectin (MBL) pathway is induced by 
peptidoglycan (PGN) and lipoteichoic acid (LTA) and some forms of LPS 
(Rooijakkers et al., 2005).
4.1.4 Chronic stimulation and evasion of the host immune response
An active/effective immune system plays a pivotal role in defence against 
invading pathogens and in inducing the reparative processes of wound healing. The 
persistence of bacteria within wounds has been shown to play an important and often 
unrecognised role in the chronic inflammation observed in chronic, non-healing 
wounds (Mirza et al., 2009). A number of human diseases are characterised by 
chronic bacterial colonisation and disrupted host/bacterial interaction e.g. periodontal 
disease and chronic lung diseases such as cystic fibrosis (Mori et al., 2003). In their 
evasion of the immune system, bacteria such as MRSA, may utilise a number of 
different mechanisms, e.g. the production of virulence factors (e.g. leucocidins and 
proteases; Chapter 3) which may lead to leucocyte apoptosis (Kahl et al., 2000, 
Homef et al., 2002, Kirketerp-Moller et al., 2008, DeLeo et al., 2009) and alteration 
of bacterial phenotype.
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Figure 4.1 Schematic overview o f complement components and effector actions. 
MASP; mannose-binding lectin associated serine protease, TCC; terminal 
complement complex (Adapted from Murphy et al., 2008).
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Furthermore, biofilm formation protects bacteria from antimicrobials and host 
responses by inhibiting phagocytosis, complement and free-oxygen radicals 
(Johnson et al., 1986, Davis et al., 2008, Percival et al., 2008, Martin et al., 2009, 
Percival et al., 2011a). Bacteria may also evade innate recognition via steric 
alterations of PAMPs, e.g. Salmonella LPS is tetra-acetylated and does not trigger 
TLR4 (Homef et al., 2002, Comer et al., 2010). The acquisition of specific innate 
immune evasion mechanisms by bacteria, which are easily transferred, enables 
bacterial survival at sites of chronic inflammation (Rooijakkers et al., 2005).
4.1.5 Staphylococcus aureus evasion of the immune system
Staphylococcus aureus is responsible for a variety of hospital- and 
community-based illnesses and is associated with acute and chronic patterns of 
disease (Massey et al., 2006). S. aureus exists as a commensal bacterium on the skin 
and mucous membranes, and possesses both passive and active mechanisms by 
which it can modify the host immune response (Keiji et al., 2006).
The production of chemotaxis inhibitory protein of staphylococci (CHIPS) by 
S, aureus interferes with the C5a and formyl peptide receptors of PMNL, leading to 
decreased chemotaxis and migration of immune cells to the site of infection (de Haas 
et al., 2004, Keiji et al., 2006, Nizet, 2007, DeLeo et al., 2009). S. aureus also 
produces a number of cytolytic leukotoxins, including Panton-Valentine leucocidin 
(PVL), and haemolysins, which are able to lyse recruited PMNL (Chapter 3). As 
well as these leucotoxins, virulence factors such as proteases (e.g. aureolysin) assist 
resistance to host antimicrobial peptides and PMNL phagosomes, thus preventing 
lysis (Foster, 2005, DeLeo et al., 2009). The polysaccharide capsule and anti- 
opsonic proteins on the surface of S. aureus prevent the deposition of antibodies and 
complement formation and resist phagocytosis by opsonization (Nizet, 2007). 
Bacterial charge also affects microbial susceptibility to host antimicrobial peptides 
e.g. lipocalin. S. aureus modifies its membrane charge by substituting the principal 
lipid membrane phosphatidylglycerol with lysine and adding D-alanine to teichoic
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acid; effectively reducing the net negative-charge (Homef et al., 2002). S. aureus is 
also able to cleave immunoglobulins IgG, IgM and IgA by the action of serine 
proteases, to escape opsonization and phagocytosis. Superantigen virulence factors, 
e.g. Toxic shock syndrome toxin (TSST-1) and the exfoliative enterotoxins, can 
over-stimulate T-cells (DeLeo et al., 2009) which may “overwhelm” the host system 
leading to severe disease and tissue destruction. The production of a biofilm is a 
further important mechanism by which S. aureus can resist immune system 
recognition and PMNL mediated lysis (DeLeo et al., 2009, Percival et al., 201 la).
4.1.6 Pseudomonas aeruginosa evasion of immune system
Pseudomonas aeruginosa is similarly associated with chronic disease states 
such as non-healing wounds and lung disease e.g. cystic fibrosis and bronchiectasis 
(Morris et al., 2009). P. aeruginosa is extensively associated with biofilm formation 
in non-healing chronic wounds (Madsen et al., 1996, Kirketerp-Moller et al., 2008). 
The production of such biofilms facilitates defences against the host immune system 
and evasion of antimicrobial therapy, and like S. aureus, produces a number of 
virulence factors (e.g. leukocidin toxin and rhamnolipid B) to limit the host immune 
response (Kirketerp-Moller et al., 2008). During lung infection with P. aeruginosa, 
host-induced apoptosis reduces the release of pro-inflammatory cytokines, and 
correspondingly reduces leukocyte infiltration, leading to increased P. aeruginosa 
survival.
4.1.7 Chronic inflammation in wound healing
Previous studies have investigated the presence of bacteria in chronic 
wounds, identifying individual species, microbial diversity and bacterial load as 
possible important factors (Andersen et al., 2007, Percival et al., 2011a; Chapter 1, 
Section 1.5.1). The complex relationship between bacteria and the local immune 
response in the chronic wound has surprisingly received little attention. It is thought 
that a chronic wound is static and dominated by a prolonged inflammatory phase
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which is attributed to the presence of the bacterial microflora (Pukstad et al., 2010). 
This process is highly dynamic with continuous influx of inflammatory cells, e.g. 
PMNL, and their release of vaso-active and lytic molecules such as cytokines, ffee- 
oxygen radicals and enzymes into the wound environment, mediating further tissue 
damage, in a potentially destructive “positive feedback loop” leading to further 
recruitment of inflammatory cells to the detriment of the healing process (Kirketerp- 
Moller et al., 2008).
Pukstad et al., (2010) characterised the potential role of bacterial modulation 
of the immune system using wound fluid samples isolated from healing and non­
healing wounds. Cytokine analysis of non-healing wound fluid demonstrated 
increased levels of pro-inflammatory cytokines with increased wound duration (e.g. 
IL-1P). The angiogenic chemokine IL-8 was associated with healing wounds, and 
was observed to decrease with time in non-healing wound fluid. Lipocalin-2, an 
important antibacterial peptide, decreased in wound fluid collected from healing 
wounds over an 8 week period, whilst non-healing wounds showed that this protein 
was continuously produced, signifying that a bacterial component was present at the 
wound site. TLR2 and TLR4 stimulation via non-healing and healing wound fluid 
also varied with time. Non-healing wound fluid continuously stimulated TLR2 and 
TLR4, and was proposed to reflect evidence of the microbial bioburden in the 
chronic wound environment.
4.1.8 Modelling the effect of bacteria and the innate immune system in human 
wound healing
4.1.8.1 NF-kB luciferase assay
Previous studies of TLR regulation in disease as a result of bacteria have 
employed immunohistochemistry (Mori et al., 2003). Gene expression and cellular 
events are now commonly studied using the aid of genetic reporter systems. Firefly 
luciferase is frequently utilized in reporter assays, as it does not require post- 
translational processing, and it has a high quantum efficiency of light production,
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making it very sensitive. Light is produced following luciferin oxidation by firefly 
luciferase to produce oxyluciferin. Dual luciferase reporter assays are often 
employed, whereby a second reporter (control e.g. Renilla) is driven by a 
constitutively expressed promoter. This second reporter normalises experimental 
results as it overcomes transfection efficacy and cytotoxicity between cells and wells 
(Adib-Conquy et al., 2006). Following stimulation of TLR by an appropriate ligand, 
NF-kB is translocated to the cell nucleus to induce cytokine translation. The NF-kB 
luciferase reporter assay utilises Elam luciferase to determine quantification of NF- 
kB intracellular activity upon TLR stimulation (Lien et al., 1999, Latz et al., 2002, 
Sandor et al., 2003).
4.1.8.2 Whole blood model
The in vitro whole blood model using lepirudin (refludan) has been used to 
investigate complement activation associated with E. coli (Mollnes et al., 2002). 
Unlike isolated cell-based assays, the whole blood model is a more physiological 
approach to simulate in vivo conditions, as it uses human blood to mimic the 
complex inflammatory processes that occur (Mollnes et al., 2002, Kirschfink and 
Mollnes, 2003). The receptor CD1 lb is expressed by activated Mo and granulocytes 
during complement activation (Thorgersen et al., 2009) and can be analysed by 
fluorescence activated cell sorting (FACS). The terminal complement complex 
(TCC) ELISA assay (Mollnes et al., 1985b) represents a reliable method for the 
detection of C5b-C9 activation (terminal pathway) rather than quantification of 
individual complement activation products e.g. C5a, C3 which have relatively short 
half-lives (Mollnes et al., 1993, Kirschfink and Mollnes, 2003, Mollnes et al., 2007).
4.1.8.3 “Scratch” wound Assay
It has been demonstrated that an important component of the innate immune 
system is cellular barrier formation and TLRs have been demonstrated to play an 
important role in re-epithelialisation and keratinocyte migration.
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The “scratch” assay is a simple in vitro cellular wound healing model which 
utilises a monolayer of cells to study cellular wound closure following experimental 
(physical or chemical) wounding (Lampugnani, 1999, Liang et al., 2007). Whilst 
the model employs single cell types e.g. keratinocytes or fibroblasts, it is devoid of 
extracellular matrix (ECM) components and inflammatory molecules. These factors 
not withstanding, it enables determination of the direct effect of stimuli (such as 
bacterial supernatants) on cell re-population and wound closure (Stephens et al., 
2003).
4.2 Aims:
S. aureus and P. aeruginosa have been extensively implicated in the 
aetiology of chronic wounds, and their critical colonisation is intimately linked to 
non-healing. Yet, little investigation of the immunogenic roles of these pathogenic 
wound bacteria or the comparison to asymptomatic colonisers has been performed. 
The aim of this study was to differentiate changes in immune stimulation via TLR, 
cytokine production and complement activation by MRSA isolated from chronic 
wounds and to compare them to an asymptomatic nasal carrier control group. In this 
way, it was hoped to determine, not only if wound MRSA exhibit 
immunomodulatory properties which aid colonisation of chronic wounds, but also to 
determine their potential role in impairing healing. These studies also compared 
bacteria from planktonic and biofilm conditions, to determine if the bacterial growth 
environment plays a further role in colonisation and non-healing of wounds. The use 
of wound assays was employed to determine the role of wound and nasal carrier 
MRSA on wound healing and to further demonstrate the role of bacterial growth 
environments in the modulation of wound healing.
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The aims of this study are to:
1. Investigate and compare the immunostimulatory properties of MRSA 
isolated from asymptomatic carriers and chronic wound sites and investigate 
the immunomodulatory properties of S. aureus and P. aeruginosa from 
biofilm and planktonic growth conditions.
2. Investigate the direct effect of MRSA bacterial supernatants isolated from 
asymptomatic carriers and chronic wounds sites and S. aureus and P. 
aeruginosa from biofilm and planktonic growth conditions on healing using a 
‘scratch wound assay’.
4.3 Materials and Methods
4.3.1 Culture of bacterial isolates
Bacteria from chronic leg wounds, chronic surgical wounds and 
asymptomatic nasal carriers were isolated and cultured as previously described 
(Chapter 3, Section 3.3.1). Clinical control isolates included: chronic venous leg 
ulcer (CVLU) Staphylococcus aureus, FC2 (Davies et al., 2004); Pseudomonas 
aeruginosa, NCTC 10662; and mucoid producing strain P. aeruginosa, ATCC 
39324. Pure cultures for the chosen bacteria in Table 4.1 were established on blood 
agar (BA; LabM) supplemented with 5% (v/v) sheep defibrinated blood (Sigma- 
Aldrich) at 37°C overnight (O/N).
4.3.2 Production of bacterial supernatants
The media used to produce bacterial supernatants were tryptone soya broth 
(TSB; Oxoid), brain heart infusion broth (BHI; Oxoid), and Dulbecco’s modified 
eagle medium with 4 g/1 D-glucose, L-glutamine, (no additional sodium pyruvate or 
phenol red; DMEM; Invitrogen) supplemented with 10% (v/v) foetal calf serum 
(FCS; Invitrogen). Working cultures used to produce bacterial growth curves and 
supernatants were prepared by inoculating a single bacterial colony into 10 ml of
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Table 4.1 Bacterial isolates used to compare immunostimulation
Isolate Number of isolates Isolate type
‘Supernatant growth condition 
(number of supernatants)
Planktonic Biofilm
Chronic surgical wound 4 MRSA 4 0
Chronic leg wound 4 MRSA 4 0
Asymptomatic nasal 
carrier 4 MRSA 4 0
FC2 1 Staphylococcus aureus 
(control isolate) 1 1
NCTC 10662 1 Pseudomonas aeruginosa 
(control isolate)
1 1
ATCC 39324 1 Mucoid Pseudomonas aeruginosa (control isolate) 1 0
MRSA, Meticillin Resistant Staphylococcus aureus; a growth condition of produced supernatant.
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corresponding sterile liquid growth media and incubated (37°C O/N) on a roller (50 
rpm).
4.3.2.1 Growth curves to determine stationary phase
Growth curves were determined for each isolate in all 3 growth media 
(Section 4.3.2). Working cultures of bacteria were produced (Section 4.3.2), diluted 
(1:50 dilution, DMEM; 1:500 dilution, broth), and 1 ml transferred to 3 wells of a 24- 
well cell culture plate (Costar®, Coming®, Sigma-Aldrich). This was sealed with
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DuraSeal (Sigma-Aldrich, UK) to prevent evaporation. Absorbance was measured 
hourly at 620 nm using a FLUOstar OPTIMA plate reader (BMG Labtech GmbH, 
Germany) over a 48 h period at 37°C with agitation prior to measurement. The 
growth curves were plotted from the recorded absorbance (with the growth media 
employed as a control) and stationary phase identified.
4.3.2.2 Supernatant preparation
Supernatants were prepared in a 250 ml conical flasks by inoculating 100 ml 
of growth media with a 1:50 or 1:500 (DMEM or broth respectively) dilution of the 
prepared working culture (Section 4.3.2). Cultures were incubated at 37°C until 
stationary phase was attained in a shaking incubator at 160 rpm for planktonically 
grown cultures or stationary for 48 h for biofilm growth conditions.
The final absorbances of the bacterial cultures were then tested using the 
FLUOstar OPTIMA at an absorbance of 620 nm (A620) to confirm stationary phase. 
Purity checks were performed on both the working and supernatant cultures and 
CFU/ml determined for the stationary phase supernatant cultures (Chapter 2, Section
2.3.5.3). Following centrifugation (13000 x g, 4°C, 10 min) the supernatants were 
filter-sterilised (0.2 pm filter; IWAKI glass Co. Ltd, Tokyo, Japan) and stored at 
- 80°C. Samples were re-filtered prior to use.
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4.3.2.3 Determination of protein content
Protein content of each supernatant was determined using a BCA™ Protein 
assay KIT in 96-well plates (Pierce Protein Research Products, Thermo scientific, 
UK; Greiner Bio-one Ltd, UK), according to the manufacture’s instructions.
4.3.3 Heat killed bacteria
Working cultures of bacteria were prepared in 20 ml TSB (Section 4.3.2) and diluted 
(1:500) in 20 ml TSB. Bacteria were incubated on a rotating platform (37°C, 220 
rpm) until stationary growth phase was achieved (Section 4.3.2.1). Cultures were 
centrifuged (2000 x g, 10 min) washed (x2) in PBS, and then re-suspended in 10 ml 
PBS. The CFU/ml was determined using the drop count method (Chapter 2, Section
2.3.5.3) on luria-bertani (LB) agar (1%, w/v tryptone; 0.5%, w/v yeast extract; 1%, 
w/v NaCl; 2% w/v agar bacteriological; pH 7.5; Oxoid). Bacteria were heat killed 
(6 8 °C, 2 h) confirmed by inoculating 20 pi of heat killed bacterial suspension on LB 
agar and incubating (37°C, 48 h) in triplicate, bacteria were stored at -80°C until use.
4.3.4 Toll-like Receptor (TLR) stimulation; Luciferase assay
The luciferase reporter assay was utilised to study TLR activation as 
previously described by Hellerud et al., (2008).
4.3.4.1 Growth of human embryonic kidney (HEK) 293E cells
Human Embryonic Kidney (HEK) 293E cells were grown in monolayer in a 
T75 flask (Coming life sciences, Sigma-Aldrich Norway AS) containing HEK 293E 
cell culture medium (DMEM, Invitrogen; supplemented with 0.68 mM L-glutamine, 
Sigma-Aldrich; 10 pg/ml ciprofloxacin, Cellgro®, Mediztech, Inc. USA and 10% 
FCS, Invitrogen) in a humid incubator (37°C, 8 % CO2) until approximately 80% 
confluent. Cells were trypsinised by removing the cell culture media and washing 
with pre-warmed PBS (Invitrogen; x2). Trypsin-EDTA (3 ml) was added to the 
flask. When the cells detached, the Trypsin-EDTA was inactivated by the addition of
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10 ml of HEK 293E cell culture medium and the resultant cell suspension centrifuged 
(350 x g, 7 min) and re-suspended in 4 ml of HEK 293E cell culture media. The cells 
were split (1:8) with luciferase media (DMEM; Euroclone, Milano, Italy), 
supplemented with 0.68 mM L-glutamine; 10 pg/ml ciprofloxacin and 10% FCS, and 
100 pi of cell suspension used to seed a 96-well cell culture plate (Coming life 
sciences, Sigma-Aldrich, Norway). The remaining cells were maintained as a stock 
in a T75 flask containing HEK 293E cell culture media.
4.3.4.2 Transfection of HEK 293E
HEK 293E cells were incubated in 96-well plates until 70 - 80% confluent 
and media changed prior to transfection. A 100 pi volume of luciferase media was 
added to each well. A total volume of transfection mixture (Appendix VI) was 
prepared in a 50 ml centrifuge tube. To each well a 25 pi total volume of transfection 
mixture was added. The transfection mixture (per well) was prepared by combining
24.7 pi of plain DMEM (Euroclone, Milano, Italy) and 0.3 pi of Gene Juice® 
(Novagen, Merck, Dramstadt, Germany) vortexed and incubated for 5 min at RT. To 
this, a total of 100 ng plasmid DNA was added. The plasmids used for transfection 
were as follows; NF-KB-dependant luciferase reporter plasmid, pELAM-luc (Chow et 
al., 1999); pcDNA3 expressing human CD14; pEFBOS expressing human MD2; 
pcDNA3 expressing TLR4; pRK7 expressing human TLR2 (Hellerud et al., 2008); 
pcDNA3 expressing TLR5 and pRL-TK expressing Renilla; the total dosage being 
corrected by the addition of pcDNA3. The transfection mixture (Appendix VI) was 
incubated (RT, 15 min) then 25 pi added to each corresponding test well. The cells 
were incubated for a further 24 h in a humid incubator (37°C, 8 % CO2) until 70 - 
90% confluent.
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4.3.4.3 Preparation of supernatants and controls for stimulation of TLR 
transfected cells
The supernatants prepared in Section 4.3.2.2 were recovered, filter-sterilized 
and serially diluted 1:5 in round bottom 96-well cell culture plates using HEK 293E 
cell culture medium (Section 4.3.4.1). Each test dilution (31 pi) was pipetted into the 
corresponding transfected test wells. S. aureus supernatants were used to stimulate 
TLR2 and TLR negative (pcDNA3) transfected cells and P. aeruginosa supernatants 
were used to stimulate TLR4, TLR5 and TLR negative (pcDNA3) transfected cells. 
TLR ligands were used as positive and negative controls for transfection and 
luciferase activity. Fibroblast stimulating lipopeptide-1 (FSL-1; EMC 
Microcollections, Germany; 20 ng/ml) was used to stimulate TLR negative and 
TLR2 transfected cells and utilised as a negative control for TLR4 transfected cells. 
Lipopolysaccharide (LPS; Ultrapure, Invitrogen; 50 ng/ml) was used to stimulate 
TLR negative and TLR4 transfected cells and as a negative control for TLR2 
transfected cells. The LPS ligand was placed in an ultrasonic bath prior to dilution to 
disrupt any micelle formation. Flagellin (InvivoGen, San Diego, California, USA; 1 
ng/ml, 10 ng/ml and 100 ng/ml) was used to stimulate TLR negative and TLR5 
transfected cells. Flagellin was also used as a control for the TLR2/4 and TLR 
negative transfected cells at 10 ng/ml working concentration. Plain DMEM and 
supernatant growth media were also used as controls for background activity and 
cytotoxicity. The cells were incubated and stimulated for 20 h (37°C, 8 % CO2).
4.3.4.4 Luciferase activity
Prior to recording luciferase activity, cells were visualised using light 
microscopy for morphological changes or evidence of cytotoxicity following 
stimulation. The cell media/supernatant was aseptically removed and 50 pi of 
passive-cell culture lysis reagent (Promega) was added to each well to obtain the 
cytoplasmic extract. Plates were then sealed in aluminium foil and placed on an 
orbital shaker for 30 min (50 rpm). Luciferase substrate was reconstituted with the
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provided buffer (Promega) and Renilla substrate (Sigma-Aldrich) diluted to 1 mg/ml 
with sterile PBS. Following lysis of the stimulated HEK 293E cells, 10 pi of the cell- 
lysate was transferred to two white, opaque 96-well microplates (OptiPlate™-96, 
Perkin Elmer). Luciferase substrate (25 pi) was then added to the cell lysate and the 
signal recorded by a Victor3™ plate reader using Wallac 1420 software (Perkin 
Elmer, Norway). Luminescence was measured following 2 s shaking, for 0.1 s per 
well. The luciferase activity was determined by normalising the Elam-luc signal 
against the Renilla signal to control for variation in transfection, cell number and 
viability. The TLR activity was calculated relative to the TLR-negative cells 
(pcDNA3).
4.3.5 Monocyte assay to determine IL-8, TNF-a and IL-ip production following 
stimulation with bacterial supernatants
4.3.5.1 Isolation of monocytes from buffycoat
Buffycoat A+ venous blood was obtained from the blood bank at St Olav’s 
Hospital, Trondheim, Norway (following approval of the Local Regional Ethical 
Committee, Appendix I). Following dilution (1:5) with preheated (37°C) Dulbecco's 
phosphate buffered saline (D-PBS; Invitrogen), 35 pi aliquots were pipetted into 50 
ml centrifuge tubes and 10 ml of pre-heated Lymphoprep™ added (Nycomed Pharma 
AS, Norway) followed by centrifugation (690 x g , 25 min). The mononuclear cell 
layer was removed and distributed between two new centrifuge tubes which were 
then centrifuged (840 x g, 10 min). The resultant cell pellet was re-suspended in 1 ml 
of preheated Hanks buffered salt solution (HBSS; Invitrogen) and 19 ml of HBSS 
added. Samples were centrifuged (345 x g, 8 min) and the washing process repeated 
(x2). The resulting cellular pellets were combined in one 50 ml centrifuge tube and 
20 ml of HBSS added. Cell number was determined using 20 pi of the mononuclear 
cell/HBSS solution diluted in 10 ml of Isoton water containing 2 drops of 
Zaptoglobin (Beckman Coulter, Norway), to lyse erythrocytes, and the white blood 
cells were counted using an automated cell counter (Beckman Coulter, Norway).
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Cells were re-suspended in plain Roswell park memorial institute media (RPMI; 
Invitrogen), and diluted to a concentration of 4 x 106 cells/ml in Mo growth media 
(RPMI; Invitrogen, supplemented with gentamicin 40 pg/ml, 0.01% glutamine and 
2% human A+ serum). A 96-well cell culture plate was seeded with 100 pi of cell 
suspension and following incubation (37°C, 5% CO2, 90 min), wells were viewed 
using a Zeiss microscope to demonstrate Mo adherence. Wells were washed with 
preheated 130 pi HBSS (x4) to remove non-adherent cells. Then 160 pi of RPMI 
growth medium supplemented with 6.25% A+ human serum, gentamicin 40 pg/ml, 
and 0 .0 1 % glutamine was added to each well.
4.3.5.2 Monocyte stimulation with bacterial supernatants
Bacterial supernatants and growth media controls were filter-sterilised (0.2 
pm) prior to use and serially-diluted (1:5) using plain RPMI in round bottom 96-well 
cell culture plates. Then 40 pi of supernatant was used to stimulate Mo cells. 
Ligands LPS and FSL-1 (10 ng/ml), Adenosine triphosphate (ATP; 5 mM) and Mo 
RPMI growth media supplemented with 2% A+ serum growth medium were used as 
controls. All controls were used in primed and non-primed Mo condition for the 
activation and analysis of IL-lp. Priming was performed using LPS (final 
concentration 50 pg/ml). Stimulated cells were incubated (37°C, 5% CO2, 5 h) and 
100 pi of supernatant was recovered to estimate IL-lp and TNFa production. After 
16 h, cell supernatants were recovered for IL-8  analysis. All Mo supernatants were 
stored at -20°C until required.
4.3.5.3 MTT assay following monocyte stimulation
Following supernatant collection for cytokine analysis, an MTT assay was 
performed to investigate cytotoxicity. After removal of cellular supernatants 100 pi 
Mo RPMI growth medium containing 50 ng/ml 3-(4,5-Dimethyl-2-thiazolyl)-2,5- 
diphenyl-2H-tetrazolium bromide, (MTT formazan; Sigma-Aldrich) was added to
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each well. Following incubation (37°C, 5% CO2, 4 h) cells were visualised 
microscopically for crystal formation. The MTT solution was removed and 150 pi of 
100% isopropanol containing 0.25% (v/v) ammonia added, and the plate shaken (30 
min) to allow cellular lysis. Absorbance was measured at 570 nm, using a Victor3™ 
plate reader (Perkin Elmer, Norway).
4.3.5.4 Enzyme-linked immunosorbent assay (ELISA) analysis of IL-8, TNFa 
and IL-lp production by monocytes
Monocyte cytokine production was assayed using commercial ELISA kits for 
IL- 8  and TNFa (R&D systems, Abington, UK) and IL-ip (BD biosciences, San 
Diego, USA). Supernatants collected from Mo cultures (Section 4.3.5.2) were 
diluted using the reagent diluents (Table 4.2). Half-area flat-bottom 96-well ELISA 
plates (Coming life sciences, Norway) were coated with 25 pi of capture antibody 
diluted to 4 pg/ml with PBS (Table 4.2). Plates were sealed with an adhesive film 
(Greiner bio-one, MedProbe, Norway) and incubated O/N at RT. The plates were 
washed three times (0.05% Tween 20 in PBS; Sigma-Aldrich) using a plate washer 
(UltrawashPlus, Thermolabsystems), and “blocked” with 100 pi of blocking agent 
(1% BSA, v/v; PBS; Sigma-Aldrich) for IL-8  and reagent diluents for IL-lp and 
TNFa (Table 4.2) and incubated at RT for 1 h. The plates were then washed (x3) 
with wash buffer and blotted by inverting onto blotting paper. Diluted Mo 
supernatant (25 pi) and standard (diluted with reagent diluents; Table 4.2) were 
added, the plates sealed with adhesive film and incubated (37°C, 1 h). Following 
washing (x3 with wash buffer) and blotting, 25 pi of detection antibody (Table 4.2) 
was added to each well. Following incubation (37°C, 1 h), washing (x3) with wash 
buffer and blotting, 25 pi of Streptavidin horse-radish peroxidase conjugate 
(Streptavidin-HRP; 1:200; R&D Systems) was added to each well and the plate 
incubated in the dark for 20 min at RT. The plates were washed again (x3), blotted 
dry, and 25 pi of tetramethylbenzidine (TMB) substrate (BioLegend, Nordic BioSite
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Table 4.2 Concentration of antibody and reagents for ELISA analysis of IL-8, TNFa and IL-lp
‘ELISA Supernatantdilution Reagent diluent
Capture
antibody Standard
Detection
antibody
IL-8 1 :1 0 0
0.1% BSA (v/v), 
0.05% Tween® 20 (v/v), PBS b4 pg/ml
0 to 4000 pg/ml e2 0  ng/ml
TNFa 1 :2 0 1% BSA (v/v), PBS °4 pg/ml 0 to 250 pg/ml f300 ng/ml
IL-lp 1 :2 0 1% BSA (v/v), PBS d4 pg/ml 0  to 1 0 0 0  pg/ml 875 ng/ml
aELISA as per manufacturer’s instruction; banti-human IL- 8  monoclonal antibody (mAb);c anti-human TNFa mAb; danti-humanIL-lp mAb; 
ebiotinylated anti-human IL-8 ; fbiotinylated anti-human TNFa; 8biotinylated anti-human IL-lp.
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AS) added to each well and incubated at RT for 15 to 20 min in darkness. The 
reaction was stopped using stop solution (2NH2.S04, 25 pi). The optical density of 
each well was determined using a Victor3™ microplate reader at an absorbance of 
450 nm and corrected by reading the absorbance at 570 nm. The concentration of 
cytokine production was calculated based on the standard values.
4.3.6 Whole blood model and complement activation
Refludan (50 pg/ml; Pharmion, Norway) anti-coagulated venous whole blood 
was obtained from a healthy volunteer using sterile 4.5 ml tubes (Nunc A/S, Thermo 
Scientific, Denmark). Following venepuncture, 375 pi of blood was aliquoted 
equally into sterile 1.8 ml polypropylene tubes (Nunc, Thermo Scientific, Denmark) 
containing 150 pi of bacterial supernatant in increasing (1:5) dilutions and 
maintained at 37°C. Control tubes contained 150 pi of PBS, 150 pi zymosan (20 
pg/ml; Sigma-Aldrich) and 150 pi LPS (0.10 pg/ml; Ultrapure, Invitrogen). Control 
(PBS/blood; 50 pi) was sampled immediately (4 min incubation) and added to a 96- 
well plate containing 50 pi of 1% v/v paraformaldehyde (PFA; BD Falcon, Norway) 
and used as a control for FACS analysis. The remaining control/PBS was added to 
9.5 pi EDTA (10.0 mM final concentration) to arrest complement activation and 
used as a negative control, Time 0 (TO). After 15 min of incubation at 37°C (T15), 
50 pi of each bacterial supernatant/blood and control/blood samples were transferred 
to 96-well (PCR) plate containing 50 pi of 1% v/v PFA, and incubated (37°C, 4 
min), then kept at RT and used for FACS analysis.
Following 30 min (T30) of incubation of the initial experimental samples, 
1 0 0  pi of bacterial supernatant/blood and control/blood sample were transferred to a 
Nunc tube containing 2 pi EDTA (10.0 mM final concentration; Sigma-Aldrich) to 
arrest complement activation and were stored on ice. Samples were centrifuged 
(2000 x g, 15 min, 4°C) plasma collected and stored at -80°C for IL-8  and terminal 
complement complex (TCC) analysis. Following 120 min of incubation (T120) at
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37°C, the remaining bacterial supernatant/blood and control/blood sample reaction 
was arrested with 3 pi EDTA (10.0 mM final concentration) and tubes centrifuged 
(2000 x  g, 15 min, 4°C) plasma collected and stored at -80°C for IL- 8  analysis.
4.3.6.1 Fluorescence-activated cell sorting (FACS) analysis
FACS analysis was performed by Mrs L. Ryan NTNU, Trondheim, Norway 
on the TO and T15 samples (Section 4.3.6) to analyse CD1 lb  expression on Mo and 
granulocytes, indicating complement activation. Fluorescently labelled antibodies 
specific for CD1 lb-PE (phycoerythrin), CD14-FITC (fluorescein isothiocyanate) and 
CD14-PE (BD Biosciences, Norway), and LDS-751 (Sigma-Aldrich, Norway) were 
used. FITC-mouse IgG2b-k was used as a negative control. Following fixation of 
samples in PFA (Section 4.3.6), 25 pi of the fixed whole blood sample was added to 
15 pi of antibody solution (FITC-control, 8.3 pg/ml; CD14-PE, 8.3 pg/ml; and LDS- 
751, 5.3 pg/ml; or CD14-FITC, 8.3 pg/ml; CD1 lb-PE, 8.3 pg/ml; and LDS-751, 5.3 
pg/ml). Samples were incubated for 15 min in darkness at RT. The stained samples 
were transferred to a plastic test tube and 450 pi of PBS added. The sample was 
then analysed using a fluorescence-activated cell sorter (BD Vantage, BD 
PharMingen) setting the threshold for the nuclear dye LDS-751 to separate 
leukocytes and erythrocytes. Granulocytes and Mo were gated on forward scatter 
(FSC) and side scatter (SSC) dotplots using CD 14, and used to analyse the cellular 
population expressing CD1 lb with regards to median fluorescence intensity (MFI).
4.3.6.2 Terminal complement complex (TCC) analysis and IL-8 production for 
the whole blood model
IL- 8  analysis was performed using an ELISA based assay as in Section
4.3.5.4 using T120 whole blood samples from Section 4.3.6. The serum collected 
was diluted (serum derived following incubation with 1:5; 1:25 and 1:125 bacterial 
supernatants were diluted 1:10; 1:3 and 1:2 respectively) using diluting reagent. 
TCC analysis was performed by Mrs L. Ryan NTNU, Trondheim, Norway. A 96-
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well ELISA plate (Nunc, Thermo scientific, Denmark) was coated using 50 pi of 
aE ll 95A antibody (a gift from Professor T. E Mollnes of Nordland Central 
Hospital, Bodo, Norway; Mollnes et al., 1985a) and incubated (4°C, O/N). The plate 
was washed with PBS containing 0.05% Tween® 20 (wash buffer). A standard curve 
was prepared using zymosan-activated serum diluted with PBS; 0.2% Tween® 20 
and 10 mM EDTA to a maximum concentration of 200 AU/ml. The standard and 
samples (50 pi) were added to the plate and incubated (RT, 1 h). The plate was 
washed (x3), and detection antibody (50 pi) biotinylated mAb 9C4 (anti-C6 ; 
Hogasen et al., 1995) added and incubated (37°C, 45 min), followed by washing 
with wash buffer (x3). Then Streptavidin-HRP (R&D Systems, Norway) was diluted 
1:200 with reagent diluents and 50 pi pipetted into each well. Plates were incubated 
(37°C, 30 min) in darkness, washed (x3) with wash buffer and blotted dry. Then 50 
pi of TMB substrate solution was added to each well. The reaction was stopped 
(2 NH2.SO4, 50 pi) after 30 min and the plate absorbance measured at 450 nm and 
corrected by reading the absorbance at 570 nm.
4.3.7 Detection of LPS in bacterial supernatants
LPS levels of P. aeruginosa supernatants were determined with the help of 
Dr 0 . Rognstad, NTNU, Trondheim, Norway, using the chromogenic Limulus 
amebocyte lysate (LAL) assay (Cambrex, Walkersvill, Maryland, USA). Bacterial 
supernatants were diluted 1:1000; 1:3000: 1:9000 with sterile water (Invitrogen). 
Using a pre-warmed microplate (37°C), 50 pi of standard (0.1 to 1 EU/ml) and test 
sample were dispensed into duplicate wells, LAL reagent water (50 pi) was used as a 
negative control. To each well, 50 pi LAL was added and incubated (37°C, 10 min) 
then 100 pi of pre-warmed (37°C) substrate solution was added. Following 
incubation (37°C, 6  min) 100 pi of stop solution (25%, v/v, glacial acetic acid in 
H2O) was added. Optical density was recorded at 405 nm using a Victor3™ 
microplate reader, and LPS concentrations calculated based on standard values.
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4.3.8 In vitro human wound healing model
Discarded human abdominal skin was acquired following abdominoplasty, 
from St Olav’s hospital, Trondheim, Norway (following approval of the Local 
Ethical Committee from the Plastic Surgery Department at St Olav’s Hospital, 
Trondheim, Norway; Appendix I). Using an aseptic technique in a laminar flow 
cabinet, the skin was cleansed with 70% alcohol and underlying adipose tissue 
removed. A 6  mm punch biopsy into the connective tissue (approximately 5 mm) 
was created for the wound explants and within this, a 3 mm punch biopsy wound 
was prepared into the epidermis (Figure 4.2). The wounded explants were incubated 
(37°C, 8 % CO2, O/N) in DMEM supplemented with 10% FCS, gentamicin 10 pg/ml 
and amphotericin B 0.25 pg/ml (Cascade biologies Inc, Portland, USA). Bacterial 
supernatants were filter-sterilised (0.2 pm) and diluted (1:10, 1:50 and 1:250) with 
DMEM supplemented with 10% FCS, gentamicin 10 pg/ml and amphotericin B 0.25 
pg/ml prior to use. The wounds were placed in 6 -well tissue culture plates (Coming 
Life Sciences, Norway). To each well, 1 ml of bacterial supernatant/media or 
growth media (control) per wound was added, incubated (37°C, 8 % CO2) for 8 d, 
and media replenished every 48 h (Jansson et al., 1996). The media was removed 
and 1 ml per wound of supplemented DMEM (10% FCS; 10 pg/ml ciprofloxacin; 
0.68 mM glutamine and 0.5 mg/ml MTT) added. Following incubation (37°C, 8 % 
CO2, 4 h), wounds were washed and re-suspended in 2 ml of PBS. Using a Cannon 
office scanner, the inverted wounds were imaged and analysed using ImageJ 
software (ImageJ 1.43v; http://rsb.info.nih.gov/ij/) to determine wound healing as a 
percentage of re-epithelialisation (Figure 4.3).
217
Figure 4.2 Wound preparation o f human abdominal skin used for in vitro wound 
model, a) Punch biopsy; b) Excision o f wound from underlying connective tissue.
Figure 4.3 Skin wound explant following MTT staining. Outline o f initial wound 
(yellow); wound following re-epithelialisation (blue).
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4.3.9 The effect of bacterial supernatants on wound healing using the “scratch” 
wound assay
These studies employed the spontaneously immortalized, epidermal 
keratinocytes, Human adult low Calcium Temperature (HaCaT) cell line (Boukamp 
et al., 1988) to study wound healing based on a monolayer “Scratch” wound assay 
(Lampugnani, 1999, Stephens et al., 2003).
4.3.9.1 Culture of keratinocyte (HaCaT) cells
Cells were cultured in T175 flasks in keratinocyte media (Flavin adenine 
dinucleotide; FAD) containing supplemented high glucose DMEM (Invitrogen; 
22.5% v/v Ham F-12 nutrient media, Invitrogen; 10% v/v FCS; 0.089 mM adenine; 
10 ng/ml epidermal growth factor; 0.08 pg/ml cholera toxin; 400 ng/ml 
hydrocortisone; 5 ng/ml insulin, Sigma-Aldrich; 100 U/ml penicillin G; 100 pg/ml 
streptomycin sulphate, and 0.25 pg/ml amphotericin B, Invitrogen) at 37°C, 5% CO2 
in a humid environment until 70 - 80% confluent.
4.3.9.2 Culturing HaCaT cells for scratch wound assay
T175 flasks were washed with pre-warmed (37°C) PBS and cells trypsinised 
by adding 3 ml of 0.05% trypsin/EDTA (Invitrogen) and incubating at 37°C for 2 
min until the cells had detached. Cells were suspended in 10 ml of FAD media, 
centrifuged (180 x g, 5 min) and re-suspended in 4 ml of FAD. Viable cells number 
was determined using a Casy® cell counter model DT (Scharfe System GmbH, 
Germany); 1.5 x 105 cells/well seeded into 24-well plates (BD Falcon™, New Jersey, 
USA) and incubated (37°C, 5% CO2, 36 h) until confluent.
4.3.9.3 “Scratch” wound assay
The DMEM prepared supernatants (Section 4.3.2.2) were filter-sterilised (0.2 
pm filter), and serially diluted (1:10) with pre-warmed (37°C) FAD media. A linear 
wound was created using a 200 pi sterile filter tip in the centre of each well. The
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media was removed and the wells washed with PBS (x2) and diluted bacterial 
supernatants (1.5 ml) added to duplicate wells. Scratch wounds incubated in FAD 
media alone were used as controls. Experiments were repeated in triplicate and cell 
migration was visualised over a 24 h period using a time-lapse microscope (Zeiss 
Axiovert 200M) attached to a Hamamatsu digital camera using Openlab 5.0.2® 
software (Improvision, Perkin Elmer) under culture conditions (37°C, 5% CO2). 
Digital images were captured at 20 min intervals and sequences recorded as 
QuickTime® (Apple Computer Inc, USA) movie files.
4.3.9.4 Image analysis
The wound area and rate (speed) of closure of each scratch wound was 
estimated for all supernatants at dilutions 1:10 and 1:31250 at times 0, 6 , 12 and 24 
h. Using OpenLab® software (Open Lab, Florence, Italy), Quicktime® images were 
exported for analysis using ImageJ software (ImageJ 1.43v; 
http://rsb.info.nih.gov/ij/). Wound outline and pixel area was recorded for each time 
point (Figure 4.4). The velocity of wound area reduction was used to deduce speed 
of wound closure (cell migration).
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Figure 4.4 Images of control (FAD media) “scratch” wound from time lapse outlining wound space for analysis, a) 0 h; b) 6 h (scale bar 
represents 100 pm).
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4.3.10 Statistics
All statistical analysis was performed using GraphPad prism3® (GraphPad 
software Inc, California USA) and Minitab® (Release 14 software, Minitab® Ltd, 
Coventry, UK). Statistical analysis of NF-kB values for the luciferase reporter 
assay, Mo cytokine production and “scratch” wound assay (speed of wound closure 
and wound area reduction) were performed using a Kruskal-Wallis test to compare 
individual and grouped isolates. Where this was significant (P<0.05) a Dunn post­
test was performed. A Mann-Whitney test was performed for the luciferase, Mo 
cytokine production and “scratch” wound assay to compare planktonic vs. biofilm 
produced supernatants (P. aeruginosa and S. aureus).
4.4 Results
4.4.1 Growth curve determination
The growth curves of all studied bacterial isolates were initially performed in 
DMEM. There was however, limited bacterial growth and DMEM supplemented 
with 10% FCS was subsequently employed. Figure 4.5 shows the typical growth 
curve achieved with bacteria grown in DMEM supplemented with 10% FCS, 
delaying stationary phase to approximately 36 h. In contrast, isolates grown in 
conventional media typically attained stationary phase within 1 0  h.
4.4.2 Protein content analysis
The protein content of the bacterial supernatants derived using the BCA 
assay and CFU/ml for each growth medium is shown in Table 4.3. It was evident 
from this that bacteria were able to survive and grow in DMEM supplemented with 
10% FCS based upon achieved CFU/ml.
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Figure 4.5 48 h growth curve for MRSA isolate (1011) in DMEM supplemented with 10% FCS and BHI.
223
Table 4.3 Protein content and colony forming units derived from growth media to produce supernatants
Isolate Origin ‘Growthcondition
"TSB
Protein
content
(pg/ml)
Mean
CFU
‘BHI
Protein
content
(pg/ml)
Mean
CFU
bDMEM & 10%FCS
Protein, A Mean content mwT 
t , ,v CFU (Hg/ml)
Control
media 1089.712 1230.13 637.32
MRSA Nasal Planktonic 606.5 ±49.7 2.5 x 107 927 ±218.5 3.1 x 107 561.1 ±151.4 3 xlO6
MRSA CSW Planktonic 557.9 ±25.1 1.9 x 107 933.7 ±85.2 2.3 x 107 500+ 178.8 2.8 x 106
MRSA CLW Planktonic 613 ±59 2.3 x 107 868.5 ±125.1 3 x  107 569.5 ±135 3.3 xlO6
S. aureus FC2 Planktonic 643.2 3.5 x 107 737.86 4.67 x 107 738.2 1.9 x 10 6
S. aureus FC2 Biofilm 691.5 1 .4 x 1 0 7 858.56 1.63 x 107 538.46 1.4 xlO 6
P.
aeruginosa
NCTC
10662 Planktonic 537.6 4.5 x 10* n/a n/a 607.2 2.1 x 108
P.
aeruginosa
NCTC
10662 Biofilm 663.8 3.2 x 10s n/a n/a 568.5 1.8x 108
P.
aeruginosa
(mucoid)
ATCC
39324 Planktonic 652.3 ± 106.7 4 x  10* n/a n/a 407.9 ± 20 1.2 x 108
CSW, chronic surgical wound; CLW, chronic leg wound; TSB, tryptone soy broth; BHI, brain heart infusion broth; DMEM & 10% FCS, 
DMEM supplemented with 10% FCS; CFU, colony forming units; n/a, not applicable; FC2, clinical (CVLU) isolate (Davies et al., 2004); 
agrowth condition in which supernatant produced; bmedia used to produce supernatant.
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4.4.3 Luciferase reporter assay (Toll-like receptor stimulation)
4.4.3.1 TLR2 response to MRS A supernatants
NF-kB activity induction relative to Renilla luciferase and TLR negative 
cells, following stimulation of TLR2 transfected HEK 293E cells with 1:25 diluted 
DMEM asymptomatic nasal carrier, chronic leg wound (CLW) and chronic surgical 
wound (CSW) MRSA supernatants is shown in Figure 4.6. Variation in NF-kB 
activation by different MRSA isolates was observed. Figure 4.6a shows activation 
for individual MRSA isolates (n = 4 per wound group). Figure 4.6b shows mean 
NF-kB activation for MRSA grouped isolates. TLR2 stimulation was relatively low 
compared with the positive control FSL-1. Nasal MRSA isolates stimulated TLR2 
more than either group of chronic wound MRSA isolates (Figure 4.6b) although this 
was not significant (P>0.05). In these experiments, the high activation of NF-kB by 
FSL-1 (positive control) indicated that transfection was successful. Also, no 
significant activation of NF-kB by LPS negative control indicated that activation was 
not due to TLR4.
4.4.3.2 TLR2 response to bacterial biofilm and planktonic supernatants
NF-kB activity induction relative to Renilla luciferase and TLR negative 
cells following stimulation of TLR2 transfected HEK 293E cells with biofilm and 
planktonic S. aureus (FC2) supernatants is shown in Figure 4.6c. No significant 
difference (P>0.05) in TLR2 stimulation was achieved for S. aureus supernatants 
prepared under different growth conditions.
225
1000
>‘>£3O
CO
CD
0)
>‘5
<1)a
100
10
n
r r
N asal Chronic surgical 
wound
Chronic leg  
wound
Individual MRSA Isolates
LPS FSL-1
Controls
1000
ul 100
N asal Chronic surgical Chronic leg  
wound wound
Grouped MRSA Isolates
LPS FSL-1
Controls
1000
>
o
<0
co
xe.
uL 100
a>
>
•»->wa>od
Biofilm P lanktonic
S. aureus
L PS FSL-1
Controls
Figure 4.6 NF-kB activity relative to Renilla luciferase and TLR negative cells 
following stimulation o f TLR2 transfected HEK 293E cells with 1:25 diluted 
DMEM bacterial supernatants, a) Individual MRSA isolates; b) Grouped MRSA i.e. 
nasal, chronic surgical or chronic leg wound; c) S. aureus (FC2) supernatant 
produced under biofilm or planktonic growth conditions. Error bars denote standard 
deviation o f the mean. LPS, lipopolysaccharide; FSL-1, fibroblast stimulating 
lipopeptide-1.
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4.4.3.3 TLR4 response to DMEM supernatants
The NF-kB activity induction relative to Renilla luciferase and TLR negative 
cells following stimulation of TLR4 transfected HEK 293E cells is shown in Figure 
4.7a. In these experiments there was no significant difference in TLR4 stimulation 
by P. aeruginosa (NCTC 10662) when grown in either planktonic or biofilm 
environments (P>0.05) for any dilution of the DMEM bacterial supernatants. In 
addition, there was negligible TLR4 activation by P. aeruginosa isolate NCTC 
10662 and DMEM control. In contrast, P. aeruginosa ATCC 39324 significantly 
stimulated TLR4 (P<0.05). The control LPS ligand indicated there was adequate 
transfection of the HEK 293E cells. Ligand FSL-1 indicated negligible background 
NF-kB via TLR2 stimulation and that the transfection was specific to TLR4 ligands. 
Interestingly, the LAL analysis of the pseudomonad experimental supernatants 
demonstrated that at dilutions <1:10,000, concentrations of LPS exceeded the 
standard curve (>900 ng/ml; results not shown).
4.4.3.4 TLR5 response to DMEM supernatants
The relative NF-kB activity following stimulation of TLR5 transfected HEK 
293E cells with DMEM supernatants is shown in Figure 4.7b. The control ligand 
flagellin indicated that the transfection was successful, whilst the DMEM negative 
control signified little background stimulation of cells. Again, no significant 
difference in TLR5 stimulation was observed between NCTC 10662 biofilm and 
planktonic growth environments. In these experiments, whilst isolate NCTC 10662 
(P. aeruginosa) failed to stimulate TLR5, the mucoid pseudomonal strain ATCC 
39324 exhibited an increased ability to stimulate TLR5 (P<0.05).
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4.4.4 Monocyte activation by bacterial supernatants
4.4.4.1 MTT cytotoxicity assay following monocyte stimulation
Cytotoxicity of all bacterial supernatants was determined using an MTT 
assay. Figure 4.8 shows a typical dose-response curve for nasal bacterial 
supernatants. The MTT assay indicated a minimal effect on the viability of the cells 
at low dilutions of the DMEM supernatants (Figure 4.8a). However, the cytotoxic 
effect was exacerbated in BHI supernatants (Figure 4.8b) necessitating normalisation 
with >1:25 supernatant dilutions.
4.4.4.2 Monocyte cytokine production stimulated with MRSA supernatants
4.4.4.2.1 IL-8 cytokine production from isolated monocytes
IL-8 cytokine production by Mo stimulated with 1:125 dilutions of DMEM 
MRSA supernatants studied by ELISA is demonstrated in Figure 4.9a. IL-8 
production was stimulated by all dilutions of MRSA supernatants. Nasal carrier 
MRSA induced significantly increased production of IL-8 compared to the chronic 
wound MRSA in these experiments, whilst results for chronic surgical and chronic 
leg wound MRSA were similar (P>0.05). This trend was evident for all dilutions of 
MRSA supernatants (1:5 to 1:625, results not shown). IL-8 production by Mo 
stimulated with (1:25 and 1:125 diluted) nasal and chronic surgical wound MRSA 
supernatants was statistically significant (P<0.01). A statistically significant 
difference was also observed for Mo IL-8 production when stimulated with nasal and 
chronic leg wound MRSA (supernatant dilution 1:5 to 1:125; P<0.01).
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Figure 4.9 Monocyte cytokine production following stimulation with MRSA 
bacterial supernatants, a) IL-8, 1:125 dilution; b) TNFa, 1:25 dilution; and c) IL-lp, 
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**P<0.01; ***P<0.001; LPS, lipopolysaccharide; FSL-1, fibroblast stimulating 
lipopeptide-1; RPMI, Roswell Park Memorial Institute medium.
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4 A A.2.2 TNFa production from isolated monocytes
TNFa production from Mo stimulated with 1:25 dilutions of MRSA DMEM 
supernatants is demonstrated in Figure 4.9b. Nasal isolates again exhibited an 
increased ability to stimulate TNFa as with IL-8 (P<0.05) compared with both 
groups of chronic wound MRSA. There was no statistical significance between 
either chronic surgical or chronic leg wound MRSA isolates (P>0.05).
4.4.4.2.3 IL-lp production from isolated monocytes
IL-lp production from Mo stimulated with 1:125 diluted DMEM MRSA 
supernatants is shown in Figure 4.9c. There was no significant difference between 
MRSA groups in their ability to stimulate IL-ip production (P>0.05), and IL-lp 
levels were similar to the RPMI control.
4.4.4.3 Monocyte cytokine production stimulated with S. aureus and P 
aeruginosa supernatants derived from planktonic and biofilm growth 
conditions
4.4.4.3.1 IL-8 production from isolated monocytes
Monocyte production of IL-8 following stimulation with 1:125 diluted 
DMEM bacterial supernatants from biofilm and planktonic growth conditions for S. 
aureus and P. aeruginosa is shown in Figure 4.10a. All bacterial supernatants 
irrespective of growth condition stimulated IL-8 release above the values observed 
for the RPMI controls. In these experiments, planktonic growth conditions induced 
significantly increased IL-8 production compared with biofilm cultures (PO.Ol). 
This increased IL-8 stimulation was observed for both P. aeruginosa and S. aureus.
4.4.4.3.2 TNFa production from isolated monocytes
The production of TNFa from stimulated Mo using 1:125 diluted DMEM 
supernatants produced in biofilm and planktonically grown S. aureus and P. 
aeruginosa are shown in Figure 4.10b. In these experiments, all supernatants
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Figure 4.10 Monocyte cytokine production following stimulation with S. aureus and 
P. aeruginosa biofilm and planktonic supernatants, a) IL-8, 1:125 dilution; b) TNFa, 
1:125 dilution; and c) IL-ip, 1:25 dilution. Error bars denote standard deviation o f 
the mean. **P<0.01; ***P<0.001; LPS, lipopolysaccharide; FSL-1, fibroblast 
stimulating lipopeptide-1; RPMI, Roswell Park Memorial Institute medium.
233
regardless of growth condition were able to stimulate TNFa production. Again, both 
planktonic grown supernatants indicated a greater stimulation of TNFa than their 
equivalent biofilm supernatant. This trend was observed at all supernatant dilutions 
for both isolates, and was statically significant for S. aureus 1:25 and 1:125 
supernatant dilutions (PO.Ol, PO.05 respectively). However, this was only 
statistically significant for P. aeruginosa using the 1:5 supernatant dilution (PO.Ol).
4.4.4.3.3 IL-lp production from isolated monocytes
Monocyte production of IL-ip following stimulation with 1:25 diluted 
DMEM planktonic and biofilm produced supernatants are shown in Figure 4.10c. 
Like the other cytokine experiments, again the planktonic grown supernatants 
exhibited an increased stimulatory effect, with minimal levels of IL-ip stimulation 
by biofilm produced supernatants. Planktonically derived S. aureus supernatants 
significantly stimulated IL-lp production using <1:125 supernatant dilutions 
(P<0.05). IL-ip stimulation by planktonic P. aeruginosa supernatants using 1:25 
dilutions yielded a statistically significant difference (P<0.001). Increased dilutions 
of biofilm supernatants resulted in stimulation similar to the RPMI control (results 
not shown).
4.4.5 Whole blood model
Complement activation by the bacterial supernatants was determined using 
the “whole blood” model. The production of IL-8, and Terminal Complement 
Complex (TCC) was determined in the EDTA arrested plasma of activated blood. 
The formation of TCC was used to assess the ability of bacterial supernatants to 
stimulate complement activation
4.4.5.1 IL-8 production in whole blood stimulated with MRSA supernatants
Whole blood production of IL-8 following stimulation with 1:5 dilutions of 
DMEM MRSA supernatants is demonstrated in Figure 4.1 la. In these assays, IL-8
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Figure 4.11 Whole blood stimulation with DMEM MRSA supernatants, a) IL-8, 1:5 
dilution; b) Terminal Complement Complex (TCC), 1:25 dilution; c) Mean 
Fluorescence Intensity (MFI) o f C D l l b  stained granulocytes, 1:25 dilution. Error 
bars denote standard deviation o f the mean. *P<0.05; **P<0.01; ***P<0.001; LPS, 
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production was significantly increased with nasal MRSA isolates, compared with 
chronic leg wound MRSA (P<0.05). There was however, no significant difference 
between the wound isolates (P>0.05). The trends observed in this assay were similar 
to that experienced in the stimulated Mo assay.
4.4.5.2 Complement activation in whole blood stimulated with MRSA 
supernatants
The TCC derived from stimulated plasma with 1:25 DMEM MRSA 
supernatants is shown in Figure 4.1 lb. Nasal isolates significantly induced increased 
formation of TCC. This was evident using nasal and chronic surgical wound MRSA 
supernatant dilutions 1:25 and 1:125 (P<0.05) and 1:25 dilutions of nasal and 
chronic leg wound isolates (P<0.05). No significant difference was observed 
between the wound group MRSA isolates (P>0.05). These data were supported by 
FACS analysis of C D llb  expression on Mo and granulocytes indicated by median 
fluorescence intensity (MFI; Figure 4.11c). A strong activation of complement was 
observed for the positive control zymosan, whilst negative controls PBS (TO and 
T15) and LPS showed no activation of complement.
4.4.5.3 IL-8 production in whole blood stimulated with S, aureus and P, 
aeruginosa planktonic and biofilm supernatants
Whole blood IL-8 production following stimulation with 1:5 diluted DMEM 
supernatants from S. aureus and P. aeruginosa grown in biofilm and planktonic 
conditions is shown in Figure 4.12a. In this assay, not only were species differences 
evident in their response, but also growth state was important. Biofilm growth 
conditions were associated with a significant decrease in IL-8 production in the 
“whole blood” model for P. aeruginosa (P<0.001). S. aureus biofilm supernatants 
also resulted in decreased IL-8 production, however, this was only significant using 
the 1:125 supernatant dilution (PO.Ol).
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4.4.5.4 Complement activation in whole blood stimulated with S, aureus and P. 
aeruginosa planktonic and biofilm supernatants
TCC activation by 1:25 diluted S. aureus and P. aeruginosa supernatants 
produced in biofilm and planktonic conditions are shown in Figure 4.12b. Whilst 
obvious differences were evident between the two species in their ability to stimulate 
complement, S. aureus stimulated TCC in both planktonic and biofilm growth 
conditions, with no significant difference observed (P>0.05). In this model, P. 
aeruginosa exhibited little ability to induce TCC activation. These data were 
supported by FACS analysis of C D llb  expression on granulocytes and Mo, 
indicated by the MFI (Figure 4.12c). The induction of CD1 lb observed in this assay 
was significantly greater for S. aureus than P. aeruginosa. Indeed P. aeruginosa 
results in the TCC and CD1 lb  assays were comparable to the PBS control (T15). It 
was observed that the planktonic grown S. aureus stimulated the CD1 lb greater than 
biofilm produced supernatants at all supernatant dilutions, and the MFI levels for 
planktonically grown S. aureus were comparable to the control zymosan.
4.4.6 In vitro human wound healing model following stimulation with MRSA 
supernatants
The percentage of epithelial healing observed following incubation of skin 
explants in DMEM and BHI grown nasal MRSA supernatants is demonstrated in 
Figure 4.13. Wound re-epithelialisation was estimated following staining of the 
wounds with MTT. In this assay, it was observed that MRSA supernatants, 
irrespective of growth media, significantly influenced re-epithelialisation at all 
supernatant dilutions studied compared with their respective controls DMEM 
(P<0.005) and BHI (PO.OOl).
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Figure 4.14 Topographic representation o f wound space closure over a 24 h period 
following incubation with FAD media control.
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4.4.7 “Scratch” wound analysis
“Scratch” wound assays employing HaCaT cells were used to quantify the 
effect of bacterial DMEM supernatants on speed of cellular migration and 
percentage closure of an in vitro wound. A topographical representation of a control 
treated “scratch” wound for 0, 6, 12 and 24 h is shown in Figure 4.14. It was 
observed that the wound space decreased with time with all supernatants. Figure 
4.15 and 4.16 demonstrate images of “scratch” wound frozen time frames for 0, 6,12 
and 24 h incubation with bacterial supernatants.
4.4.7.1 Wound area reduction following incubation with MRSA supernatants
Percentage wound area reduction of the initial “scratch” wound was 
determined over a 24 h period. Figure 4.17a and b represents the area reduction for 
12 and 24 h wounds treated with MRSA supernatants. In these experiments, no 
difference in wound area reduction was observed for MRSA isolated from nasal 
carriers or wound patients. However, a significant difference in percentage wound 
closure was observed at 24 h between the control media (FAD) and MRSA 
supernatants (P<0.05).
4.4.7.2 Wound area reduction following incubation with S. aureus and P. 
aeruginosa planktonic and biofilm supernatants
Growth conditions also significantly affected wound closure. Planktonic 
derived supernatants significantly decreased the ability of cellular migration, which 
was evident at 12 and 24 h (Figure 4.16). Percentage wound area reduction for 12 
and 24 h incubation of the “scratch wound” assay treated with biofilm and 
planktonic P. aeruginosa and S. aureus supernatants are shown in Figure 4.17c and
d. In these experiments, a significant difference in percentage wound area reduction 
was observed for P. aeruginosa supernatants at times greater than 12 h (P<0.05). A 
significant difference in wound area reduction was also observed for times greater 
than 12 h for both planktonic supernatants and control media (PO.Ol).
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Figure 4.15 HaCaT cell migration at 0, 6, 12 and 24 h time points in response to bacterial supernatants, a) Control media, FAD; b) nasal 
MRSA, S07 154; c) chronic surgical wound MRSA, 2018; d) chronic leg wound MRSA, 1011. Scale bar represents 100 pm.
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Figure 4.16 HaCaT cell migration at 0, 6, 12 and 24 h time points in response to S. aureus and P. aeruginosa bacterial supernatants, a) and c) 
biofilm; b) and d) planktonic. Scale bar represents 100 pm.
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No significant difference was noted between biofilm produced supernatants and 
control media over the 24 h period (P>0.05).
4.4.7.3 Speed of wound closure following incubation with MRSA supernatants
The speed of wound closure (cell migration) for 1:10 diluted DMEM MRSA 
supernatants at 6 and 12 h are shown in Figure 4.18a and b. A significant difference 
in speed of wound closure was observed with 1:10 diluted supernatants at 6 h time 
point for nasal carrier and chronic surgical wound MRSA (P<0.05). No significant 
difference was observed when comparing nasal carrier and chronic leg wound 
MRSA isolates, or between the two wound groups. However, there was a trend that 
chronic surgical wound MRSA wounds healed more slowly than the nasal carrier 
and chronic leg wound MRSA groups. No significant differences in speed of wound 
closure were observed for increased dilutions of supernatant (P>0.05).
4.4.7.4 Speed of wound closure following incubation with S. aureus and P. 
aeruginosa planktonic and biofilm supernatants
The speed of wound closure (cell migration) following incubation with 1:10 
DMEM S. aureus (FC2) and P. aeruginosa (NCTC 10662) biofilm and planktonic 
supernatants is shown in Figure 4.18c and d. Biofilm supernatants were observed to 
produce a greater speed of closure than wounds treated with planktonic supernatants. 
Prolonged exposure to S. aureus supernatants (24 h) in both biofilm and planktonic 
growth conditions did not show detrimental effects on the rate of wound closure. A 
significant difference in the speed of wound closure was observed for planktonic and 
biofilm S. aureus supernatant treated scratch wounds at 6 h (PO.Ol) although no 
significant difference was observed with prolonged treatment times (>12 h; P>0.05). 
The growth condition of P. aeruginosa significantly affected the speed of wound 
closure at > 6 h (PO.Ol). Increased dilutions of bacterial supernatants did not affect 
the speed of wound closure significantly (P>0.05; results not shown).
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4.5 Discussion
These studies investigated the immunostimulatory properties of commonly 
isolated chronic wound bacteria and the effect of biofilm growth conditions on their 
role in wound healing. Bacterial supernatants of MRSA from asymptomatic nasal 
earners were compared with those from chronic wounds. The effect of S. aureus and 
P. aeruginosa growth conditions (biofilm and planktonic) was also studied in 
immunological response assays and in a relatively simple model of wound 
repopulation i.e. scratch wound assay.
In these experiments, bacterial supernatants were produced in two broths 
(TSB and BHI) and supplemented cell culture media (DMEM with 10% v/v FCS). 
The proliferation of the bacteria varied as expected, according to nutrient and 
substrate levels in the media, witnessed by delayed stationary phase growth 
measurements (logio CFU/ml) and protein content. Despite this, the CFU/ml of 
bacteria was similar to that observed clinically (Bowler et al., 2001). In these 
experiments, bacterial supernatants were produced in supplemented DMEM to 
overcome cytotoxicity issues identified in preliminary studies associated with 
concentrated broth supernatants and background TLR and cytokine activation 
(personal communication Dr J. Stenvik). Thus cytotoxic issues observed in the MTT 
assay may have been associated with broth components and increased concentration 
of bacterial metabolites. The use of supplemented cell culture media to produce the 
supernatants allowed biological variation in experimental analysis to be attributed to 
bacterial products and not to the supernatant growth media.
There was inter-experimental variation in protein content for each of the 
growth media used. The BCA™ assay employed to determine the protein content in 
each of the growth media demonstrated that it was not possible to discern the exact 
amount of protein derived from bacteria from that already present in the growth 
media. Therefore, the concentration of protein in each supernatant may be attributed 
to growth media or/and solely bacterial metabolism.
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The Luciferase reporter assay was utilised to study TLR activation. Intra­
species variation was observed for TLR2 stimulation by nasal isolates, which may 
reflect the greater variation in the sequence type (ST) of these MRSA. It is likely 
that differences in the ST of nasal isolates are associated with the route of 
colonisation. Nasal carriage can frequently be transient, but is also more likely to be 
associated with community-acquired (CA) MRSA for which there is greater 
variation in the ST populations. Less variation in chronic wound (CW) MRSA TLR 
stimulation was observed and these isolates were associated with a more 
homogenous ST; the hospital-acquired ST (ST22) being predominant amongst this 
group (Chapter 3). Two possible reasons exist for this. Patients are more likely to 
have been hospitalised or institutionalised e.g. in a nursing home, or these STs 
preferentially colonise such chronic wounds and survive (Chapter 3). Importantly, 
the variation in stimulation did not reflect variation in protein content or CFU/ml of 
bacteria in the supernatants, in that the nasal MRSA with the greatest TLR2 
stimulation had the lowest CFU/ml. It is likely therefore, that this result reflects 
increased “shedding” or generation of a more stimulatory ligand e.g. LTA or PGN.
The greatest stimulation of TLR2 was observed by nasal MRSA isolates 
although this was not statistically significant. Broth supernatants and heat-killed 
MRSA produced similar results, represented by nasal MRSA providing increased 
TLR2 stimulation (results not shown). An interesting finding was that >108 CFU/ml 
heat killed nasal isolates induced greater activation of TLR2 than both chronic 
surgical and leg wound MRSA. This finding may be explained by either a structural 
component (e.g. LTA or PGN) being more abundant in the nasal isolates, or that the 
wound MRSA exhibit steric alterations in key ligands e.g. alanylation of LTA 
(Travassos et al., 2004, Fournier and Philpott, 2005). This variation in TLR 
stimulation may indicate that wound MRSA have adapted to allow chronic 
colonisation in the absence of significant (effective) inflammation (Mirza et al., 
2009, Pukstad et al., 2010). In these experiments, TLR2 stimulation in biofilm and 
planktonic growth environments exhibited marginal differences in NF-kB activation
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via TLR2, as would be expected since the PAMP should be identical, due to the use 
of the same isolate in both growth conditions.
Lipopolysaccharide (LPS) is major constituent of Gram-negative bacterial 
cell walls (e.g. P. aeruginosa) and known to be a potent stimulator of TLR4, as 
observed by the control LPS in the Luciferase assay. In these studies, P. aeruginosa 
isolate NCTC 10662 (a clinical strain able to form both biofilm and mucoid 
phenotypes; www.hpacultures.org.uk/collections/nctc; accessed 17/1/11) did not 
elicit a TLR4 response, despite significant levels of LPS endotoxin being present in 
the bacterial supernatant as assessed by the LAL assay. The low NF-kB activation 
may be associated with structural differences in LPS isoforms, specifically the lipid 
A component and O-antigen side chain, associated with acylation such as penta, hexa 
or hepta acylated LPS (Currie et al., 2003, Pier, 2007). Such conformational changes 
have been observed in Y. pestis organisms during plague infection (Comer et al., 
2010). Previous investigations in cystic fibrosis patients have shown that P. 
aeruginosa change their phenotype to become more mucoid, which is often 
associated with changes in LPS structure (Rocchetta et al., 1999) and Mg2+ levels 
(Pier, 2007). This conformational change is a possible mechanism by which these 
bacteria may alter PAMPs to evade the immune response and decrease TLR4 
recognition in vivo. Further investigation is warranted to confirm this mechanism. 
There was no difference in TLR4 stimulation by planktonic and biofilm grown P. 
aeruginosa as expected. As the planktonic form did not stimulate TLR4, it is 
unlikely that the biofilm form would, based on potential ligand structural differences. 
Evasion of the immune system was also witnessed in the TLR5 study, which is 
associated with bacterial flagella. Little activation of TLR5 was observed with 
isolate NCTC 10662 and this may be related to the loss of flagella from this 
bacterium which is often observed in mucoid forming bacteria and represents a 
mechanism to evade host immune responses (Garrett et al., 1999, Jensen et al., 
2010).
4
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Cytokine induction following bacterial invasion is a pivotal component of 
both the innate and acquired immune response in humans, and these responses are 
essential in modulating repair following injury. In these studies, Mo cytokine 
expression by nasal MRSA isolates exhibited increased stimulatory ability compared 
with MRSA from wounds (which themselves were similar). These differences in the 
immunostimulatory properties of the two groups (i.e. carrier vs. disease) were 
reflected in the TLR2 studies. Decreased immunological responsiveness in the 
wound environment may facilitate increased bacterial survival and chronicity of 
inflammation. This is in keeping with previous studies of S. aureus from sites of 
chronic inflammation which have been associated with reduced induction of TNFa, 
IL-8 or IL-ip (Sladek et al., 2005). Differences in PAMP (e.g. LTA, PGN and 
capsular polysaccharide) are known to elicit varying levels of IL-8 production from 
Mo and may also be associated with these findings (DeLeo et al., 2009). The 
observed variations following MRSA stimulation may be associated with the ST and 
secreted virulence factors (Chapter 3). Increased TLR and cytokine stimulation by 
nasal isolates may be associated with expression of specific virulence factors e.g. 
SEA and TSST-1, released from the nasal carrier MRSA strains in culture or 
infection (DeLeo et al., 2009). A reduced production of these pro-inflammatory 
cytokines (TNFa, IL-ip and IL-8) would result in reduced cellular migration and 
proliferation of inflammatory cells at the site of infection (Homef et al., 2002) 
allowing uncontrolled bacterial proliferation at the wound site leading to further 
tissue destruction by released factors such as matrix metalloproteinases (MMP).
Numerous studies have demonstrated that increased wound closure has been 
associated with microbial factors that induce IL-lp, TNFa and IL-8 (Zhang and 
Schluesener, 2006, Kirketerp-Moller et al., 2008, Shaykhiev et al., 2008). These 
cytokines and bacterial products signalling via TLR2, TLR4 and TLR5 are thought 
to play a role in the migration and proliferation of epithelial cells and stimulation of 
epithelial wound repair (Zhang and Schluesener, 2006, Shaykhiev et al., 2008, 
Pukstad et al., 2010). It is interesting therefore, that bacterial cells isolated from
i
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chronic non-healing wounds are associated with decreased cytokine stimulation. 
The increased immunostimulatory properties expressed by nasal MRSA are reflected 
in the lack of symptoms in these patients. In this situation, there is an effective 
immunological response, which quickly removes the MRSA via the innate immune 
system, unlike the chronic wound MRSA which appear to have adapted to evade the 
host immune system leading to a reduced functional immune response.
In contrast to the Mo cytokine release experiments, the “whole blood” model 
is a complex assay, allowing stimulation of the complement system in a 
physiological environment, and is the closest in vitro representative of the host 
response. As in the TLR and Mo cytokine assays, nasal MRSA exhibited a 
markedly higher stimulation of complement than the wound isolates. Increased 
levels of IL-8 production were again observed for the nasal isolates, as was 
confirmed with heat-killed bacteria and broth supernatants. This again stressed the 
ability of the chronic wound MRSA to evade the immune system, which is likely to 
occur through production of altered PAMPs. Heat-killed bacteria indicated that 
nasal isolates simulated whole blood to produce greater IL-8 levels than wound 
isolates, indicating a potential structural difference in the bacterial cell e.g. LTA 
alanylation or PGN formation (Fournier and Philpott, 2005). Quantification of the 
terminal complement complex (TCC) also suggested that nasal MRSA isolates were 
more potent immune stimulators than wound isolates; a finding mirrored by CD1 lb 
expression on granulocytes and Mo, a complement-dependent receptor studied using 
FACS analysis (Thorgersen et al., 2009). Heat-killed bacteria demonstrated similar 
complement activation between MRSA groups, suggesting the observed differences 
were likely to be associated with soluble bacterial products, rather than with bacterial 
surface components. S. aureus is known to produce factors that modify complement 
activation e.g. staphylococcal complement inhibitor (SCIN) and chemotaxis 
inhibitory protein of staphylococci (CHIPS) which may mediate the variation 
observed in TCC and CD l ib  activation between the nasal and wound MRSA 
isolates (Nizet, 2007, DeLeo et al., 2009).
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Cytokine stimulation via bacterial supernatants produced under different 
growth conditions for both S. aureus and P. aeruginosa indicated that planktonically 
grown supernatants had an increased ability to stimulate Mo IL-8, TNFa and IL-lp 
production. The bacterial biofilm environment within the wound is believed to 
provide specific protection (obstructing recognition by the immune system) from 
immunological responses (Kirketerp-Moller et al., 2008, Percival et al., 2008, Martin 
et al., 2009). This concept is supported by the data in this study, which demonstrated 
reduced stimulation by the biofilm supernatants. Within the biofilm, not only do 
phenotypic changes in the bacterial population present support reduced immune 
stimulation properties, but the physical dynamics of the biofilm may also play a role, 
such as in containment of the bacterial products within the extracellular 
polysaccharide substance (EPS) and contact with the wound. Apart from the biofilm 
EPS providing a physical barrier to the immune system, immunomodulating 
molecules released (e.g. PGN, LTA, and LPS) may be less stimulatory. 
Compounding this is the continuous production of bacterial degradative proteins 
encased and released from the biofilm matrix.
In the studies of biofilm vs. planktonic growth conditions, a major limitation 
of the study design is that, whilst the immune properties of released microbial 
products in the culture media could be determined, the potential effect of the biofilm 
structure itself in these assays was unknown. Bacteria in biofilms express 
differences in genotype, phenotype, physiology and biochemistry (Davis et al.,
2008). Whilst important changes occur during the growth of bacterial biofilms, it is 
uncertain whether the potential down-regulation of growth and protein synthesis in 
these studies was due to density-dependent quorum sensing or just reduced bacterial 
growth rate both of which are known to occur in biofilm environments (Kirketerp- 
Moller et al., 2008). Simple protein estimation was performed utilising the BCA 
assay, however this was unable to characterise proteins encased in the biofilm (EPS). 
It was unclear whether the planktonic supernatants are more immunostimulatory 
simply due to non-specific trapping of the biofilm-produced proteins and/or secreted
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immunomodulatory ligands, or is directly related to down-regulation of metabolism 
and transcription in the biofilm environment. In this respect, further investigation of 
the functional and potential immune stimulation of the structure and contents of 
wound biofilms is required, and would clearly be an interesting area of further 
research. However, this would be challenging without altering the biofilm structure 
itself. IL-8 production in the whole blood model for both P. aeruginosa and S. 
aureus indicated again like previous experiments, that the planktonically grown 
bacteria stimulated the resident immune cells greater than those from the biofilm. 
Moreover, variability of IL-8 production by P. aeruginosa from both the biofilm and 
planktonic growth environments was greater than for S. aureus.
Complement activation analysis of P. aeruginosa revealed minimal 
expression of CD1 lb  and formation of TCC; a finding similar to that for the control 
LPS. A previous study by Brekke et al., (2008) when investigating complement 
regulation of E. coli, and Sprong et al., (2004) when investigating N. meningitides, 
also found almost complete inhibition of the inflammatory response by LPS. Whilst 
differences in response to LPS activity in the whole blood model could be 
rationalised by the formation of micelle structures, this is unlikely in the present 
study because LPS within the supernatant clearly stimulated IL-8 production. 
Complement activation by the heat-killed bacteria also indicated the role of other cell 
wall components in complement activation. Sprong et al., (2004), suggested that the 
outer membrane proteins porin and opacity protein induce the mannose-binding 
lectin pathway in N. meningitidis. The minimal activation of complement by the 
soluble LPS could simply be associated with a low concentration or LPS structure of 
this P. aeruginosa (Brekke et al., 2008). Planktonic S. aureus supernatants 
stimulated increased complement activation which was reflected in the increased 
TCC, monocyte and granulocyte C D llb  expression. These data further support the 
idea that bacteria in biofilms are able to evade the immune system by dampening its 
response, via the decrease or alteration in production of antigenic molecules or by 
their entrapment in the matrix itself.
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The in vitro human wound healing model employing MTT staining to 
determine healing made analysis simple, less time-consuming and less technique- 
sensitive than the original cryosectioned haematoxylin-eosin (HE) stained cross- 
sectional studies previously used to characterise the kinetics of re-epithelialisation 
(Jansson et al., 1996). This model represents more closely the intricate process of 
skin healing than mono-layer cultures, although it does not contain all the elements 
of the functional immune response. The use of mounted skin equivalent systems 
would avoid the contraction associated with the healing in this model, a current 
major limitation. Both DMEM- and broth- produced MRSA supernatants reduced 
epithelial migration compared with the matched control, indicating that bacterial 
products/metabolites impaired healing.
In contrast to the immunological assays, the monolayer “scratch wound” 
assay was a simple model in that it measured only one component of wound healing 
i.e. cellular repopulation. Therefore, it could be used to directly study the effect of 
bacterial supernatants on cellular migration. Moreover, the epithelial responses in 
this model are known to be modulated via the action of cytokines and the expression 
of TLRs on the keratinocytes themselves. Stephens et al., (2003) demonstrated how 
anaerobic bacterial supernatants inhibited wound closure by both fibroblasts and 
keratinocytes using the “scratch wound” assay. Two parameters were studied using 
this model; rate of cellular migration (i.e. speed of wound closure), and percentage 
healing (i.e. % wound space closed). These were used to compare supernatants 
derived from nasal MRSA isolates with chronic wound MRSA isolates, and also the 
effect of bacterial growth conditions. In these experiments, nasal and wound isolate 
variances were evident in the initial 6 h following wounding. Interestingly, the 
speed of wound closure for wounds treated with nasal MRSA supernatants was 
similar to that of the control. The accelerated scratch wound closure with S. aureus 
noted here has previously been observed (Shaykhiev et al., 2008) the author found 
that PGN significantly increased wound repair. In these experiments, MRSA
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supernatants of different colonisation origins appeared to have little effect on the 
migration of keratinocytes following prolonged exposure.
Comparison of wound healing associated with specific growth conditions 
(biofilm and planktonic) for the 2 common chronic wound pathogens P. aeruginosa 
and S. aureus was also performed. Planktonic supernatants inhibited wound closure 
more than the biofilm supernatants. As with the immunological studies, this may be 
associated with the protein content of the supernatants, (i.e. the trapping of bacterial 
products or due to decreased formation and cellular turnover in the biofilm 
environment). Moreover, in this study the P. aeruginosa biofilm speed of wound 
closure was quicker than the control. Shaykhiev et al., (2008) found that microbial 
factors inducing wound closure, cellular migration and proliferation, induced IL-ip, 
TNFa, IL-6 and IL-8 in epithelial cells, and may potentially be the cause of this 
increased speed of closure in the bacterial-stimulated wounds.
There are a number of limitations to this assay, a major one being its 
oversimplified nature. Human epidermal keratinocytes in this system are able to 
secrete cytokines and chemokines such as IL-8, IL-6, TNFa and IL-ip following 
exposure to Gram-positive and Gram-negative bacteria via the expression of TLR2 
and TLR4 (Froy, 2005, Shirakata, 2010). The production and accumulation of such 
products in this in vitro model may have affected cellular migration. It has also been 
postulated that bacterial ligands can induce the production of MMP in the wound 
environment, which would have a profound effect on cell migration and wound 
healing (Stephens et al., 2003). The method used in this study was unable to 
replicate the many products produced in vivo by cellular populations, nor the 
dynamic physiology of the wound environment (Fong et al., 2010). Also the use of 
HaCaT cells used for the scratch wound assay does not reflect the phenotype of the 
wound keratinocyte, which may behave differently to bacterial supernatants under 
similar conditions.
Biofilms in the chronic wound environment are associated with delayed 
healing (Kirketerp-Moller et al., 2008, Percival et al., 2008, Kirker et al., 2009,
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Schierle et al., 2009). These scratch wound data do not wholly support this theory. 
It is clear that the biofilm supernatants contained a lot less protein than the other 
supernatants, suggesting that some of the bacterial biomass and biofilm-related 
products may have been trapped in the biofilm matrix itself, rather than being 
released into the supernatant. This may certainly be the case for P. aeruginosa 
biofilm treated scratch wounds, whereby LPS is trapped in the biofilm matrix. This 
theory is supported by Loryman and Mansbridge (2008) who found that keratinocyte 
migration inhibition was LPS dose dependent. Biofilms represent highly structured 
communities with co-ordinated metabolic activities which are known to differ 
considerably in their gene expression from matched planktonically grown cells. In 
all, this indicates that the chronic wound environment and the role of bacteria is a 
highly complex relationship. The effect of the structure (architecture) of a biofilm 
on cellular migration is also not evident from these experiments. Kirker et al.,
(2009) demonstrated a significant reduction in cell migration with both biofilm and 
planktonic S. aureus conditioned media The migration of cells in co-culture with S. 
aureus biofilms showed initial increases in wound size. Such differences between 
this study and Kirker’s could be a result of the bacterial cell number, i.e. Kirker used 
3 logio greater bacterial cell numbers than in this present study.
These studies have demonstrated that bacteria are able to adapt to their 
environment to facilitate survival and colonisation, and is reflected in the in vivo 
non-infected wound. Adaptation is likely to occur via alteration in excreted products 
and surface factors (PAMP). The development of a biofilm is a clear way in which 
these bacteria are able to evade the host, thus making them more recalcitrant to 
eradication, not only by host immune system, but also antibiotics and other 
antimicrobials. This delayed response, or lack of a significant response, by the 
immune system to the bacteria and biofilms may result in continued exposure to 
bacterial stimuli which results in maximal host activation (Hume et al., 2001). This 
increased or prolonged exposure to pro-inflammatory cytokines and MMPs results in 
tissue destruction via host mediation, providing further nutrients for the bacteria
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present (Zhang and Schluesener, 2006, Martin et al., 2009). The origin of MRSA 
appeared to have little effect on cellular migration. However, the specific bacterial 
growth conditions i.e. biofilm or planktonic, proved to be important.
This study employed a series of in vitro experiments to understand immune 
modulation by bacteria from different colonising environments and growth 
conditions. Further investigation is warranted to understand the intricacies of 
colonisation during wound healing, and the role of MRSA. Initial 
immunostimulatory experiments using the same ST MRSA isolated from wound and 
nasal cavities of chronic wound patients and nares of asymptomatic patients needs to 
be investigated to understand the significance of MRSA ST. This will further 
determine if the immunomodulatory responses are localised to the disease/wound or 
associated only with specific bacteria. Further investigation to determine if the 
bacteria are able to induce immunosuppressive cytokines e.g. IL-10, which decreases 
TNFa (Homef et al., 2002) would also be pertinent. Attempts to address this on 
other models have employed array technologies such as gene expression, and more 
recently, cytokine arrays systems (using wound fluid samples; Pukstad et al., 2010).
There were a number of limitations in this study; firstly (as in many previous 
studies) the immune response was studied in isolation, whereas systemic disease, co­
morbidity and tissue perfusion would modulate immune function in vivo. The use of 
immunocompetent cells also makes direct comparison to the wound environment 
difficult. Secondly, cells were used in isolation, unlike the dynamic wound 
environment.
Importantly, bacterial biofilms for which many authors have tried to establish 
a working biofilm model resembling the wound colonisation and evolution of 
species (Hill et al., 2010) need to be employed to study the immune response in these 
assays, e.g the use of a constant depth film fermenter or microtiter plate assays to 
produce a biofilm and its conditioned media. A limitation of the growth condition 
experiments was that biofilms were produced as mono-species. Chronic wounds are 
often polymicrobial and recent evidence indicates that wound bioflms show
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aggregates of single species in a polymicrobial environment (Burmolle et al., 2010). 
Therefore, testing of wound related biofilms produced in a polymicrobial 
environment and mixed-species biofilms (i.e. S. aureus and P. aeruginosa) may be 
of considerably more relevance. The age of the biofilm may also be of importance. 
Kirker et aL, (2009) studied keratinocyte migration inhibition using >72 h biofilms 
in co-culture finding that cell migration was significantly impaired. Further studies 
of the biofilm physical structure and its impact on cellular migration and 
proliferation would be interesting. Finally, structural and cellular component 
examination of P. aeruginosa and S. aureus to determine potential alterations in 
ligands, which lead to reduced immune stimulation, would be pertinent.
Whilst there are a number of limitations to these experiments in their direct 
relationship to the chronic wound environment, the data generated highlights 
potential mechanisms bacteria use to effectively evade the host immune response.
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Chapter 5: 
General Discussion
5.1 General discussion
This study has attempted to further understanding of the relationship between 
bacteria found within chronic non-healing skin wounds and the observed failure of 
the normal dermal repair processes. These studies focussed on Staphylococcus 
aureus and meticillin resistant Staphylococcus aureus (MRSA) utilising a sample 
population of patients (with differing wound aetiologies) from a previous 
antimicrobial audit undertaken in the Wound Healing Research Unit at this hospital 
(Howell-Jones, 2007). Whilst S. aureus, including MRSA, was frequently isolated 
in this population (75 of 150 patients) the rate of MRSA in this patient cohort was 
lower than in previous studies or reported in contemporaneous MRSA UK 
surveillance rates (ECDC, 2005 - 2011). This study however, showed that these 
chronic wound patients harboured multi-drug resistant (MDR) organisms which pose 
a significant health and cross-infection problem (Chapter 2). Utilising conventional 
cultural techniques to isolate organisms from this population of chronic non-healing 
skin wounds was valid, although to further understand the complexity of the 
relationship of bacterial communities and non-healing phenotypes, molecular 
methods should be employed. The use of high-throughput sequencing techniques
e.g. pyrosequencing (Dowd et al., 2008, Wolcott et al., 2010) would aid the 
identification of bacterial species present, particularly of the uncultivable population, 
much like the human and oral microbiome project (Grice, 2008, Dewhirst et al., 
2010). A greater understanding of the microbiome of chronic diseases such as 
chronic skin wounds, may inform the development of novel therapeutic strategies, 
but the adoption of such techniques was beyond the scope of this project.
Current clinical practice of the Wound healing research unit (WHRU) does 
not routinely screen for MRSA in the general population attending these clinics. At 
present only 1 microbiological sample per 20 patients is undertaken, for wounds 
unresponsive to empirical treatment. Following personal communication with Dr M. 
Heginbothom, of the antimicrobial surveillance unit for Wales, regarding current 
levels of MRSA in patients attending the WHRU; identified 40% (7 MRSA
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idenitifed in 17 Staphylococcus aureus isolates) of the Staphylococcus aureus 
isolates from the WHRU were classified as MRSA during 2010. Whilst it is difficult 
to compare these numbers with data from the patient cohort in this study due to the 
likely bias of sample, it is a clear indication that further investigation and 
surveillance of chronic wound patients who harbour MDR organisms is required.
Many of the wounds harboured coagulase negative staphylococci (CNS), 
which have become an important human pathogen; biofilms being of particular 
relevance where this species is concerned (Watts et al., 1990, Piette and 
Verschraegen, 2009). Again the direct role of CNS in the chronic wound 
environment has not been elucidated. Whilst it may be relatively innocuous, it is far 
more likely to be involved in some synergistic role with other pathogens e.g. in 
biofilm formation and transfer of antibiotic resistance (Hanssen and Ericson Sollid, 
2006, Hellmark et al., 2010).
In the attempt to type MRSA, sequence-based typing methods were more 
conclusive than the other methods used (Chapter 3). Interestingly, in this study the 
majority of wound MRSA were classified as sequence type (ST) 22, also known as 
EMRSA-15, frequently associated with hospital-acquired (HA) MRSA. In contrast 
to this, nasal MRSA STs were more diverse, a pattern typical of community-acquired 
(CA) MRSA. Whilst it is impossible from this study to determine the route by 
which these bacteria were acquired, it is remarkable that 88.2% of MRSA were 
associated with ST 22; possibly reflecting the wound environment that these bacteria 
inhabit. Such a study would require longitudinal data to identify bacterial succession 
within the wounds. However, such a study would be fraught with difficulty 
notwithstanding patients’ age and underlying co-morbidity in this elderly population, 
who are at increased risk of antibiotic treatment and resistance development 
(Howell-Jones et al., 2006).
MRSA are known to express a range of virulence factors to aid survival and 
these may induce host damage and potentiate disease (Van der Mee-Marquet et al., 
2004, Argudin et al., 2009). This is the first study in the known literature to compare
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in detail MRSA virulence factor expression in chronic wound and asymptomatic 
nasal earner patients (Chapter 3). The presence of enterotoxin genes appeared to be 
more specific to ST than wound type/origin. This has been previously documented 
in other disease processes, and is likely because enterotoxin genes are frequently 
associated with the presence of pathogenicity islands (Bohach, 2006, Varshney et al., 
2009). However, variation in wound and nasal carrier MRSA isolates was observed 
for expression of several chosen virulence factors specifically cna and hysA which 
are associated with colonisation and tissue destruction. Interestingly, hyaluronate 
lyase (HysA) may degrade hyaluronic acid (HA) to generate low molecular weight 
HA oligomers. These may potentially induce the innate immune system via TLR4 
recognition (Termeer et al., 2002, Taylor et al., 2004) and possibly linked to chronic 
stimulation of the immune process leading to further tissue damage. A major 
limitation of this study could be perceived to be the small sample size and a lack of 
similar sequence types between the 2 diverse groups of patients to draw clear 
comparisons.
Variation in virulence expression was observed when comparing wound 
aetiology i.e. leg wound vs. surgical wound. Again the differences seen were 
associated with colonisation (cna), tissue degradation (hysA), and host evasion (hlg, 
PVL) with all these virulence factors more highly expressed in surgical than leg 
wounds. One can hypothesize that this is potentially associated with the underlying 
aetiology of the wound; based upon decreased vascular perfusion associated with 
VLUs, resulting in reduced immune infiltrate, therefore leading to less pressure on 
the colonising bacteria to survive. It must be remembered however, that the original 
study population was 157 patients. This population allowed us to make fascinating 
comparisons between the nasal, chronic leg and surgical wound groups. Future 
investigations would require an expanded virulence factor repertoire and intra­
patient control samples (e.g. wound vs. normal skin vs. nose) to identify firstly 
whether MRSA were colonising the entire host or just present in the wound, and 
secondly whether expression of virulence factors is altered according to their
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environment. Much larger patient studies are required and should include acute 
wounds (healing and infected) and nasal carriers with ideally similar ST 
distributions. In this aim, the latter would, in particular, be difficult to achieve, 
particularly as the diversity of STs in nasal carriers is so broad. Gene array studies 
(Saunders et al., 2004) and quantitative RT-PCR would be methods of choice due to 
their high levels of discrimination. Ideally testing should be performed immediately 
on isolates to mimic in situ expression, and virulence factor expression should be 
studied in relation to the biofilm growth state. In an attempt to obtain insight into 
bacterial physiology within the respective environments, metabolomic studies of the 
isolates may also potentially be employed (Yang et al., 2011).
Whilst the immune system plays a pivotal role in the delayed healing of 
chronic wounds, surprisingly little research has been conducted on the role of 
immune regulation by chronic wound bacteria. These are the first studies in the 
known literature comparing the immune modulation potential of MRSA isolated 
from chronic wounds with asymptomatic carriers (Chapter 4). These studies clearly 
indicated that bacteria isolated from nasal carriers were more immunogenic than 
those from either chronic leg or surgical wounds. This may reflect alterations in 
pathogen associated molecular patterns (PAMP) or potentially ST. Within the 
wounds, this altered immune modulation in vivo could theoretically be associated 
with a reduced bacterial clearance, leading to prolonged tissue damage mediated by 
the host and bacteria.
An important point to remember with these studies however, is the variation 
in ST of the MRSA utilised. To conclusively determine that the variations seen with 
these bacteria are significant, it would be necessary to employ a much larger group 
of nasal carriers (preferentially with similar STs, which would be difficult to obtain; 
vide supra). Nevertheless, these data, give valuable insight into the potential 
importance of immunogenicity and immunological recognition in determining 
outcome following MRSA colonisation of body surfaces. Comparative studies in
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these symptomatic and asymptomatic hosts suggest how this pathogen may 
potentially evade the host immune response.
As previously suggested, biofilm formation is a method of immune evasion 
(Percival et al., 2011a). These studies used two common wound organisms (S. 
aureus and P. aeruginosa) revealed that planktonic-derived supernatants were more 
immunogenic than biofilm-derived supernatants in these in vitro assay systems. This 
may be associated with the biofilm structure itself acting as a diffusion barrier to 
secreted products, or reducing the passage of immunogenic molecules through the 
extracellular polymeric substance (EPS) of the biofilm. The data observed for 
planktonic vs. biofilm conditions demonstrate another potential mechanism by which 
bacteria within biofilms may evade host defenses.
The scratch wound assay employed in these studies failed to elicit an 
association between MRSA origin and healing over the 24 hour period of this assay. 
However, the initial delayed healing response to chronic wound MRSA supernatants 
may indicate a relationship between early MRSA wound colonisation and delayed 
healing in medically compromised patients. The data observed for planktonic vs. 
biofilm conditions demonstrated delayed healing, particularily for planktonic P. 
aeruginosa. These data give insight into the importance of bacterial growth 
conditions in the wound environment and indicate that biofilm trapping of bacterial 
metabolites may lead to localised effects.
A significant limitation of such studies is the use of immunocompetent cells 
employed for these assay systems, in contrast to the often immunocompromised 
effector cells of elderly patients and diseased sites. Whilst further studies with 
isolated immune cells from chronic wound patients would be attractive, caution must 
be applied to the artificial environment that the laboratory process introduces in their 
isolation.
The treatment of non-infected chronic wounds poses many quandaries. 
Biocide use is more routinely used for the control of bacterial bio-burdens (Fonder et 
al., 2008, Atiyeh et al., 2009, Lipsky and Hoey, 2009, O'Meara et al., 2010).
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Furthermore, there are still limitations on the translation of biocide laboratory testing 
to the bedside (Thomas and McCubbin, 2003, Fong et al., 2005, Maillard and 
Denyer, 2006, Cooper, 2007, Verran, 2010b). The biocide testing method employed 
in these studies utilised bacterial arangements more representative of those found in 
the wound when compared to the traditional suspension tests, i.e. bacteria were in 
multiple layers and on a surface. This study implicitly observed that iodine was the 
most effective biocide to reduce MRSA CFU/ml (Chapter 2) and is supported by 
other studies in biofilm environments (Hill et al., 2010). Whilst iodine is an “old” 
and cheap remedy, it unfortunately receives little attention (BNF, 2010). In contrast 
to this, silver has gained considerable popularity for the treatment of wounds and is 
relatively expensive (BNF, 2010) its prominence in the literature being related to 
marketing and reports of decreased matrix metalloproteinase (MMP) activity 
properties (Lansdown et al., 1997, Chopra, 2007). There is however, little clinical 
evidence of its benefit or in vivo activity (Vermeulen et al., 2007).
Silver ions are taken up by bacteria by either non-specific mechanisms using 
cell membrane transporters, or by controlled substrate-specific transporters. The 
silver ions then interact with thiol groups affecting cellular respiration and binding to 
nucleic acids; possibly affecting bacterial DNA transcription (Maillard and Denyer, 
2006). However, these studies like others indicated the limited biocidal ability of 
silver, which may be associated with resistance determinants such as silE (Loh et al.,
2009) or lack of uptake by the bacterial cell itself. For silver to exert its effect on a 
cell, it must first be able to diffuse across the cell membrane. Chapter 3 showed that 
MRSA isolates expressed icaA a gene associated with biofilm formation, which 
could affect the cellular uptake and activity of silver. Previous studies have observed 
poor silver activity in the presence of bacterial biofilms (Percival et al., 2007, Hill et 
al., 2010). The type of silver compound used in these studies (namely AgNOs) may 
explain its limited biocidal effect based on a decreased ability to release silver ions.
A study of the more commercial nanocrystalline silver and other silver 
compounds would in retrospect have been useful as it is the clinical treatment
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received by most of the study patients. It is believed that the nanocrystals produce a 
large surface area, enabling a continuous release of silver ions (Strohal et al., 2005) 
from non-ionic silver. Thus, it is believed to be less affected by organic matter and 
chloride ions and is able to interact more intimately with bacterial membranes 
(Ruparelia et al., 2008).
Future studies employing the carrier method using an ex vivo model such as 
porcine skin may be more relevant to human wounds. This could then be followed 
by a wound model with bacteria grown in a biofilm environment and exposed to the 
biocide for varying contact times employing image analyses e.g. confocal laser 
scanning microscopy (CLSM) and live-dead staining. This study adopted 
conventional techniques i.e. monoculture. The testing of multi-species bacterial 
communities may afford greater insight and be more relevant to the in vivo wound 
environment (Hill et al., 2010, Percival et al., 2011a, Percival et al., 2011b). 
Furthermore, clinical testing of biocides could be performed in vivo, with wound 
swabs sampled prior to and after application of the biocide, and with growth effects 
determined from bacterial growth counts, and live-dead staining of swab or biopsy 
samples. In addition, used dressings (e.g. iodine and silver-containing) incorporating 
biocides could themselves be studied directly to observe bactericidal effects using 
cultural and image analysis. In this study, no correlation with ST or previous biocide 
use was observed. However, the limited patient data and small numbers of STs 
available to test these theories indicate that further research in this field is warranted.
5.2 Conclusions
This study has provided an insight into the roles of bacteria that in their 
attempts to colonise, invade and survive in the human wound site, may modulate 
wound healing processes. These studies have characterised MRSA and have shown 
that in addition to the potential problem of antibiotic resistance, this organism 
possesses the ability to modulate the activity of the extracellular matrix, immune 
cells and resident cells such as keratinocytes. Whilst these bacteria are unlikely to be
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the sole cause of a chronic wound failing to heal and are likely to be present as 
“colonisers”, in these actions they may effectively provide an environment in which 
other genera may proliferate and survive. The ability of these organisms to 
potentiate disease is modulated by their growth conditions, with the biofilm state 
potentially modifying a number of these responses. Whilst the implementation of 
silver-containing products to treat chronic skin wounds is rising inexorably (Chopra, 
2007, Beam, 2009) the study has clearly shown that iodine, an often-overlooked 
biocide, may have considerable future utility in the treatment of these wounds and 
MRSA.
5.3 Future studies
Future studies to understand the epidemiology of MRSA in chronic wounds 
might include prospective longitudinal studies of patients at risk of chronic wounds, 
with intra-patient controls (nares, skin and wounds) using high-throughput 
sequencing and metagenomic methods. Such a study would facilitate our 
understanding of virulence factor expression, and could be linked to array-based 
studies to compare virulence factor expression in patient and wound-matched MRSA 
with qRT-PCR. Increased understanding of the role of the innate immune system in 
chronic wound healing is essential. The data obtained indirectly by Pukstad et al.,
(2010) and in this thesis (in vitro) should be substantiated by prospective 
examination of immune responses using cytokine array, immunocytochemistry 
and/or imaging techniques. Further investigation of MRSA activity and biocide 
treatment may usefully examine the acquisition of biocide tolerance, in particular its 
association with MRSA ST and previous exposure, which would require a 
prospective study.
Appendix I 
Ethics
19 December 2007
Rebecca Howell-Jones 
Department of Oral Surgery 
Dental School 
Cardiff University
Dear Rebecca
Thank you for your recent enquiry seeking clarification of matters relating to the 
audit that you undertook with us in the Directorate of Wound Healing as part of your 
PhD work.
I am writing to confirm that work was in-part generated by myself asking the 
question “Do we prescribe excessive amounts of antibiotics which would increase 
the risk of patients attending my clinics developing resistant organisms and how 
much impact does general practitioner prescribing have on the pattern of bacteria 
present and bacterial resistance in patients who attend my clinics?”.
I can confirm that the ideas were discussed and the final plan was agreed in a 
departmental audit meeting in Spring 2005 and the results of the study were 
presented to us in autumn 2005.
The access to records that are held by my clinic was not an issue as this was an 
agreed departmental audit. The obtaining of information regarding the same patients 
from their general practitioner to determine whether additional courses of antibiotics 
had been prescribed for those patients were, in my opinion, an extension and a 
legitimate question to ensure validity of the audit findings. While it would have 
been possible to have requested this information from the patient’s GP as part of 
their routine care I made the decision as Clinical Director to ask patients for consent 
to ensure there was clarity of purpose in requesting this information.
We did complete the audit cycle as a result of the information generated by the 
project and I have reduced further my prescription of oral antibiotics for patients 
seen in my clinics.
I trust this clarifies the position. If you or anyone else wishes to discuss this matter 
with me further I would be delighted to do so.
Yours sincerely
Keith Harding
Clinical Director of Wound Healing Cardiff & Vale NHS Trust 
Head, Department of Wound Healing 
Professor of Rehabilitation (Wound Healing)
Private and Confidential
[Headed paper] 
Date 2005
Dear,
Subject: Antibiotic resistance audit in patients with wounds
We are currently undertaking an audit, of the patients we treat at our wound healing 
clinics in Cardiff, with which we would be very grateful for your support.
As part of the audit, we are investigating our prescription of antibiotics and the levels 
of antibiotic resistant organisms in patients’ wounds. We are also interested in 
looking at those factors which predispose patients to having such organisms when 
they attend at our clinics.
To be able to place our prescribing for wound infection in the context of antibiotics 
that patients may have received for other conditions, we require information about 
patients’ previous exposure to commonly known risk factors. Therefore, we would 
be most grateful if you would assist us with our enquiry by completing the attached 
single-sided form for the following patient(s):
Name; Date of birth; Patient's postcode
We understand that it takes time to find this information and to complete the forms 
and, we are able to provide payment of £3 per patient, on return of the information.
Thank you in advance for your co-operation with this interesting and relevant 
investigation. If you have any queries, feel free to contact Rebecca Howell-Jones on
Yours sincerely
Prof. Keith G. Harding
Clinical Director of Wound Healing
Head of University Department of Surgery
Professor of Rehabilitation Medicine (Wound Healing)
(029) 2074 4252.
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Fra: Regional komite for tnedislnsk og helsefaglig forskningsetikk REK midi 
Til;
Asbjam Magne Nilsen 
asbjom.nllsen@ntnu.no
Dokumentreferanse: 2009/2245-2 
Dokumentdato: 05.01.2010
HUMANT BLOD OG CELLER FRA BLOD TIL BASALFORSKNING OG SERUM TIL CELLEDYRKING. INFORMASJON OM 
VEDTAK
Med hjcmmet I lov om bchandling av etikk og redelighet i forskning § 4 og helseforskningstoven § 10 har Regional koinitd for medisinsk og 
helsefaglig forskningsetikk, Midt-Norge vurdert prosjektet i silt mote 4. desember 2009 ined felgende vilkAr og vurdering;
Vedlak:
"Koraiteen godkjcnner oppretting av generell forskningsbiobank: Humant blod og oeller fra blod til basalforskning og serum til 
cclledyrking. Ansvarshavende person et forsteamanuensis Asbjem Magne Nilsen og forskningsansvarlig er NTNU, Del medisinske 
fakultet."
20.01.2010 09:12
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G
Saksbehandler 
Seniorkonsulent Jacob Helen 
Telefon 73 86 72 72 
Epost: jacob.chr.holen@ntnu.no 
rek-4@medisin.ntnu.no 
Postadresse: Det medisinske fakultet 
Medisinsk teknisk forskningssenter 
7489 Trondheim 
Besoksadr: ISM, Rode Kors 3 etg.
St.01avs Hospital
Virdato: V irref.: Deresdato: Deresref.:
11.02.2008 4.2008.217
Bruk av human overskuddshud i studier av alginateffekter p& s&rtilheling.
Med hjemmel i lov om behandling av etikk og redelighet i forskning § 4 har Regional komite for 
medisinsk og helsefaglig forskningsetikk, Midt-Norge vurdert prosjektet i sitt mote 25. januar 2008 
med felgende vilk&r og vurdering:
Hensikten med studien er ved 4 undersoke om overskuddshud fra bryst- og 
magereduserende kirurgi kan brukes i en in vitro (”i glass”) hudmodell for 4 under,soke 
hvordan ulike alginater p&virker s4rhelingsprosessen. En slik modell med hel human hud 
vil vaere et viktig supplement til andre metoder som blir brukt i prosjektet. I tillegg 
onsker vi 4 isolere og bruke hudceller (keratinocytter) fra overskuddshuden, for 4 
sammenlikne disse med keratinocytter som kjopes kommersielt. Hypotesen er at 
alginater har gunstige effekter p i tilheling av sir i en hudmodell ved 4 aktivere celler og 
beskytte celler mot bakterielle toksiner.
Hudbiopsier med sm4 sir vil lages fra overskuddshud fra frivillige donorer. Huden 
dyrkes i laboratoriet in vitro. Effekten av ulike alginater p4 s4rheling vil undersokes ved 
ulike betingelser. En vil undersoke om alginater bedrer tilhelingen av s4r ved naervaer og 
fraveer av bakterier og bakterielle komponenter. Relevante bakterier for kroniske s4r vil 
brukes. Stimulering av hudceller og induksjon av bioaktive komponenter som er viktige 
for s&rtilheling (eks. vekstfaktorer, cytokiner, og hyaluronsyre) i hud og hudceller 
(keratinocytter) isolert fra hud vil ogs4 unders0kes. Forsokene vil p4g4 s4 snart som 
mulig og vil vare ut FUGE-prosjektets varighet (ut 2009). Hud fra frivillige donorer som 
gjennomg&r bryst- eller magereduserende inngrep vil brukes. Foresporsel om egnede 
pasienter vil gjores ved kontakt med plastiske kiruger/klinikker i Trondheim. Det vil 
brukes hud fra friske personer av begge kjonn i alder 18-60 4r. Hud fra 4-5 personer vil 
brukes for 4 teste og standardisere forsoksbetingelsene. Det vil undersokes s4r i 
minimum triplette for hver parameter, og det vil vaere nodvendig med minst tre replikate 
fors0k (donorer) for 4 bekrefte de funn man kommer fram til. Da flere alginater i 
kombinasjon med ulike bakterier/bakteriekomponenter skal brukes under ulike 
konsentrasjoner, kan et anslag p4 25 personer vaere nodvendig. Dette ansees ogs4 som 
realistisk 4 gjennomfore sett i forhold til prosjektets varighet.
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Appendix II: 
Control isolates
Table ILi Control isolates used
Isolate name Other name Isolate type Control Chapter Reference/AccessionNo. Acknowledgement
NCTC 6571 Oxford Staphylococcus mecA negative 2
Staphylococcus aureus
PVL Oaureus J
NCTC 12493 MRSA mecA 2
NCTC 11047/ Meticillin Staphylococcus mecA 2
ATCC14990 resistant CNS epidermidis TcR Tetracycline
resistance
ATCC 6538/ Staphylococcus Biocide testing 2 BSEN 13697:2001
NCIMB 9518 aureus
ITU 1 Clinical ITU 
strain
MRSA MRSA typing 3 Dr R. Howe, 
SACU
ITU2 Clinical ITU MRSA MRSA typing 3 Dr R. Howe,
strain Biocide testing 2 SACU
ITU 3 Clinical ITU 
strain
MRSA MRSA typing 3 Dr R. Howe, 
SACU
ITU 4 Clinical ITU 
strain
MRSA MRSA typing 3 Dr R. Howe, 
SACU
EMRSA 15 MRSA MRSA PFGE 3 Dr R. Howe, 
SACU
ATCC, American type culture collection; CNS, coagulase negative staphylococci; EMRSA, epidemic MRSA; ITU, Intensive therapy unit; 
MRSA; meticillin resistant Staphylococcus aureus; NCTC, National collection of type cultures; PVL, Panton-Valentine leucocidin; PFGE, 
Pulsed field gel electrophoresis; SACU, Specialist Antimicrobial Chemotherapy Unit; TcR, tetracycline resistant.
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Isolate name Other name Isolate type Control Chapter Reference/Accession
No.
Acknowledgement
EMRSA 16 MRSA MRSA PFGE 3 Dr R. Howe, SACU
NCTC 13142 EMRSA-15 MRSA agrl 
J type h 
SCCmec IV
3 (Gomes et al., 2005)
NCTC13130 EMRSA-3 MRSA agrll
PFGE
3 (Howe et al., 2004)
NCTC 13143 EMRSA-16 MRSA agrlll
PFGE
3 (Gomes et al., 2005)
RN4850 MRSA agrYV
etA/etB
3 (Jarraud et al., 2000, 
Holmes et al., 2005, 
Rossney et al., 2007)
Professor R. 
Novick, New 
York School of 
Medicine, USA
E0898 MRSA Class A mec 
ccrl/ccrC 
SCC mec III
3 (Shore et al., 2008) Dr A. Shore, 
EARS-Net, TCD
agr, accessory gene regulator; ccr, cassette chromosome recombinase; EARS-Net, European Antimicrobial Resistance Surveillance Network; 
EMRSA, epidemic MRSA; J type, joining region of SCCmec; mec, meticillin resistant determinant; MRSA; meticillin resistant 
Staphylococcus aureus; NCTC, National collection of type cultures; PFGE, Pulsed field gel electrophoresis; SCC mec, staphylococcal cassette 
chromosome mec; TCD, Trinity College, Dublin; USA, United States of America.
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Isolate name Other name Isolate type Control Chapter Reference/Accession
No.
Acknowledgement
M00.005.2 MRSA Class B mec 3 (Shore et al., 2008) Dr A. Shore, TCD
ccr4 National ReferenceLaboratory, St
SCC mec VI James Hospital, 
Ireland
CA05 MRSA Class B mec 
ccr2
3 (Ma et al., 2002, 
Milheirico et al., 
2007, Chen et al., 
2009
WIS MRSA Class C mec 
ccrC 
SCCmec V
3 (Ito et al., 2004, Chen 
et al., 2009)
Professor T. Ito, 
Juntendo 
University, Japan
PHI 143.2 MRSA ccrl 3 (Shore et al., 2005) Dr A. Shore, TCD
FRI913 Staphylococcus
aureus
sea/sec/see/tst 3 (Monday and 
Bohach, 1999, Smyth 
et al., 2005)
Professor C. 
Smyth, TCD
NCTC 10652 Staphylococcus
aureus
sea/sej
agrl
3 (Holmes et al., 2005) Professor A. 
Kearns, HPA
agr, accessory gene regulator; ccr, cassette chromosome recombinase; HP A, Health protection agency MRSA; meticillin resistant 
Staphylococcus aureus; NCTC, National collection of type cultures; SCC mec, staphylococcal cassette chromosome mec; se, staphylococcal 
enterotoxin; mec, meticillin resistant determinant; TCD, Trinity College, Dublin.
Isolate name Other name Isolate type Control Chapter Reference/AccessionNo. Acknowledgement
NY19 Staphylococcus
aureus
seb 3 (Smyth et al., 2005, 
Rossney et al., 2007)
Professor C. 
Smyth, TCD
NCTC 10654 Staphylococcus
aureus
seb 3 (Holmes et al., 2005) Professor A. 
Kearns, HPA
NCTC 10655 Staphylococcus
aureus
sec 3 (Holmes et al., 2005) Professor A. 
Kearns, HPA
NCTC 10656 Staphylococcus
aureus
sed
agrll
3 (Holmes et al., 2005) Professor A. 
Kearns, HPA
FRI472 Staphylococcus
aureus
sed/sei/seg/sej 3 (Monday and 
Bohach, 1999, Smyth 
et al., 2005)
Professor C. 
Smyth, TCD
ATCC 27644 Thermobifida
alba
see 3 (Holmes et al., 2005) Professor A. 
Kearns, HPA
FRI572 Staphylococcus
aureus
seg/sei 3 (Monday and 
Bohach, 1999)
Professor A. 
Kearns, HPA
ATCC 51811 Staphylococcus
aureus
seh 3 Professor A. 
Kearns, HPA
FRI569 Staphylococcus
aureus
seh 3 (Monday and 
Bohach, 1999, Smyth 
et al., 2005)
Professor C. 
Smyth, TCD
agr, accessory gene regulator; ATCC, American type culture collection; HP A, Health protection agency; MRSA; NCTC, National collection 
of type cultures; se, staphylococcal enterotoxin; TCD, Trinity College, Dublin.
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Isolate name Other name Isolate type Control Chapter Reference/AccessionNo. Acknowledgement
TY114 Staphylococcus
aureus
etD
agrlll
3 (Yamaguchi et al., 
2002, Holmes et al., 
2005, Rossney et al., 
2007)
Professor M. 
Sugai, Hiroshima 
University, Japan.
NCTC 11963 
NCTC 8178 Newman
Staphylococcus
aureus
MRSA
tst 
agrlll 
PVL /cna negative
hysA/geh/hlgA/hlgB/hlgC/icaA/etA
positive
agrlll
3
3
(Holmes et al., 2005)
(Linaetal., 1999) 
NC_009641
Professor A. 
Kearns, HPA
Mu50 LLA hVISA PVL Icna negative
hysA/geh/hlgA/hlgB/hlgC/icaA/etA
positive
agrll
3 (Kuroda et al., 2001) 
NC_002758
Dr M. Wootton, 
SACU
agr, accessory gene regulator; cna, collagen binding gene; et, exfoliative toxin; geh, glycerol ester hydrolase; hlg, gamma-haemolysin; hysA, 
hyaluronate lyase gene; icaA, intercellular adhesin gene; HPA, Health protection agency; MRSA; meticillin resistant Staphylococcus aureus; 
NCTC, National collection of type cultures; PVL, Panton-Valentine leucocidin; SACU, Specialist Antimicrobial Chemotherapy Unit; tst, 
toxic shock toxin gene; VISA, vancomycin intermediate Staphylococcus aureus.
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Isolate name Othername Isolate type Control Chapter
Reference/Accession
No. Acknowledgement
MRSA 252 MRSA PVL negative
geh/cna/hysA precursor 
ZhlgA/hlgB/hlgC/icaA positive
agrl
3 (Holden et al., 2004) 
NC_002952
Professor T. Foster, 
Dublin
HT2000 132 MRSA PVL 3 (Rossney et al., 2007) Jerome Etienne 
Staphylococcal
agrlll reference lab, Lyon
France
NCTC 13300 Staphylococcus
aureus
PVL Professor A. 
Kearns, HPA
NCTC 8325 Staphylococcus
aureus
cna/hysA/geh/hlgA/hlgB/hlgC/icaA
negative
agrl
3 (Jarraud et al., 2000, 
Rossney et al., 2007) 
NC_007795
PJ141 Staphylococcus
aureus
icaA 3 (Malic, 2008) Dr S. Malic, CU
PJ156 Staphylococcus
aureus
icaA 3 (Malic, 2008) Dr S. Malic, CU
agr, accessory gene regulator; cna, collagen binding gene; CU, Cardiff University geh, glycerol ester hydrolase; hlg, gamma-haemolysin; 
hysA, hyaluronate lyase gene; icaA, intercellular adhesin gene; MRSA; meticillin resistant Staphylococcus aureus; NCTC, National collection 
of type cultures; PVL, Panton-Valentine leucocidin.
Isolate name Other name Isolate type Control Chapter Reference/Accession Acknowledgement
No.
FC2 CVLU Staphylococcus
aureus
Clinical MSSA 
immunostimulation 
(Planktonic/Biofilm)
4 (Davies et al., 2004) Dr K.E. Hill, CU
NCTC 10662 Pseudomonas
aeruginosa
Clinical strain P. 
aeruginosa 
immunostimulation 
(Planktonic/Biofilm)
4
ATCC 19142 Mucoid
Pseudomonas
aeruginosa
Mucoid strain P. 
aeruginosa 
immunostimulation
4 (Linker and Jones, 
1964)
ATCC 39324 Mucoid
Pseudomonas
aeruginosa
Mucoid P. 
aeruginosa 
immunostimulation
4 (Pieretal., 1983)
ATCC, American type culture collection; CU, Cardiff University; CVLU, chronic venous leg ulcer; MSSA; meticillin sensitive 
Staphylococcus aureus; NCIMB, National Collection of Industrial, food and Marine Bacteria; NCTC, National collection of type cultures.
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Appendix III: 
Biocide testing
Appendix IH.i Validation o f the drop count method
The results from the validation o f the drop count method are shown in Table 
IILi. Values represent the 10 repeats o f the drop count method recorded from the 106 
serial dilutions. The first column represents the mean CFU/ml for each triplicate per 
plate, while the second column shows the mean transformed CFU/ml to log data per 
plate. The validation indicated that there was no significant intra-researcher variance 
between the replicates or method.
Normality testing and distribution o f variance was perform ed using the mean 
logio values per plate and ANOVA in Minitab®. A P-value o f 0.588 was achieved 
using the Anderson-Darling test indicating the residuals were normally distributed, 
thus satisfying this assumption for the parametric test. Figure IILi shows the 
normality plot for the logio CFU/ml. A test for equal variances was performed as 
shown in Figure Ill.ii, resulting in a. Bartlett test, P-value = 0.453 and Levene test, P 
= 0.806 at a 95% confidence interval, indicating the variances were equal, satisfying 
the second criteria for a one-way ANOVA test.
No significant difference (P>0.05) between the m ean values o f the validation 
plates and CFU/ml was achieved using ANOVA. The drop count method therefore 
was a valid test o f bacterial growth following biocide testing.
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Table IILi Drop count validation results o f each plate and average triplicate
Mean CFU/ml 
per 106 dilution
Mean logio CFU/ml per 
106 dilution Plate series Plate number
8.33 8.92 1 1
8.67 8.94 1 2
8.33 8.92 1 3
8.00 8.90 2 1
7.33 8.87 2 2
6.67 8.82 2 3
7.67 8.88 3 1
8.33 8.92 3 2
7.33 8.87 3 3
7.67 8.88 4 1
8.33 8.92 4 2
9.00 8.95 4 3
7.67 8.88 5 1
8.33 8.92 5 2
8 8.9 5 3
7.67 8.88 6 1
7.33 8.87 6 2
7.33 8.87 6 3
7.67 8.88 7 1
7.00 8.85 7 2
7.00 8.85 7 3
8.67 8.94 8 1
7.67 8.88 8 2
7.33 8.87 8 3
8.33 8.92 9 1
8.00 8.90 9 2
7.67 8.88 9 3
8.67 8.94 10 1
7.00 8.85 10 2
7.67 8.88 10 3
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Normal Probability Plot
nrono
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StDev: 0 
N: 30
RESI1
0.0000000
0240211
Anderson-Darling Normality T est 
A -Squared: 0 .2 9 0  
P-Value: 0 .5 8 8
Figure IILi Normality plot for the logio mean CFU/ml for each validation plate.
Test for Equal Variances for response
Bartlett's Test
Test Statistic: 8.829 
P-Value : 0.453
Levene's Test
Test Statistic: 0.569 
P-Value : 0.806
Factor Levels95% Confidence Intervals for S igm as
0.0 0.1 0.2 0.3 0.4 0.5 0.8 0.7 0.8 0.9  1.0
Figure Ill.ii A chart o f equal variances for validation plates indicating the ^-values 
for Levene and Bartletts test.
Appendix Ill.ii Relationship between Bioscreen and optical density
The relationship between Bioscreen optical density and viable counts is shown in 
Figure Ill.iii. The fitted line plot was used to determine the viable count (logio 
CFU/ml) o f bacterial growth from the recorded Bioscreen OD. The equation logio 
CFU/ml = 8.461-0.01216(t) (where t is the number of min to reach OD 0.2) was used 
to determine bacterial growth using the Bioscreen enumeration method.
Fitted Line Plot
Log 10 cfu/ml = 8 .461  - 0 .01216  Number min to OD 0 .2
9
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5au
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2
1
0
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s 0.554260
R-Sq 94.3%
R -Sq(ad j) 94.2%
Number min to OD 0.2 
Figure Ill.iii Relationship of Bioscreen OD to viable count.
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Appendix Ill.iii Bioscreen honeycomb plate layout
A B C D E F G H I J
1 -8 -8 -8 -8 Blank Control a Control c Control e Test b Test d
2 -7 -7 -7 -7 Blank Control a Control c Control e Testb Test d
3 -6 -6 -6 -6 Blank Control a Control c Control e Testb Test d
4 -5 -5 -5 -5 Blank Control a Control c Control e Test b Test d
5 -4 -4 -4 -4 Blank Control a Control c Control e Test b Test d
6 -3 -3 -3 -3 Neutraliser Control b Control d T esta Teste Test e
7 -2 -2 -2 -2 Neutraliser Control b Control d Test a Teste Test e
8 -1 -1 -1 -1 Neutraliser Control b Control d T esta Test c Test e
9 -8 -7 -6 -5 Neutraliser Control b Control d T esta Teste Teste
10 -4 -3 -2 -! Neutraliser Control b Control d Test a Test c Test e
Figure Ill.iv Organisation of honeycomb plate. -1 to -8, serial dilutions of the 
working solutions (10'1 to 10'8); Blank, Tryptone soy broth (TSB) media control; 
Neutraliser, TSB with experimental neutraliser; Control, bacteria employing sterile 
water as a biocide (experimental control); Test, bacteria under test condition 
employing the investigated biocide (experimental test); a,b,c,d,e, individual test 
strains.
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Appendix Ill.iv Patient biocide treatment and experimental biocide test contact times
Table Ill.ii Relationship of contact time (min) necessary for 3 logio bacterial reductions based on drop count enumeration and previous
known clinical history o f patient biocide exposure
Biocide Treatment o f Patient Wound Over a 90 Day Period
Isolate Iodine Povidone-iodine Silver Silver nitrate Potassium Potassiumpermanganate
1004 a3 15 a4 N/A 0 N/A
1011 0 30 0 N/A 0 30
1021 0 15 0 30 a3 30
1106 0 30 a2 N/A 0 30
1108 al 30 0 N/A 0 30
2018 *2 30 2 30 0 30
2124 al 15 0 30 0 30
N/A, not applicable, did not reach a 3 logio bacterial growth reduction; 0, no biocide treatment in 90 d period before MRSA isolation; 
Reported number o f biocide exposures in a 90 day period.
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Appendix IV: 
MRSA typing
Appendix IV.i RAPD typing
0.00__________________ 0 2 0 __________________ 0 4 0 __________________ OgO__________________ 0 8 0 ___________________TOO
h
29
Group A39
33
26
Group C
Group B
Figure IV.i (a) Agarose gel showing RAPD fingerprint using Primer E2. (b)
Phylogenetic tree using UPGAMA analysis by Quantity One software to identify 
similarity patterns in fingerprints produced by primer E2. Lane numbers match 
those denoted on the phylogenetic tree. Lanes 1, 10, 19, 28 and 40, 100 bp and 500 
bp molecular weight markers (Fermentas). Lane 2 and 38, negative H20  control; 
lanes 8, 9, 11 to 18, 20 to 27, 29, 31, 32 and 39, MRSA isolates; lanes 3 to 7, 
EMRSA 15, EMRSA 16, NCTC 13143, NCTC 6571 and NCTC 12493 control 
isolates respectively; lanes 30 and 33 to 37, CNS, MSSA and MRSA controls.
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Figure IV.ii (a) Agarose gel showing RAPD fingerprint using Primer 1. (b)
Phylogenetic tree UPGAMA analysis by Quantity One software to identify similarity 
patterns in fingerprints produced by Primer 1. Lane numbers match those denoted 
on the phylogenetic tree. Lanes 1, 10, 19, 28, and 40, 100 bp and 500 bp molecular 
weight markers (Fermentas). Lane 2, negative H20  control; lanes 8, 9, 11 to 18, 20 
to 27, 29, 31, 32 and 39, MRSA isolates; lanes 3 to 7, EMRSA 15, EMRSA 16, 
NCTC 13143, NCTC 6571 and NCTC 12493 control isolates respectively; lane 30 
and 33 to 37, CNS, MSSA and MRSA controls.
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Appendix V:
PVL alignment sequences
Appendix IV.ii PFGE typing
339.5 kb
145.5 kb
Figure IV.iii Agarose gel o f pulse-type B fragment restriction digests. Lanes 1 and 
13, PFG lambda ladder molecular weight markers (NEB); lanes 2 to 9, MRSA 
wound isolates; lane 10, control isolate NCTC 6571; lanes 11 and 12, MRSA isolates.
Figure IY.iv Agarose gel o f pulse-type C fragment restriction digests. Lanes 1 and 
9, PFG lambda ladder molecular weight markers (NEB), a) Lanes 3, 4 and 7, MRSA 
isolates; lane 2, control isolates NCTC 12493; lane 5, control isolate NCTC 13130 
(EMRSA 3); lane 6, control isolate NCTC 13143 (EMRSA 16); lane 8, ICU MRSA 
control; b) lanes 3, 5, and 7, MRSA isolates.
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Appendix V.i Alignment using Lina PVL PCR primer sequences
Control isolate NCTC 6571 consensus sequence alignment with accession 
number AB532026. Sequence alignments with Staphylococcus aureus strain C5 
Panton-Valentine leucocidin S start codon.
1 ATATAGTCAAAATCCGAGAGACTATTTTGTGCCAGACAATGAATTACCCC 50
I I I I I I I I I I I I I I II I I II I I I I I II II I I I II I I I I I I I I I I I I I I I I 
633  a t a t a g t c a a a a t c c g a g a g a c t a t t t t g t g c c a g a c a a t g a a t t a c c c c  682
51 CATTAGTACACAGTGGTTTCAATCCTTCATTTATTGCAACTGTTTCTCAT 100
I I I I I I I I I I I I I I I I I I I I I I I I II I II I I I I I I I I 1 I I I I I I I I I I I I 
683  c a t t a g t a c a c a g t g g t t t c a a t c c t t c a t t t a t t g c a a c t g t t t c t c a t  732
101  GAAAAAGGCTCAGGAGATACAAGTGAATTTGAAATAACGTATGGCAGAAA 150
I I I I I II I I II I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II II I 
7 3 3  g a a a a a g g c t c a g g a g a t a c a a g t g a a t t t g a a a t a a c g t a t g g c a g a a a  782
151  TATGGATGTTACTCATGCTACTAGAAGAACAACACACTATGGCAATAGTT 200
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I 
7 8 3  t a t g g a t g t t a c t c a t g c t a c t a g a a g a a c a a c a c a c t a t g g c a a t a g t t  832
20 1  AT T TAGAAGGATC TAGAATACACAACGCAT T TGTAAACAGAAAT TACACA 250
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I 
833  a t t t a g a a g g a t c t a g a a t a c a c a a c g c a t t t g t a a a c a g a a a t t a c a c a  882
25 1  G T T AAAT AT G AAG T G AAC T GG AAAAC T CAT G AAAT T AAAGT G AAAGG AC A 300
I II I I I I I I I I I I I I I I I I I I II I II I I I I II I I I I II II I I I I II II I I 
883  g t t a a a t a t g a a g t g a a c t g g a a a a c t c a t g a a a t t a a a g t g a a a g g a c a  932
324301  TAATTGATATGAAAAAAATAGTCA 
. I I I I I I II I I I I I I I I I I II I I I I 
933 t a a t t g a t a t g a a a a a a a t a g t c a 956
TO/I
Control isolate HT2000 132 consensus sequence alignment with accession
number AB532026. Sequence alignments with Staphylococcus aureus strain C5
Panton-Valentine leucocidin S start codon.
1 T GG AC AT GAT CCAAAT T TAT T TGT T GGAT AT AAACC AT AT AGT CAAAAT C 50
I I I II I I I I II I I I I I I I II I I I 11 I I I I I I I I I I I I II II I I I I I I I I I 
597  T GG AC AT GAT C C AAAT TTATTTGT T GG AT AT AAAC CAT AT AG T C AAAAT C 64 6
51 CGAGAGACTATTTTGTGCCAGACAATGAATTACCCCCATTAGTACACAGT 100
I I II II I I I I I I I I I I I I I I II I I I II II I I I I I II I I I I II I I I II I I I 
647 C GAG AG AC TAT T T T G T GC C AG AC AAT G AAT T AC C C C CAT TAG T AC AC AG T 696
101 GGTTTCAATCCTTCATTTATTGCAACTGTTTCTCATGAAAAAGGCTCAGG 150
I I I I I I I I I I I I I I I I I I II II I I I I I I I I II I I I I I I II II II I I II I I 
697 GGTTTCAATCCTTCATTTATTGCAACTGTTTCTCATGAAAAAGGCTCAGG 74 6
151 AGATACAAG T GAAT T T GAAATAAC G TAT GG CAGAAATAT G GAT G T TAC T C 200
I I I I I I I I I I I I I I I I I I I I I I  I I I I I  I I I I I I I I  I I I I I I I  I I I  I I I I I  
747  AGATACAAG T GAAT T T GAAATAACGTAT GGCAGAAATAT GGAT GT TACT C 7 96
201  AT GC TAC TAGAAGAACAACACAC TAT G GCAATAG T TAT T TAGAAG GAT C T 250
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I II I I II I I I I I I I 
7 97 ATGCTACTAGAAGAACAACACACTATGGCAATAGTTATTTAGAAGGATCT 84 6
251  AGAATACACAAC GCAT T T G TAAACAGAAAT TACACAG T TAAATAT GAAG T 300
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
84 7 AG AAT AC AC AACG CAT T T G T AAAC AG AAAT T AC AC AG T T AAAT AT GAAG T 896
301  G AAC T GG AAAAC T CAT GAAAT T AAAG T G AAAG G AC AT AAT T GAT AT GAAA 350
I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
897 GAAC T G GAAAAC T CAT GAAAT TAAAG T GAAAG GACATAAT T GAT AT GAAA 94 6
351  AAAATAGTCAAATCATCA 368
I II I I I I I II II I I I I I I 
947 AAAATAGTCAAATCATCA 964
295
Blind MRSA isolate 5155 consensus sequence alignment with accession
number AB532026. Sequence alignments with Staphylococcus aureus strain C5
Panton-Valentine leucocidin S start codon.
1 GACTATTTTGTTCCAGACAATGAATTACCCCCATTAGTACACAGTGGTTT 50
I II I I I I I I I I • I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I 
652  g a c t a t t t t g t g c c a g a c a a t g a a t t a c c c c c a t t a g t a c a c a g t g g t t t  701
51 CAATCCTTCATTTATTGCAACTGTTTCTCATGAAAAAGGCTCAGGAGATA 100
I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I II I 1 I I I I I I I I I I I I I 
7 0 2  c a a t c c t t c a t t t a t t g c a a c t g t t t c t c a t g a a a a a g g c t c a g g a g a t a  751
101  CAAGTGAATTTGAAATAACGTATGGCAGAAATATGGATGTTACTCATGCT 150
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I 
7 5 2  c a a g t g a a t t t g a a a t a a c g t a t g g c a g a a a t a t g g a t g t t a c t c a t g c t  801
151  AC T AGAAGAACAAC AC AC T AT GGC AAT AG T TAT T T AGAAGGAT C T AGAAT 200
I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I 
802  a c t a g a a g a a c a a c a c a c t a t g g c a a t a g t t a t t t a g a a g g a t c t a g a a t  851
2 0 1  ACACAACGCAT T T G TAAACAGAAAT TACACAG T TAAATAT GAAG T GAAC T 250
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
852  a c a c a a c g c a t t t g t a a a c a g a a a t t a c a c a g t t a a a t a t g a a g t g a a c t  901
2 5 1  GGAAAAC T CAT GAAAT TAAAG T GAAAG GACATA 2 8 3
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
902 g g a a a a c t c a t g a a a t t a a a g t g a a a g g a c a t a  934
296
Blind MRSA isolate 554 consensus sequence alignment with accession
number AB532026. Sequence alignments with Staphylococcus aureus strain C5
Panton-Valentine leucocidin S start codon.
1 GAGAGAC TAT T T T GGT GC C AG AC AAT G AAT TACCCCCAT T AGT AC AC AG T
i i i i i i i i i i i i i i i i i i i i i  i i i i  i i i i i i i i i i i i i i i i i i i i  i i i i
50
648
1 i 1 1 II II II II 1 II 1 II 1 II II II 1 1 1 1 1 II II 1 1 1 1 II 1 1 1 1 II 1 1 1 
g a g a g a c t a t t t t - g t g c c a g a c a a t g a a t t a c c c c c a t t a g t a c a c a g t 696
51 GGTTTCAATCCTTCATTTATTGCAACTGTTTCTCATGAAAAAGGCTCAGG
i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i
100
697
l l 1 l 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 
g g t t t c a a t c c t t c a t t t a t t g c a a c t g t t t c t c a t g a a a a a g g c t c a g g 74 6
101 AGATACAAGTGAATTTGAAATAACGTATGGCAGAAATATGGATGTTACTC
i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i
150
747
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 II 1 1 1 II 1 1 1 
a g a t a c a a g t g a a t t t g a a a t a a c g t a t g g c a g a a a t a t g g a t g t t a c t c 79 6
151 AT GCT ACT AGAAGAAC AAC ACAC T AT GGCAAT AGT T AT T T AGAAGG AT C T 
1 I 1 1 1 1 1 1 1 1 1 II 1 1 i 1 1 1 1 1 1 1 1 1 1 1 I 1 1 1 1 I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
a t g c t a c t a g a a g a a c a a c a c a c t a t g g c a a t a g t t a t t t a g a a g g a t c t
200
797 846
20 1 AGAATACACAACGCAT T TGTAAACAGAAAT TACACAGT TAAATAT GAAGT 
i i  i i  i i  i i i i i i i i i i i i i i i i i  i i i i i i i i i  i i i i i i i i i i i i i i i i i i
250
847
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 
a g a a t a c a c a a c g c a t t t g t a a a c a g a a a t t a c a c a g t t a a a t a t g a a g t 896
25 1 GAAC T GGAAAACT CAT GAAAT TAAAG T GAAAGGACATAAT T GATAT GAAA 
i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i  i i i i i i
300
897
301
1 1 1 II 1 1 II II II 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 II 1 1 1 1 II 1 1 1 1 1 1 
g a a c t g g a a a a c t c a t g a a a t t a a a g t g a a a g g a c a t a a t t g a t a t g a a a
AAAATAGTCA 31 0
946
947 a a a a t a g t c a  956
297
Blind MRSA isolate 597 consensus sequence alignment with accession
number AB532026. Sequence alignments with Staphylococcus aureus strain C5
Panton-Valentine leucocidin S start codon.
1 AT AT AG T C AAAAT C C GAG AG AC TAT T T T G T T C C AG AC AAT G AAT T AC C C C 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
a t a t a g t c a a a a t c c g a g a g a c t a t t t t g t t c c a g a c a a t g a a t t a c c c c
50
633 682
51 CATTAGTACACAGTGGTTTCAATCCTTCATTTATTGCAACTGTTTCTCAT 
1 I I I I I I i I i m  i i  i i  i i i i i i i i i i i i i  i i i i i i i i i i i i i i i i i i i i i
100
683
1 1 1 1 1 1 1 I I  1 1 1 I I  I I  1 I I  1 I I  1 I I  I I  1 1 I I  1 I I  1 1 1 I I  I I  I I  1 1 1 I I  I I  
c a t t a g t a c a c a g t g g t t t c a a t c c t t c a t t t a t t g c a a c t g t t t c t c a t 732
101 G AAAAAG G C T C AG GAG AT AC AAG T G AAT T T GAAAT AAC G T AT G G C AG AAA 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
g a a a a a g g c t c a g g a g a t a c a a g t g a a t t t g a a a t a a c g t a t g g c a g a a a
150
733 782
151 TATGGATGT T AC T C AT G C T AC TAG AAG AAC AAC AC AC T AT G G C AAT AG T T 
1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
200
783 t a t g g a t g t t a c t c a t g c t a c t a g a a g a a c a a c a c a c t a t g g c a a t a g t t 832
201 AT T T AGAAGGAT CT AGAAT ACACAACGCAT T TGTAAACAGAAAT T ACACA 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 
a t t t a g a a g g a t c t a g a a t a c a c a a c g c a t t t g t a a a c a g a a a t t a c a c a
250
833 882
251 G T T AAAT AT GAAG T G AAC T G G AAAAC T CAT GAAAT T AAAG T G AAAG G AC A 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
g t t a a a t a t g a a g t g a a c t g g a a a a c t c a t g a a a t t a a a g t g a a a g g a c a
300
883 932
301 TAATTGATATGAAAAAAATAGTCA 324  
II II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 
t a a t t g a t a t g a a a a a a a t a g t c a  956933
298
Wound MRSA isolate 1011 consensus sequence alignment with accession
number AB532026. Sequence alignments with Staphylococcus aureus strain C5
Panton-Valentine leucocidin S start codon.
1 TCCGAGAGACTATTTTGTGCCAGACAATGAATTACCCCCATTAGTACACA 50
I II I I 1 I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
645  t c c g a g a g a c t a t t t t g t g c c a g a c a a t g a a t t a c c c c c a t t a g t a c a c a  694
51 GTGGTTTCAATCCTTCATTTATTGCAACTGTTTCTCATGAAAAAGGCTCA 100
I I I I I I I I I I I I II I I I I I I I I I I II II I I II I I I I I I I I I I I I I I II II 
695 g t g g t t t c a a t c c t t c a t t t a t t g c a a c t g t t t c t c a t g a a a a a g g c t c a  744
101 GGAGATACAAGT GAAT T TGAAATAACGTATGGCAGAAATATGGATGT TAC 150
I I I I I I I I I I I I I I I II I I II I I II II I I I I I I I I I I I I I I II I I I I I I I 
7 4 5  g g a g a t a c a a g t g a a t t t g a a a t a a c g t a t g g c a g a a a t a t g g a t g t t a c  794
151  T CAT GCT ACT AG AAG AAC AAC AC ACT AT GGC AAT AGT T AT T T AGAAGGAT 200
I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
79 5  t c a t g c t a c t a g a a g a a c a a c a c a c t a t g g c a a t a g t t a t t t a g a a g g a t  844
20 1  C TAGAATACACAAC G CAT T T G TAAACAGAAAT TACACAG T TAAATAT GAA 250
I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I II I I I I II I I I II I II II I 
8 4 5  c t a g a a t a c a c a a c g c a t t t g t a a a c a g a a a t t a c a c a g t t a a a t a t g a a  894
2 5 1  GTGAACT GGAAAAC T CAT GAAAT TAAAG T GAAAGGACATAAT T GATAT GA 300
I I I I I I I I I I II I II I I I I I I I II I I II II I II I I I I I I I I I I I I I I I I I 
8 9 5  g t g a a c t g g a a a a c t c a t g a a a t t a a a g t g a a a g g a c a t a a t t g a t a t g a  944
301  AAAAAATAGTCA 312
I I I I I I I I I I I I 
945 a a a a a a t a g t c a  956
Wound MRSA wound isolate 1057 consensus sequence alignment with 
accession number AP009363. Sequence alignment with the Staphylococcus phage 
0295 8PVL precursor o f the Panton-Valentine leukocidin S chain open reading 
frame JP059, for the LukS-PV gene.
1 ACACAGTGGTTTCAATCCTTCATTTATTGCAACTGTTTCTCATGAAAAAG
I i i I I I i i i i I i i i i i i i i  i i i i i i i i  i i  i i i i i i  i i i i i i i i i i i i i i i
5 0
4 5 4 8 4
1 1 1 I I  I I  1 I I  I I  I I  1 1 1 1 I I  I I  1 I I  I I  1 I I  I I  1 1 1 1 I I  I I  I I  I I  I I  I I  I I  
a c a c a g t g g t t t c a a t c c t t c a t t t a t t g c a a c t g t t t c t c a t g a a a a a g 4 5 5 3 3
5 1 GCTCAGGAGATACAAGTGAATTTGAAATAACGTATGGCAGAAATATGGAT 
I I i i I I I i i i  i i i i  i i i i i i i  i i i i t i  i i i i i i i i i i i i i i i i i i i i i  i i
1 0 0
4 5 5 3 4
1 1 1 1 I I  I I  I I  I I  I I  1 I I  I I  1 1 I I  I I  I I  I I  I I  1 I I  I I  1 I I  1 1 I I  1 1 1 1 1 I I  
g c t c a g g a g a t a c a a g t g a a t t t g a a a t a a c g t a t g g c a g a a a t a t g g a t 4 5 5 8 3
1 0 1 GT TAC TCAT GCTAC TAGAAGAACAACACAC TAT GGCAATAGT TAT T TAGA 
I I i I i I I I i i i i I I i i i i i i  I i I i i i i i i i i i i i m  I i I I i i i i I I i i i i
1 5 0
4 5 5 8 4
1 I I  1 I I  I I  I I  1 I I  1 I I  I I  1 1 I I  1 I I  I I  I I  1 1 I I  I I  I I  I I  1 1 I 1 1 1 1 1 I I I  
g t t a c t c a t g c t a c t a g a a g a a c a a c a c a c t a t g g c a a t a g t t a t t t a g a 4 5 6 3 3
1 5 1 AGGATCTAGAATACACAACGCAT T TGTAAACAGAAATTACACAGTTAAAT
1 1 1 1 1 1 1 1 1 1 1 1 ! 1 1 1 1 I I  1 1 I I  1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
2 0 0
4 5 6 3 4
I I  1 I I  I I  I I  I I  I I  1 I I  I I  1 1 I I  I I  I I I  1 ( 1 1 I I  1 I I  1 1 I I  I I  I I  1 I I  1 1 1 
a g g a t c t a g a a t a c a c a a c g c a t t t g t a a a c a g a a a t t a c a c a g t t a a a t 4 5 6 8 3
2 0 1 AT GAAGT GAAC T G GAAAACT CAT GAAATTAAAGT GAAAGGACATAAT T GA 
I I I I i i i I I I i i i i I I i i i i i i i I i I i i i i I I i i i i i i I I i i i i i i i  i I i
2 5 0
4 5 6 8 4
1 I I  I I  1 1 1 1 1 1 1 1 1 1 1 1 I I  I I  I I  1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I  1 I I  I I  I I  1 1 1 
a t g a a g t g a a c t g g a a a a c t c a t g a a a t t a a a g t g a a a g g a c a t a a t t g a 4 5 7 3 3
251 TA 252  
I I
45 7 3 4  t a  4 5 7 3 5
Wound MRSA wound isolate 1108 reverse sequence alignment with 
accession number AP009363. Sequence alignment with the Staphylococcus phage 
0295 8PVL precursor o f the Panton-Valentine leukocidin S chain open reading 
frame JP059, for the LukS-PV gene.
1 CAT TAGGTAAAAT GT CT GGACAT GAT C CAAATT TAT T T GTT GGATATAAA 
1 1 I I i i  I i I I I i I i i I i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i
50
4 5 3 7 5
I I  1 I I  1 I I  I I  I I  I I  I I  I I  I I  I I  I I  I I  I I  I I  I I  I I  I I  I I  I I  I I  I I  I I  I I  I I  
c a t t a g g t a a a a t g t c t g g a c a t g a t c c a a a t t t a t t t g t t g g a t a t a a a 45424
51 C CAT ATAG T CAAAAT C C GAGAGAC T AT T T T G T GC CAGACAAT GAAT T AC C 
I I  1 1 1 1 1 I 1 1 I I 1 I I I I I i I I I i I i i i i i i i i  i i I i i i I i i i I i i i i i i i
100
4 5 4 2 5
1 1 1 1 I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
c c a t a t a g t c a a a a t c c g a g a g a c t a t t t t g t g c c a g a c a a t g a a t t a c c 4 5474
101 CCCATTAGTACACAGTGGTTTCAATCCTTCATTTATTGCAACTGTTTCTC 
1 1 I I 1 i i  I 1 i i  i I I i I I i i  I I i i I i i i I i i  i i i i I i i i i i i i i i i i i i i i
150
4 5 475
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I  1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
c c c a t t a g t a c a c a g t g g t t t c a a t c c t t c a t t t a t t g c a a c t g t t t c t c 45524
151 ATGAAAAAGGCTCAGGAGATACAAGTGAATTTGAAATAACGTATGGCAGA
1 I I I I I i i I I i i i I i I I i i I i i i i i i i i i i i i i i I i i i i i i i i i i i i i i i
200
4 5 525
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
a t g a a a a a g g c t c a g g a g a t a c a a g t g a a t t t g a a a t a a c g t a t g g c a g a 45574
201 AAT AT G G AT GTT AC T C AT G C T AC T AG AAG AAC AAC AC AC T AT G G C AAT AG 
1 I I I I I I i I I i i I i i I i i i I I i i I i i i i i i i i i i I I i i I i i  i I i i i I i i i
250
4 5575
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
a a t a t g g a t g t t a c t c a t g c t a c t a g a a g a a c a a c a c a c t a t g g c a a t a g 4 5 624
251 T TAT T T AGAAGGAT C T AGAAT AC AC AAC GC AT T T G T AAAC AG AAAT T AC A 300
4 5625
II II 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
t t a t t t a g a a g g a t c t a g a a t a c a c a a c g c a t t t g t a a a c a g a a a t t a c a 4 5674
301 CAG T TAAATAT GAAG T GAAC T G GAAAACACAG GAAAT TAAAG T GAAAG GA
1 1 I I 1 I I i 1 I I I I I I I I I I I I i i I I I i I i i  I i i I I i 1 I I I I I I I I I I I
350
45675
I 1 1 1 I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 • 1 1 • 1 I I  1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
c a g t t a a a t a t g a a g t g a a c t g g a a a a c t c a t g a a a t t a a a g t g a a a g g a 4 5724
351 CATAATTGATA-GAAAAAAATAGTCA 37 5
1 1 I I  1 1 1 1 1 1 1 1 1 I I  1 1 | | 1 1 1 1 1 |
45725
1 I I I  1 I I  I !  1 1 1 1 I I  1 1 1 1 1 1 1 1 1 1 
c a t a a t t g a t a t g a a a a a a a t a g t c a  4 5 7 5 0
301
Wound MRS A wound isolate 1047 reverse sequence alignment with 
accession number AP009363. Sequence alignment with the Staphylococcus phage 
02958PVL precursor o f the Panton-Valentine leukocidin S chain open reading 
frame JP059, for the LukS-PV gene.
1 ATCATTAGGTAAAATGTCTGGACATGATCCAAATTTATTTGTTGGATATA 
1 1 I i i  I I I i I i i I i i  i I i i i  i i i i i  i i i i i i i i i i i i i i i i i i i i i i i i i
50
4 5 3 7 3
1 1 1 1 1 1 1 1 II 1 II 1 1 1 1 1 II 1 1 1 1 II II II 1 II II 1 II 1 II 1 II 1 II II 1 
a t c a t t a g g t a a a a t g t c t g g a c a t g a t c c a a a t t t a t t t g t t g g a t a t a 4 5 4 2 2
51 AAC CAT AT AG T CAAAAT C C GAGAGAC TATTTTGTGC CAGACAAT GAAT T A
1 1 I 1 I 1 I M  1 I i I I I i I i i I i i i I i I i i I i i i i i i i i i i i i i i i i i i i i i
100
4 5 4 2 3
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 II 1 1 II II II 1 II 
a a c c a t a t a g t c a a a a t c c g a g a g a c t a t t t t g t g c c a g a c a a t g a a t t a 4 5 4 7 2
101 CCCCCATTAGTACACAGTGGTTTCAATCCTTCATTTATTGCAACTGTTTC 
I I I I I I i i  i i i  i i  i i i I i i i i I i i  i i  i i i i  i i i i i i i i i i i i i i i i i i i i
150
4 5 4 7 3
1 M II 1 II II 1 1 II 1 II 1 II II 1 1 1 1 1 II 1 II M 1 II 1 II 1 II 1 1 II 1 II 
c c c c c a t t a g t a c a c a g t g g t t t c a a t c c t t c a t t t a t t g c a a c t g t t t c 45 5 2 2
151 TCATGAAAAAGGCTCAGGAGATACAAGTGAATTTGAAATAACGTATGGCA 
I I I I i I I I I i I i i i i  i i i i i i I i i i i i i i i i i i i i i i i i I i i i i i i i i I i
200
4 5 5 2 3
1 1 1 II 1 1 1 II 1 1 II 1 1 II 1 1 1 1 1 1 1 II 1 1 1 1 II 1 1 1 1 II 1 1 II 1 II 1 1 1 1 
t c a t g a a a a a g g c t c a g g a g a t a c a a g t g a a t t t g a a a t a a c g t a t g g c a 4 5 572
201 GAAATATGGATGTTACTCATGCTACTAGAAGAACAACACACTATGGCAAT 
1 I i I I I i i i  i i i i i I i I i i i i I i i i i i i I i i i i i i i i i i I i i I i i i  I i i I
250
4 5 5 7 3
1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 II II 1 1 II II 1 1 II 1 1 1 II II 
g a a a t a t g g a t g t t a c t c a t g c t a c t a g a a g a a c a a c a c a c t a t g g c a a t 4 5 6 2 2
251 AG T TAT T TAGAAG GAT C TAGAATACACAACGCAT T T G T AAACAGAAAT 298
4 5 6 2 3
........................... ..  i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i
a g t t a t t t a g a a g g a t c t a g a a t a c a c a a c g c a t t t g t a a a c a g a a a t  4 5 670
Appendix V.ii Alignment using Fey PVL PCR primer sequences
Control isolate NCTC 6571 consensus sequence alignment with accession 
number AB532027. Sequence alignments with Staphylococcus aureus strain NN47 
Panton-Valentine leucocidin S and F start codons.
1 C T CAT G AAAT T AAAGT G AAAG GAC AT AAT T GAT AT GAAAAAAAT AGT C AA
1 1 1 1 1 1 1 1 1 1 1 1 1 I I  1 1 1 ! 1 1 I I  1 1 1 1 1 1 1 I t  1 ! I I  I I  1 1 1 1 1 1 I I  I I  I I
50
908
M  1 1 1 I I  1 I I  I I  1 1 I I  I I  I I  I I  1 I I  I I  11 1 1 1 1 I I  1 1 1 1 1 1 I I  1 I I  1 I I  1 
c t c a t g a a a t t a a a g t g a a a g g a c a t a a t t g a t a t g a a a a a a a t a g t c a a 957
51 ATCATCAGTTGTTACATCAATTGCATTGCTTTTGCTATCCAATACAGTTG 
1 I 1 I I  I 1 I I I i i  I i I i i i  i I i I i i i i i i i i i i i i i  i i  i i i i i i i i i i i i i
100
958
I I  1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I  1 I !  1 1 1 1 I I  I I  I I  I I  1 I I  1 1 1 1 I I  I I  I I  
a t c a t c a g t t g t t a c a t c a a t t g c a t t g c t t t t g c t a t c c a a t a c a g t t g 1007
101 ATGCAGCTCAACATATCACACCTGTAAGTGAGAAAAAGGTTGATGATAAA 
1 1 1 1 1 I I  I 1 I I I  I I i I I I I I i I i I i I i I i I i i  i i  i I i i i i i i I i I i I i I I
150
1008
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
a t g c a g c t c a a c a t a t c a c a c c t g t a a g t g a g a a a a a g g t t g a t g a t a a a 1057
151 ATTACTTTGTACAAAACAACTGCAACATCAGATTCCGATAAGTTAAAAAT 
i i i i i i i i i i i i i i i i i i m  i i i i i i i i i i i i  i i i i i i i i i i i i  i i i i  i i
200
1058
1 1 1 1 1 1 1 1 1 1 I I  1 1 1 1 1 1 1 I I  1 1 1 1 I I  1 1 1 1 1 1 1 1 1 1 1 1 I I  I I  1 I I  I I  I I  
a t t a c t t t g t a c a a a a c a a c t g c a a c a t c a g a t t c c g a t a a g t t a a a a a t 1107
201 TTCTCAGATTTTAACTTTTAATTTTATTAAAGATAAAAGTTATGATAAAG 
1 I 1 I I I 1 I I I i i i I i i i i i I i i i I i i i  I i i i i i i i i i i i i i i i i i i i i i i
250
1108
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
t t c t c a g a t t t t a a c t t t t a a t t t t a t t a a a g a t a a a a g t t a t g a t a a a g 1157
251 ATACATTAATACTCAAAGCTGCTGGAAACATTTATTCTGGCTATACAAAG 
I i i i i i i i i i i i i i i i i i i i i i  i i i  i i i i i i  i i i i i i i i i i i i i i i i i i i
300
1158
1 1 1 1 1 I I  1 I I  1 I I  1 1 I I  1 1 1 I I  I I  I I  1 1 1 1 1 1 I I  I I  1 1 I I  1 I I  1 I I  I I  I I  
a t a c a t t a a t a c t c a a a g c t g c t g g a a a c a t t t a t t c t g g c t a t a c a a a g 1207
301 CCAAATCCAAAAGACACTATTAGTTCTCAATTTTA 335  
I I i i  M  I I i i  i i  i i i  I i i i  i i i i  i i  i i  m  i i  m  i i
1208
I I  1 1 I I  1 1 1 1 1 1 1 1 1 1 1 I I  1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
c c a a a t c c a a a a g a c a c t a t t a g t t c t c a a t t t t a  12 4 2
Wound MRSA wound isolate 1011 consensus sequence alignment with
accession number AB532027. Sequence alignments with Staphylococcus aureus
strain NN47 Panton-Valentine leucocidin S and F start codons.
1 CAT AAT T GAT AT GAAAAAAAT AG T C AAAT CAT C AG T T G T T AC AT C AAT T G 50
I II I I I II I I I I I I I I I II I I I I I I I I II I I I I I I I I I I I I I II I I I II I 
931 CATAATTGATATGAAAAAAATAGTCAAATCATCAGTTGTTACATCAATTG 98 0
51 CAT TGCTTTTGCTATC CAATACAG T T GAT G CAG C T CAACATAT CACAC C T 100
I  I  I I  I  I  I  I  I  I I  I  I I  I  I  I  I  I  I  I  I  I I  I  I  I  I I  I I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  
981 CATTGCTTTTGCTATCCAATACAGTTGATGCAGCTCAACATATCACACCT 1030
101 GTAAGTGAGAAAAAGGTTGATGATAAAATTACTTTGTACAAAACAACTGC 150
I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I I  I  I I  I I  I  I  I  I  I  I  I  I I  I  I I  I  I  I  I  I I  I  I  I I I  I I I
103 1  GTAAGTGAGAAAAAGGTTGATGATAAAATTACTTTGTACAAAACAACTGC 1080
151 AACATCAGATTCCGATAAGTTAAAAATTTCTCAGATTTTAACTTTTAATT 200
I I  I  I I  I  I  I I  I  I  I  I I  I  I  I  I I  I  I  I  I  I  I  I  I  I I  I  I  I  I I  I  I  I  I  I I  I  I  I  I  I  I  I  I I  I
108 1  AACAT CAGAT T C C GATAAGT TAAAAAT T T C T CAGAT T T TAAC T T T TAAT T 1130
201  TTATTAAAGATAAAAGTTATGATAAAGATACATTAATACTCAAAGCTGCT 250
I  I  I I  I  I I  I I  I  I  I I  I I  I  I I  I  I I  I I  I  I  I  I  I  I  I I  I  I  I I  I I  I  I  I  I  I  I  I  I  I  I  I  I  I  
1131  TTATTAAAGATAAAAGTTATGATAAAGATACATTAATACTCAAAGCTGCT 1180
251  GGAAACATTTATTCTGGCTATACAAAG 27 7
I  I  I I  I I  I I  I  I I  I I  I I  I I  I  I I  I I  I  I I  I  I  
1181  GGAAACATTTATTCTGGCTATACAAAG 1207
Wound MRSA wound isolate 1021 consensus sequence alignment with
accession number FJ713816. Sequence alignment with the Staphylococcus phage
G>PVL-CN125 precursor for Panton-Valentine leucocidin F chain.
1 C AG C T C AAC AT AT C AC AC C T G T AAG T G AG AAAAAG GTT GAT GAT AAAAT T 50
I I I I I I I  I ! l  I I I I I I I I I I I I I I I  I I I I I I I I I I I I I  I I I I I I  I I I I I  I 
4 2 6 7 4  c a g c t c a a c a t a t c a c a c c t g t a a g t g a g a a a a a g g t t g a t g a t a a a a t t  4 2 7 2 3
51 ACTTTGTACAAAACAACTGCAACATCAGATTCCGATAAGTTAAAAATTTC 100  
I I I I  I I I I  I I I I I I I I  I I I I I I I I  I I I I I I I I I I I I I I I I I I I I I I I I I  I 
42 7 2 4  a c t t t g t a c a a a a c a a c t g c a a c a t c a g a t t c c g a t a a g t t a a a a a t t t c  4 2 7 7 3
101 TCAGATTTTAACTTTTAATTTTATTAAAGATAAAAGTTATGATAAAGATA 150  
I I I I I I I I I I II I I I II I I I I I I I I I I I I I I I I I II I I I I I I II I I I I I I 
42 7 7 4  t c a g a t t t t a a c t t t t a a t t t t a t t a a a g a t a a a a g t t a t g a t a a a g a t a  4 2 8 2 3
151 CATTAATACTCAAAGCTGCTGGAAACATTTATTCTGGCTATAC 193  
I I I  I I I  I I I I I I  I I  I I I I I I I I I I  I I I I I I I I I I  I I I  I I I I I  I 
4 2 8 2 4  c a t t a a t a c t c a a a g c t g c t g g a a a c a t t t a t t c t g g c t a t a c  4 2 8 6 6
Wound MRSA wound isolate 1106 consensus sequence alignment with
accession number X64389. Sequence alignment with the Staphylococcus aureus
leuF-P83 gene for F component o f leucocidin R.
1 TAGTCAAATCATCCGTTGCTACATCTATGGCATTATTATTACTTTCTGGT 50
I I  I I  I I  I  I I  I I  I  I  I I  I  I  I  I  I I  I  .  I I  I I  I I  I  I  I  I  I  I I  I  I  I  I  I I  I I  I  I  I  •  •  i  
1186  t a g t c a a a t c a t c c g t t g c t a c g t c t a t g g c a t t a t t a t t a c t t t c t a a t  123 5
51 ACTGCTAATGCTGAAGGCAAAATCACACCAGTTAGCGTCAAAAAAGTAGA 100
I I  I  I I  .  I I  I  I  I I  I I I  I  I I I I I  I  I  I  I  I  I  I  I  I I  I  I  I  I  I  I I  I  I I  I I  I I I  I I I I
1 23 6  a c t g c a a a t g c t g a a g g c a a a a t c a c a c c a g t t a g c g t c a a a a a a g t a g a  1285
101 TGATAAAGTTACTTTATACAAAACTACAGCTACAGCAGATTCAGATAAAT 150
I I  I I  I I  I I  I  I I  I I  I I  I I  I I  I  I  I  I  I  I I I  I I  I  I I  I  I  I  I  I  I  I I  I  I  I  I  I  I  I  I  I  I
1 28 6  t g a t a a a g t t a c t t t a t a c a a a a c t a c a g c t a c a g c a g a t t c a g a t a a a t  1335
151 T CAAAAT T T CACAGAT T T TAACAT T TAAT T T CAT CAAAGATAAAAGT TAT 200
I I II I I I I I I I I I I I I I I I I I I I I I . I I I I I I I I I I I I II I I II II I I I I 
1336  t c a a a a t t t c a c a g a t t t t a a c a t t c a a t t t c a t c a a a g a t a a a a g t t a t  1385
201 G 201  
I
1 38 6  g 1 3 8 6
306
Wound MRSA wound isolate 1067 consensus sequence alignment with
accession number X64389. Sequence alignment with the Staphylococcus aureus
leuF-P83 gene coding the F component of leucocidin R.
1 ACTCGGTGGTAATGGATCCTTTATACAAAACTACAGCTACAGCAGATTCA 
I  I  I  I I  i l l  1 I  1 I  1 I  i  I i  I i  I i  i  i i  i  i i  i  i i  i  i  i i  i  i  i  i  i  i  i  i
50
1280
1 •  1 • 1 • 1 1 •  1 I I  •  1 •  1 •  1 1 1 1 1 1  1 1 I I  1 1 1 1 I I  1 1 1 I I  1 1 1 1 1 1 1 1 1  1 1 
a g t a g a t g a t a a - a g t t a c t t t a t a c a a a a c t a c a g c t a c a g c a g a t t c a 1328
51 GATAAATTCAAAATTTCACAGATTTTAACATTTAATTTCATCAAAGATAA 
1 I 1 I  1 I  1 I  I  I I  I  I  I I  i  i i  I  i  I i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i i  i  i  i
100
1329
I I  1 1 1 1 1  1 1  1 1 1  I I  1 1 1 1 1 1 1 1 1  1 I I  1 1 1 1 1 1 •  1 1 I I  1 1 1 1 1 1  1 I I  I I  I I  
g a t a a a t t c a a a a t t t c a c a g a t t t t a a c a t t c a a t t t c a t c a a a g a t a a 1378
101 AAGTTATGATAAAGATACTTTAGTACTTAAAGCTGCAGGTAATATTAACT
1 1 I I  1 1 1 I  I 1 I 1 I  1 I I  I  I  I I I i  i  I  I  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i
150
1379
1 1 1 1 1 1 1 1 1 1 1 1 I I  1 1 1 1 1 1 1 1 I I  •  1 1  1 1 1 1 1 1 I I  1 1 1 1 1 I I  1 I I  1 1 I I  1 
a a g t t a t g a t a a a g a t a c t t t a g t g c t t a a a g c t g c a g g t a a t a t t a a c t 1428
151 CAG G T T AT GAAAGAC CAAAC C C T AAAGAC TATGACTTTT CAAAAAG T G T T 
1 i i  I 1 I 1 I  I I  I I  i  I  i i  I  i  I i  I i  i  i i  i  i i  i  i  i  i  i  i  i  i  i  i  i i  i  i  i  i
200
1429
1 1 1 1 1 1 1 1 1  1 1 I I  1 1 1  1 1 1  •  1 1 1 1 I I  I I  I I  1 •  1 I I  1 I I  I I  1 I I  1  1 1 
c a g g t t a t g a a a g a c c a a a t c c t a a a g a c t a c g a c t t t t c a a a a a ------- t 1474
201 ATATTGGGGTGTCAAAGCGAATTCATTCGTCACTGCATCAGGTCAAAAGT 
I  i  I I  I I I I i  I i  i l l  i l l  i i  i  i i  i i  i  i  i  i  i  i l l  i i  i
250
1475
I I  I I  I I  1 M  1 1 I I I  1 1  1  •  1 1 •  1 I I  •  •  1 1 1 1 1 1 1  •  I I  1 •  I I  1 
a t a t t g g g g t g - c a a - - - - - - - - - - - - a a t a c a a t - g t g t c t - - a t c a g t t c a c a a - t 1515
251 CAGCATTTGATAGTGATTCGGTTAATCGTAGGATACAATGCACCTAAAAA 
1 i i  I  I  i  I  i  I  i i  i  i  I  i  I  i  i  i  i  I  i i  i  i  I  i  i  i  i  i  i  i  i  i  i
300
1516
1 1 1 •  1 1 1 1 I I  1 1  I I  1 1 1 1 1 1 1 •  1 •  1 1 •  1 I I  1 1 1 1 1 1 1 1 1 1 
c t a a t g a t t c g g t t a a t  g t a g t a g a c t a t g c a c c t a a a a a 1555
301 T CAAAAT GAAGAAT T T CAAG T G CAAAACAC T T TAG GATACACAT T T G G T G 
1 I 1 I I I  1 M  I  I  I I  i i  i  I i i  I  i  i i  i  I I i i  i  m  I i  i i  i i  i  i  i i  I i  i  I i i
350
1556
1 1 1 1 1 1 I I  1 I I  1 1 1 1  1 1 1 I I  1 •  1 1 1 1  1 1 1 1 1 1  1 1 1 1 •  1 1 •  I I  1 1 1 1  1 I I  1 
t c a a a a t g a a g a a t t t c a a g t t c a a a a c a c t t t a g g c t a t a c a t t t g g t g 1605
351 GTGACATCAGTATTACCACCTCTAATGGTTTATCTGCAAAGTGGATTTAA 
i  i  i i  i i  i  i  i  i  i i  i  i i  i  i  i  i  i  i i  m  i i  i i  i  i  i  m i  i  i  i  i
400
1606
I I  1 1 1 1 1 1 1 I I  1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 •  1 1 1 •  1 1 1 1 
g t g a c a t c a g t a t ----------- c t c t a a t g g t t t a t c t g --------g c g g a c t t a a 1645
401 CGGAAACACT GCAT T TAT C T GAAACAAT TAAC TACAAACAAGAAAGT TAC 
I I I I 1 I i i  i i  M  i l l  I i i  i  I I I I  i i  i i  i i  I I  i i  I I 1 I  I I i  I I i  i i  I
450
1646
1 1 1 1 1 1 1 1 1 1 1 1 I I  1 •  1 1 1 1 1 1 1 1 1 1 I I  1 1 •  I I  •  1 1 1 1 1 1 1 1 1 1 1 1 1 I I  
c g g a a a c a c t g c - t t t t t c t g a a a c a a t t a a t t a t a a a c a a g a a a g t t a c 1694
451 AGAACAACTTTAAGTCGCAACACGAGCGAATTTGAAAAATGTCGGTTGGG 
i  i  i  i  i  i  i  i  i  i  i i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i  i
500
1695
1 1 1 1 I I  1 1 •  1 I I  I I  1 1 1 1 1 I I  1 1 •  1 I I  1 •  •  1 1 1  I I  I I  I I  I I  I I  I I  1 
a g a a c a a c a t t a a g t c g c a a c a - - - - - - - - - - - - c a a a t t a t a a a a a t g t c g g t t g g g 1740
501 GTGTAGAAGCACATAAAATTATGAATAATGGTTGGGGCCCCTCATGGCCA 
i  i  i  i  i  i  i  i  i  i  i  i i  i  i  i  i  i i  i  i  i  i  i  i i  i  i  i  i  i i  i  i  i i  i  i l l  i i  i  i
550
1741
1 I I  I I  1 1 I I  1 1 1 1 1  1 I I  I I  I I  I I  1 1 I I  1 1 I I  1 1 I I  I I  •  1 1 1 •  1 1 1 1 
g t g t a g a a g c a c a t a a a a t t a t g a a t a a t g g t t g g g g - a c c t t a t g g - - - - - - - - - 178 6
551 TTAAAAGATAGCTTCCATCCAACACATTATGGCAACAGTTA--TCTTCTT 
I  I  i i  i i  i i  i  i  m  i  i  i i  i  i  I  i i  i  I  i  i i  i  I  i  I  I  i  I  i  I
598
1787
1 •  •  1 1 1 1 I I  I I  I I  1 1 • I I  1 1 1 1 M i l l ' l l  1 •  1 1 1 1 1 1 I I  
- - a c g a g a t a g c t t c c a c c c a a c a - - - - - - - - - t a t g g t a a - - - - - - - - - - t g a a c t c t t c t t 1828
599 AGCTGGTAGACAAAGCAGTTCATA--ATG--CATTTAAAAACTTCATAGC
I i I i I i i i i i I i i i i I i i i I i i ii  i I i i i i I i I I i I I I
644
1829
1 1 1 1 1 1 • 1 1 1 1 1 I I  1  1 1 I I  • 1 1 1 1  M l 1 I I  I I  I I  1 1 I I  I I  1 
a g c t g g c a g a c a a a g c a g t g c a t a c g c t g g c c --------- a a a a c t t e a t a g e 1873
307
64 5 G C AAC AC C AAAT G C C AT TAT T AT C TAT G AAGT AAC T T C AAT C C AGAAT T T 694
I  I  I  I  I  I  I  I I I  I I  I I  I  I  I  I  I  I  I  I I  I I  I  I  I  I  I I I  I I  I  I  I  I  I I  I I I I I  I I  I  I
1874  g c a a c a c c a a a t g c c a t t a t t a t c t a - g a a g t a a c t t c a a t c c a g a a t t t  1922
695 TTAAGCGTACTATCACACAGACAAGATGGCGCTAAAAAATCTAAAATTAC 74 4
I I  I I  I I  I I  I I  I  I I  I I  I  I I  I I  I I  I I  I  I  I I  I I  I  I  I  I  I  I I  I  I  I  I  I  I  I  I  I  I  I I  I
1 9 2 3  t t a a g c g t a c t a t c a c a c a g a c a a g a t g g c g c t a a a a a a t c t a a a a t t a c  1972
7 45 AGTACACTTATCAACGTGAAATGGATTTATACCAAATTAGTCAAATCATC 7 94
I  I  I  I  I  I  I  I  I I  I  I I  I  I I  I  I  I  I  I  I  I  I  I  I  I  I  I  I I  I  I  I  I  I  I  
1 9 7 3  a g t a - a c t t a t c a a c g t g a a a t g g a t t t a t a c c a a a t t ------------------------  2009
795  CGTTG 799
2 0 1 0  c g t t g  2014
308
Wound MRSA wound isolate 2124 reverse sequence alignment with 
accession number X64389. Sequence alignments with the Staphylococcus aureus 
leuF-P83 gene coding for the F component o f leucocidin R.
1 AAAATATATTGGGGTGCAAAATACAATGTGTCTATCAGTTCACAATCTAA
I I I I I I I  I I l l I l l I l l l I I l I I i I I i i i i i I i i i i i i i i i i i i i i i i i i
50
147 0
1 1 1 1 1 1 1 1 1 1 1 I I  1 1 1 1 1 1 I I  1 1 1 I I  1 1 1 1 I I  1 I I  I I  1 I I  I I  I I  1 1 1 1 I I  
a a a a t a t a t t g g g g t g c a a a a t a c a a t g t g t c t a t c a g t t c a c a a t c t a a 1519
51 TGATTCGGTTAATGTAGTAGACTATGCACCTAAAAATCAAAATGAAGAAT 
1 1 I I  1 I I  I I  1 I 1 I 1 1 I I I I I I I I i I i i i i i i i i i i i  i i i i i i i i i i i i i i
100
1520
1 1 I I  1 1 1 1 1 I I  1 1 1 I I  1 1 I I  1 1 1 1 1 I I  I I  1 I I  1 1 I I  1 1 1 I I  1 1 1 I I  I I  I I  
t g a t t c g g t t a a t g t a g t a g a c t a t g c a c c t a a a a a t c a a a a t g a a g a a t 1569
101 T T CAAG T GCAAAACAC T T TAGGATACACAT T T GGT GGT GACAT CAGTAT C 
I 1 1 I I I  I I 1 i i  I i i  i i i  i i  i i  i i  i i i  i i i i i i i  i i i  i i i i i i i i i i  i
150
1 5 7 0
11 1 1 1 1 1 • 1 1 1 1 1 1 1 1 1 1 1 1 1 1 • 1 1 • 1 1 1 1 1 1 1 1 I I  1 1 1 1 I I  1 1 1 1 1 1 I I  
t t c a a g t t c a a a a c a c t t t a g g c t a t a c a t t t g g t g g t g a c a t c a g t a t c 1619
151 TCTAATGGTTTATCTGGTGGACTTAACGGAAACACTGCTTTTTCTGAAAC 
I I i i  I I i I I i i I i i i i  i i i i i i i i i i i i  i i i  i i i  i i i  i i i  i i  i i  i i i i i
200
1 6 2 0
1 1 1 I I  I I  I I  I I  1 I I  I I  1 • I I  1 I I  I I  1 1 I I  1 I I  I I  I I  1 1 1 1 1 1 1 1 1 1 1 1 1 1 
t c t a a t g g t t t a t c t g g c g g a c t t a a c g g a a a c a c t g c t t t t t c t g a a a c 1669
201 AAT TAAC TACAAACAAGAAAG T TACAGAACAAC T T TAAG T C G CAACAC AA 
i i i i i i i i  i i i i i i i i  i i i i i i i i i i i i i i i i i i i i i i i i i i  i i i i i
250
167 0
1 1 1 I I  1 • 1 1 • 1 1 1 1 I I  1 1 1 1 1 1 1 1 1 1 1 1 I I  1 1 1 • 1 1 1 1 1 1 1 1 1 1 I I  I I  1 1 
a a t t a a t t a t a a a c a a g a a a g t t a c a g a a c a a c a t t a a g t c g c a a c a c a a 1719
251 ATTATAAAAATGTCGGTTGGGGTGTAGAAGCACATAAAATTATGAATAAT 
i i i  i I I i i i i i i  i i i i i i  i i i i i i i I i I i i  i i i i i i I i i  I i I I i i I i I I I
300
1 72 0
1 I I  1 1 1 1 I I  1 1 1 1 1 1 I I  1 1 I I  1 1 1 1 1 1 1 1 1 1 1 1 I I  1 1 1 1 1 1 1 I I  1 1 1 1 I I  
a t t a t a a a a a t g t c g g t t g g g g t g t a g a a g c a c a t a a a a t t a t g a a t a a t 1769
301 GGTTGGGGCCCCTATGGCCGAGATAGCTTCCATCCAACATATGGCAATGA 
i i i i i i i  i i i  i i i i i i i i i i i i i i i i i i i i i i I i i  I i i i  i I i I i i
350
177 0
1 1 1 1 1 1 1 1 • 1 1 . 1 1 1 1 1 • 1 I I  1 I 1 1 1 1 1 1 1 1 1 • 1 1 1 1 1 1 1 1 I I  1 • 1 1 1 1 1 
g g t t g g g g a c c t t a t g g a c g a g a t a g c t t c c a c c c a a c a t a t g g t a a t g a 1819
351 AATCTTCTTAGCTGGTAGACAAAGCAGTTCATATGCAGGCCAAAACTTCA 
i i i  i i  i i i m  i i  i i i i i m  i m  i i i  I i I i I i i  i I 1 i i  1 i i  I I  1 I I
400
182 0
1 • I I  1 I I  1 I I  I I  1 I I  • 1 I I  1 1 I I  1 I I  1 1 • I I  I I  • 1 1 • I I  1 1 1 1 1 1 1 1 1 1 1 
a c t c t t c t t a g c t g g c a g a c a a a g c a g t g c a t a c g c t g g c c a a a a c t t c a 1869
401 TAGCGCAACACCAAATGCCATTATTATCTAGAAGTAACTTCAATCCAGAA 
i i i i i  i i i  i i i  i m  i i i i  i i i I i i i i  I I I I 1 I I 1 I I I I  1 1 I 1 I 1 1 1 1 I M
450
1 8 7 0
I I  I I  1 1 I I  1 1 1 1 1 1 1 I I  1 I I  I I  1 1 I I  1 I I  1 1 1 1 I 1 I I  1 I I  I I  I I  I I I I I I 
t a g c g c a a c a c c a a a t g c c a t t a t t a t c t a g a a g t a a c t t c a a t c c a g a a 1919
451 TTTTTAAGCGTACTATCACACAGACAAGATGGCGCTAAAAAATCTAAAAT 
i i i i i i i i i i i i i i i i i  i i i i i i i i i i  i i i m  i i  i m  m  i i  I m  I i I I M
500
192 0
I I  I I  1 1 M  1 I I  1 1 1 1 I I  1 1 1 1 1 1 I I  1 1 1 1 1 1 I I  I I  I I  I I  1 I I  I I  1 1 1 1 1 1 
t t t t t a a g c g t a c t a t c a c a c a g a c a a g a t g g c g c t a a a a a a t c t a a a a t 1969
501 TACAGTAACTTATCAACGTGAAATGGATTTATACCAAATTCGTTGGAATG 
i i i i i i i i i i I i i i i i i i i i i I i I I i I I I I 1 I I I  1 I I  I I 1 I I I  I I  I I  I I  I
550
1 97 0
1 1 1 1 1 1 1 1 I I  1 1 I I  1 1 1 1 1 1 1 1 1 I I  1 1 I I  I I  1 1 I I  1 1 1 I I  1 I I  I I  I I I 1 I 
t a c a g t a a c t t a t c a a c g t g a a a t g g a t t t a t a c c a a a t t c g t t g g a a t g 2 0 1 9
551 GGTTCTACTGGGCAGGC 5 67
1 1 1 1 1 1 1 1 1 1 1 1 1 1 I 1
2 0 2 0
1 • I I  I I  I I  1 I I  I I  I I  M 
g c t t c t a c t g g g c a g g c  2 0 3 6
Appendix VI: 
TLR transfection
Table Vl.i Transfection mixture and concentration per well (ng/pl; 25jj.1 well)
aTransfection mix fEIam-luc gRen-Iuc CD14
Transfected plasmid content (ng/pl) 
MD2 TLR4 TLR2 TLR5 pCDNA3 DMEM (pi) GeneJuice (pi)
bTLR-neg 21.6 11.8 66.8 24.7 0.3
°TLR2 21.6 11.8 22.2 44.5 24.7 0.3
dTLR4/MD2/CD14 21.6 11.8 25.3 22.0 23.1 0 24.7 0.3
eTLR5
i - i t
21.6 11.8
r  . ___z' .• b-
22.2 44.5 24.7
1 Ct 't
0.3
aContents o f media added to each well for transfection; Transfection mixture containing no TLR, used as control; CTLR2 plasmid transfection 
mixture; dTLR4 plasmid transfection mixture; eTLR5 plasmid transfection mixture; fElam-luciferase plasmid; 8renilla luciferase plasmid.
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